Compounds > neostigmine
Page last updated: 2024-10-31

neostigmine and Neuromuscular Blockade

neostigmine has been researched along with Neuromuscular Blockade in 360 studies

Neostigmine: A cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. Neostigmine, unlike PHYSOSTIGMINE, does not cross the blood-brain barrier.
neostigmine : A quaternary ammonium ion comprising an anilinium ion core having three methyl substituents on the aniline nitrogen, and a 3-[(dimethylcarbamoyl)oxy] substituent at position 3. It is a parasympathomimetic which acts as a reversible acetylcholinesterase inhibitor.

Neuromuscular Blockade: The intentional interruption of transmission at the NEUROMUSCULAR JUNCTION by external agents, usually neuromuscular blocking agents. It is distinguished from NERVE BLOCK in which nerve conduction (NEURAL CONDUCTION) is interrupted rather than neuromuscular transmission. Neuromuscular blockade is commonly used to produce MUSCLE RELAXATION as an adjunct to anesthesia during surgery and other medical procedures. It is also often used as an experimental manipulation in basic research. It is not strictly speaking anesthesia but is grouped here with anesthetic techniques. The failure of neuromuscular transmission as a result of pathological processes is not included here.

Research Excerpts

ExcerptRelevanceReference
" However, there is a paucity of evidence demonstrating possible effects of magnesium on neostigmine-induced recovery from neuromuscular blockade with rocuronium."9.69Effects of magnesium sulphate on neostigmine-induced recovery from moderate neuromuscular blockade with rocuronium: a randomized controlled trial. ( Chung, SH; Do, SH; Han, J; Park, HY; Shin, HJ, 2023)
" The aim of the study is to comparison of neuromuscular blockade and reversal using cisatricurium and neostigmine with rocuronium and sugamadex on the quality of recovery from general anaesthesia for percutaneous closure of left atria appendage."9.51A comparison of neuromuscular blockade and reversal using cisatricurium and neostigmine with rocuronium and sugamadex on the quality of recovery from general anaesthesia for percutaneous closure of left atria appendage. ( Li, Q; Wu, D; Wu, J; Xie, H; Xu, M; Yao, H, 2022)
"Meta-analysis of 40 trials with 5455 patients showed an overall lower risk of postoperative nausea and vomiting in the sugammadex group than in the neostigmine group (risk ratio: 0."9.41The effect of sugammadex versus neostigmine on postoperative nausea and vomiting: a meta-analysis of randomized controlled trials with trial sequential analysis. ( Hsieh, YL; Lin, CR; Liu, YC; Wang, CJ; Weng, WT, 2023)
" It is not known whether there is a dose-dependent relationship between the dosage of calcium gluconate and the probability of transmitter release for non-depolarizing neuromuscular blockade (NMB) recovery by acetylcholinesterase inhibitors (AchEIs)."9.41Comparison of neuromuscular blockade recovery co-administered with neostigmine and different doses of calcium gluconate: a randomized control trial. ( Choi, SR; Kim, JH; Lee, KH; Park, SY, 2021)
"The use of neostigmine after neuromuscular blockade (NMB) has been associated with postoperative respiratory complications."9.30Respiratory muscle activity after spontaneous, neostigmine- or sugammadex-enhanced recovery of neuromuscular blockade: a double blind prospective randomized controlled trial. ( Janssens, K; Jorens, PG; Maes, S; Saldien, V; Schepens, T; Vellinga, J; Wildemeersch, D, 2019)
"To evaluate the influence of reversal of neuromuscular blockade with sugammadex or neostigmine on postoperative quality of recovery following a single bolus dose of rocuronium after pars plana vitrectomy (PPV) under general anesthesia."9.30Influence of reversal of neuromuscular blockade with sugammadex or neostigmine on postoperative quality of recovery following a single bolus dose of rocuronium: A prospective, randomized, double-blinded, controlled study. ( Bai, SJ; Hong, JH; Kim, NY; Kim, SS; Koh, JC; Lee, KY; Nam, HJ, 2019)
"This randomized controlled study compared the recovery times of sugammadex and neostigmine as antagonists of moderate rocuronium-induced neuromuscular block in patients with liver cirrhosis and controls undergoing liver resection."9.27Sugammadex antagonism of rocuronium-induced neuromuscular blockade in patients with liver cirrhosis undergoing liver resection: a randomized controlled study. ( Abdulatif, M; Afifi, MH; Lotfy, M; Mousa, M; Yassen, K, 2018)
"Sugammadex reverses the effect of rocuronium more rapidly and effectively than neostigmine, at all levels of neuromuscular blockade (NMB)."9.24Half dose sugammadex combined with neostigmine is non-inferior to full dose sugammadex for reversal of rocuronium-induced deep neuromuscular blockade: a cost-saving strategy. ( Alfahel, WS; Aouad, MT; Kaddoum, RN; Siddik-Sayyid, SM, 2017)
"Calcium chloride coadministered with neostigmine enhanced neuromuscular recovery in the early period of nondepolarising neuromuscular blockade reversal."9.24Effects of calcium chloride coadministered with neostigmine on neuromuscular blockade recovery: A double-blind randomised study. ( Hong, DM; Ju, JW; Kim, HC; Park, HP; Yoon, S, 2017)
"This study aimed to assess the effects of sugammadex and neostigmine/atropine on postoperative cognitive dysfunction (POCD) in adult patients after elective surgery."9.24Effect of sugammadex versus neostigmine/atropine combination on postoperative cognitive dysfunction after elective surgery. ( Batistaki, C; Kostopanagiotou, G; Lyrakos, G; Matsota, P; Riga, M; Zafeiropoulou, F, 2017)
" The current trial was aimed to compare between sugammadex and neostigmine concerning the recovery time from neuromuscular blockade."9.24A comparison of sugammadex and neostigmine for reversal of rocuronium-induced neuromuscular blockade in children. ( Ammar, AS; Kasemy, ZA; Mahmoud, KM, 2017)
"To compare the electromyographic activity of the diaphragm (EMGdi) during recovery from neuromuscular blockade using neostigmine and sugammadex."9.20Electromyographic activity of the diaphragm during neostigmine or sugammadex-enhanced recovery after neuromuscular blockade with rocuronium: a randomised controlled study in healthy volunteers. ( Cammu, G; De Neve, N; Foubert, L; Jorens, PG; Saldien, V; Schepens, T; Vercauteren, M, 2015)
"Sugammadex provided significantly faster reversal of vecuronium-induced neuromuscular blockade compared with neostigmine."9.14Sugammadex provides faster reversal of vecuronium-induced neuromuscular blockade compared with neostigmine: a multicenter, randomized, controlled trial. ( Alvarez-Gómez, JA; Khuenl-Brady, KS; Lora-Tamayo, JI; Rietbergen, H; Vanacker, BF; Wattwil, M, 2010)
" This study compared the efficacy of sugammadex and neostigmine for reversal of neuromuscular blockade induced by rocuronium for facilitating elective surgery."9.14Reversal of rocuronium-induced neuromuscular blockade with sugammadex compared with neostigmine during sevoflurane anaesthesia: results of a randomised, controlled trial. ( Blobner, M; Della Rocca, G; Eriksson, LI; Motsch, J; Prins, ME; Scholz, J, 2010)
"Sixty patients undergoing elective surgery procedures with a standardized desflurane-remifentanil-rocuronium anesthetic technique received either sugammadex, 4 mg/kg IV (n = 20), edrophonium, 1 mg/kg IV and atropine, 10 microg/kg IV (n = 20), or neostigmine, 70 microg/kg IV and glycopyrrolate, 14 microg/kg IV (n = 20) for reversal of neuromuscular blockade at 15 min or longer after the last dose of rocuronium using acceleromyography to record the train-of-four (TOF) responses."9.12Sugammadex reversal of rocuronium-induced neuromuscular blockade: a comparison with neostigmine-glycopyrrolate and edrophonium-atropine. ( Klein, K; Sacan, O; Tufanogullari, B; White, PF, 2007)
"The effects of neostigmine on the incidence of postoperative nausea and vomiting (PONV) are controversial."9.09The effects of antagonizing residual neuromuscular blockade by neostigmine and glycopyrrolate on nausea and vomiting after ambulatory surgery. ( Garg, SA; Hailey, A; Joshi, GP; Yu, SY, 1999)
"We performed this randomized, double-blind, placebo-controlled study to determine whether reversal of neuromuscular block with neostigmine increases the incidence and severity of postoperative nausea and vomiting (PONV)."9.08Reversal of neuromuscular blockade with neostigmine has no effect on the incidence or severity of postoperative nausea and vomiting. ( Halonen, P; Hovorka, J; Korttila, K; Nelskylä, K; Paatero, H; Sarvela, J; Soikkeli, A; Yli-Hankala, A, 1997)
"We compared the efficacy and safety of sugammadex and neostigmine in reversing neuromuscular blockade in adults."8.98The comparative efficacy and safety of sugammadex and neostigmine in reversing neuromuscular blockade in adults. A Cochrane systematic review with meta-analysis and trial sequential analysis. ( Afshari, A; Allingstrup, M; Duch, P; Hristovska, AM, 2018)
"Neostigmine is the anticholinesterase drug most commonly used to reverse blockade or speed up recovery from neuromuscular blockade from nondepolarizing neuromuscular blocking drugs."8.98Atrio-ventricular Block Following Neostigmine-Glycopyrrolate Reversal in Non-heart Transplant Patients: Case Report. ( Nkemngu, NJ; Tochie, JN, 2018)
"Sugammadex has been introduced for reversal of rocuronium (or vecuronium)-induced neuromuscular blockade (NMB)."8.93Efficacy and safety of sugammadex compared to neostigmine for reversal of neuromuscular blockade: a meta-analysis of randomized controlled trials. ( Carron, M; Ori, C; Tellaroli, P; Zarantonello, F, 2016)
"We reviewed systematically sugammadex vs neostigmine for reversing neuromuscular blockade."8.91A systematic review of sugammadex vs neostigmine for reversal of neuromuscular blockade. ( Abad-Gurumeta, A; Calvo-Vecino, JM; Casans-Francés, R; Espinosa, A; Fernández-Pérez, C; López-Timoneda, F; Martínez-Hurtado, E; Ramírez, JM; Ripollés-Melchor, J, 2015)
"We aimed to compare the effect of sugammadex to that of neostigmine with respect to the occurrence of postoperative nausea and vomiting (PONV) during the first 24 h following general anesthesia."8.31Effects of sugammadex versus neostigmine on postoperative nausea and vomiting after general anesthesia in adult patients:a single-center retrospective study. ( Cho, HY; Hwang, IE; Ju, JW; Kim, WH; Lee, HJ; Yang, SM, 2023)
" The authors hypothesized that the choice of neuromuscular blockade reversal (neostigmine vs."7.96Sugammadex versus Neostigmine for Reversal of Neuromuscular Blockade and Postoperative Pulmonary Complications (STRONGER): A Multicenter Matched Cohort Analysis. ( Bardia, A; Bartels, K; Bash, LD; Colquhoun, DA; Dubovoy, TZ; Kheterpal, S; Mathis, MR; McCormick, PJ; Saager, L; Schonberger, RB; Shah, NJ; Shanks, AM; Soto, RG; Vaughn, MT, 2020)
"Fewer cases of bradycardia were observed in the sugammadex group compared to the neostigmine group in the overall cohort (P < ."7.91Retrospective Analysis of the Safety and Efficacy of Sugammadex Versus Neostigmine for the Reversal of Neuromuscular Blockade in Children. ( Brenn, BR; Donahue, BS; Gartley, A; Gaver, RS, 2019)
"The objective of this systematic review is to identify the effectiveness of sugammadex versus neostigmine on the reversal of rocuronium-induced neuromuscular blockade in surgical patients with myasthenia gravis undergoing general anesthesia."7.88Effectiveness of sugammadex versus neostigmine on restoration of neuromuscular function in surgical patients with myasthenia gravis undergoing rocuronium-induced neuromuscular blockade: a systematic review protocol. ( Badeaux, J; Martin, J; Schiavo, JH; Yellott, E, 2018)
"To summarize and compare efficacy of sugammadex with neostigmine or placebo for reversal of rocuronium- or vecuronium-induced neuromuscular blockade (NMB), and to demonstrate consistency of sugammadex results across various patient populations."7.85Sugammadex efficacy for reversal of rocuronium- and vecuronium-induced neuromuscular blockade: A pooled analysis of 26 studies. ( Assaid, CA; Blobner, M; Herring, WJ; Khuenl-Brady, KS; Lemmens, HJ; Lupinacci, RJ; Woo, T, 2017)
"Prospective observational series of consecutive patients scheduled for laparoscopic bariatric surgery in whom neuromuscular blockade was reverted with sugammadex were compared with a historical matched cohort of patients reverted with neostigmines."7.80Postoperative respiratory outcomes in laparoscopic bariatric surgery: comparison of a prospective group of patients whose neuromuscular blockade was reverted with sugammadex and a historical one reverted with neostigmine. ( Cabrera, A; Camprubí, I; Ferreres, E; Llauradó, S; Sabaté, A, 2014)
"It was a prospective comparative clinical study carried out in the Department of Anaesthesia, Combined Military Hospital (CMH), Dhaka, to evaluate the heart rate changes during reversal of neuromuscular blockade by using 3 different doses of atropine (in a mixture with neostigmine) and thereby detect comparatively safer dose."7.77Different doses of atropine on heart rate fluctuations during reversal of neuromuscular blockade. ( Haque, MM; Islam, MA; Islam, MR; Rashid, MH; Shahida, SM, 2011)
"The purpose of this study was to compare neostigmine-induced reversal of vecuronium in normal weight, overweight and obese female patients."7.73Neostigmine-induced reversal of vecuronium in normal weight, overweight and obese female patients. ( Masaki, G; Ogawa, S; Suzuki, T, 2006)
"Both streptomycin and dihydrostreptomycin in large doses produced neuromuscular blockade in different types of skeletal nerve-muscle preparations."7.64Neuromuscular blockade by streptomycin and dihydrostreptomycin. ( DESHPANDE, VR; JINDAL, MN, 1960)
"Pulmonary complications related to residual neuromuscular blockade lead to morbidity and mortality."6.94Neostigmine Versus Sugammadex for Reversal of Neuromuscular Blockade and Effects on Reintubation for Respiratory Failure or Newly Initiated Noninvasive Ventilation: An Interrupted Time Series Design. ( Bartels, K; Bullard, KJ; Fernandez-Bustamante, A; Jameson, LC; Krause, M; Mayes, LM; McWilliams, SK; Mikulich-Gilbertson, SK, 2020)
"Mivacurium is a short-acting non-depolarizing muscle relaxant, which is hydrolyzed by butyrylcholinesterase."6.61Reversal of mivacurium-induced neuromuscular blockade with a cholinesterase inhibitor: A systematic review. ( Brinch, JHW; Gätke, MR; Madsen, MV; Söderström, CM, 2019)
"Cholinesterase inhibitors, such as neostigmine and edrophonium, commonly used to reverse the residual effects of nondepolarizing neuromuscular blocking drugs at the end of surgery are associated with a high rate of residual neuromuscular blockade (NMB)."5.94Sugammadex ( Chhabra, R; Gupta, LK; Gupta, R, 2024)
" Sugammadex exhibits advantages over indirect reversal agent acetylcholinesterase inhibitor neostigmine with less adverse effects."5.72Sugammadex reversal of muscle relaxant blockade provided less Post-Anesthesia Care Unit adverse effects than neostigmine/glycopyrrolate. ( Chang, HC; Lee, MJ; Lee, SO; Liu, SY; Wong, CS, 2022)
" There was no neostigmine-induced muscle paralysis in either group."5.69Routine administration of neostigmine after recovery of spontaneous breathing versus neuromuscular monitor-guided administration of neostigmine in pediatric patients: a parallel, randomized, controlled study. ( Chang, H; Hu, N; Yang, D; Yang, L; Zuo, Y, 2023)
" However, there is a paucity of evidence demonstrating possible effects of magnesium on neostigmine-induced recovery from neuromuscular blockade with rocuronium."5.69Effects of magnesium sulphate on neostigmine-induced recovery from moderate neuromuscular blockade with rocuronium: a randomized controlled trial. ( Chung, SH; Do, SH; Han, J; Park, HY; Shin, HJ, 2023)
" Participants aged 2 to <17 years, under moderate or deep neuromuscular blockade, were administered sugammadex (2 or 4 mg/kg) or neostigmine (50 µg/kg; for moderate neuromuscular blockade only)."5.51Sugammadex for reversal of neuromuscular blockade in pediatric patients: Results from a phase IV randomized study. ( DeAngelis, M; Hammer, GB; Herring, WJ; Saldien, V; Speek, M; Voss, T; Wang, A; Wrishko, R, 2022)
"The use of sugammadex at a lower dose after a routine reversal dose of neostigmine may prevent residual neuromuscular blockade (rNMB)."5.51Half-Dose Sugammadex After Neostigmine Versus Neostigmine as a Routine Reversal Agent: A Pilot Randomized Trial. ( Baysal, A; Dogukan, M; Ozkaynak, I; Sagıroglu, G, 2022)
" Sugammadex reversal of neuromuscular blockade is rapid and complete, and there appear to be fewer postoperative complications than with neostigmine."5.51Comparison of the effects of neostigmine and sugammadex on postoperative residual curarization and postoperative pulmonary complications by means of diaphragm and lung ultrasonography: a study protocol for prospective double-blind randomized controlled tr ( Chen, Y; Yi, J; Zhang, YG; Zhang, YL, 2022)
" Patients were randomly assigned to the control group (traditional linear processing for induction of anesthesia and OR cleaning and neuromuscular blockade reversal with neostigmine/glycopyrrolate) and the active group (parallel processing for induction of anesthesia and OR cleaning and neuromuscular blockade reversal with sugammadex)."5.51Reduction of Nonoperative Time Using the Induction Room, Parallel Processing, and Sugammadex: A Randomized Clinical Trial. ( Abi Shadid, C; Aouad, MT; Bou Ali, A; Bouez, J; Kaddoum, R; Karam, C; Shebbo, FM; Tarraf, S, 2022)
" The aim of the study is to comparison of neuromuscular blockade and reversal using cisatricurium and neostigmine with rocuronium and sugamadex on the quality of recovery from general anaesthesia for percutaneous closure of left atria appendage."5.51A comparison of neuromuscular blockade and reversal using cisatricurium and neostigmine with rocuronium and sugamadex on the quality of recovery from general anaesthesia for percutaneous closure of left atria appendage. ( Li, Q; Wu, D; Wu, J; Xie, H; Xu, M; Yao, H, 2022)
"Compared with neostigmine/glycopyrrolate, incidence of TE sinus bradycardia was significantly lower with sugammadex 2 mg/kg and incidence of TE sinus tachycardia was significantly lower with sugammadex 2 mg/kg and 4 mg/kg."5.41A randomized trial evaluating the safety profile of sugammadex in high surgical risk ASA physical class 3 or 4 participants. ( Blobner, M; Broussard, DM; Herring, WJ; Lin, L; Lombard, JF; Lutkiewicz, J; Mukai, Y; Wang, A; Watkins, M, 2021)
"To evaluate the effect of sugammadex compared with neostigmine on speed and quality of recovery after rocuronium neuromuscular blockade (NMB) in geriatric patients undergoing posterior lumbar spine surgery."5.41Comparison of recovery after sugammadex or neostigmine reversal of rocuronium in geriatric patients undergoing spine surgery: a randomized controlled trial. ( Choma, TJ; Mraovic, B; Timko, NJ, 2021)
"Meta-analysis of 40 trials with 5455 patients showed an overall lower risk of postoperative nausea and vomiting in the sugammadex group than in the neostigmine group (risk ratio: 0."5.41The effect of sugammadex versus neostigmine on postoperative nausea and vomiting: a meta-analysis of randomized controlled trials with trial sequential analysis. ( Hsieh, YL; Lin, CR; Liu, YC; Wang, CJ; Weng, WT, 2023)
"We concluded that sugammadex is more effective at reducing the incidence of PPCs including pneumonia, atelectasis, NIV and reintubation compared with neostigmine."5.41Postoperative pulmonary complications after sugammadex reversal of neuromuscular blockade: a systematic review and meta-analysis with trial sequential analysis. ( Liang, P; Liu, HM; Yu, H; Zuo, YD, 2023)
" The aim of this clinical investigation was to assess the incidence of postoperative residual neuromuscular blockade in adult thoracic surgical patients administered neostigmine or sugammadex when optimal dosing and reversal strategies for these agents were used."5.41Neuromuscular and Clinical Recovery in Thoracic Surgical Patients Reversed With Neostigmine or Sugammadex. ( Avram, MJ; Benson, J; Bilimoria, S; Greenberg, SB; Maher, CE; Murphy, GS; Szokol, JW; Teister, KJ, 2021)
"Despite the use of quantitative neuromuscular monitoring together with the administration of reversal drugs (neostigmine or sugammadex), the incidence of residual neuromuscular blockade defined as a train-of-four ratio (TOFr) <0."5.41Recovery of early postoperative muscle strength after deep neuromuscular block by means of ultrasonography with comparison of neostigmine versus sugammadex as reversal drugs: study protocol for a randomised controlled trial. ( Huang, C; Li, Y; Niu, L; Wang, X; Xiao, Y; Xiong, W; Zhou, Q, 2021)
"Eighty patients with thyroid neoplasms undergoing thyroidectomy were randomly allocated to sugammadex group (group S) or neostigmine group (group N)."5.41Effects of Sugammadex versus Neostigmine on Intraoperative Coagulation Profiles in Patients with Thyroidectomy. ( Chen, W; Fang, J; Lin, J; Wu, C; Xiong, W; Zhao, D, 2021)
"The incidence of postoperative nausea and vomiting (PONV) in PACU was higher in neostigmine-reversed than sugammadex-reversed patients (21."5.40Retrospective investigation of postoperative outcome after reversal of residual neuromuscular blockade: sugammadex, neostigmine or no reversal. ( De Mel, A; Falke, L; Gillies, E; Greenaway, M; Johnston, F; Ledowski, T; Phillips, M; Tiong, WS, 2014)
"Propofol is a widely used drug in anesthesia practice, and its pharmacological characteristics are well known."5.37Possible augmentation of neuromuscular blockade by propofol during recovery from rocuronium. ( Braehler, MR; Miller, RD; Ruschulte, H; Ward, TA, 2011)
"Neuromuscular blockade was induced with 0."5.37[Neostigmine-induced neuromuscular blockade in the corrugator supercilii muscle]. ( Carrascosa Fernández, AJ; García Miranda, MC; Gilsanz Rodríguez, F; Martínez Torrente, F; Pérez-Cerdá Silvestre, F, 2011)
"We examined and compared the incidence of residual neuromuscular blockade when the recommended dose of neostigmine or sugammadex was administered according to a qualitative nerve stimulator response."5.34Postoperative residual neuromuscular blockade after reversal based on a qualitative peripheral nerve stimulator response: A randomised controlled trial. ( Han, JW; Hong, JP; Koo, BW; Lee, YJ; Oh, AY; Park, JH; Seo, KS, 2020)
"Measures of postoperative strength, such as incentive spirometry, hand group strength, and the ability to sit up in the early postoperative period were not different in patients who received neostigmine or sugammadex for the reversal of neuromuscular blockade."5.34A randomized-controlled trial of sugammadex versus neostigmine: impact on early postoperative strength. ( Abola, RE; Bennett-Guerrero, E; Gupta, R; Lung, B; Rizwan, S; Romeiser, J, 2020)
"The use of neostigmine after neuromuscular blockade (NMB) has been associated with postoperative respiratory complications."5.30Respiratory muscle activity after spontaneous, neostigmine- or sugammadex-enhanced recovery of neuromuscular blockade: a double blind prospective randomized controlled trial. ( Janssens, K; Jorens, PG; Maes, S; Saldien, V; Schepens, T; Vellinga, J; Wildemeersch, D, 2019)
"To evaluate the influence of reversal of neuromuscular blockade with sugammadex or neostigmine on postoperative quality of recovery following a single bolus dose of rocuronium after pars plana vitrectomy (PPV) under general anesthesia."5.30Influence of reversal of neuromuscular blockade with sugammadex or neostigmine on postoperative quality of recovery following a single bolus dose of rocuronium: A prospective, randomized, double-blinded, controlled study. ( Bai, SJ; Hong, JH; Kim, NY; Kim, SS; Koh, JC; Lee, KY; Nam, HJ, 2019)
"In this single-center, experimental, randomized, controlled trial, ventilatory responses to 5-min hypoxia (oxygen saturation, 80 ± 2%) and ventilation at hyperoxic isohypercapnia (end-tidal carbon dioxide concentration, 55 mmHg) were obtained at baseline, during rocuronium-induced partial neuromuscular block (train-of-four ratio of 0."5.30Reversal of Partial Neuromuscular Block and the Ventilatory Response to Hypoxia: A Randomized Controlled Trial in Healthy Volunteers. ( Aarts, LPHJ; Boon, M; Broens, SJL; Dahan, A; Martini, CH; Niesters, M; van Velzen, M, 2019)
"This randomized controlled study compared the recovery times of sugammadex and neostigmine as antagonists of moderate rocuronium-induced neuromuscular block in patients with liver cirrhosis and controls undergoing liver resection."5.27Sugammadex antagonism of rocuronium-induced neuromuscular blockade in patients with liver cirrhosis undergoing liver resection: a randomized controlled study. ( Abdulatif, M; Afifi, MH; Lotfy, M; Mousa, M; Yassen, K, 2018)
" Registered on 18 June 2014, as "Evaluation of muscle function recovery after deep neuromuscular blockade by acceleromyography of the adductor pollicis or diaphragmatic echography: comparison between sugammadex and neostigmine."5.27Recovery of muscle function after deep neuromuscular block by means of diaphragm ultrasonography and adductor of pollicis acceleromyography with comparison of neostigmine vs. sugammadex as reversal drugs: study protocol for a randomized controlled trial. ( Adembri, C; Cappellini, I; Danti, G; De Gaudio, AR; Ostento, D; Picciafuochi, F, 2018)
"Calcium chloride coadministered with neostigmine enhanced neuromuscular recovery in the early period of nondepolarising neuromuscular blockade reversal."5.24Effects of calcium chloride coadministered with neostigmine on neuromuscular blockade recovery: A double-blind randomised study. ( Hong, DM; Ju, JW; Kim, HC; Park, HP; Yoon, S, 2017)
"This study aimed to assess the effects of sugammadex and neostigmine/atropine on postoperative cognitive dysfunction (POCD) in adult patients after elective surgery."5.24Effect of sugammadex versus neostigmine/atropine combination on postoperative cognitive dysfunction after elective surgery. ( Batistaki, C; Kostopanagiotou, G; Lyrakos, G; Matsota, P; Riga, M; Zafeiropoulou, F, 2017)
" The current trial was aimed to compare between sugammadex and neostigmine concerning the recovery time from neuromuscular blockade."5.24A comparison of sugammadex and neostigmine for reversal of rocuronium-induced neuromuscular blockade in children. ( Ammar, AS; Kasemy, ZA; Mahmoud, KM, 2017)
"Rocuronium for cesarean delivery under general anesthesia is an alternative to succinylcholine for rapid-sequence induction of anesthesia because of the availability of sugammadex for reversal of neuromuscular blockade."5.22Low-Dose or High-Dose Rocuronium Reversed with Neostigmine or Sugammadex for Cesarean Delivery Anesthesia: A Randomized Controlled Noninferiority Trial of Time to Tracheal Intubation and Extubation. ( Adamus, M; Bartikova, I; Francakova, J; Harazim, H; Hejduk, K; Hlozkova, J; Hodicka, Z; Janku, P; Kirchnerova, M; Klucka, J; Kosinova, M; Krikava, I; Mrozek, Z; Obare Pyszkova, L; Pavlik, T; Prochazka, M; Robotkova, H; Seidlova, D; Sevcik, P; Stoudek, R; Stourac, P, 2016)
"Adult patients undergoing abdominal surgery received rocuronium, followed by randomized allocation to sugammadex (2 or 4 mg kg(-1)) or usual care (neostigmine/glycopyrrolate, dosing per usual care practice) for reversal of neuromuscular blockade."5.20Effects of sugammadex on incidence of postoperative residual neuromuscular blockade: a randomized, controlled study. ( Brueckmann, B; de Bie, J; Eikermann, M; Grobara, P; Kwo, J; Lee, J; Li, MK; Maktabi, M; McGovern, F; Pino, R; Sabouri, AS; Sasaki, N; Staehr-Rye, AK; Woo, T, 2015)
"Seventy-four patients undergoing TURBT were randomly allocated to receive either glycopyrrolate 10 μg/kg (glycopyrrolate group, n = 37) or atropine 15 μg/kg (atropine group, n = 37) in combination with neostigmine 25 μg/kg at the end of surgery for reversal of neuromuscular blockade."5.20Effect of glycopyrrolate versus atropine coadministered with neostigmine for reversal of rocuronium on postoperative catheter-related bladder discomfort in patients undergoing transurethral resection of bladder tumor: a prospective randomized study. ( Kim, HC; Lim, SM; Park, HP; Seo, H, 2015)
"To compare the effects of neostigmine/atropine combination and sugammadex on intraocular pressure during tracheal extubation period."5.20Intraocular pressure changes associated with tracheal extubation: Comparison of sugammadex with conventional reversal of neuromuscular blockade. ( Canakci, E; Hanci, V; Karakahya, RH; Tas, N; Yagan, O; Yurtlu, BS, 2015)
"After elective ear surgery with cisatracurium neuromuscular blockade, 48 adults were randomly assigned to receive neostigmine: (a) at appearance of the fourth twitch of a 'train-of-four'; (b) at loss of fade to train-of-four; or (c) at loss of fade to double-burst stimulation, all monitored using a TOF-Watch SX® on one arm."5.20Timing of reversal with respect to three nerve stimulator end-points from cisatracurium-induced neuromuscular block. ( Do, SH; Hwang, JW; Jeon, YT; No, HJ; Oh, AY; Park, SH; Seo, KS; Song, IA, 2015)
"This study compared efficacy and safety of the selective relaxant binding agent sugammadex (2 mg/kg) with neostigmine (50 μg/kg) for neuromuscular blockade (NMB) reversal in Chinese and Caucasian subjects."5.19Rocuronium blockade reversal with sugammadex vs. neostigmine: randomized study in Chinese and Caucasian subjects. ( Abels, E; Claudius, C; Dahl, V; Huang, Y; Liu, J; Oerding, H; Rietbergen, H; Vanacker, B; Woo, T; Wu, X; Xiong, L; Yao, S; Yue, Y, 2014)
" We evaluated the role of sugammadex versus neostigmine in the quality of recovery from profound rocuronium-induced neuromuscular blockade (NMB) in patients with morbid obesity."5.17Sugammadex allows fast-track bariatric surgery. ( Carron, M; Foletto, M; Ori, C; Veronese, S, 2013)
"Sugammadex provided significantly faster reversal of vecuronium-induced neuromuscular blockade compared with neostigmine."5.14Sugammadex provides faster reversal of vecuronium-induced neuromuscular blockade compared with neostigmine: a multicenter, randomized, controlled trial. ( Alvarez-Gómez, JA; Khuenl-Brady, KS; Lora-Tamayo, JI; Rietbergen, H; Vanacker, BF; Wattwil, M, 2010)
" Reversal of neuromuscular blockade was achieved with neostigmine, either at 0."5.14Neostigmine injected 5 minutes after low-dose rocuronium accelerates the recovery of neuromuscular function. ( Khuenl-Brady, KS; Lederer, W; Reiner, T, 2010)
" This study assessed the efficacy and safety of sugammadex versus neostigmine for reversal of profound rocuronium-induced neuromuscular blockade."5.13Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine. ( Brull, SJ; Caldwell, JE; Jones, RK; Soto, RG, 2008)
"We investigated the influence of the timing of neostigmine administration on recovery from rocuronium or vecuronium neuromuscular blockade."5.09Early and late reversal of rocuronium and vecuronium with neostigmine in adults and children. ( Bevan, DR; Bevan, JC; Collins, L; de Scheepers, LD; Fowler, C; Kahwaji, R; Rosen, HD; Smith, MF; Stephenson, CA, 1999)
"The effects of neostigmine on the incidence of postoperative nausea and vomiting (PONV) are controversial."5.09The effects of antagonizing residual neuromuscular blockade by neostigmine and glycopyrrolate on nausea and vomiting after ambulatory surgery. ( Garg, SA; Hailey, A; Joshi, GP; Yu, SY, 1999)
" In this double-blind randomized trial, 30 ASA physical status I and II patients undergoing minor surgery received either atropine 20 micrograms/kg and neostigmine 50 micrograms/kg (Group A), glycopyrrolate 8 micrograms/kg and neostigmine 50 micrograms/kg (Group G), or placebo (Group P) for reversal of neuromuscular blockade."5.08The effects of reversal of neuromuscular blockade on autonomic control in the perioperative period. ( Parlow, JL; van Vlymen, JM, 1997)
"We performed this randomized, double-blind, placebo-controlled study to determine whether reversal of neuromuscular block with neostigmine increases the incidence and severity of postoperative nausea and vomiting (PONV)."5.08Reversal of neuromuscular blockade with neostigmine has no effect on the incidence or severity of postoperative nausea and vomiting. ( Halonen, P; Hovorka, J; Korttila, K; Nelskylä, K; Paatero, H; Sarvela, J; Soikkeli, A; Yli-Hankala, A, 1997)
"This report analyzes the comparative costs, efficacy and side effects of a newer, more expensive reversal drug, sugammadex, with its generic counterpart, neostigmine combined with glycopyrrolate, or no reversal agent when used routinely to reverse rocuronium-induced neuromuscular blockade in adult patients."5.05Sugammadex versus neostigmine for routine reversal of rocuronium block in adult patients: A cost analysis. ( Eckman, MH; Hurford, WE; Welge, JA, 2020)
"Neostigmine is the anticholinesterase drug most commonly used to reverse blockade or speed up recovery from neuromuscular blockade from nondepolarizing neuromuscular blocking drugs."4.98Atrio-ventricular Block Following Neostigmine-Glycopyrrolate Reversal in Non-heart Transplant Patients: Case Report. ( Nkemngu, NJ; Tochie, JN, 2018)
"Sugammadex has been introduced for reversal of neuromuscular blockade (NMB) induced by rocuronium (or vecuronium)."4.95Role of sugammadex in accelerating postoperative discharge: A meta-analysis. ( Carron, M; Lazzarotto, N; Ori, C; Tellaroli, P; Zarantonello, F, 2017)
" Glycopyrrolate (Robinul), which has been in short supply in recent years, is one of the most widely used anticholinergic agents, especially in conjunction with the anticholinesterase neostigmine, for reversal of neuromuscular blockade (NMB) drugs."4.95Glycopyrrolate: It's time to review. ( D'mello, J; Howard, J; Rosen, G; Wigley, J, 2017)
"Acetylcholinesterase inhibitors (neostigmine, edrophonium) and encapsulating agents (sugammadex and calabadion) can be used to reverse residual neuromuscular blockade (NMB)."4.93Reversing neuromuscular blockade: inhibitors of the acetylcholinesterase versus the encapsulating agents sugammadex and calabadion. ( Eikermann, M; Haerter, F, 2016)
"Sugammadex has been introduced for reversal of rocuronium (or vecuronium)-induced neuromuscular blockade (NMB)."4.93Efficacy and safety of sugammadex compared to neostigmine for reversal of neuromuscular blockade: a meta-analysis of randomized controlled trials. ( Carron, M; Ori, C; Tellaroli, P; Zarantonello, F, 2016)
"We reviewed systematically sugammadex vs neostigmine for reversing neuromuscular blockade."4.91A systematic review of sugammadex vs neostigmine for reversal of neuromuscular blockade. ( Abad-Gurumeta, A; Calvo-Vecino, JM; Casans-Francés, R; Espinosa, A; Fernández-Pérez, C; López-Timoneda, F; Martínez-Hurtado, E; Ramírez, JM; Ripollés-Melchor, J, 2015)
" Some anaesthesiologists use neostigmine to reverse neuromuscular blockade for all paediatric surgical patients."4.90Neostigmine for reversal of neuromuscular block in paediatric patients. ( Li, Q; Lu, D; Yang, D; Yang, L; Zuo, Y, 2014)
" The results suggest that, compared with placebo or neostigmine, sugammadex can more rapidly reverse rocuronium-induced neuromuscular blockade regardless of the depth of the block."4.86Cochrane corner: sugammadex, a selective reversal medication for preventing postoperative residual neuromuscular blockade. ( Abrishami, A; Chung, F; Ho, J; Wong, J; Yin, L, 2010)
" Sugammadex is a A-cyclodextrin designed to encapsulate rocuronium bromide, providing a rapid reversal of neuromuscular blockade."4.85A novel approach to reversal of neuromuscular blockade. ( Della Rocca, G; Pompei, L, 2009)
" The results suggest that, compared with placebo or neostigmine, sugammadex can more rapidly reverse rocuronium-induced neuromuscular blockade regardless of the depth of the block."4.85Sugammadex, a selective reversal medication for preventing postoperative residual neuromuscular blockade. ( Abrishami, A; Chung, F; Ho, J; Wong, J; Yin, L, 2009)
"Non-depolarizing neuromuscular blockade can be reversed with neostigmine/glycopyrrolate or sugammadex."4.31Effects of Reversal Technique for Neuromuscular Paralysis on Time to Recovery of Bowel Function after Craniotomy. ( Deljou, A; Schroeder, DR; Soleimani, J; Sprung, J; Weingarten, TN, 2023)
"During general anaesthesia for VATS, compared with cisatracurium and neostigmine, use of rocuronium and sugammadex was associated with a significant decrease in the incidence of postoperative delayed removal of the chest tube, atelectasis, and pulmonary consolidation."4.31Use of rocuronium and sugammadex for video-assisted thoracoscopic surgery is associated with reduced duration of chest tube drainage: a propensity score-matched analysis. ( Chin, JC; Huang, CJ; Huang, SC; Illias, AM; Lu, HI; Shih, TH; Wang, PM; Wu, EB; Wu, SC, 2023)
"In 2020, the Sugammadex vs Neostigmine for Reversal of Neuromuscular Blockade and Postoperative Pulmonary Complications (STRONGER) study provided evidence for the first time that use of sugammadex is associated with fewer postoperative pulmonary complications than use of neostigmine."4.31How robust are the STRONGER and STIL-STRONGER studies? ( Blobner, M; Hunter, JM; Ulm, K, 2023)
"We aimed to compare the effect of sugammadex to that of neostigmine with respect to the occurrence of postoperative nausea and vomiting (PONV) during the first 24 h following general anesthesia."4.31Effects of sugammadex versus neostigmine on postoperative nausea and vomiting after general anesthesia in adult patients:a single-center retrospective study. ( Cho, HY; Hwang, IE; Ju, JW; Kim, WH; Lee, HJ; Yang, SM, 2023)
"Sugammadex and neostigmine given to reverse residual neuromuscular blockade can cause side effects including bradycardia, anaphylaxis, bronchospasm, and even cardiac arrest."4.12Sugammadex Versus Neostigmine for Reversal of Residual Neuromuscular Blocks After Surgery: A Retrospective Cohort Analysis of Postoperative Side Effects. ( Chahar, P; Chhabada, S; Khanna, S; Li, K; Maheshwari, K; Ruetzler, K; Schmidt, MT; Sessler, DI; Turan, A; Yang, D, 2022)
"The aim of this study was to determine whether use of acceleromyography (1) changes dosing of neuromuscular blocking agents (NMBAs), and (2) increases the time between neostigmine administration and extubation, when compared with subjective assessment of neuromuscular blockade."4.12Vigilance: the behavioral impact of quantitative monitoring on administration and antagonism of neuromuscular blocking agents. ( Grivoyannis, AD; Lien, CA; Tangel, V, 2022)
" Two groups were defined: 1) monitoring + reversal of the neuromuscular blockade (M+R) group: all patients receiving neuromuscular blockade monitoring plus reversal of it with any drug (neostigmine or sugammadex) were included; and 2) no monitoring nor reversal (noM+noR) group."4.02Neuromuscular blockade management and postoperative outcomes in enhanced recovery colorectal surgery: secondary analysis of POWER trial. ( Abad-Gurumeta, A; Aldecoa, C; Bordonaba-Bosque, D; Cabellos-Olivares, M; DÍaz-Cambronero, Ó; Gil-Trujillo, S; JordÁ, L; MartÍnez-Ubieto, J; Melchor-RipollÉs, J; Ramirez-Rodriguez, JM; Rodriguez, R; SÁnchez-Merchante, M; Serrano, AB, 2021)
" We compared the incidence of PPCs between patients receiving neostigmine (neostigmine group) and those receiving sugammadex (sugammadex group) as a neuromuscular blockade reversal agent."4.02Sugammadex versus neostigmine on postoperative pulmonary complications after robot-assisted laparoscopic prostatectomy: a propensity score-matched analysis. ( Hwang, JH; Kim, YK; Lee, Y; Park, JY; Yu, J, 2021)
"Nondepolarizing neuromuscular blockade is reversed with neostigmine/glycopyrrolate or sugammadex."4.02Urinary Retention Following Inguinal Herniorrhaphy: Role of Neuromuscular Blockade Reversal. ( Ghanem, OM; Heller, SF; Schroeder, DR; Sprung, J; Stewart, BR; Valencia Morales, DJ; Weingarten, TN, 2021)
" The authors hypothesized that the choice of neuromuscular blockade reversal (neostigmine vs."3.96Sugammadex versus Neostigmine for Reversal of Neuromuscular Blockade and Postoperative Pulmonary Complications (STRONGER): A Multicenter Matched Cohort Analysis. ( Bardia, A; Bartels, K; Bash, LD; Colquhoun, DA; Dubovoy, TZ; Kheterpal, S; Mathis, MR; McCormick, PJ; Saager, L; Schonberger, RB; Shah, NJ; Shanks, AM; Soto, RG; Vaughn, MT, 2020)
"Fewer cases of bradycardia were observed in the sugammadex group compared to the neostigmine group in the overall cohort (P < ."3.91Retrospective Analysis of the Safety and Efficacy of Sugammadex Versus Neostigmine for the Reversal of Neuromuscular Blockade in Children. ( Brenn, BR; Donahue, BS; Gartley, A; Gaver, RS, 2019)
" The automated MedDRA query method showed no apparent increase in hypersensitivity or anaphylaxis with sugammadex as compared to placebo or neostigmine."3.88Incidence of hypersensitivity and anaphylaxis with sugammadex. ( Adkinson, F; Assaid, C; Gurner, DM; Herring, WJ; McCrea, J; Min, KC; Sisk, CM; Woo, T, 2018)
"Inappropriate dosing of neostigmine for antagonism of neuromuscular blockade has been associated with postoperative pulmonary complications."3.88Implementation of a new strategy to improve the peri-operative management of neuromuscular blockade and its effects on postoperative pulmonary complications. ( Agarwala, AV; Chitilian, HV; Doney, AB; Eikermann, M; Houle, TT; Ng, PY; Ramachandran, SK; Rudolph, MI; Timm, FP, 2018)
"The objective of this systematic review is to identify the effectiveness of sugammadex versus neostigmine on the reversal of rocuronium-induced neuromuscular blockade in surgical patients with myasthenia gravis undergoing general anesthesia."3.88Effectiveness of sugammadex versus neostigmine on restoration of neuromuscular function in surgical patients with myasthenia gravis undergoing rocuronium-induced neuromuscular blockade: a systematic review protocol. ( Badeaux, J; Martin, J; Schiavo, JH; Yellott, E, 2018)
"To summarize and compare efficacy of sugammadex with neostigmine or placebo for reversal of rocuronium- or vecuronium-induced neuromuscular blockade (NMB), and to demonstrate consistency of sugammadex results across various patient populations."3.85Sugammadex efficacy for reversal of rocuronium- and vecuronium-induced neuromuscular blockade: A pooled analysis of 26 studies. ( Assaid, CA; Blobner, M; Herring, WJ; Khuenl-Brady, KS; Lemmens, HJ; Lupinacci, RJ; Woo, T, 2017)
"Neuromuscular blockade (NMB) reversal with neostigmine and glycopyrrolate has been reported to cause cardiac arrest in patients with a history of cardiac transplantation."3.83The Safety of Neuromuscular Blockade Reversal in Patients With Cardiac Transplantation. ( Barbara, DW; Christensen, JM; Dearani, JA; Hyder, JA; Mauermann, WJ, 2016)
" We also examined if dosing regimens reflect current practice guidelines of using ideal body weight (IBW) for NMB agents and total body weight (TBW) for neostigmine."3.83Observational study on patterns of neuromuscular blockade reversal. ( Devine, S; Dubovoy, T; Housey, M; Kheterpal, S, 2016)
" She developed a prolonged and deep neuromuscular blockade, which was antagonized three hours later with neostigmine."3.83Prolonged neuromuscular block in a preeclamptic patient induced by magnesium sulfate. ( Berdai, MA; Harandou, M; Labib, S, 2016)
"Residual paralysis is common at tracheal extubation and PACU arrival, despite qualitative neuromuscular monitoring and the use of neostigmine."3.81The RECITE Study: A Canadian Prospective, Multicenter Study of the Incidence and Severity of Residual Neuromuscular Blockade. ( Chaput, A; de Médicis, É; Fortier, LP; Galarneau, A; Jones, PM; McKeen, D; Pouliot, JF; Turner, K; Warriner, B, 2015)
"Prospective observational series of consecutive patients scheduled for laparoscopic bariatric surgery in whom neuromuscular blockade was reverted with sugammadex were compared with a historical matched cohort of patients reverted with neostigmines."3.80Postoperative respiratory outcomes in laparoscopic bariatric surgery: comparison of a prospective group of patients whose neuromuscular blockade was reverted with sugammadex and a historical one reverted with neostigmine. ( Cabrera, A; Camprubí, I; Ferreres, E; Llauradó, S; Sabaté, A, 2014)
" Neostigmine was used to antagonize rocuronium-induced neuromuscular blockade in the first phase, and sugammadex was used in the second phase."3.79Reversal with sugammadex in the absence of monitoring did not preclude residual neuromuscular block. ( Kotake, Y; Nakatsuka, I; Ochiai, R; Ogawa, S; Ozaki, M; Suzuki, T; Takagi, S; Takeda, J, 2013)
"It was a prospective comparative clinical study carried out in the Department of Anaesthesia, Combined Military Hospital (CMH), Dhaka, to evaluate the heart rate changes during reversal of neuromuscular blockade by using 3 different doses of atropine (in a mixture with neostigmine) and thereby detect comparatively safer dose."3.77Different doses of atropine on heart rate fluctuations during reversal of neuromuscular blockade. ( Haque, MM; Islam, MA; Islam, MR; Rashid, MH; Shahida, SM, 2011)
"We investigated the differences between males and females in the reversal effect of neostigmine on neuromuscular blockade."3.75Reversal of vecuronium with neostigmine: a comparison between male and female patients. ( Aoki, K; Hirama, T; Isosu, T; Murakawa, M; Okazaki, M; Saitoh, Y, 2009)
" Neostigmine and calcium antagonized the neuromuscular blockade caused by gentamicin, but augmented that caused by clindamycin."3.74Calcium and neostigmine antagonize gentamicin, but augment clindamycin-induced tetanic fade in rat phrenic nerve-hemidiaphragm preparations. ( Lee, JH; Lee, JM; Lee, SC; Lee, SI, 2008)
"The purpose of this study was to compare neostigmine-induced reversal of vecuronium in normal weight, overweight and obese female patients."3.73Neostigmine-induced reversal of vecuronium in normal weight, overweight and obese female patients. ( Masaki, G; Ogawa, S; Suzuki, T, 2006)
"Reversal of vecuronium-induced neuromuscular blockade with neostigmine was compared in two groups of 16 subjects: patients with Type 2 diabetes mellitus and normal controls."3.72Reversal of vecuronium with neostigmine in patients with diabetes mellitus. ( Akatu, M; Hattori, H; Murakawa, M; Nakajima, H; Saitoh, Y; Sanbe, N, 2004)
"To investigate the relationship between total body weight (TBW) or body mass index (BMI) and atracurium reversal time."3.70Antagonism of atracurium-induced block in obese patients. ( Kirkegaard-Nielsen, H; Lindholm, P; Petersen, HS; Severinsen, IK, 1998)
" The optimal positioning of these thumb pressure sensing (TPS) devices and their sensitivity and accuracy during onset, spontaneous (partial) recovery and pharmacologic reversal of NMB, were determined in anesthetized patients during muscle relaxation (Vecuronium) and reversal (Neostigmine)."3.69Simple and cost effective clinical methods for measuring neuromuscular fade responses with emphasis on "train of four" fade. ( Gyermek, L, 1997)
"Both streptomycin and dihydrostreptomycin in large doses produced neuromuscular blockade in different types of skeletal nerve-muscle preparations."3.64Neuromuscular blockade by streptomycin and dihydrostreptomycin. ( DESHPANDE, VR; JINDAL, MN, 1960)
"Benzoquinonium (Mytolon) has been shown to produce a curare-like rather than a decamethonium-like paralysis of neuromuscular transmission in the tibialis anterior and soleus muscle of cats and the gastrocnemius muscle of hens."3.63The neuromuscular blocking action of benzoquinonium chloride in the cat and in the hen. ( BOWMAN, WC, 1958)
"Neostigmine is a widely used antagonist, but its optimal dose for elderly patients is unclear."3.30Optimal dose of neostigmine antagonizing cisatracurium-induced shallow neuromuscular block in elderly patients: a randomized control study. ( Cao, M; Huang, H; Liao, Y; Ou, Y; Tong, J, 2023)
"Sugammadex-induced bradycardia is common and, in most instances, of minimal clinical consequence."3.01Clarifying the grey space of sugammadex induced bradycardia. ( Chacin, R; Johnson, KB, 2023)
"Pulmonary complications related to residual neuromuscular blockade lead to morbidity and mortality."2.94Neostigmine Versus Sugammadex for Reversal of Neuromuscular Blockade and Effects on Reintubation for Respiratory Failure or Newly Initiated Noninvasive Ventilation: An Interrupted Time Series Design. ( Bartels, K; Bullard, KJ; Fernandez-Bustamante, A; Jameson, LC; Krause, M; Mayes, LM; McWilliams, SK; Mikulich-Gilbertson, SK, 2020)
"Sugammadex decreased residual neuromuscular block (10% vs 49%; OR=0."2.94Randomised controlled trial of sugammadex or neostigmine for reversal of neuromuscular block on the incidence of pulmonary complications in older adults undergoing prolonged surgery. ( Aziz, MF; Higgins, JR; Tekkali, P; Togioka, BM; Treggiari, MM; Yanez, D, 2020)
"Neostigmine was intravenously injected in the post-anesthesia care unit (PACU) according to the train-of-four ratio (TOFR) T4/T1."2.94The effects of neostigmine on postoperative cognitive function and inflammatory factors in elderly patients - a randomized trial. ( Deng, C; Feng, Y; Sun, D; Sun, Z; Yang, L; Zhu, B, 2020)
"Median [interquartile range (IQR)] atelectasis area was 9."2.90Effects of neuromuscular block reversal with sugammadex versus neostigmine on postoperative respiratory outcomes after major abdominal surgery: a randomized-controlled trial. ( Alday, E; Alvarez, C; Mata, E; Muñoz, M; Planas, A, 2019)
"When edrophonium was used, no cases of recurarization were observed."2.84Effects of neostigmine or edrophonium on force of contraction when administered at a train-of-four ratio of 0.9 in anesthetized dogs. ( Campoy, L; Gleed, RD; Martin-Flores, M; Romano, M; Sakai, DM; Tseng, CT, 2017)
"This hypotonia has been linked to muscle relaxants and volatile anesthetics and may persist in spite of neostigmine administration and train-of-four (TOF) monitoring suggesting full reversal."2.82Postoperative hypotonia in a patient with stiff person syndrome: a case report and literature review. ( Backman, SB; Elsherbini, N; Weingartshofer, A, 2022)
"Neostigmine was not able to fulfil the end points."2.82Sugammadex and neostigmine dose-finding study for reversal of residual neuromuscular block at a train-of-four ratio of 0.2 (SUNDRO20)†,. ( Baumüller, E; Blobner, M; Fink, H; Kaufhold, N; Schaller, SJ; Stäuble, CG; Ulm, K, 2016)
"Postoperative residual neuromuscular blockade (RNMB) is a common complication in the postanesthesia care unit (PACU), but also one of the most controversial issues."2.82Cisatracurium- and rocuronium-associated residual neuromuscular dysfunction under intraoperative neuromuscular monitoring and postoperative neostigmine reversal: a single-blind randomized trial. ( Barbieri, S; Feltracco, P; Frigo, AC; Ori, C; Tonetti, T, 2016)
" The dose-response relationship was analyzed with a biexponential model using the dose as the independent variable and the logarithm of the recovery time as the dependent variable."2.75Sugammadex and neostigmine dose-finding study for reversal of shallow residual neuromuscular block. ( Blobner, M; Fink, H; Schaller, SJ; Ulm, K, 2010)
"Fentanyl was continued at the designated rate through the initial postoperative phase."2.71Effect-site concentration of propofol for recovery of consciousness is virtually independent of fentanyl effect-site concentration. ( Iwakiri, H; Matsukawa, T; Nagata, O; Ozaki, M; Sessler, DI, 2003)
"Rapacuronium is a new, rapid-onset, short-duration, nondepolarizing neuromuscular blocking drug."2.70A comparison of neuromuscular effects, tracheal intubating conditions, and reversibility of rapacuronium versus mivacurium in female patients. ( Coppens, S; Geerts, E; van Iersel, M; Vanacker, BF, 2002)
"Cisatracurium is a new nondepolarizing muscle relaxant."2.68A comparison of cisatracurium and atracurium: onset of neuromuscular block after bolus injection and recovery after subsequent infusion. ( Buzello, W; Diefenbach, C; Mellinghoff, H; Radbruch, L, 1996)
"Mivacurium infusion was titrated to give a 90% block of first twitch height."2.68Recovery from mivacurium block with or without anticholinesterase following continuous infusion in obstetric patients. ( Chan, AM; Hui, TW; Jan, GS; Lo, JW; Tong, WN, 1996)
" We have examined the dose-response relationships for neostigmine antagonism of 90% rocuronium-induced neuromuscular block in children and adults, during nitrous oxide-1 MAC of isoflurane anaesthesia."2.68Dose-response relationships for neostigmine antagonism of rocuronium-induced neuromuscular block in children and adults. ( Abdulatif, M; al-Ghamdi, A; el-Sanabary, M; Mowafi, H, 1996)
" Peripherally acting acetylcholinesterase inhibitors such as neostigmine should then only be administered when indicated and dosed based on results of the train-of-four ratio."2.66The effects of acetylcholinesterase inhibitors on morbidity after general anesthesia and surgery. ( Eikermann, M; Schaefer, MS; Shay, D; Wongtangman, K, 2020)
"Postoperative residual neuromuscular block (train of four ratio <0."2.61[Algorithm-based preventive strategies for avoidance of residual neuromuscular blocks]. ( Ehehalt, K; Graf, B; Unterbuchner, C, 2019)
"Mivacurium is a short-acting non-depolarizing muscle relaxant, which is hydrolyzed by butyrylcholinesterase."2.61Reversal of mivacurium-induced neuromuscular blockade with a cholinesterase inhibitor: A systematic review. ( Brinch, JHW; Gätke, MR; Madsen, MV; Söderström, CM, 2019)
"Even small degrees of residual neuromuscular blockade, i."2.55[Residual neuromuscular blockade]. ( Fuchs-Buder, T; Schmartz, D, 2017)
"The management of neuromuscular blocks in day case surgery requests a comprehensive approach that should include an adequate dosing of the muscle relaxant, quantitative objective monitoring, and a sufficient and appropriate reversal."2.50Management of neuromuscular blockade in ambulatory patients. ( Schreiber, JU, 2014)
"Neostigmine was administered if no fade was detected in the TOF response at the thumb."1.91Evaluation of a Protocol for the Management of Maintenance and Reversal of Rocuronium Block Using Neostigmine or Sugammadex. ( Bhananker, SM; Cain, KC; Kruse, TN; Liang, T; Thilen, SR; Treggiari, MM, 2023)
"Rocuronium (0."1.72Investigation of potential neuropharmacological activity of neostigmine-glycopyrrolate for intraoperative neural monitoring in thyroid surgery. ( Chai, YJ; Choi, HS; Dionigi, G; Huang, TY; Kim, HY; Lee, JM; Oh, MY; Seo, M; Won, D; Wu, CW, 2022)
"Due to excessive sugammadex expenditures at our institution, we designed dosing guidelines that utilize adjusted body weight and informatics-based tools aimed at reducing variability in dosing practices."1.72Use of provider education, intra-operative decision support, and an email-feedback system in improving compliance with sugammadex dosage guideline and reducing drug expenditures. ( Clifton, JC; Gupta, RK; Pregnall, AM; Wanderer, JP, 2022)
" Sugammadex exhibits advantages over indirect reversal agent acetylcholinesterase inhibitor neostigmine with less adverse effects."1.72Sugammadex reversal of muscle relaxant blockade provided less Post-Anesthesia Care Unit adverse effects than neostigmine/glycopyrrolate. ( Chang, HC; Lee, MJ; Lee, SO; Liu, SY; Wong, CS, 2022)
"Neostigmine is a non-specific broad-spectrum and inexpensive reversal agent for neuromuscular blocking agents (NMBAs)."1.72A comparison between cisatracurium and rocuronium-induced neuromuscular block on laryngeal electromyography recovery after neostigmine reversal in a porcine model. ( Chai, YJ; Chang, PY; Chiang, FY; Dionigi, G; Huang, TY; Lu, IC; Tan, H; Tseng, HY; Wang, JJ; Wu, CW; Wu, SH, 2022)
" Inappropriate dosing of neostigmine can lead to post-operative respiratory complications."1.62Identifying high dose neostigmine as a risk factor for post-operative respiratory complications: a case-control study. ( Al-Zarah, M; Drzymalski, DM; Hall III, RR; Quraishi, SA; Ranjan, S, 2021)
"Complete avoidance of residual neuromuscular blockade (RNMB) during the postoperative period has not yet been achieved in current anesthesia practice."1.51Usefulness of intra-operative neuromuscular blockade monitoring and reversal agents for postoperative residual neuromuscular blockade: a retrospective observational study. ( Domenech, G; Fornari, GG; García Guzzo, ME; Kampel, MA; Novas, DS; Terrasa, SA, 2019)
"Improved understanding of the monitoring and dosing practices of anesthesia providers regarding neuromuscular blockade is necessary."1.51Evaluating a Quality Improvement Initiative to Increase Anesthesia Providers' Use of and Understanding of Quantitative Neuromuscular Monitors. ( Bedsworth, MB; Goode, VM; Grant, SA; Harris, EM; Thompson, JA; Vacchiano, CA, 2019)
" The goal of our study was to investigate the real-world practice pattern of dosing of neuromuscular blocking agents (NMBA), utilizing the amount of NMBA used during the course of a case, adjusted for patient weight and case duration, as a surrogate measure of depth of NMB."1.51Investigation of intraoperative dosing patterns of neuromuscular blocking agents. ( Beutler, SS; Gimlich, R; Palsen, S; Urman, RD; Wu, A; Yang, HK, 2019)
"Neostigmine was administered in adjusted doses after a train-of-four count of four was confirmed at the thumb."1.48Management of rocuronium neuromuscular block using a protocol for qualitative monitoring and reversal with neostigmine. ( Bhananker, SM; Cain, KC; Ng, IC; Thilen, SR; Treggiari, MM, 2018)
"The incidence of postoperative nausea and vomiting (PONV) in PACU was higher in neostigmine-reversed than sugammadex-reversed patients (21."1.40Retrospective investigation of postoperative outcome after reversal of residual neuromuscular blockade: sugammadex, neostigmine or no reversal. ( De Mel, A; Falke, L; Gillies, E; Greenaway, M; Johnston, F; Ledowski, T; Phillips, M; Tiong, WS, 2014)
"A 59-year-old man with chronic renal failure underwent the ascending colectomy."1.37[Neuromuscular blockade after a chain of two laparotomies in a few hours]. ( Saito, A; Takahashi, H; Yamazaki, Y, 2011)
"Propofol is a widely used drug in anesthesia practice, and its pharmacological characteristics are well known."1.37Possible augmentation of neuromuscular blockade by propofol during recovery from rocuronium. ( Braehler, MR; Miller, RD; Ruschulte, H; Ward, TA, 2011)
"Neuromuscular blockade was maintained with rocuronium (visual train-of-four [TOF] count of 2) and all subjects were reversed with neostigmine at a TOF count of 2-4."1.33Residual paralysis at the time of tracheal extubation. ( Avram, MJ; Franklin, M; Marymont, JH; Murphy, GS; Szokol, JW; Vender, JS, 2005)
"Rapacuronium is a new non-depolarizing relaxant with a fast onset and rapid recovery."1.31Rapacuronium: first experience in clinical practice. ( Bartkowski, RR; Witkowski, TA, 2001)

Research

Studies (360)

TimeframeStudies, this research(%)All Research%
pre-199010 (2.78)18.7374
1990's25 (6.94)18.2507
2000's36 (10.00)29.6817
2010's165 (45.83)24.3611
2020's124 (34.44)2.80

Authors

AuthorsStudies
Oh, MY1
Lee, JM2
Won, D1
Huang, TY2
Wu, CW2
Dionigi, G2
Kim, HY1
Seo, M1
Choi, HS1
Chai, YJ2
Hile, GB1
Healy, KJ1
Almassalkhi, LR1
Herring, WJ4
Mukai, Y1
Wang, A2
Lutkiewicz, J1
Lombard, JF1
Lin, L1
Watkins, M1
Broussard, DM1
Blobner, M6
Bash, LD7
Black, W2
Turzhitsky, V2
Urman, RD4
Voss, T1
DeAngelis, M1
Speek, M1
Saldien, V3
Hammer, GB1
Wrishko, R1
Mraovic, B1
Timko, NJ1
Choma, TJ1
Deljou, A1
Soleimani, J1
Sprung, J5
Schroeder, DR2
Weingarten, TN2
Pregnall, AM1
Gupta, RK1
Clifton, JC1
Wanderer, JP2
Ruetzler, K3
Li, K1
Chhabada, S1
Maheshwari, K1
Chahar, P1
Khanna, S3
Schmidt, MT2
Yang, D4
Turan, A3
Sessler, DI3
Beltran, RJ1
Mpody, C1
Nafiu, OO1
Tobias, JD2
Sreedharan, R1
Carron, M10
Tessari, I1
Linassi, F3
Baysal, A1
Sagıroglu, G1
Dogukan, M1
Ozkaynak, I1
Weigel, WA2
Williams, BL1
Hanson, NA1
Blackmore, CC1
Johnson, RL1
Nissen, GM1
James, AB1
Strodtbeck, WM1
Ranjan, S1
Hall III, RR1
Al-Zarah, M1
Quraishi, SA1
Drzymalski, DM2
Sonny, A1
Bose, S2
Vishneski, SR1
Saha, AK1
Fram, MR1
Templeton, LB1
Lee, LK1
Ririe, DG1
Goenaga-Diaz, EJ1
Smith, LD1
Templeton, TW1
Powell, L1
Kidd, L1
Zhang, YG1
Chen, Y2
Zhang, YL1
Yi, J1
Chang, HC1
Liu, SY1
Lee, MJ1
Lee, SO1
Wong, CS1
Yu, Y1
Wang, H1
Bao, Q1
Zhang, T1
Chen, B1
Ding, J1
Colquhoun, DA2
Vaughn, MT3
Janda, A1
Shah, N1
Ghaferi, A1
Sjoding, M1
Mentz, G2
Kheterpal, S5
Sharma, A1
Campos, JH1
Kaddoum, R1
Tarraf, S1
Shebbo, FM1
Bou Ali, A1
Karam, C1
Abi Shadid, C1
Bouez, J1
Aouad, MT2
Togioka, BM3
Schenning, KJ1
Elsherbini, N1
Weingartshofer, A1
Backman, SB1
Lu, IC1
Tan, H1
Wu, SH1
Tseng, HY1
Wang, JJ1
Chiang, FY1
Chang, PY1
Li, Q2
Yao, H1
Wu, J1
Xu, M1
Xie, H1
Wu, D1
Wu, EB1
Huang, SC1
Lu, HI1
Illias, AM1
Wang, PM1
Huang, CJ1
Shih, TH1
Chin, JC1
Wu, SC1
Traeger, L1
Hall, TD1
Bedrikovetski, S1
Kroon, HM1
Dudi-Venkata, NN1
Moore, JW1
Sammour, T1
Gonzalez-Estrada, A1
Carrillo-Martin, I1
Morgenstern-Kaplan, D1
Garzon-Siatoya, WT1
Renew, JR4
Hernandez-Torres, V1
Volcheck, GW1
Moro, ET1
da Mata Lucena, G1
de Souza, MAR1
Bona, JE1
Benette, GL1
Yang, JL1
Chen, KB1
Shen, ML1
Hsu, WT1
Lai, YW1
Hsu, CM1
Neira-Somoza, P1
Lopez-Lopez, D1
Hunter, JM5
Ulm, K3
Huang, C3
Wang, X2
Gao, S1
Luo, W1
Zhao, X1
Zhou, Q2
Huang, W1
Xiao, Y2
Fuchs-Buder, T8
Romero, CS1
Lewald, H1
Lamperti, M1
Afshari, A2
Hristovska, AM2
Schmartz, D3
Hinkelbein, J1
Longrois, D1
Popp, M1
de Boer, HD7
Sorbello, M1
Jankovic, R1
Kranke, P1
Özbey, NB3
Abdullah, T3
Deligöz, Ö3
Ho, AM3
Klar, G3
Mizubuti, GB3
Azimaraghi, O3
Ahrens, E3
Wongtangman, K3
Witt, AS3
Rupp, S2
Suleiman, A3
Tartler, TM3
Wachtendorf, LJ3
Fassbender, P2
Choice, C1
Houle, TT5
Eikermann, M13
Schaefer, MS4
Munoz-Acuna, R1
Chen, G1
Azizi, BA1
Shay, D2
Linhardt, FC1
Blank, M1
Nabel, SY1
Chao, JY1
Goriacko, P1
Mirhaji, P1
Sidebotham, D1
Frampton, C1
Yang, L3
Hu, N1
Chang, H1
Zuo, Y2
Paredes, S4
Rössler, J1
Mukhia, R1
Pu, X2
Mao, G2
Tan, J1
He, J1
Wang, L1
Fang, J2
Li, P1
Song, Z1
Bian, Q1
Hsieh, YL1
Lin, CR1
Liu, YC1
Wang, CJ1
Weng, WT1
Martin-Flores, M6
Hackman, MC1
Araos, JD1
Campoy, L4
Gleed, RD3
Chhabra, R1
Gupta, R2
Gupta, LK1
Han, D1
Xie, S1
Wang, LK1
Lin, YT1
Chen, JT1
Lan, W1
Hung, KC1
Chen, JY1
Liu, KJ1
Yen, YC1
Chou, YY1
Cherng, YG1
Tam, KW1
Ju, JW2
Hwang, IE1
Cho, HY1
Yang, SM1
Kim, WH1
Lee, HJ1
Liu, H1
Luo, R1
Cao, S1
Zheng, B1
Ye, L1
Zhang, W2
Tamburini, E1
Ieppariello, G3
Liu, HM1
Yu, H1
Zuo, YD1
Liang, P1
Díaz-Cambronero, Ó3
Mazzinari, G1
Errando, CL1
Garutti, I1
Gurumeta, AA1
Serrano, AB2
Esteve, N1
Montañes, MV1
Neto, AS1
Hollmann, MW1
Schultz, MJ1
Argente Navarro, MP1
Thilen, SR3
Liang, T1
Kruse, TN1
Cain, KC2
Treggiari, MM3
Bhananker, SM2
Gaston, IN1
Lange, EMS1
Farrer, JR1
Toledo, P1
Bartels, K6
Fernandez-Bustamante, A4
Vidal Melo, MF1
Ji, Y1
Yuan, H1
Zhang, X1
Wu, F1
Tang, W1
Lu, Z1
Todd, MM1
Kopman, AF5
Torres, VH2
Chaves-Cardona, H2
Matus, M1
Porter, S2
Johnson, KB1
Chacin, R1
Bai, YX1
Han, JJ1
Liu, J4
Li, X1
Xu, ZZ1
Lv, Y1
Liu, KX1
Wu, QP1
Cao, M1
Huang, H1
Tong, J1
Ou, Y1
Liao, Y1
Brown, SES1
Spellman, K1
Cassidy, R1
Nause-Osthoff, R1
Bailey, M1
Wagner, D1
Haydar, B1
Chimbira, W1
Colquhoun, D1
Chowdhury, S1
Baidya, D1
Han, J1
Park, HY1
Shin, HJ1
Chung, SH1
Do, SH2
Domenech, G1
Kampel, MA1
García Guzzo, ME1
Novas, DS1
Terrasa, SA1
Fornari, GG1
Arslantas, R1
Cevik, BE1
Fernandes, HDS1
Ximenes, JLS1
Nunes, DI1
Ashmawi, HA1
Vieira, JE1
Gaver, RS1
Brenn, BR1
Gartley, A1
Donahue, BS1
Bedsworth, MB1
Harris, EM1
Vacchiano, CA1
Thompson, JA1
Grant, SA1
Goode, VM1
Schepens, T3
Janssens, K1
Maes, S1
Wildemeersch, D2
Vellinga, J1
Jorens, PG3
Unterbuchner, C1
Ehehalt, K1
Graf, B1
Krause, M3
McWilliams, SK1
Bullard, KJ1
Mayes, LM1
Jameson, LC1
Mikulich-Gilbertson, SK1
Williams, WH1
Cata, JP1
Lasala, JD1
Navai, N1
Feng, L1
Gottumukkala, V1
Lee, YJ1
Oh, AY5
Koo, BW3
Han, JW2
Park, JH1
Hong, JP1
Seo, KS4
Cammu, GV2
Klewais, LR1
Vandeput, DM1
Foubert, LA1
Alsuhebani, M1
Sims, T1
Hansen, JK1
Hakim, M1
Walia, H1
Miller, R1
Tumin, D1
Oh, TK3
Ryu, JH2
Nam, S1
Yanez, D1
Aziz, MF1
Higgins, JR1
Tekkali, P1
Yorulmaz, IS1
Demiraran, Y1
Özlü, O1
Dost, B1
Pereira, R1
Salgado-Seixas, F1
Esteves, S2
Trzcinka, A1
Schumann, R1
Azocar, RJ1
Dubovoy, TZ1
Shah, NJ1
Shanks, AM1
Mathis, MR1
Soto, RG2
Bardia, A1
McCormick, PJ1
Schonberger, RB1
Saager, L4
Leslie, K2
Boggett, S1
Chahal, R1
Griffiths, J1
Lin, J2
Wang, D1
Williams, Z1
Riedel, B1
Bowyer, A1
Royse, A1
Royse, C1
Abola, RE1
Romeiser, J1
Rizwan, S1
Lung, B1
Bennett-Guerrero, E1
De Cassai, A2
Hunt, ME1
Yates, JR1
Vega, H1
Heidel, RE1
Buehler, JM1
Buonanno, P1
Vargas, M1
Marra, A1
Iacovazzo, C1
Servillo, G1
Xu, X2
Banner-Goodspeed, V1
Raval, AD1
Anupindi, VR1
Ferrufino, CP1
Arper, DL1
Brull, SJ6
Min, BH1
Song, IA2
Jeon, YT2
Suzuki, K1
Takazawa, T1
Saito, S1
Bray, JP1
Adams, DR1
Phadke, AS1
Adams, PS1
Porter, SB1
Porter, IE1
Li, L2
Jiang, Y2
Hurford, WE1
Welge, JA1
Eckman, MH1
Zhu, B2
Sun, D1
Sun, Z1
Feng, Y1
Deng, C1
Karim, HMR1
Bhakta, P1
O'Brien, B1
Esquinas, AM1
Li, G1
Freundlich, RE1
Murphy, GS3
Avram, MJ2
Greenberg, SB1
Bilimoria, S1
Benson, J1
Maher, CE1
Teister, KJ1
Szokol, JW2
Melchor-RipollÉs, J1
Abad-Gurumeta, A3
Ramirez-Rodriguez, JM1
MartÍnez-Ubieto, J2
SÁnchez-Merchante, M1
Rodriguez, R1
JordÁ, L1
Gil-Trujillo, S1
Cabellos-Olivares, M1
Bordonaba-Bosque, D1
Aldecoa, C1
Li, Y1
Xiong, W2
Niu, L1
Zhao, D1
Chen, W1
Wu, C1
Yu, J1
Park, JY1
Lee, Y1
Hwang, JH1
Kim, YK1
Choi, SR1
Kim, JH1
Lee, KH1
Park, SY1
Bartlett, E1
Urits, I1
Kaye, AD1
Viswanath, O1
Story, DA1
Parker, A1
Chen, PF1
Lin, MC1
Luo, SC1
Shen, CH1
Farag, E1
Rivas, E1
Bravo, M1
Hussain, S2
Argalious, M1
Seif, J1
Bain, M1
Elgabaly, M1
Esa, WAS1
Ledowski, T2
Szabó-Maák, Z1
Loh, PS1
Turlach, BA1
Yang, HS1
Asztalos, L1
Shariffuddin, II1
Chan, L1
Fülesdi, B1
Grivoyannis, AD1
Tangel, V1
Lien, CA1
Suganuma, E1
Ishikawa, T1
Kitamura, Y1
Hayashida, T1
Matsumura, T1
Fujie, M1
Nozaki-Taguchi, N1
Sato, Y1
Isono, S1
Valencia Morales, DJ1
Stewart, BR1
Heller, SF1
Ghanem, OM1
Raft, J1
Anastasy, C1
Lambaudie, E1
Saillio, E1
Mackosso, C1
Petrica, N1
Le Dissez, C1
Alfonsi, P1
Olesnicky, BL1
Lindberg, A1
Marroquin-Harris, FB1
Ren, K1
Alfahel, WS1
Kaddoum, RN1
Siddik-Sayyid, SM1
Choi, ES2
Hwang, JW3
Ahn, SH1
Jeong, WJ1
Zarantonello, F2
Lazzarotto, N1
Tellaroli, P2
Ori, C6
Marshall, SD2
Serpell, J2
Cumberworth, A1
Caruso, LJ1
Reed, H1
Zhang, RV1
Veiga Ruiz, G1
García Cayuela, J1
Orozco Montes, J1
Parreño Caparrós, M1
García Rojo, B1
Aguayo Albasini, JL1
Kim, HC2
Yoon, S1
Hong, DM1
Park, HP2
Woo, T4
Assaid, CA1
Lupinacci, RJ1
Lemmens, HJ1
Khuenl-Brady, KS3
Batistaki, C2
Riga, M1
Zafeiropoulou, F1
Lyrakos, G1
Kostopanagiotou, G2
Matsota, P1
Belcher, AW1
Leung, S1
Cohen, B1
Mascha, EJ1
Romano, M1
Sakai, DM1
Tseng, CT1
Naguib, M4
Dahan, A5
Boon, M5
Martini, C2
Prielipp, RC1
Bailey, CR1
Paech, MJ2
Kaye, R2
Baber, C2
Nathan, EA1
Duch, P1
Allingstrup, M1
Bertoncello, F1
Abdulatif, M2
Lotfy, M1
Mousa, M1
Afifi, MH1
Yassen, K1
Cappellini, I2
Picciafuochi, F1
Ostento, D2
Danti, G1
De Gaudio, AR2
Adembri, C2
Min, KC1
Assaid, C1
McCrea, J1
Gurner, DM1
Sisk, CM1
Adkinson, F1
Rudolph, MI1
Chitilian, HV1
Ng, PY1
Timm, FP1
Agarwala, AV1
Doney, AB1
Ramachandran, SK1
Ng, IC1
Nicolardot, J1
Engelman, E1
Coeckelenbergh, S1
Jungels, C1
Baurain, M1
Palsen, S1
Wu, A1
Beutler, SS1
Gimlich, R1
Yang, HK1
Nathan, E1
Zealley, K1
Taylor, A1
Raju, P1
Rodney, G1
Kent, NB1
Liang, SS1
Phillips, S1
Smith, NA1
Khandkar, C1
Stewart, PA1
Nkemngu, NJ1
Tochie, JN1
Yellott, E1
Badeaux, J1
Martin, J1
Schiavo, JH1
Carlos, RV1
Brinch, JHW1
Söderström, CM1
Gätke, MR2
Madsen, MV1
Maiese, EM1
Meyer, TA1
Minkowitz, H1
Groudine, S1
Philip, BK1
Tanaka, P1
Gan, TJ1
Rodriguez-Blanco, Y1
Soto, R1
Heisel, O1
Szental, JA1
Bramley, D1
Kopman, A1
Franz, AM1
Chiem, J1
Martin, LD1
Rampersad, S1
Phillips, J1
Grigg, EB1
Kim, NY1
Koh, JC1
Lee, KY1
Kim, SS1
Hong, JH1
Nam, HJ1
Bai, SJ1
Broens, SJL1
Martini, CH3
Niesters, M2
van Velzen, M2
Aarts, LPHJ1
Alday, E1
Muñoz, M1
Planas, A1
Mata, E1
Alvarez, C1
Ji, E1
Na, HS1
Richardson, MG1
Raymond, BL1
Kim, D1
Ahn, JH1
Jung, H1
Choi, KY1
Jeong, JS1
Xia, R1
Kachru, N1
Tuazon, DM1
Bostan, F1
Fuentes, A1
Loriga, B1
Tofani, L1
Honing, G1
Bom, A2
Aarts, L2
Øberg, E1
Claudius, C2
Aarts, LP1
Bevers, RF1
Veronese, S1
Foletto, M1
Donati, F4
Kotake, Y2
Ochiai, R1
Suzuki, T4
Ogawa, S3
Takagi, S1
Ozaki, M3
Nakatsuka, I1
Takeda, J3
Baumann, C1
De Guis, J1
Guerci, P1
Meistelman, C5
Thompson, CA1
Della Rocca, G3
Pompei, L2
Pagan DE Paganis, C1
Tesoro, S1
Mendola, C1
Boninsegni, P1
Tempia, A1
Manstretta, S1
Zamidei, L1
Gratarola, A1
Murabito, P1
Fuggiano, L1
DI Marco, P1
Arkes, HR1
Webster, CS1
Baraka, A2
Van Gestel, L1
Cammu, G3
Dubois, PE3
Mulier, JP1
Falke, L1
Johnston, F1
Gillies, E1
Greenaway, M1
De Mel, A1
Tiong, WS1
Phillips, M1
Llauradó, S1
Sabaté, A1
Ferreres, E1
Camprubí, I1
Cabrera, A1
Lorenzutti, AM2
Baldivieso, JM1
Himelfarb, MA1
Litterio, NJ2
Bennett, A1
Booij, LH4
Nagelhout, JJ1
Lu, D1
Cassel, J1
Staehr-Rye, AK2
Nielsen, CV1
De Neve, N2
Foubert, L2
Vercauteren, M1
Amorim, P1
Lagarto, F1
Gomes, B1
Bismarck, J1
Rodrigues, N1
Nogueira, M1
Wu, X2
Oerding, H1
Vanacker, B1
Yao, S1
Dahl, V1
Xiong, L1
Yue, Y1
Huang, Y1
Abels, E1
Rietbergen, H4
Schreiber, JU1
Fortier, LP1
McKeen, D1
Turner, K1
de Médicis, É1
Warriner, B1
Jones, PM1
Chaput, A1
Pouliot, JF1
Galarneau, A2
Brueckmann, B1
Sasaki, N1
Grobara, P1
Li, MK1
de Bie, J1
Maktabi, M1
Lee, J1
Kwo, J1
Pino, R1
Sabouri, AS1
McGovern, F1
Jones, RS1
Auer, U1
Mosing, M1
Boden, E1
Toniolo, A1
Lim, SM1
Seo, H1
Welliver, M1
Tentes, P1
Deligiannidi, P1
Karakosta, A1
Florou, P1
Gupta, D1
Yu, B1
Ouyang, B1
Ge, S1
Luo, Y1
Li, J1
Ni, D1
Hu, S1
Xu, H1
Min, S1
Ma, Z1
Xie, K1
Miao, C1
Ortega-Lucea, S1
Pascual-Bellosta, A1
Arazo-Iglesias, I1
Gil-Bona, J1
Jimenez-Bernardó, T1
Muñoz-Rodriguez, L1
Ripollés-Melchor, J1
Casans-Francés, R1
Espinosa, A1
Martínez-Hurtado, E1
Fernández-Pérez, C1
Ramírez, JM1
López-Timoneda, F1
Calvo-Vecino, JM1
Yagan, O1
Karakahya, RH1
Tas, N1
Canakci, E1
Hanci, V1
Yurtlu, BS1
No, HJ1
Park, SH1
Paré, MD1
Barbara, DW1
Christensen, JM1
Mauermann, WJ1
Dearani, JA1
Hyder, JA1
Kaufhold, N1
Schaller, SJ2
Stäuble, CG1
Baumüller, E1
Fink, H2
Haerter, F1
Kim, BG1
Stourac, P1
Adamus, M2
Seidlova, D1
Pavlik, T1
Janku, P1
Krikava, I1
Mrozek, Z1
Prochazka, M1
Klucka, J1
Stoudek, R1
Bartikova, I1
Kosinova, M1
Harazim, H1
Robotkova, H1
Hejduk, K1
Hodicka, Z1
Kirchnerova, M1
Francakova, J1
Obare Pyszkova, L1
Hlozkova, J1
Sevcik, P1
Montague, J1
Halloran, C1
Cheng, Z1
Preault, A1
Capron, F1
Chantereau, C1
Dimet, J1
Rossetti, VL1
Zarazaga, MP1
Bonetto, CC1
Aguirre, GE1
Sen, A1
Erdivanli, B1
Tomak, Y1
Pergel, A1
Bulka, CM1
Terekhov, MA1
Martin, BJ1
Dmochowski, RR1
Hayes, RM1
Ehrenfeld, JM1
Broens, S1
van Rijnsoever, E1
van der Zwan, T1
Gunduz Gul, G1
Ozer, AB1
Demirel, I1
Aksu, A1
Erhan, OL1
Nemes, R1
Dubovoy, T1
Housey, M1
Devine, S1
Insinga, RP1
Joyal, C1
Goyette, A1
Putz, L1
Dransart, C1
Jamart, J1
Marotta, ML1
Delnooz, G1
Feltracco, P1
Tonetti, T1
Barbieri, S1
Frigo, AC1
Berdai, MA1
Labib, S1
Harandou, M1
Howard, J1
Wigley, J1
Rosen, G1
D'mello, J1
Ammar, AS1
Mahmoud, KM1
Kasemy, ZA1
Muggleton, E1
Muggleton, T1
Bronsert, MR1
Henderson, WG1
Monk, TG1
Richman, JS1
Nguyen, JD1
Sum-Ping, JT1
Mangione, MP1
Higley, B1
Hammermeister, KE1
Zaremba, S1
Malhotra, A1
Jordan, AS1
Rosow, C1
Chamberlin, NL1
Jones, RK1
Caldwell, JE1
Lee, SI1
Lee, JH2
Lee, SC1
Lee, C1
Katz, RL1
Mizutani, H1
Miyake, E1
Fukano, N1
Saeki, S1
Wattwil, M1
Vanacker, BF2
Lora-Tamayo, JI1
Alvarez-Gómez, JA1
Abrishami, A2
Ho, J2
Wong, J2
Yin, L2
Chung, F2
El-Moursy, SA1
Shawky, HM1
Abdel Wahab, Z1
Rashed, L1
Debaene, B1
Plaud, B1
Alla, F1
Grandjean, A1
Wuthrich, Y1
Alvarez Gómez, JA1
Ariño Irujo, JJ1
Errando Oyonarte, CL1
Matínez Torrente, F1
Roigé i Solé, J1
Gilsanz Rodríguez, F2
Baso, AC1
Serra, CS1
Oliveira, AC1
Savarese, JJ1
McGilvra, JD1
Sunaga, H1
Belmont, MR1
Van Ornum, SG1
Savard, PM1
Heerdt, PM1
Saitoh, Y2
Aoki, K1
Okazaki, M1
Hirama, T1
Isosu, T1
Murakawa, M2
Meretoja, OA3
Eriksson, LI1
Scholz, J1
Motsch, J1
Prins, ME2
Lederer, W1
Reiner, T1
Paton, F1
Paulden, M1
Chambers, D1
Heirs, M1
Duffy, S1
Sculpher, M1
Woolacott, N1
Illman, HL1
Laurila, P2
Antila, H1
Alahuhta, S1
Olkkola, KT1
Herbstreit, F1
Zigrahn, D1
Ochterbeck, C1
Peters, J1
Yamazaki, Y1
Saito, A1
Takahashi, H1
Ruschulte, H1
Ward, TA1
Miller, RD1
Braehler, MR1
Schwartz, AE1
Martínez Torrente, F2
Carrascosa Fernández, AJ1
García Miranda, MC1
Pérez-Cerdá Silvestre, F1
Hrabalek, L1
Wanek, T1
Gabrhelik, T1
Zapletalova, J1
Gaszynski, T1
Szewczyk, T1
Gaszynski, W1
Islam, MA1
Shahida, SM1
Islam, MR1
Haque, MM1
Rashid, MH2
Parotto, E1
Fabregat-López, J2
Ortiz-Gómez, JR2
Velázquez-Gil María, D1
Aho, AJ1
Kamata, K1
Yli-Hankala, A2
Lyytikäinen, LP1
Kulkas, A1
Jäntti, V1
Dahaba, AA1
Bornemann, H1
Hopfgartner, E1
Ohran, M1
Kocher, K1
Liebmann, M1
Wilfinger, G1
Metzler, H1
Watts, RW1
London, JA1
van Wijk, RM1
Lui, YL1
Geldner, G2
Niskanen, M1
Mizikov, V1
Hübler, M1
Beck, G1
Nicolayenko, E1
Jain, A1
Sahni, N1
Banik, S1
Solanki, SL1
Lal Solanki, S1
de Menezes, CC1
Peceguini, LA1
Silva, ED1
Simões, CM1
Smet, V1
De Jongh, K1
Vandeput, D1
McHugh, SM1
Ibinson, JW1
Jain, D1
Gandhi, K1
Stewart, PJ1
Laird, R1
Torlot, FJ1
Iwakiri, H1
Nagata, O1
Matsukawa, T1
Ingvast-Larsson, JC1
Axén, VC1
Kiessling, AK1
Fawcett, WJ2
Stone, JP1
KOHN, R1
BOVET, D1
HOUGS, W1
JOHANSEN, SH1
BOWMAN, WC1
JINDAL, MN1
DESHPANDE, VR1
ICHIYANAGI, K1
KANAI, H1
ITO, Y1
KUBIKOWSKI, P1
SZRENIAWSKI, Z1
PANDEY, K1
KUMAR, S1
BADOLA, RP1
BONO, F1
LANZETTA, A1
MAGGI, U1
MAPELLI, A1
Hokkanen, E1
PETERSON, DI1
HARDINGE, MG1
TILTON, BE1
Hattori, H1
Sanbe, N1
Nakajima, H1
Akatu, M1
Vasella, FC1
Frascarolo, P1
Spahn, DR1
Magnusson, L1
Wu, HL1
Ye, TH1
Hao, RR1
Ramirez, JG1
Keegan, MT1
Hall, BA1
Bourke, DL1
Marymont, JH1
Franklin, M1
Vender, JS1
Kido, K1
Mizuta, K1
Mizuta, F1
Yasuda, M1
Igari, T1
Takahashi, M1
van Egmond, J1
van de Pol, F1
Masaki, G1
Sacan, O1
White, PF2
Tufanogullari, B1
Klein, K1
Nicholson, WT1
Jankowski, CJ1
Flockton, EA1
Mastronardi, P1
Gomar, C1
Mirakhur, RK4
Aguilera, L1
Giunta, FG1
Baurain, MJ1
Dernovoi, BS1
D'Hollander, AA1
Hennart, DA1
Cantraine, FR1
Osmer, C1
Vogele, C1
Zickmann, B1
Hempelmann, G1
Taivainen, T1
Wirtavuori, K1
Mellinghoff, H1
Radbruch, L1
Diefenbach, C1
Buzello, W1
Jan, GS1
Tong, WN1
Chan, AM1
Hui, TW1
Lo, JW1
van Vlymen, JM1
Parlow, JL1
Mowafi, H1
al-Ghamdi, A1
el-Sanabary, M1
Gyermek, L1
Izawa, H1
Fukushima, K1
Hovorka, J1
Korttila, K1
Nelskylä, K1
Soikkeli, A1
Sarvela, J1
Paatero, H1
Halonen, P1
Kirkegaard-Nielsen, H2
Lindholm, P2
Petersen, HS1
Severinsen, IK2
D'Honneur, G1
Lofaso, F1
Drummond, GB1
Rimaniol, JM1
Aubineau, JV1
Harf, A1
Duvaldestin, P1
Muir, AW1
Sleigh, T1
Marshall, RJ1
Pow, E1
Anderson, KA1
Hill, DR1
Watcha, MF1
Carroll, MT2
Lowry, D1
Glover, P1
Kerr, CJ1
Castellani, WJ1
Srinivasan, V1
Udayashankar, S1
Fruergaard, K1
Viby-Mogensen, J1
Berg, H1
el-Mahdy, AM1
Pleym, H1
Bathen, J1
Spigset, O1
Gisvold, SE1
Ziegenfuss, T1
Lysakowski, K1
Tassonyi, E1
Bevan, JC1
Collins, L1
Fowler, C1
Kahwaji, R1
Rosen, HD1
Smith, MF1
de Scheepers, LD1
Stephenson, CA1
Bevan, DR1
Jain, AK1
Ahuja, S1
Joshi, GP1
Garg, SA1
Hailey, A1
Yu, SY1
Pedersen, HS1
McCourt, KC1
Lowry, DW1
Sparr, HJ1
Driessen, JJ1
Robertson, EN1
Hayes, A1
Breslin, D1
Reid, J1
McNicholas, JJ1
Harban, FM1
Laothong, C1
Sitprija, V1
Mencke, T1
Bartkowski, RR1
Witkowski, TA1
Geerts, E1
Coppens, S1
van Iersel, M1

Clinical Trials (87)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase 4 Randomized, Active-Comparator Controlled Clinical Trial to Study the Safety of Sugammadex (MK-8616) for the Reversal of Neuromuscular Blockade Induced by Either Rocuronium Bromide or Vecuronium Bromide in American Society of Anesthesiologists (A[NCT03346057]Phase 4344 participants (Actual)Interventional2017-12-20Completed
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex (MK-8616) for Reversal of Neuromuscular Blockade in Pediatric Participants[NCT03351608]Phase 4288 participants (Actual)Interventional2018-02-12Completed
A Prospective, Randomized, Double-Blind Clinical Trial Evaluating the Speed of Recovery and Safety of Reversal of Neuromuscular Blockade With Sugammadex (Bridion™) Versus Neostigmine in Geriatric Patients Undergoing Spine Surgery[NCT03112993]Phase 440 participants (Actual)Interventional2017-05-30Completed
Sugammadex Reversal VS Neostigmine and Glycopyrrolate Competitive Antagonism of Neuromuscular Blockade for GI-2 Recovery After Bowel Resection: Prospective, Randomized, Triple-blinded Clinical Trial for Quality Improvement[NCT06112353]Phase 4128 participants (Anticipated)Interventional2023-11-30Not yet recruiting
Comparison of the Effects of Neostigmine and Sugammadex on Postoperative Residual Curarization and Postoperative Pulmonary Complications Detected by Diaphragm and Lung Ultrasonography: A Study Protocol for Prospective Double-blind Randomized Controlled Tr[NCT05040490]414 participants (Anticipated)Interventional2021-08-31Not yet recruiting
Redesigned Process in the Operating Room: Monitoring and Evaluating Success of Reducing Non Operative Time[NCT01937247]Phase 2/Phase 3120 participants (Actual)Interventional2018-05-18Completed
The ED95 Dose Determined by Classical Train-of-four Ratio of Sugammadex to Reverse Rocuronium-Induced Deep Neuromuscular Block Back to Shallow Neuromuscular Block[NCT05841316]40 participants (Anticipated)Observational [Patient Registry]2023-10-31Not yet recruiting
Sugammadex and the Diaphragm: Recovery of Diaphragmatic Function and Neuromuscular Blockade. A Double-blind Randomized Controlled Trial[NCT01962298]Phase 375 participants (Actual)Interventional2013-10-31Completed
Efficiency And Quality In Post-Surgical Pain Therapy After Discharge[NCT05221866]711 participants (Actual)Interventional2022-03-14Completed
The Effect of Deep Neuromuscular Blockade With Sugammadex Reversal on Shoulder Pain of Elderly Patients Undergoing Robotic Surgery: A Single-Center Double-Blinded Randomized Controlled Trial[NCT03210376]Phase 4100 participants (Actual)Interventional2017-11-17Completed
Risk Factors for Postoperative Shoulder-tip Pain After Laparoscopic Surgery Undergoing General Anesthesia[NCT04386603]1,311 participants (Actual)Observational [Patient Registry]2019-06-01Completed
Monitoring of Postoperative Residual Neuromuscular Blockade in Laparoscopic Surgery: Comparison of Neostigmine and Sugammadex[NCT03292965]80 participants (Actual)Interventional2017-09-28Completed
The Effect of Sugammadex Versus Neostigmine on Postoperative Pulmonary Complications in Patients 70 Years or Older and Scheduled for 3 Hour or Longer Surgery-A Randomized Controlled Trial[NCT02861131]Phase 4200 participants (Actual)Interventional2017-01-24Completed
A Randomized Trial of Deep Neuromuscular Blockade Reversed With Sugammadex Versus Moderate Neuromuscular Block Reversed With Neostigmine, on Postoperative Quality of Recovery[NCT03034577]Phase 4350 participants (Actual)Interventional2017-06-16Completed
Pulmonary Function, Muscle Strength, Time to Extubation and Quality of Recovery in the Post Anesthesia Care Unit After Reversal of Neuromuscular Blockade With Neostigmine or Sugammadex.[NCT02909439]Phase 480 participants (Actual)Interventional2016-11-30Completed
Diaphragm Ultrasound to Evaluate the Antagonistic Effect of Sugammadex on Rocuronium After Liver Surgery in Patients With Different Liver Child-Pugh Grades[NCT05028088]Phase 499 participants (Anticipated)Interventional2021-07-01Recruiting
A Prospective Randomized Blinded Controlled Trial Comparing Clinical Outcomes in Cardiac Surgical Patients Who Receive Sugammadex vs. Placebo[NCT05801679]Phase 3175 participants (Anticipated)Interventional2023-07-03Recruiting
Reversal of Neuromuscular Blockade in Thoracic Surgical Patients[NCT01837498]200 participants (Actual)Observational2014-02-28Completed
Sugammadex Versus Neostigmine for Reversal of Rocuronium Neuromuscular Block in Patients Having Catheter-based Neurointerventional Procedures[NCT03322657]Phase 469 participants (Actual)Interventional2017-11-14Completed
"Low Dose Sugammadex Combined With Neostigmine and Glycopyrrolate Versus Full Dose Sugammadex for Reversal of Rocuronium-induced Neuromuscular Blockade: a Cost Saving Strategy"[NCT02375217]Phase 456 participants (Actual)Interventional2014-10-31Completed
The Reversal of Residual Neuromuscular Blockade After Neostigmine and Half-dose Sugammadex: A Comparison With Standard Reversal of Full-dose Neostigmine[NCT05066035]Phase 4113 participants (Actual)Interventional2013-05-01Completed
Comparison Sugammadex With Neostigmine in Laryngeal Microsurgery.[NCT02330172]44 participants (Actual)Interventional2014-05-31Completed
Comparison of the Effect of Continuous Infusion and Bolus Doses of Rocuronium During Anesthesia for Lumbal Discectomy on Muscle Strength and Quality of Patient Recovery[NCT04236050]80 participants (Actual)Interventional2015-12-31Completed
Comparison of General Anesthesia With Use of Muscle Relaxation and General Anesthesia Without Muscle Relaxation on Recovery of Muscle Strength of the Patients[NCT04760912]60 participants (Anticipated)Interventional2020-04-01Enrolling by invitation
Comparison of the TOFCuff Monitor Versus Electromyography in Neuromuscular Monitoring[NCT04282213]32 participants (Actual)Observational2020-01-15Completed
The Comparison of the TOF Cuff Monitor® With the TOF Watch SX® Monitor:[NCT03256955]40 participants (Actual)Interventional2017-06-23Completed
PACU or ICU for Postoperative Care After Major Thoracic and Abdominal Surgery：a Prospective Randomized Clinical Trial[NCT05046925]18,000 participants (Anticipated)Observational2021-10-01Not yet recruiting
Influence of the Neuromuscular Blockade and Its Reversal on Perioperative Arrhythmias[NCT04720573]80 participants (Actual)Interventional2019-06-01Completed
Recovery of Muscle Function After Deep Neuromuscular Block by Means of Dia-phragm Ultrasonography and Adductor Pollicis Acceleromyography: Comparison of Neostigmine vs. Sugammadex as Reversal Drugs.[NCT02698969]Phase 458 participants (Anticipated)Interventional2014-11-30Recruiting
Validation of the REPS Prediction Tool to Improve Quality of Perioperative Care[NCT03585400]101,510 participants (Actual)Observational2018-06-29Completed
Importance of Understanding Provider Variability in the Use of Neuromuscular Blocking Drugs and Reversal Agents[NCT03585348]265,537 participants (Actual)Observational2018-06-29Completed
Incidence and Severity of Residual Neuromuscular Blockade With Application of a Protocol for Paralysis and Neostigmine Reversal of Rocuronium[NCT02660398]Phase 478 participants (Actual)Interventional2016-01-31Completed
Sugammadex Dosing: Anaesthesiologist Clinical Perception Versus Quantitative Monitoring[NCT04762420]66 participants (Actual)Observational2019-02-01Completed
Comparison the Postoperative Quality of Recovery Between Neostigmine and Sugammadex in Elderly Patients Undergoing Trans Pars Plana Vitrectomy With General Anesthesia -Randomized Controlled Trial-[NCT03108989]90 participants (Actual)Interventional2017-02-08Completed
Maternal and Fetal Outcomes of Sugammadex Administration During Pregnancy: A Retrospective Cohort Study[NCT05708469]35 participants (Anticipated)Observational2023-03-15Not yet recruiting
Effect of Deep BLock on Intraoperative Surgical Conditions, Perioperative Hemodynamic Status and Respiratory Parameters Following Reversal With Sugammadex in Patients Undergoing Laparoscopic Renal and Prostate Surgery.[NCT01631149]Phase 424 participants (Actual)Interventional2012-06-30Completed
Effect of Deep Neuromuscular Blockade on Surgical Conditions and Recovery After Robotic Radical Prostatectomy: a Prospective Randomized Study[NCT02513693]Phase 480 participants (Anticipated)Interventional2015-07-31Recruiting
Comparing Deep Neuromuscular Block and Moderate Neuromuscular Block in Patients Undergoing Laparoscopic Gynaecological Surgeries: Impact on Surgical Satisfaction of Operating Conditions and Patient Satisfaction[NCT02794714]Phase 40 participants (Actual)Interventional2016-06-30Withdrawn (stopped due to unresolved budget issues)
The Effect of Sugammadex Versus Neostigmine During Neuromuscular Blockade Reversal in Outpatient Surgeries - An Evaluation of Clinical and Associated Health Care Cost[NCT03579589]Phase 140 participants (Actual)Interventional2018-08-15Completed
Assessment of Residual Paralysis in Patients Who Receive Mini-dose Atracurium During Supraglottic Airway Insertion[NCT02673853]337 participants (Actual)Observational2016-02-29Completed
The Effectiveness of Neostigmine on the Recovery of Rocuronium-Induced Neuromuscular Blockade: A Comparison Between Partial Dose and TOF Ratio-Based Adjustment Dose[NCT03058263]Phase 1/Phase 266 participants (Actual)Interventional2016-10-31Completed
Development of an Algorithm Using Clinical Tests to Avoid Post-operative Residual Neuromuscular Block[NCT03219138]265 participants (Actual)Interventional2008-01-08Completed
Comparison of Weight-based Versus External Ear-size Based Technique for Selection of Laryngeal Mask Airway in Pediatric Surgical Patients.[NCT03931122]136 participants (Anticipated)Interventional2019-12-11Recruiting
A Randomized, Blinded-assessor, Single Center Study to Determine if Administration of Sugammadex, When Used to Reverse Deep Neuromuscular Blockade (NMB) After Open Abdominal Surgery, Impacts Hospital Efficiency[NCT02860507]Phase 450 participants (Actual)Interventional2016-08-31Completed
Electromyographic Activity of the Diaphragm and of the Rectus Abdominis and Intercostal Muscles During Neostigmine, Sugammadex, or Neostigmine-sugammadex Enhanced Recovery After Neuromuscular Blockade With Rocuronium. A Randomised Controlled Study in Heal[NCT02403063]Phase 418 participants (Actual)Interventional2015-09-30Completed
Visualization of Regional Lung Ventilation During Neostigmine or Sugammadex Enhanced Recovery From Moderate Residual Neuromuscular Blockade in the Anaesthetized Rat Using Functional Respiratory Imaging[NCT02284412]Phase 413 participants (Actual)Interventional2014-12-31Completed
The VivaSight Double Lumen Tube Versus Conventional Double Lumen Tube in Thoracic Surgical Patients[NCT03690284]50 participants (Actual)Interventional2019-06-19Completed
A Multi-center, Randomized, Parallel-group, Active-controlled, Safety-assessor Blinded Trial, Comparing the Efficacy and Safety of 2.0 mg.Kg-1 Sugammadex With 50 μg.Kg-1 Neostigmine Administered at Reappearance of T2 After Rocuronium in Chinese and Europe[NCT00825812]Phase 3308 participants (Actual)Interventional2010-01-31Completed
Accessor Blinded Randomized Controlled Study Evaluating the Efficacy and Safety of Sugammadex in High-Risk Ambulatory Surgeries[NCT03944473]Phase 40 participants (Actual)Interventional2019-06-20Withdrawn (stopped due to Stopped before IRB approval)
Residual Curarization and Its Incidence at Tracheal Extubation[NCT01318382]Phase 4302 participants (Actual)Interventional2011-06-30Completed
Effect of Sugammadex Compared With Usual Care for Reversal of Neuromuscular Blockade Induced by Rocuronium on Incidence of Residual Blockade at PACU Entry[NCT01479764]Phase 3154 participants (Actual)Interventional2011-12-02Completed
Does Deep Neuromuscular Blockade Improve Operating Conditions During Total Hip Replacements?[NCT03219294]Phase 4116 participants (Actual)Interventional2017-05-01Completed
Effect of Glycopyrrolate and Atropine as Adjuncts to Reversal of Non-Depolarizing Neuromuscular Blocking Agents on Postoperative Catheter-Related Bladder Discomfort[NCT02228473]76 participants (Anticipated)Interventional2014-09-30Recruiting
Residual Curarization and Its Incidence at Tracheal Extubation in China[NCT01871064]1,571 participants (Actual)Observational2012-12-31Completed
Efficacy and Safety of Sugammadex (2mg/kg) to Shorten Time-to-extubation Among Postoperative ICU Patients Following AVR, CABG Surgery, or AVR/CABG Surgery- a Prospective Randomized Placebo-controlled Trial.[NCT03196167]Phase 490 participants (Actual)Interventional2017-05-13Completed
Dose Finding Study for Reversal of Vecuronium-induced Neuromuscular Blockade at Train-of-four Ratio 0.3 With Sugammadex and Neostigmine[NCT03656614]121 participants (Actual)Observational [Patient Registry]2018-07-26Completed
Dose Finding Study for Sugammadex and Neostigmine at Residual Neuromuscular Blockade (T4/T1 = 0.2)[NCT01006720]99 participants (Actual)Observational2009-03-31Completed
The Effect of Prophylactic Magnesium Use in Pregnant Women on Reversal of Neuromuscular Block With Sugammadex:Evaluation With TOF[NCT05558969]30 participants (Anticipated)Interventional2022-09-28Recruiting
The Effect of Intraoperative Neuromuscular Blockade on Postoperative Atelectasis in Patients Undergoing Thoracic Surgery With One Lung Ventilation: Moderate vs. Deep Block[NCT03503565]118 participants (Actual)Observational2018-10-11Completed
Combined General and Spinal Anesthesia vs. Combined General and Spinal Anesthesia With Neuromuscular Blockade for Operative Repair of Hip Fractures[NCT03226080]Phase 40 participants (Actual)Interventional2017-07-19Withdrawn (stopped due to Study terminated with IRB on 20Feb2019 due to lack of enrollment.)
Role of Sugammadex as Reversal Agent in Patients Extubated Immediately After Isolated Coronary Artery Bypass Grafting Surgery[NCT03939923]Phase 484 participants (Actual)Interventional2019-05-01Completed
Sugammadex Versus Neostigmine in Pediatric Day-case Cancer Surgery[NCT03996655]Phase 480 participants (Anticipated)Interventional2019-06-30Not yet recruiting
Effect of Deep Curarisation and Reversal With Sugammadex on Surgical Conditions and Perioperative Morbidity in Patients Undergoing Laparoscopic Gastric Bypass Surgery[NCT01748643]Phase 460 participants (Actual)Interventional2013-04-30Completed
Dose Finding Study for Sugammadex and Neostigmine at Residual Neuromuscular Blockade (T4/T1 = 0.5)[NCT00895609]Phase 499 participants (Actual)Interventional2009-03-31Completed
Sugammadex Compared With Neostigmin/Atropin for Neuromuscular Block Reversal in Patients With Obstructive Sleep Apnea[NCT02160223]Phase 474 participants (Actual)Interventional2012-01-31Completed
Sugammadex Versus Neostigmine After Rocuronium Infusion During Liver Transplantation[NCT02697929]40 participants (Actual)Interventional2014-01-31Completed
A Multicenter, Randomized, Parallel Group Comparative, Active-Controlled, Safety-assessor Blinded. Phase IIIa, Pivotal Trial in Adult Subjects Comparing Org 25969 With Neostigmine as Reversal Agent of a Neuromuscular Block Induced by Maintenance Dosing of[NCT00473694]Phase 3182 participants (Actual)Interventional2005-11-28Completed
The Effects of Deep Neuromuscular Blockade During Robot-assisted Transaxillary Thyroidectomy on Postoperative Pain and Sensory Change; Prospective Randomized Control Trial[NCT03871387]88 participants (Actual)Interventional2019-03-04Completed
Neuromuscular Blockade Improves Surgical Conditions[NCT00895778]57 participants (Actual)Interventional2009-03-31Completed
Effects of Neuromuscular Block Reversal With Sugammadex vs Neostigmine on Postoperative Respiratory Outcomes After Major Abdominal Surgery - A Randomized Controlled Trial[NCT02361060]Phase 4130 participants (Actual)Interventional2015-02-28Completed
A Multi -Center Randomized Parallel Group Comparative Active Controlled Safety Assessor Blinded Phase 3a Pivotal Trial in Adult Subjects Comparing Org 25969 With Neostigmine as Reversal Agents of a Neuromuscular Block Induced by Rocuronium or Vecuronium a[NCT00451217]Phase 3198 participants (Actual)Interventional2005-11-17Completed
Comparison Between the Efficacy of Neostigmine Versus Sugammadex Reversal of Rocuronium Induced Neuromuscular Blockade In Paediatric Patients.[NCT03137290]80 participants (Actual)Interventional2014-12-01Completed
Neostigmine and Atropine for the Treatment of Post Dural Puncture Headache After Known Dural Puncture With a Tuohy Needle: A Pilot Study[NCT05116930]Phase 218 participants (Anticipated)Interventional2021-11-19Recruiting
No Need for Neuromuscular Blockade in Day Case Standardised Laparoscopic Surgery. A Consecutive Retrospective Study[NCT02782832]1,245 participants (Actual)Observational2016-05-31Completed
Comparison of Sugammadex Versus Neostigmine in Women at High Risk of Postoperative Nausea and Vomiting After Laparoscopic Gynaecological Surgery: A Randomized Controlled Trial[NCT02666014]Phase 3184 participants (Actual)Interventional2015-06-30Completed
A Phase I, Single-Site, Tri-Institutional, Open-Label, Three-Part, Dose-Escalation Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of CW002 in Healthy Adult Anesthetized Volunteers[NCT01338935]Phase 1136 participants (Actual)Interventional2011-05-31Terminated (stopped due to Pharmacokinetic stopping criteria for the study were met.)
Deep Neuromuscular Block During General Anaesthesia in Laparoscopic (and Robotic Laparoscopic) Surgery and Its Potential Benefits for Certain Physiological Parameters in Perioperative Period[NCT03420937]Phase 4138 participants (Actual)Interventional2016-06-30Completed
Sugammadex Versus Neostigmine for Antagonism of Rocuronium-induced Neuromuscular Blockade in Patients With Liver Cirrhosis Undergoing Liver Resection: A Controlled Randomized Study[NCT02414880]Phase 460 participants (Actual)Interventional2014-12-31Completed
Effects of Postoperative Residual Paralysis on Costs of Hospital Care, Length of Hospitalization and Intensive Care Unit Admission Rate[NCT01718860]3,000 participants (Anticipated)Observational2011-04-30Active, not recruiting
Effect of Sugammadex in Wakeup Procedure[NCT02390817]Phase 460 participants (Actual)Interventional2015-03-31Completed
A Multi-center, Randomized, Parallel-group, Comparative, Active-controlled, Safety-assessor Blinded Trial in Adult Subjects Comparing the Efficacy and Safety of Sugammadex (SCH 900616, ORG 25969) Administered at 1-2 PTC With Neostigmine Administered at Re[NCT00724932]Phase 3140 participants (Actual)Interventional2008-07-16Completed
Neuromuscular Monitoring, Reversal of Block and Postoperative Residual Curarization: the Situation in 2018[NCT03665805]587 participants (Actual)Observational2018-07-30Completed
Pilot Study of EEG Signs of Awakening Secondary to Injection of Sugammadex: Evaluation by Recording Bispectral Index and NeuroSENSE (Prospective, Double-blind Study)[NCT01161004]Phase 450 participants (Actual)Interventional2010-09-30Completed
A Perspective, Multicentre, Randomized，Blind Study of Residual Curarization Incidence in China[NCT01690338]Phase 46,090 participants (Anticipated)Interventional2012-10-31Recruiting
Sugammadex ED90 Dose to Reverse the Rocuronium Blockade in the Obese Patients[NCT02568345]Phase 431 participants (Actual)Interventional2013-01-31Completed
Optimal Dose of Combination of Rocuronium and Cisatracurium: A Randomized Double-blinded Clinical Trial[NCT02495038]81 participants (Actual)Interventional2014-03-31Completed
Comparison of Rocuronium and Org25969 With Cisatracurium and Neostigmine When Neuromuscular Block is Reversed at Reappearance of T2[NCT00451100]Phase 384 participants (Actual)Interventional2005-11-10Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Percentage of Participants Experiencing a Serious Adverse Event (SAE) Up To 7 Days After Administration of Study Intervention

As per the protocol primary analysis, the percentage of participants experiencing an SAE up to 7 days after administration of study intervention was reported. An SAE was an adverse event that: resulted in death; was life threatening; resulted in persistent or significant disability or incapacity; resulted in or prolonged an existing inpatient hospitalization; was a congenital anomaly or birth defect; was an other important medical event, was a cancer; or was associated with an overdose. (NCT03346057)
Timeframe: Up to 7 days

InterventionPercentage of Participants (Number)
Sugammadex 2 mg/kg11.4
Sugammadex 4 mg/kg7.5
Sugammadex 16 mg/kg10.3
Neostigmine + Glycopyrrolate5.9

Percentage of Participants Experiencing an Adverse Event (AE) Up To 7 Days After Administration of Study Intervention

As per the protocol primary analysis, the percentage of participants experiencing an AE up to 7 days after administration of study intervention was reported. An AE was defined as any untoward medical occurrence in a participant which did not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition that was temporally associated with the use of the Sponsor's product was also an AE. (NCT03346057)
Timeframe: Up to 7 days

InterventionPercentage of participants (Number)
Sugammadex 2 mg/kg94.3
Sugammadex 4 mg/kg88.8
Sugammadex 16 mg/kg92.6
Neostigmine + Glycopyrrolate88.2

Percentage of Participants With Other Treatment-Emergent Cardiac Arrhythmia Events

The percentage of participants experiencing other treatment-emergent cardiac arrhythmia events was identified with continuous ECG monitoring. Other treatment-emergent cardiac arrhythmias were defined as new or worsening arrhythmias (e.g., atrial fibrillation, atrial tachycardia, ventricular fibrillation, or ventricular tachyarrhythmia), sustained for at least 1 minute after administration of study intervention. Worsening arrhythmia events may or may not have been considered an AE, as determined by investigator judgment. (NCT03346057)
Timeframe: Up to approximately 35 minutes post-administration

InterventionPercentage of participants (Number)
Sugammadex 2 mg/kg1.0
Sugammadex 4 mg/kg0.0
Sugammadex 16 mg/kg1.5
Neostigmine + Glycopyrrolate2.0

Percentage of Participants With Treatment-Emergent Sinus Bradycardia Events

The percentage of participants experiencing treatment-emergent sinus bradycardia events was identified with continuous electrocardiogram (ECG) monitoring. Treatment-emergent sinus bradycardia were defined as a heart rate <60 bpm that has also decreased more than 20% compared to participant baseline heart rate value, sustained for at least 1 minute after administration of study intervention. Treatment-emergent sinus bradycardia events may or may not have been considered an adverse event (AE), as determined by investigator judgment. (NCT03346057)
Timeframe: Up to approximately 35 minutes post-administration

InterventionPercentage of participants (Number)
Sugammadex 2 mg/kg1.0
Sugammadex 4 mg/kg1.9
Sugammadex 16 mg/kg7.4
Neostigmine + Glycopyrrolate7.8

Percentage of Participants With Treatment-Emergent Sinus Tachycardia Events

The percentage of participants experiencing treatment-emergent sinus tachycardia events was identified with continuous ECG monitoring. Treatment-emergent sinus tachycardia is defined as a heart rate ≥100 bpm that has also increased more than 20% compared to participant baseline heart rate value, sustained for at least 1 minute after administration of study intervention. Treatment-emergent sinus tachycardia events may or may not have been considered an AE, as determined by investigator judgment. (NCT03346057)
Timeframe: Up to approximately 35 minutes post-administration

InterventionPercentage of participants (Number)
Sugammadex 2 mg/kg6.7
Sugammadex 4 mg/kg9.3
Sugammadex 16 mg/kg8.8
Neostigmine + Glycopyrrolate21.6

Percentage of Participants Experiencing an Event of Clinical Interest (ECI) Up To 7 Days After Administration of Study Intervention

As per the protocol primary analysis, the percentage of participants experiencing an ECI up to 7 days after administration of study intervention was reported. ECIs were a discrete set of both AEs and SAEs, specifically designated as such for the trial. For the purposes of this investigation, ECIs included 1) drug-induced liver injury; 2) clinically-relevant arrhythmias, inclusive of bradycardia and tachycardia defined as events necessitating intervention, as determined by investigator judgment; and 3) instances of hypersensitivity and/or anaphylaxis adjudicated by an external expert Adjudication Committee. A participant could have experienced more than one type of ECI. (NCT03346057)
Timeframe: Up to 7 days

,,,
InterventionPercentage of Participants (Number)
With one or more ECIsAdjudicated HypersensitivityAdjudicated AnaphylaxisClinically Relevant BradycardiaClinically Relevant TachycardiaOther Clinically Relevant Cardiac ArrhythmiaDrug Induced Liver Injury
Neostigmine + Glycopyrrolate3.90.00.02.00.02.00.0
Sugammadex 16 mg/kg7.40.00.00.05.91.50.0
Sugammadex 2 mg/kg1.90.00.00.01.90.00.0
Sugammadex 4 mg/kg5.60.00.02.81.90.90.0

Apparent Volume of Distribution (Vz) of Sugammadex [Part A]

The Vz of sugammadex, defined as the amount of drug administered relative to plasma concentrations, was determined in each Part A arm. (NCT03351608)
Timeframe: 2 minutes (min), 15 min, 30 min, 60 min, 4-6 hours (hrs), and 10 hrs post-dose

InterventionLiters (Geometric Mean)
Part A: Sugammadex 2 mg (2 to <6 Years)3.58
Part A: Sugammadex 2 mg (6 to <12 Years)6.65
Part A: Sugammadex 2 mg (12 to <17 Years)10.8
Part A: Sugammadex 4 mg (2 to <6 Years)4.00
Part A: Sugammadex 4 mg (6 to <12 Years)8.22
Part A: Sugammadex 4 mg (12 to <17 Years)12.3

Area Under the Plasma Concentration-Time Curve (AUC) From Dosing to Infinity (AUC0-∞) of Sugammadex [Part A]

The AUCo-∞ for sugammadex, defined as the area under the plasma concentration versus time plot, was determined in each Part A arm. (NCT03351608)
Timeframe: 2 minutes (min), 15 min, 30 min, 60 min, 4-6 hours (hrs), and 10 hrs post-dose

Interventionhr*μg/mL (Geometric Mean)
Part A: Sugammadex 2 mg (2 to <6 Years)14.1
Part A: Sugammadex 2 mg (6 to <12 Years)18.8
Part A: Sugammadex 2 mg (12 to <17 Years)27.6
Part A: Sugammadex 4 mg (2 to <6 Years)26.9
Part A: Sugammadex 4 mg (6 to <12 Years)38.2
Part A: Sugammadex 4 mg (12 to <17 Years)49.2

Maximum Plasma Concentration (Cmax) of Sugammadex [Part A]

The Cmax of sugammadex, defined as the maximum plasma concentration, was determined in each Part A arm. (NCT03351608)
Timeframe: 2 minutes (min), 15 min, 30 min, 60 min, 4-6 hours (hrs), and 10 hrs post-dose

Interventionµg/mL (Geometric Mean)
Part A: Sugammadex 2 mg (2 to <6 Years)17.5
Part A: Sugammadex 2 mg (6 to <12 Years)32.2
Part A: Sugammadex 2 mg (12 to <17 Years)41.3
Part A: Sugammadex 4 mg (2 to <6 Years)47.1
Part A: Sugammadex 4 mg (6 to <12 Years)51.6
Part A: Sugammadex 4 mg (12 to <17 Years)61.9

Percentage of Participants With ≥1 Adverse Event (AE) [Parts A and B]

The percentage of participants with ≥1 AE(s) for up to 7 days after treatment was determined for each treatment group, pooled according to treatment received. An AE is defined as any unfavorable and unintended medical occurrence, symptom, or disease witnessed in a participant, regardless of whether or not a causal relationship with the study treatment can be demonstrated. (NCT03351608)
Timeframe: Up to 7 days

InterventionPercentage of Participants (Number)
Part B: Neostigmine + (Glycopyrrolate or Atropine)97.1
Parts A and B: Sugammadex 2 mg78.4
Parts A and B: Sugammadex 4 mg74.9

Plasma Clearance (CL) of Sugammadex [Part A]

The CL of sugammadex, defined as the rate of elimination relative to plasma concentration, was determined in each Part A arm. (NCT03351608)
Timeframe: 2 minutes (min), 15 min, 30 min, 60 min, 4-6 hours (hrs), and 10 hrs post-dose

InterventionL/hr (Geometric Mean)
Part A: Sugammadex 2 mg (2 to <6 Years)2.30
Part A: Sugammadex 2 mg (6 to <12 Years)3.58
Part A: Sugammadex 2 mg (12 to <17 Years)4.68
Part A: Sugammadex 4 mg (2 to <6 Years)2.26
Part A: Sugammadex 4 mg (6 to <12 Years)3.43
Part A: Sugammadex 4 mg (12 to <17 Years)5.69

Plasma Half-Life (t½) of Sugammadex [Part A]

The t½ of sugammadex, defined as the time required for the plasma concentration to decrease to 50% of maximum, was determined in each Part A arm. (NCT03351608)
Timeframe: 2 minutes (min), 15 min, 30 min, 60 min, 4-6 hours (hrs), and 10 hrs post-dose

InterventionHours (Median)
Part A: Sugammadex 2 mg (2 to <6 Years)1.15
Part A: Sugammadex 2 mg (6 to <12 Years)1.19
Part A: Sugammadex 2 mg (12 to <17 Years)1.49
Part A: Sugammadex 4 mg (2 to <6 Years)1.12
Part A: Sugammadex 4 mg (6 to <12 Years)1.56
Part A: Sugammadex 4 mg (12 to <17 Years)1.51

Time to Recovery of Participant TOF Ratio to ≥0.7 [Part B]

The time to recovery of TOF ratio to ≥0.7 after administration of study intervention was determined for each Part B arm. The TOF ratio is the ratio of the magnitude of the fourth (T4) and first (T1) thumb twitches elicited by 4 electrical stimulations of the ulnar nerve, indicating the current degree of NMB as a decimal from 0 (loss of T4 twitch) to 1 (no NMB). Values closer to 1 indicate less NMB. (NCT03351608)
Timeframe: Up to 30 minutes post-dose

InterventionMinutes (Geometric Mean)
Part B: Sugammadex 2 mg/kg1.1
Part B: Sugammadex 4 mg/kg1.3
Part B: Neostigmine + (Glycopyrrolate or Atropine)3.7

Time to Recovery of Participant TOF Ratio to ≥0.8 [Part B]

The time to recovery of TOF ratio to ≥0.8 after administration of study intervention was determined for each Part B arm. The TOF ratio is the ratio of the magnitude of the fourth (T4) and first (T1) thumb twitches elicited by 4 electrical stimulations of the ulnar nerve, indicating the current degree of NMB as a decimal from 0 (loss of T4 twitch) to 1 (no NMB). Values closer to 1 indicate less NMB. (NCT03351608)
Timeframe: Up to 30 minutes post-dose

InterventionMinutes (Geometric Mean)
Part B: Sugammadex 2 mg/kg1.3
Part B: Sugammadex 4 mg/kg1.5
Part B: Neostigmine + (Glycopyrrolate or Atropine)5.0

Time to Recovery of Participant Train-of-Four (TOF) Ratio to ≥0.9 [Part B]

The time to recovery of TOF ratio to ≥0.9 after administration of study intervention was determined for each Part B arm. The TOF ratio is the ratio of the magnitude of the fourth (T4) and first (T1) thumb twitches elicited by 4 electrical stimulations of the ulnar nerve, indicating the current degree of NMB as a decimal from 0 (loss of T4 twitch) to 1 (no NMB). Values closer to 1 indicate less NMB. Per protocol, the efficacy analysis is based on comparison of the Part B: Sugammadex 2 mg arm versus the Part B: Neostigmine + (Glycopyrrolate or Atropine) arm. (NCT03351608)
Timeframe: Up to 30 minutes post-dose

InterventionMinutes (Geometric Mean)
Part B: Sugammadex 2 mg/kg1.6
Part B: Sugammadex 4 mg/kg1.9
Part B: Neostigmine + (Glycopyrrolate or Atropine)7.5

Difference in Length of Stay in PACU

Length of PACU stay measured in minutes. (NCT03112993)
Timeframe: Day 1

Interventionminutes (Mean)
Sugammadex Group81.4
Neostigmine Group85.3

Difference in Time From Neuromuscular Reversal to Exit From OR

Difference in time from neuromuscular reversal to exit from OR was measured in minutes. (NCT03112993)
Timeframe: Day 1

Interventionminutes (Mean)
Sugammadex Group3.9
Neostigmine Group19.8

Difference in Time From Neuromuscular Reversal to Tracheal Extubation

Difference in time from neuromuscular reversal to tracheal extubation was measured in minutes. (NCT03112993)
Timeframe: Day 1

Interventionminutes (Mean)
Sugammadex Group5.3
Neostigmine Group23.6

Difference in Time of Neuromuscular Recovery From a Neuromuscular Moderate Blockade

Speed of neuromuscular recovery in minutes measured by recovery of the T4:T1 ratio ≥ 0.9 (measured with a TOF-Watch SX) (NCT03112993)
Timeframe: Day 1

InterventionMinutes (Mean)
Sugammadex Group3.9
Neostigmine Group26.29

Difference in Time to First Ambulation After Surgery

Time from end of anesthesia to the first subject ambulation in hours. (NCT03112993)
Timeframe: From Day 1 up to 1 week, depending on individual recovery time

Interventionhours (Mean)
Sugammadex Group17.4
Neostigmine Group17.8

Electric Activity of the Diaphragm (Microvolts)

(NCT01962298)
Timeframe: From the start of spontaneous breathing till extubation, limited to maximum ten minutes after the onset of spontaneous breathing

Interventionmicrovolt (Median)
Single Rocuronium Dose - Placebo3.7
Single Rocuronium Dose - Sugammadex4.5
Repeated Rocuronium Dose - Neostigmine3.2
Repeated Rocuronium Dose - Sugammadex2.9
Continuous Rocuronium Dose4.4

Electric Activity of the Intercostal Muscles

(NCT01962298)
Timeframe: From the start of spontaneous breathing till extubation, limited to maximum ten minutes after the onset of spontaneous breathing

Interventionmicrovolt (Median)
Single Rocuronium Dose - Placebo2.4
Single Rocuronium Dose - Sugammadex2.2
Repeated Rocuronium Dose - Neostigmine1.5
Repeated Rocuronium Dose - Sugammadex2.2
Continuous Rocuronium Dose1.8

Cumulative Intraoperative Insufflation Pressure

Intra-abdominal insufflation time and pressure directed by the surgeon and recorded continuously by the clinical coordinator until the time of desufflation. (NCT03210376)
Timeframe: Day 0 - IntraOperative-From beginning of pneumoperitoneum to desufflation (an average of 166 minutes)

InterventionmmHg (Median)
Deep Neuromuscular Blockade (NMB) + Sugammadex1995
Moderate Neuromuscular Blockade (NMB) + Neostigmine1581

Length of Hospital Stay

(NCT03210376)
Timeframe: length of hospital stay(average of 3 days)

Interventiondays (Mean)
Deep Neuromuscular Blockade (NMB) + Sugammadex2.2323
Moderate Neuromuscular Blockade (NMB) + Neostigmine1.8623

Percentage of Muscle Response Using Train-of-Four (TOF) in Post-Anesthesia Care Unit (PACU) to Measure Residual Muscle Relaxation

The patients will be started on a continuous Rocuronium intravenous infusion following intubation. Insert recommendations and Institutional Standards will be used for Rocuronium. For the DNMB group, the rate will be adjusted and boluses given to maintain 1-2 post tetanic responses during the pneumoperitoneum. NMB will be reversed with Sugammadex 4 mg/Kg, intravenously as a single bolus injection, at the end of the surgery. Percentage of measured contraction strength of the fourth stimulus compared to the first stimulus. (NCT03210376)
Timeframe: Day 0 - Arrival time at PACU, an average of 3 minutes

InterventionPercentage of measured contraction (Median)
Deep Neuromuscular Blockade (NMB) + Sugammadex110
Moderate Neuromuscular Blockade (NMB) + Neostigmine100

Percentage of Patients Who Reported Shoulder Pain

Visual Analog Scale (VAS) pain score (0-10) for shoulder pain recorded, where 0 means no pain and 10 means the worst pain ever experienced . Percentage of participants who experienced should pain. (NCT03210376)
Timeframe: 30 days

Interventionpercentage of participants (Number)
Deep Neuromuscular Blockade (NMB) + Sugammadex12
Moderate Neuromuscular Blockade (NMB) + Neostigmine10

Percentage of Participants With Nausea and/or Vomiting in PACU

Degree of Post-Operative Nausea determined per Visual Analog Scale per nurse in Post-Anesthesia Care Unit (PACU). (NCT03210376)
Timeframe: Day 0 - PACU stay, an average of 120 minutes

,
Interventionpercentage of participants (Number)
NauseaVomiting
Deep Neuromuscular Blockade (NMB) + Sugammadex71
Moderate Neuromuscular Blockade (NMB) + Neostigmine60

Readiness to Discharge From the Post-Anesthesia Care Unit (PACU)

Determined by the Dansk Selskab for Anæstesiologi og Intensiv Medicin(DASAIM)discharge criteria.Pts considered ready to discharge when the sum of all categories is<4 and no single category has a score of >1.Sedation.0:Patient is fully awake.1: Patient is asleep,aroused by verbal stimulation.2:Patient is asleep, aroused by physical stimulation.3:Patient is asleep,cannot be aroused.Respiratory Rate.0:Respiratory rate>10. 1: Snoring,10< RR<30. 2:R<10 or RR>30/min.3:Periods of apnea or obstructive patterns.Oxygen Saturation.0:SpO2 ≥ 94%.1:90%≤SpO2<94%. 2:85%≤ SpO2 < 90%.3:SpO2 < 85%. Systolic Blood Pressure. 0:SBP ≥ 100mmHg.1:90mmHg≤SBP< 100mmHg.2:80mmHg≤SBP< 90mmHg or SBP>220mmHg.3:SBP<80mmHg.Heart Rate.0:50130.Pain at rest.0:No pain 1:Light pain.2:Moderate pain.3:Severe pain.Nausea.0:No nausea or vomiting.1:Light nausea or vomiting without previous nausea. 2:Moderate nausea and/or vomiting.3:Severe nausea and/or vomiting. (NCT03210376)
Timeframe: Assessed at 15, 45, 90 minutes during PACU stay.

,
InterventionScore on a scale (Median)
DASAIM at 15 minDASAIM at 45 minDASAIM at 90 min
Deep Neuromuscular Blockade (NMB) + Sugammadex2.922.822.12
Moderate Neuromuscular Blockade (NMB) + Neostigmine3.162.861.8

Surgical Exposure Grading

(NCT03210376)
Timeframe: Day 0 - IntraOperative, from incision time to closing time(average 190 minutes)

,
InterventionParticipants (Count of Participants)
OptimalGoodAcceptablePoor
Deep Neuromuscular Blockade (NMB) + Sugammadex251951
Moderate Neuromuscular Blockade (NMB) + Neostigmine33881

Hospital Length of Stay

Defined as the number of days between hospital admission and discharge (NCT02861131)
Timeframe: Length of hospitalization, an average of 1 week

Interventiondays (Mean)
Sugammadex4.0
Neostigmine4.5

Number of Participants Diagnosed With a National Surgical Quality Improvement Program (NSQIP) Defined Respiratory Complication

pneumonia, unplanned re-intubation for any reason other than a return trip to the operating room, and ventilator times greater than 48 hours - excluding operating room time (NCT02861131)
Timeframe: Length of hospitalization, an average of 1 week

InterventionParticipants (Count of Participants)
Sugammadex4
Neostigmine2

Number of Participants With a Postoperative Pulmonary Complication

A composite outcome which includes any of the following: postoperative pneumonia, aspiration pneumonitis, atelectasis, pneumothorax, desaturation/hypoxemia, upper airway obstruction, or acute respiratory insufficiency (NCT02861131)
Timeframe: Length of hospitalization, an average of 1 week

InterventionParticipants (Count of Participants)
Sugammadex33
Neostigmine40

Number of Participants With Hospital Readmission Within 30 Days

The proportion of patients that require hospital readmission for any cause within 30 days of hospital discharge (NCT02861131)
Timeframe: Length of hospitalization plus 30 days post-discharge

InterventionParticipants (Count of Participants)
Sugammadex5
Neostigmine15

Number of Participants With Residual Neuromuscular Blockade in the PACU

Residual neuromuscular blockade will be defined as a train-of-four ratio < 0.9 taken within 5 minutes of subject arrival in the PACU (NCT02861131)
Timeframe: 1 day

InterventionParticipants (Count of Participants)
Sugammadex9
Neostigmine46

PACU Phase 1 Recovery Time

Defined as duration of time required to attain pain control and stable respiratory, haemodynamic, and neurological status (NCT02861131)
Timeframe: 1 day

Interventionminutes (Mean)
Sugammadex97.3
Neostigmine110.0

Duration of Anesthesia From Induction to Cessation of the Anesthetic

Duration of Anesthesia from induction to cessation of the anesthetic up to 6 hours (NCT03034577)
Timeframe: Up to 6 hours

Interventionminutes (Mean)
Moderate Neuromuscular Blockade Reversed With Neostigmine165.4
Deep Neuromuscular Blockade Reversed With Sugammadex164

Duration of Hospital Length of Stay

Duration of hospital length of stay following their procedure until hospital discharge (NCT03034577)
Timeframe: 3 days

Interventiondays (Mean)
Moderate Neuromuscular Blockade Reversed With Neostigmine2.6
Deep Neuromuscular Blockade Reversed With Sugammadex1.8

Number of Participants With Full Reversal of Neuromuscular Blockade Prior to Extubation

Compliance with protocol to ensure deep block or light/moderate block, using the train of four ratio and post tetanic count (NCT03034577)
Timeframe: 6 hours

Interventionparticipants (Number)
Moderate Neuromuscular Blockade Reversed With Neostigmine158
Deep Neuromuscular Blockade Reversed With Sugammadex161

Percentage of Patients Recovered Cognitively at 1 Week

The primary outcome will be the cognitive domain at 1 week after surgery, when it is expected that most of the acute inflammation will have resolved, and analgesia requirements minimal. (NCT03034577)
Timeframe: 1 week

Interventionpercentage of patients recovered (Number)
Moderate Neuromuscular Blockade Reversed With Neostigmine91.8
Deep Neuromuscular Blockade Reversed With Sugammadex92.9

Percentage of Patients Recovered in All Domains of the Postoperative Quality of Recovery Scale at 3 Months After the Operation

Recovery for all domains and within domains of the PostopQRS scale at the other time points of measurement (15 minutes, 40 minutes 1 day, 3 days, 1 and 2 weeks, and 3 months following cessation of anesthesia). The domains of recovery are physiological, nociceptive, emotive activities of daily living, cognitive and overall patient perspective. (NCT03034577)
Timeframe: 3 months

Interventionpercentage of patients recovered (Number)
Moderate Neuromuscular Blockade Reversed With Neostigmine75.7
Deep Neuromuscular Blockade Reversed With Sugammadex73

Number of Participants Categorized by Level of Surgical Satisfaction

Overall surgical satisfaction using a 1-5 Likert scale (1 = very unacceptable, 2 = unacceptable, 3 = acceptable, 4 = good, 5 = excellent). (NCT03034577)
Timeframe: 2 hours

,
Interventionparticipants (Number)
ExcellentGoodAcceptableUnacceptableVery Unacceptable
Deep Neuromuscular Blockade Reversed With Sugammadex94481611
Moderate Neuromuscular Blockade Reversed With Neostigmine104382031

Grip Strength, Change From Baseline and Recovery Profile 120 Min

Grip strength will be measured with a hand dynamometer (NCT02909439)
Timeframe: 120 minutes after surgery

Interventionpsi (Mean)
Neostigmine7.84
Sugammadex11.85

Grip Strength, Change From Baseline and Recovery Profile 30 Min

Grip strength will be measured with a hand dynamometer (NCT02909439)
Timeframe: 30 minutes

InterventionPSI (Mean)
Neostigmine24.15
Sugammadex21.38

Grip Strength, Change From Baseline and Recovery Profile 60 Min

Grip strength will be measured with a hand dynamometer (NCT02909439)
Timeframe: 60 minutes after reversal

Interventionpsi (Mean)
Neostigmine12.68
Sugammadex17.69

Incentive Spirometry, Change From Baseline and Recovery Profile - 120 Minutes

Incentive spirometry measurements will be done at 30, 60 and 120 minutes after surgery. The change from baseline and recovery profile will be measured. (NCT02909439)
Timeframe: 120 minutes after reversal

InterventionmL (Median)
Neostigmine-400
Sugammadex-850

Incentive Spirometry, Change From Baseline and Recovery Profile - 30 Minutes

Incentive spirometry measurements will be done at 30, 60 and 120 minutes after surgery. The change from baseline and recovery profile will be measured. (NCT02909439)
Timeframe: 30 Minutes

InterventionmL (Median)
Neostigmine-700
Sugammadex-862

Incentive Spirometry, Change From Baseline and Recovery Profile - 60 Minutes

Incentive spirometry measurements will be done at 30, 60 and 120 minutes after surgery. The change from baseline and recovery profile will be measured. (NCT02909439)
Timeframe: 60 Minutes after reversal

InterventionmL (Median)
Neostigmine-500
Sugammadex-1150

Quality of Recovery 15 Survey

"15 question survey to assess patient's overall quality of recovery after anesthesia/surgery.~Quality of Recovery 15 Survey. Minimum: 0 Maximum: 150 Higher Scores mean a better outcome and better quality of recovery.~Part A: How have you been feeling in the last 24 hours? 0 = none of the time (poor), 10 = all of the time (excellent). Examples: able to breath easily, able to enjoy food, feeling rested. etc.~Part B: Have you had any of the following in the last 24 hours? 10 to 0, where 10 = none of the time (Excellent) and 0 = all of the time (poor). Examples: moderate pain, nausea or vomiting, feeling worried or anxious, etc." (NCT02909439)
Timeframe: Postoperative day number one

Interventionscores on a scale (Median)
Neostigmine117
Sugammadex105

Time to Extubation

Measured time between surgery end and time of extubation (removal of breathing tube) (NCT02909439)
Timeframe: Immediately after surgery, up to 30 minutes

Interventionminutes (Median)
Neostigmine8
Sugammadex7

Time to Readiness for Post Anesthesia Care Unit (PACU) Discharge (Aldrete Score >9)

Measured time between PACU admission and meeting PACU discharge readiness. PACU discharge was defined as when the patient had an Aldrete score of 9 or higher as determined by the PACU nurse. The Aldrete score is a measure of post anesthesia recovery. 0 is poor condition and 10 is excellent condition. There are 5 assessment items (able to move voluntary, breathing, consciousness, circulation (BP) and spO2) which are graded on a 0-2 point scale with 0 being poor and 2 being excellent. (NCT02909439)
Timeframe: Within 4 hours from the end of surgery

Interventionminutes (Median)
Neostigmine109
Sugammadex112

Train of Four Ratio > 90% During PACU Admission

Train of four ratio (TOFR) is the ration of the twitch height of the 4th twitch compared to the 1st twitch during train of four neuromuscular stimulation. This measurement was performed using a TOF Watch, which in an accelemyographer. Electric current is applied to the ulnar nevre and the twitches are measured in the thumb. Adequate reversal of neuromuscular blockade is defined as a TOFR >90%. (NCT02909439)
Timeframe: At PACU admission, approximately within one hour of reversal of neuromuscular blockade reversal.

InterventionParticipants (Count of Participants)
Neostigmine25
Sugammadex25

Change of Diaphragmatic Contractility Speed- Sniff (Breathing From the Nose), cm/s

The change of diaphragmatic contractility speed was defined as baseline minus postoperative diaphragmatic contraction. (NCT03322657)
Timeframe: from baseline to 90 minutes after the administration of the reversal agent

Interventioncm/s (Mean)
Neostigmine With Glycopyrrolate-0.04
Sugammadex0.29

Change of Diaphragmatic Contractility Speed, Deep Breathing From Mouth, cm/s

The change of diaphragmatic contractility speed was defined as baseline minus postoperative diaphragmatic contraction. (NCT03322657)
Timeframe: from baseline to 90 minutes after the administration of reversal agent

Interventioncm/s (Mean)
Neostigmine With Glycopyrrolate-0.02
Sugammadex0.80

The Time for Extubation After Administration of Reversal Agents

Time from administration of reversal agent to tracheal extubation (NCT03322657)
Timeframe: Up to 4 hours after administration of reversal agents

Interventionminutes (Median)
Neostigmine With Glycopyrrolate8
Sugammadex8

Time in Minutes to Reach Train of Four (TOF) Ratio ≥ 0.9 After the Administration of Reversal Agent

The primary outcome was a time-to-TOF ratio ≥ 0.9 after the administration of the reversal agent. The TOF ratio was measured in a continuous manner every 12 seconds from the administration of the reversal drug until TOF ratio ≥ 0.9 or until 90 minutes after administration of the reversal agent. (NCT03322657)
Timeframe: within 90 minutes after endotracheal extubation

Interventionminutes (Median)
Neostigmine With Glycopyrrolate8
Sugammadex3

TOF Ratio at 90 Min

"TOF (train of four), also known as a peripheral nerve stimulator, is used to assess nerve function in patients receiving neuromuscular blocking agents (paralytic medications). Before giving the medications, the baseline must be measured because this tells how much electrical stimulation the patient needs for nerve stimulation without any paralytic on board.~Our primary outcome TOF ratio between TOF at 90 minutes after the administration of the reversal agent versus the TOF at baseline tells us how well the treatment is working to reverse the rocuronium Neuromuscular. This is a sensitivity analysis of primary analysis." (NCT03322657)
Timeframe: at 90 minutes after the administration of the reversal agent

Interventionratio (Median)
Neostigmine With Glycopyrrolate1.07
Sugammadex1.16

Recovery Time From Neuromuscular Blockade

We measured recovery time ffrom the injection of neostigmine or sugammadex to TOF ratio 0.9 (NCT02330172)
Timeframe: from the injection of neostigmine or sugammadex up to 30 minutes

Interventionminute (Mean)
Rocuronium 0.45 - Neostigmine9.9
Rocuronium 0.9 - Sugammadex2.1

Laryngoscopic Score

"Definitions for evaluation of Laryngoscopycondition.~: Easy = jaw relaxed, no resistance to blade insertion, fair = jaw not fully relaxed, slight resistance to blade insertion, difficult = poor jaw relaxation, active resistance of the patient to laryngoscopy.~Variables Excellent Good Poor" (NCT02330172)
Timeframe: At the beginning of surgery, the surgeon rated the laryngoscopy condition

,
InterventionParticipants (Count of Participants)
DifficultFairEasy
Rocuronium 0.45 - Neostigmine1119
Rocuronium 0.9 - Sugammadex0019

Breathing

"In the recovery room the respiratory rate will be measured continuously using the Respir8 respiratory rate monitor. The data will be recorded on the CRF at 15 min intervals.~Breathing rate units are number of breaths as measured in 1 min.~Comparison by t-test: NS between treatments" (NCT01631149)
Timeframe: Measurements will be made during the stay in the recovery room for an average period of 3 hours

Interventionbreaths per min (Mean)
Moderate/Normal Surgical Block14.5
Deep Surgical Block14.5

Nausea and Vomiting

"Using a yes - no questionnaire, the patients will be asked whether they are nauseated or not or whether they vomited. In fact yes indicates the nr of participants.~No statistical analysis was performed." (NCT01631149)
Timeframe: Measurements will be made during the stay in the operating room for an average period of 3 hours

Interventionparticipants (Number)
Moderate/Normal Surgical Block0
Deep Surgical Block0

Post-operative Pain

"Using a 10 cm visual analogue score pain relief score will be measured. 0 = no pain 10 = most severe pain~No statistical analysis was performed!" (NCT01631149)
Timeframe: measurements are made in the recovery room following surgery for an average prior of 1 hour

Interventionunits on a scale (0-10 cm) (Mean)
Moderate/Normal Surgical Block2.6
Deep Surgical Block2.1

Postoperative Sedation Score

"Using a 5-point sedation scale, sedation levels will be obtained throughout the postoperative period.~0 = wide awake 5= severely sedated, The sedation data were averaged over time." (NCT01631149)
Timeframe: Measurements will be made during the stay in the operating room for an average period of 3 hours

Interventionunits on a scale (0-5) (Mean)
Moderate/Normal Surgical Block2.0
Deep Surgical Block1.3

Surgical Rating Scale

"During the procedure, the surgical condition will be scored by the surgeon using a 5-point surgical rating scale. In order to reduce variability in the surgical rating all surgeries will be performed by one single surgeon. The rating scale will be a 5-point ordinal scale ranging from 1 = poor condition to 5 = optimal surgical conditions. The surgeon will score the condition at 15 minute intervals. In case of a sudden change in surgical conditions additional scores will be added to the case record form. If conditions are poor (score 1 or 2), muscle relaxation will be increased, a score of 1 will be used.~In each subject the scores over time were averaged and a comparison between treatments was performed using a t-test" (NCT01631149)
Timeframe: Measurements will be made during the stay in the operating room for an average period of 3 hours

Interventionunits on a scale (1-5) (Mean)
Moderate/Normal Surgical Block4
Deep Surgical Block4.7

Number of Patients Who Experience Postoperative Nausea and Vomiting, Post-operative Pain, and Post-operative Complications

(NCT02860507)
Timeframe: through discharge from hospital, average of 72 hours

InterventionParticipants (Count of Participants)
Neostigmine + Glycopyrrolate8
Sugammadex10

Operating Room (OR) Turnover Time When Using Sugammadex Instead of Combination of Neostigmine and Glycopyrrolate.

(NCT02860507)
Timeframe: through start of next surgery, average of 2 hours

InterventionMinutes (Mean)
Neostigmine + Glycopyrrolate49.7
Sugammadex49.45

Number of Participants Requiring Flexible Fiberoptic Bronchoscopy

The number of participants requiring flexible fiberoptic bronchoscopy during double-lumen tube intubation for a single lung ventilation. (NCT03690284)
Timeframe: Intraoperative, within the time the double lumen was in the trachea

InterventionParticipants (Count of Participants)
Conventional Double Lumen Tube25
VivaSight Double Lumen Tube7

Number of Participants With Malposition

The number of participants with malposition of double lumen tube for a single lung intubation (NCT03690284)
Timeframe: Intraoperative, within the time the double lumen was in the trachea

InterventionParticipants (Count of Participants)
Conventional Double Lumen Tube12
VivaSight Double Lumen Tube4

The Intubation Time

The time required to place double lumen endotracheal tube for a single lung intubation (NCT03690284)
Timeframe: Intraoperative, time to successfully intubate patient.

Interventionseconds (Median)
Conventional Double Lumen Tube156
VivaSight Double Lumen Tube54

Time From Start of Administration of Investigational Medicinal Product (IMP) to Recovery of the T4/T1 Ratio to 0.9.

"Neuromuscular functioning was monitored by applying repetitive train of four (TOF) electrical stimulations to the ulnar nerve every 15 seconds and assessing twitch response at the adductor pollicis muscle. Nerve stimulation was to continue until the ratio of the magnitude of the fourth twitch (T4) to first twitch (T1) reached >= 0.9. The greater the T4/T1 ratio the greater the recovery from neuromuscular blockade, with a value of 1.0 representing full recovery.~The primary analysis was the comparison between sugammadex & neostigmine among Chinese subjects; other comparisons were secondary." (NCT00825812)
Timeframe: start of administration of sugammadex/neostigmine to recovery from neuromuscular blockade

Interventionminutes (Geometric Mean)
Sugammadex in Caucasian Subjects1.4
Neostigmine in Caucasian Subjects6.7
Sugammadex in Chinese Subjects1.6
Neostigmine in Chinese Subjects9.1

Time From Start of Administration of IMP to Recovery of the T4/T1 Ratio to 0.7 and 0.8.

Neuromuscular functioning was monitored by applying repetitive TOF electrical stimulations to the ulnar nerve every 15 seconds and assessing twitch response at the adductor pollicis muscle. The greater the T4/T1 ratio the greater the recovery from neuromuscular blockade. (NCT00825812)
Timeframe: start of administration of sugammadex/neostigmine to recovery from neuromuscular blockade

,,,
Interventionminutes (Geometric Mean)
Recovery of T4/T1 ratio to 0.7Recovery of T4/T1 ratio to 0.8
Neostigmine in Caucasian Subjects3.44.6
Neostigmine in Chinese Subjects4.46.0
Sugammadex in Caucasian Subjects1.01.2
Sugammadex in Chinese Subjects1.11.3

Percentage of Participants With Residual Neuromuscular Blockade (NMB)(Train of Four [TOF] Ratio <0.9) at Time of Tracheal Extubation

Neuromuscular functioning was monitored at time of tracheal extubation by applying three TOF electrical stimulations to the ulnar nerve and assessing twitch response at the adductor pollicis muscle. T1 and T4 refer to the magnitudes (height) of the first and fourth twitches, respectively, after TOF nerve stimulation. The T4/T1 Ratio (expressed as a decimal of up to 1.0) indicates the extent of recovery from NMB, with a higher ratio indicating greater recovery from NMB. A T4/T1 Ratio of <0.9 is indicative of residual NMB. (NCT01318382)
Timeframe: Up to 1 minute prior to tracheal extubation

Interventionpercentage of participants (Number)
TOF-Watch SX®56

Percentage of Participants With Residual NMB (TOF Ratio <0.9) Upon Arrival to the Post-anesthesia Care Unit (PACU)

Neuromuscular functioning was monitored at time of PACU arrival by applying three TOF electrical stimulations to the ulnar nerve and assessing twitch response at the adductor pollicis muscle. T1 and T4 refer to the magnitudes (height) of the first and fourth twitches, respectively, after TOF nerve stimulation. The T4/T1 Ratio (expressed as a decimal of up to 1.0) indicates the extent of recovery from NMB, with a higher ratio indicating greater recovery from NMB. A T4/T1 Ratio of <0.9 is indicative of residual NMB. (NCT01318382)
Timeframe: Up to 2 minutes prior to PACU arrival

Interventionpercentage of participants (Number)
TOF-Watch SX®44

Percentage of Participants With Residual NMB at Various TOF Ratios (<0.6, ≥ 0.6 to <0.7, ≥ 0.7 to <0.8, ≥0.8 to <0.9) Upon Arrival to the PACU

Neuromuscular functioning was monitored at time of PACU arrival by applying three TOF electrical stimulations to the ulnar nerve and assessing twitch response at the adductor pollicis muscle. T1 and T4 refer to the magnitudes (height) of the first and fourth twitches, respectively, after TOF nerve stimulation. The T4/T1 Ratio (expressed as a decimal of up to 1.0) indicates the extent of recovery from NMB, with a higher ratio indicating greater recovery from NMB. (NCT01318382)
Timeframe: Up to 2 minutes prior to PACU arrival

Interventionpercentage of participants (Number)
TOF Ratio <0.6TOF Ratio ≥0.6 to <0.7TOF Ratio ≥0.7 to <0.8TOF Ratio ≥0.8 to <0.9TOF Ratio ≥0.9
TOF-Watch SX®7.77.213.515.556.0

Percentage of Participants With Residual NMB at Various TOF Ratios (<0.6, ≥0.6 to <0.7, ≥0.7 to <0.8, ≥0.8 to <0.9) at Tracheal Extubation

Neuromuscular functioning was monitored at time of tracheal extubation by applying three TOF electrical stimulations to the ulnar nerve and assessing twitch response at the adductor pollicis muscle. T1 and T4 refer to the magnitudes (height) of the first and fourth twitches, respectively, after TOF nerve stimulation. The T4/T1 Ratio (expressed as a decimal of up to 1.0) indicates the extent of recovery from NMB, with a higher ratio indicating greater recovery from NMB. (NCT01318382)
Timeframe: Up to 1 minute prior to tracheal extubation

Interventionpercentage of participants (Number)
TOF Ratio <0.6TOF Ratio ≥0.6 to <0.7TOF Ratio ≥0.7 to <0.8TOF Ratio ≥0.8 to <0.9TOF Ratio ≥0.9
TOF-Watch SX®19.111.68.716.644.0

Incidence of Residual Neuromuscular Blockade (NMB) as Defined by a Train-of-Four (TOF) Ratio <0.9 at Post Anesthesia Care Unit (PACU) Entry

Neuromuscular functioning was monitored by applying four TOF electrical stimulations to the ulnar nerve and assessing twitch response at the adductor pollicis muscle. T1 and T4 refer to the magnitudes (height) of the first and fourth twitches, respectively, after TOF nerve stimulation. The T4/T1 Ratio (expressed as a decimal of up to 1.0) indicates the extent of recovery from NMB, with a higher ratio indicating greater recovery from NMB. A T4/T1 Ratio of <0.9 is indicative of residual NMB. (NCT01479764)
Timeframe: At PACU entry on Day 1

Interventionparticipants (Number)
Sugammadex0
Neostigmine/Glycopyrrolate33

Time From Start of Study Drug Administration to Operating Room Discharge-ready

The time of operating room discharge readiness was determined by the surgical team based on clinical evaluations. (NCT01479764)
Timeframe: Day 1

Interventionminutes (Least Squares Mean)
Sugammadex15.02
Neostigmine/Glycopyrrolate18.05

Duration of Surgery

Time from incision to joint reduction (NCT03219294)
Timeframe: Through study completion, an average of 24 hours for each patient and up to one year for the whole study.

Interventionminutes (Mean)
Moderate NMB32.6
Deep NMB33.8

Change in Renal Function

Change in renal function was defined as Creatinine elevation >0.5 mg/dl (NCT03196167)
Timeframe: Up to 2 weeks

InterventionParticipants (Count of Participants)
Sugammadex Group5
Placebo Group3

Length of Hospital Stay

Length of Hospital stay after surgery (NCT03196167)
Timeframe: 2 weeks

InterventionDays (Median)
Sugammadex Group5
Placebo Group5

Length of ICU Stay

Days in the ICU post opertaitvely (NCT03196167)
Timeframe: Up to 2 weeks

Interventiondays (Median)
Sugammadex Group2
Placebo Group2

Negative Inspiratory Force

NIF=Negative Inspiratory Force (NCT03196167)
Timeframe: Up to 2 weeks

Interventioncm per H2O (Median)
Sugammadex Group-33.0
Placebo Group-31.0

New Dysrhythmia

Any dysrhythmia after surgery in patients without history of dysrhythmia (NCT03196167)
Timeframe: Up to 2 weeks

InterventionParticipants (Count of Participants)
Sugammadex Group3
Placebo Group6

Postoperative CHF

Postoperative congestive heart failure (NCT03196167)
Timeframe: Up to 2 weeks

InterventionParticipants (Count of Participants)
Sugammadex Group0
Placebo Group1

RSBI

Rapid Shallow Breathing Index (NCT03196167)
Timeframe: Upto 2 weeks

Interventionbreaths/min/L (Median)
Sugammadex Group40.0
Placebo Group32.7

Time to Extubation

The primary outcome of this study aims to test the time to extubation among patients in the cardiothoracic ICU who have undergone isolated CABG. (NCT03196167)
Timeframe: Up to 2 weeks

Interventionminutes (Median)
Sugammadex126.0
Placebo219.0

Atelectasis Area on Chest CT

Atelectasis on Chest CT The lung area was delineated manually. To calculate atelectasis, a region of interest was laid out that encircled the dense part of the lung, excluding large vessels. For further analysis, the lung was divided into four categories: areas with densities ranging from -1000 to -900 Hounsfield units (HU) were classified as over-aerated, from -900 to -500 HU as normally aerated, from -500 to -100 HU as poorly aerated, and from -100 to +100 HU as non-aerated (atelectasis). The proportion of non-aerated lung tissue (-100 to +100 HU) was calculated by dividing the area of the region of interest with the whole lungs. (NCT03503565)
Timeframe: 1 day after the end of surgery

Interventionpercentage of atelectasis volume (Median)
Moderate Block Group1.32
Deep Block Group1.41

Blood Pressure (First Measurement of Systolic Blood Pressure Post Reversal)

Blood pressure; measure of systolic blood pressure of subject is obtained post-reversal prior to extubation of trachea (NCT03939923)
Timeframe: 0 minutes to 2 hours after study drug administration

InterventionmmHg (Mean)
Neostigmine/Glycopyrrolate105.6
Sugammadex112.1

Heart Rate

Heart rate post-reversal prior to extubation (NCT03939923)
Timeframe: 0 minutes to 2 hours after study drug administration

Interventionbeats per minute (Mean)
Neostigmine/Glycopyrrolate81.5385
Sugammadex81.1622

Peak Flow Rate

Peak flow rate - measured by peak flow meter post-extubation at 30-60 mins (NCT03939923)
Timeframe: 30-60 minutes post-extubation

InterventionL/min (Mean)
Neostigmine/Glycopyrrolate1.4609
Sugammadex1.416

Tidal Volume

Tidal volume post-reversal prior to extubation (NCT03939923)
Timeframe: between 30 minutes to 1 hour after extubation

InterventionLiters (Mean)
Neostigmine/Glycopyrrolate1.16
Sugammadex1.0975

Time to Extubation

"Time to extubation: West Virginia University Hospitals use an electronic medical record (EMR) to chart procedure stop. The definition for time to extubation is from the time the investigators chart procedure stop to the time of extubation." (NCT03939923)
Timeframe: 0 minutes of study drug to 3 days after study drug administration

InterventionMinutes (Mean)
Neostigmine/Glycopyrrolate10.4
Sugammadex6

Duration of Surgery

Measured from the time of first skin incision to completion of skin closure. (NCT01748643)
Timeframe: Participants will be followed for the duration of the laparoscopic gastric bypass surgery, an expected average of 1.5h

Interventionminutes (Mean)
Deep Neuromuscular Blockade, Reversal With Sugammadex61.3
Normal Neuromuscular Blockade, Reversal With Neostigmine70.6

Forced Expiratory Volume in 1 Second

Forced expiratory volume in 1 second is measured with the Vitalograph® electronic portable peak flow meter. A mean of 3 measurements in the upright posture in bed before and after surgery will be used. (NCT01748643)
Timeframe: Measured the day before surgery and 30min after completion of surgery (when the modified observer's assessment of alertness/sedation scale is 5 (Patient responds readily to name spoken in normal tone))

Interventionpercent change from baseline (Mean)
Deep Neuromuscular Blockade, Reversal With Sugammadex45.2
Normal Neuromuscular Blockade, Reversal With Neostigmine48.8

Forced Vital Capacity

Forced vital capacity is measured with the Vitalograph® electronic portable peak flow meter. A mean of 3 measurements in the upright posture in bed before and after surgery will be used. (NCT01748643)
Timeframe: Measured the day before surgery and 30min after completion of surgery (when the modified observer's assessment of alertness/sedation scale is 5 (Patient responds readily to name spoken in normal tone))

Interventionpercent change from baseline (Mean)
Deep Neuromuscular Blockade, Reversal With Sugammadex51.9
Normal Neuromuscular Blockade, Reversal With Neostigmine49.0

Number of Intra-abdominal Pressure Rises > 18cmH2O

The number of intra-abdominal pressure rises > 18cmH2O detected by the intra-abdominal CO2 insufflator. (NCT01748643)
Timeframe: Participants will be followed for the duration of the laparoscopic gastric bypass surgery, an expected average of 1.5h

Interventionnumber of intra-abdominal pressure rises (Mean)
Deep Neuromuscular Blockade, Reversal With Sugammadex0.2
Normal Neuromuscular Blockade, Reversal With Neostigmine0.3

Peak Expiratory Flow

Peak expiratory flow is measured with the Vitalograph® electronic portable peak flow meter. A mean of 3 measurements in the upright posture in bed before and after surgery will be used. (NCT01748643)
Timeframe: Measured the day before surgery and 30min after completion of surgery (when the modified observer's assessment of alertness/sedation scale is 5 (Patient responds readily to name spoken in normal tone))

Interventionpercent change from baseline (Mean)
Deep Neuromuscular Blockade, Reversal With Sugammadex51.3
Normal Neuromuscular Blockade, Reversal With Neostigmine51.5

Subjective Evaluation of the View on the Operating Field by the Surgeon

"At the end of surgery, the view on the operating field will be graded by the surgeon using a 5-point rating scale:~Extremely poor~Poor~Acceptable~Good~Optimal" (NCT01748643)
Timeframe: Participants will be followed for the duration of the laparoscopic gastric bypass surgery, an expected average of 1.5h

Interventionunits on a scale (Mean)
Deep Neuromuscular Blockade, Reversal With Sugammadex4.2
Normal Neuromuscular Blockade, Reversal With Neostigmine3.9

Time From Start of Administration of Sugammadex or Neostigmine to Recovery of the T4/T1 Ratio to 0.7 After Neuromuscular Block (NMB) Induced by Rocuronium

Mean time from start of sugammadex or neostigmine administration to recovery of T4/T1 ratio to 0.7 was assessed by applying repetitive train of four (TOF) electrical stimulations to the ulnar nerve every 15 seconds and assessing twitch response at the adductor pollicis muscle. Nerve stimulation continued until the ratio of the magnitude of the fourth twitch (T4) to first twitch (T1) reached at least 0.7. The greater the T4/T1 ratio represented the greater the recovery from NMB; with a value of 0.0 representing no recovery and 1.0 representing full recovery. Reduced recovery time of the T4/T1 ratio to 0.7 indicated faster recovery from NMB. Mean time was collected in minutes and seconds but converted to and presented in minutes only. The analysis included a procedure for the imputation of missing recovery times. (NCT00473694)
Timeframe: Up to approximately 2 hours after administration of study drug

InterventionMinutes (Mean)
Rocuronium+Sugammadex2.27
Rocuronium+Neostigmine37.68

Time From Start of Administration of Sugammadex or Neostigmine to Recovery of the T4/T1 Ratio to 0.7 After Neuromuscular Block (NMB) Induced by Vecuronium

Mean time from start of sugammadex or neostigmine administration to recovery of T4/T1 ratio to 0.7 was assessed by applying repetitive train of four (TOF) electrical stimulations to the ulnar nerve every 15 seconds and assessing twitch response at the adductor pollicis muscle. Nerve stimulation continued until the ratio of the magnitude of the fourth twitch (T4) to first twitch (T1) reached at least 0.7. The greater the T4/T1 ratio represented the greater the recovery from NMB; with a value of 0.0 representing no recovery and 1.0 representing full recovery. Reduced recovery time of the T4/T1 ratio to 0.7 indicated faster recovery from NMB. Mean time was collected in minutes and seconds but converted to and presented in minutes only. The analysis included a procedure for the imputation of missing recovery times. (NCT00473694)
Timeframe: Up to approximately 4 hours after administration of study drug

InterventionMinutes (Mean)
Vecuronium+Sugammadex4.10
Vecuronium+Neostigmine56.17

Time From Start of Administration of Sugammadex or Neostigmine to Recovery of the T4/T1 Ratio to 0.8 After Neuromuscular Block (NMB) Induced by Rocuronium

Mean time from start of sugammadex or neostigmine administration to recovery of T4/T1 ratio to 0.8 was assessed by applying repetitive train of four (TOF) electrical stimulations to the ulnar nerve every 15 seconds and assessing twitch response at the adductor pollicis muscle. Nerve stimulation continued until the ratio of the magnitude of the fourth twitch (T4) to first twitch (T1) reached at least 0.8. The greater the T4/T1 ratio represented the greater the recovery from NMB; with a value of 0.0 representing no recovery and 1.0 representing full recovery. Reduced recovery time of the T4/T1 ratio to 0.8 indicated faster recovery from NMB. Mean time was collected in minutes and seconds but converted to and presented in minutes only. The analysis included a procedure for the imputation of missing recovery times. (NCT00473694)
Timeframe: Up to approximately 3 hours after administration of study drug

InterventionMinutes (Mean)
Rocuronium+Sugammadex2.65
Rocuronium+Neostigmine45.82

Time From Start of Administration of Sugammadex or Neostigmine to Recovery of the T4/T1 Ratio to 0.8 After Neuromuscular Block (NMB) Induced by Vecuronium

Mean time from start of sugammadex or neostigmine administration to recovery of T4/T1 ratio to 0.8 was assessed by applying repetitive train of four (TOF) electrical stimulations to the ulnar nerve every 15 seconds and assessing twitch response at the adductor pollicis muscle. Nerve stimulation continued until the ratio of the magnitude of the fourth twitch (T4) to first twitch (T1) reached at least 0.8. The greater the T4/T1 ratio represented the greater the recovery from NMB; with a value of 0.0 representing no recovery and 1.0 representing full recovery. Reduced recovery time of the T4/T1 ratio to 0.8 indicated faster recovery from NMB. Mean time was collected in minutes and seconds but converted to and presented in minutes only. The analysis included a procedure for the imputation of missing recovery times. (NCT00473694)
Timeframe: Up to approximately 5 hours after administration of study drug

InterventionMinutes (Mean)
Vecuronium+Sugammadex5.55
Vecuronium+Neostigmine67.42

Time From Start of Administration of Sugammadex or Neostigmine to Recovery of the T4/T1 Ratio to 0.9 After Neuromuscular Block (NMB) Induced by Rocuronium

Mean time from start of sugammadex or neostigmine administration to recovery of T4/T1 ratio to 0.9 was assessed by applying repetitive train of four (TOF) electrical stimulations to the ulnar nerve every 15 seconds and assessing twitch response at the adductor pollicis muscle. Nerve stimulation continued until the ratio of the magnitude of the fourth twitch (T4) to first twitch (T1) reached at least 0.9. The greater the T4/T1 ratio represented the greater the recovery from NMB; with a value of 0.0 representing no recovery and 1.0 representing full recovery. Reduced recovery time of the T4/T1 ratio to 0.9 indicated faster recovery from NMB. Mean time was collected in minutes and seconds but converted to and presented in minutes only. The analysis included a procedure for the imputation of missing recovery times. (NCT00473694)
Timeframe: Up to approximately 3 hours after administration of study drug

InterventionMinutes (Mean)
Rocuronium+Sugammadex3.28
Rocuronium+Neostigmine55.50

Time From Start of Administration of Sugammadex or Neostigmine to Recovery of the T4/T1 Ratio to 0.9 After Neuromuscular Block (NMB) Induced by Vecuronium

Mean time from start of sugammadex or neostigmine administration to recovery of T4/T1 ratio to 0.9 was assessed by applying repetitive train of four (TOF) electrical stimulations to the ulnar nerve every 15 seconds and assessing twitch response at the adductor pollicis muscle. Nerve stimulation continued until the ratio of the magnitude of the fourth twitch (T4) to first twitch (T1) reached at least 0.9. The greater the T4/T1 ratio represented the greater the recovery from NMB; with a value of 0.0 representing no recovery and 1.0 representing full recovery. Reduced recovery time of the T4/T1 ratio to 0.9 indicated faster recovery from NMB. Mean time was collected in minutes and seconds but converted to and presented in minutes only. The analysis included a procedure for the imputation of missing recovery times. (NCT00473694)
Timeframe: Up to approximately 6 hours after administration of study drug

InterventionMinutes (Mean)
Vecuronium+Sugammadex8.73
Vecuronium+Neostigmine77.80

Number of Participants Able to Perform a 5-second Head Lift

The number of participants who were able to lift their head for 5 seconds was assessed by the investigator as a measure of recovery from NMB at 2 timepoints: prior to transfer to the recovery room after extubation and prior to discharge from the recovery room. The assessment was performed every 15 minutes until the first successful 5-second head lift was achieved. Participants who were not cooperative with the examination were not included in the assessment. (NCT00473694)
Timeframe: Up to 24 hours

,,,
InterventionParticipants (Count of Participants)
Prior to transfer to recovery roomPrior to discharge from recovery room
Rocuronium+Neostigmine2833
Rocuronium+Sugammadex3334
Vecuronium+Neostigmine2433
Vecuronium+Sugammadex3641

Number of Participants Aroused With Minimal Stimulation After Anesthesia (Clinical Assessment of Level of Consciousness)

The number of participants aroused with minimal stimulation was assessed as part of an overall assessment of the clinical level of consciousness by the investigator. The clinical level of consciousness was used as a measure of recovery from NMB at 2 timepoints: prior to transfer to the recovery room after extubation and prior to discharge from the recovery room. Attempts were made to arouse participants every 15 minutes with mild prodding, mild shaking, and asking questions regarding name, location, and day of the week. The assessment ended once the participant was awake and fully orientated, 24 hours, or discharged from the hospital if discharge occurs before 24 hours; whichever occurred first. Participants were given a level of consciousness based on what type of stimulation they responded to. Participants who were not cooperative with the examination were not included in the assessment. (NCT00473694)
Timeframe: Up to 24 hours

,,,
InterventionParticipants (Count of Participants)
Prior to transfer to recovery roomPrior to discharge from recovery room
Rocuronium+Neostigmine111
Rocuronium+Sugammadex90
Vecuronium+Neostigmine81
Vecuronium+Sugammadex122

Number of Participants Awake and Oriented After Anesthesia (Clinical Assessment of Level of Consciousness)

The number of participants who were awake and oriented was assessed as part of an overall assessment of the clinical level of consciousness by the investigator. The clinical level of consciousness was used as a measure of recovery from NMB at 2 timepoints: prior to transfer to the recovery room after extubation and prior to discharge from the recovery room. Attempts were made to arouse participants every 15 minutes with mild prodding, mild shaking, and asking questions regarding name, location, and day of the week. The assessment ended once the participant was awake and fully orientated, 24 hours, or discharged from the hospital if discharge occurs before 24 hours; whichever occurred first. Participants were given a level of consciousness based on what type of stimulation they responded to. Participants who were not cooperative with the examination were not included in the assessment. (NCT00473694)
Timeframe: Up to 24 hours

,,,
InterventionParticipants (Count of Participants)
Prior to transfer to recovery roomPrior to discharge from recovery room
Rocuronium+Neostigmine2032
Rocuronium+Sugammadex2634
Vecuronium+Neostigmine2033
Vecuronium+Sugammadex2739

Number of Participants Experiencing General Muscle Weakness

The number of participants experiencing general muscle weakness was assessed by the investigator as a measure of recovery from NMB at 2 timepoints: prior to transfer to the recovery room after extubation and prior to discharge from the recovery room. The assessments were performed every 15 minutes until the absence of general muscle weakness. A standardized examination form was used to determine the presence or absence of muscle weakness in various muscle groups. Participants who were not cooperative with the examination were not included in the assessment. (NCT00473694)
Timeframe: Up to 24 hours

,,,
InterventionParticipants (Count of Participants)
Prior to transfer to recovery roomPrior to discharge from recovery room
Rocuronium+Neostigmine53
Rocuronium+Sugammadex32
Vecuronium+Neostigmine23
Vecuronium+Sugammadex41

Number of Participants Responsive Only to Tactile Stimulation After Anesthesia (Clinical Assessment of Level of Consciousness)

The number of participants responsive only to tactile stimulation was assessed as part of an overall assessment of the clinical level of consciousness by the investigator. The clinical level of consciousness was used as a measure of recovery from NMB at 2 timepoints: prior to transfer to the recovery room after extubation and prior to discharge from the recovery room. Attempts were made to arouse participants every 15 minutes with mild prodding, mild shaking, and asking questions regarding name, location, and day of the week. The assessment ended once the participant was awake and fully orientated, 24 hours, or discharged from the hospital if discharge occurs before 24 hours; whichever occurred first. Participants were given a level of consciousness based on what type of stimulation they responded to. Participants who were not cooperative with the examination were not included in the assessment. (NCT00473694)
Timeframe: Up to 24 hours

,,,
InterventionParticipants (Count of Participants)
Prior to transfer to recovery roomPrior to discharge from recovery room
Rocuronium+Neostigmine30
Rocuronium+Sugammadex20
Vecuronium+Neostigmine70
Vecuronium+Sugammadex70

Time From Start of Administration of Sugammadex or Neostigmine to Recovery of the Fourth Twitch/First Twitch (T4/T1) Ratio to 0.9.

Neuromuscular functioning was monitored by applying repetitive Train-Of-Four (TOF) electrical stimulations to the ulnar nerve every 15 seconds and assessing twitch response at the adductor pollicis muscle. T1 and T4 refer to the amplitudes (heights) of the first and fourth twitches, respectively, after TOF nerve stimulation. The T4/T1 Ratio (expressed as a decimal of up to 1.0) indicates the extent of recovery from neuromuscular blockade (NMB). In this study, twitch responses were recorded until the T4/T1 Ratio reached >= 0.9, the minimum acceptable ratio that indicated recovery from NMB. A faster time to recovery of the T4/T1 Ratio to 0.9 indicates a faster recovery from NMB. (NCT00451217)
Timeframe: Day 1: From start of sugammadex or neostigmine administration to recovery of T4/T1 ratio to 0.9

InterventionMinutes (Mean)
Rocuronium + Sugammadex1.62
Rocuronium + Neostigmine26.78
Vecuronium + Sugammadex4.47
Vecuronium + Neostigmine23.43

Time From Start of Administration of Sugammadex or Neostigmine to Recovery of the T4/T1 Ratio to 0.7

Neuromuscular functioning was monitored by applying repetitive TOF electrical stimulations to the ulnar nerve every 15 seconds and assessing twitch response at the adductor pollicis muscle. T1 and T4 refer to the amplitudes (heights) of the first and fourth twitches, respectively, after TOF nerve stimulation. The T4/T1 Ratio (expressed as a decimal of up to 1.0) indicates the extent of recovery from NMB. A faster time to recovery of the T4/T1 Ratio to 0.7 indicates a faster recovery from NMB. (NCT00451217)
Timeframe: Day 1: From start of sugammadex or neostigmine administration to recovery of T4/T1 ratio to 0.7

InterventionMinutes (Mean)
Rocuronium + Sugammadex1.17
Rocuronium + Neostigmine9.60
Vecuronium + Sugammadex1.68
Vecuronium + Neostigmine9.52

Time From Start of Administration of Sugammadex or Neostigmine to Recovery of the T4/T1 Ratio to 0.8

Neuromuscular functioning was monitored by applying repetitive TOF electrical stimulations to the ulnar nerve every 15 seconds and assessing twitch response at the adductor pollicis muscle. T1 and T4 refer to the amplitudes (heights) of the first and fourth twitches, respectively, after TOF nerve stimulation. The T4/T1 Ratio (expressed as a decimal of up to 1.0) indicates the extent of recovery from NMB. A faster time to recovery of the T4/T1 Ratio to 0.8 indicates a faster recovery from NMB. (NCT00451217)
Timeframe: Day 1: From start of sugammadex or neostigmine administration to recovery of T4/T1 ratio to 0.8

InterventionMinutes (Mean)
Rocuronium + Sugammadex1.32
Rocuronium + Neostigmine15.32
Vecuronium + Sugammadex2.12
Vecuronium + Neostigmine15.33

Number of Participants With Clinical Signs of Recovery Assessed by Level of Consciousness, Head Lift and Muscle Weakness, Prior to Discharge From the Recovery Room

Just prior to discharge from the recovery room, neuromuscular recovery was assessed by monitoring every 15 minutes the following clinical signs of recovery: level of consciousness (i.e., awake and oriented, arousable with minimal stimulation, responsive only to tactile stimulation); 5-second head lift test (ability to lift the head for 5 seconds); and general muscle weakness (NCT00451217)
Timeframe: Day 1

,,,
InterventionParticipants (Count of Participants)
Consciousness: Awake and orientedConsciousness: Arousable with minimal stimulationConsciousness: Responsive only to tactile stimuliAble to perform the 5 second head liftHas general muscle weakness
Rocuronium + Neostigmine4800480
Rocuronium + Sugammadex4610470
Vecuronium + Neostigmine4310440
Vecuronium + Sugammadex4800480

Number of Participants With Clinical Signs of Recovery Assessed by Level of Consciousness, Head Lift and Muscle Weakness, Prior to Transfer to the Recovery Room After Extubation

After anesthesia and prior to transfer to the recovery room after extubation, neuromuscular recovery was assessed by monitoring every 15 minutes the following clinical signs of recovery: level of consciousness (i.e., awake and oriented, arousable with minimal stimulation, responsive only to tactile stimulation); 5-second head lift test (ability to lift the head for 5 seconds); and general muscle weakness (NCT00451217)
Timeframe: Day 1

,,,
InterventionParticipants (Count of Participants)
Consciousness: Awake and orientedConsciousness: Arousable with minimal stimulationConsciousness: Responsive only to tactile stimuliAble to perform the 5 second head liftHas general muscle weakness
Rocuronium + Neostigmine35130379
Rocuronium + Sugammadex30162383
Vecuronium + Neostigmine26145326
Vecuronium + Sugammadex29172404

Monitoring of Clinical Signs of Recovery According to Routine Anesthetic Procedures at the Trial Sites

The monitoring of clinical signs of recovery was to be conducted based on the routine anesthetic procedures at each site. (NCT00724932)
Timeframe: Up to PACU discharge (up to ~4.5 hours)

Interventionparticipants (Number)
SugammadexNA
NeostigmineNA

Number of Female Participants or Partners of Male Participants Who Became Pregnant During Study

Thirty days after administration of IMP, female participants of childbearing potential were asked whether they became pregnant during the trial and male participants were asked whether their partner (if of childbearing potential) became pregnant during the trial. (NCT00724932)
Timeframe: Up to 30 days after IMP administration

Interventionparticipants (Number)
Sugammadex0
Neostigmine0

Number of Participants With Clinical Evidence of Reoccurrence of Neuromuscular Blockade or Residual Neuromuscular Blockade (Routine Oxygen Saturation by Pulse Oximetry and Breath Frequency Measurement)

Clinical evidence of reoccurrence of NMB or residual NMB was assessed by oxygen saturation (by pulse oximetry) and breath frequency measurements as per routine practice after anesthesia and neuromuscular monitoring. (NCT00724932)
Timeframe: Up to 24 hours after IMP administration

Interventionparticipants (Number)
Sugammadex1
Neostigmine0

Number of Participants With Events Due to a Possible Interaction of Sugammadex With Endogenous Compounds or With Exogenous Compounds Other Than Rocuronium

Any evidence of events due to a possible interaction of sugammadex with endogenous compounds or with exogenous compounds other than rocuronium, was to be recorded. (NCT00724932)
Timeframe: Up to 7 days after IMP administration

Interventionparticipants (Number)
Sugammadex Only0

Number of Participants With Reoccurrence of Neuromuscular Blockade Based on the Train-of-Four- (TOF-) Watch® SX Recording (i.e. a Decline in T4/T1 Ratio From >=0.9 to <0.8 in at Least Three Consecutive TOF Values)

Neuromuscular functioning was monitored by applying repetitive TOF electrical stimulations to the ulnar nerve every 15 seconds and assessing twitch response at the adductor pollicis muscle. T1 and T4 refer to the magnitudes (heights) of the 1st and 4th twitches, respectively, after TOF stimulation. The T4/T1 Ratio is expressed as a decimal of up to 1.0. A higher ratio indicates greater recovery from NMB. A decline in the T4/T1 ratio from >=0.9 (indicating a recovery from NMB) to <0.8 for at least three consecutive TOF values was considered to be a reoccurrence of NMB. (NCT00724932)
Timeframe: Up to 30 minutes after IMP administration

Interventionparticipants (Number)
Sugammadex0
Neostigmine0

Number of Participants With Train-of-Four- (TOF-) Watch® SX and Arm Board Related Adverse Events

Events were to be collected for the entire period of neuromuscular transmission monitoring and were defined as an occurrence that resulted or could have resulted in: death; a serious deterioration in the state of health of a user; an occurrence which might, if it recurred, lead to death or serious deterioration in health; inaccuracy as well as any inadequacy in the labeling or instructions which could cause misuse or incorrect maintenance or adjustment which might lead to a death or serious deterioration in health; an examination of the medical device or the information supplied with the medical device indicated some factor with the potential for an incident involving death or serious deterioration in health; malfunction or deterioration in characteristics and/or performance of a medical device, which might lead to death, or serious deterioration in health; technical/medical recalls involving risk of death or serious deterioration in the state of health of the user. (NCT00724932)
Timeframe: From induction of anesthesia to recovery from NMB (up to ~3 hours)

Interventionparticipants (Number)
Sugammadex0
Neostigmine0

Time From Actual Operating Room Discharge to Actual PACU Discharge

The time of Operating Room discharge was defined as the actual time the participant was discharged from the Operating Room. The time of PACU discharge was defined as the actual time the participant was discharged from the PACU. (NCT00724932)
Timeframe: From actual Operating Room discharge to actual PACU discharge (up to ~4.4 hours)

Interventionminutes (Mean)
Sugammadex264
Neostigmine207

Time From Actual Operating Room Discharge to PACU Discharge Ready

The time of Operating Room discharge was defined as the actual time the participant was discharged from the Operating Room. The time of PACU discharge ready was defined as the time at which the participant had a Modified Aldrete Score >=9. The Modified Aldrete Score was to be assessed at PACU arrival, at 5, 15, 30, 45, 60 minutes after PACU arrival and every 15 minutes thereafter (if applicable) until the participant was ready to be discharged from the PACU. The Modified Aldrete Postoperative Recovery Score (range = 0-10) is calculated based on scores of 0 to 2 each for Activity, Respiration, Circulation, Consciousness and Oxygen Saturation, with a higher score indicating increased postoperative recovery. (NCT00724932)
Timeframe: From actual Operating Room discharge to PACU discharge ready (up to ~30 minutes)

Interventionminutes (Mean)
Sugammadex24
Neostigmine29

Time From Operating Room Admission to Actual Operating Room Discharge

The time of Operating Room admission was defined as the time at which the participant was physically placed into the Operating Room. The time of Operating Room discharge was defined as the actual time the participant was discharged from the Operating Room. (NCT00724932)
Timeframe: From Operating Room admission to actual Operating Room discharge (up to ~3 hours)

Interventionminutes (Mean)
Sugammadex158
Neostigmine169

Time From Operating Room Admission to Operating Room Discharge Ready

The time of Operating Room admission was defined as the time at which the participant was physically placed into the Operating Room. The time of Operating Room discharge ready was defined as time at which the participant had T4/T1 ratio of ≥0.9 and the participant's wound dressing was in place. (NCT00724932)
Timeframe: From Operating Room admission to Operating Room discharge ready (up to ~3 hours)

Interventionminutes (Mean)
Sugammadex154
Neostigmine165

Time From Operating Room Discharge Ready to Actual Operating Room Discharge

The time of Operating Room discharge ready was defined as time at which the participant had T4/T1 ratio of >=0.9 and the participant's wound dressing was in place. The time of Operating Room discharge was defined as the actual time the participant was discharged from the Operating Room. (NCT00724932)
Timeframe: From Operating Room discharge ready to actual Operating Room discharge (up to ~5 minutes)

Interventionminutes (Mean)
Sugammadex4
Neostigmine5

Time From Operating Room Discharge Ready to Actual PACU Discharge

The time of Operating Room discharge ready was defined as time at which the participant had T4/T1 ratio of >=0.9 and the participant's wound dressing was in place. The time of PACU discharge was defined as the actual time the participant was discharged from the PACU. (NCT00724932)
Timeframe: From Operating Room discharge ready to actual PACU discharge (up to ~4.5 hours)

Interventionminutes (Mean)
Sugammadex268
Neostigmine210

Time From Operating Room Discharge Ready to Post Anesthetic Care Unit (PACU) Discharge Ready

The time of Operating Room discharge ready was defined as time at which the participant had T4/T1 ratio of >=0.9 and the participant's wound dressing was in place. The time of PACU discharge ready was defined as the time at which the participant had a Modified Aldrete Score >=9. The Modified Aldrete Score was to be assessed at PACU arrival, at 5, 15, 30, 45, 60 minutes after PACU arrival and every 15 minutes thereafter (if applicable) until the participant was ready to be discharged from the PACU. The Modified Aldrete Postoperative Recovery Score (range = 0-10) is calculated based on scores of 0 to 2 each for Activity, Respiration, Circulation, Consciousness and Oxygen Saturation, with a higher score indicating increased postoperative recovery. (NCT00724932)
Timeframe: From Operating Room discharge ready to PACU discharge ready (up to ~33 minutes)

Interventionminutes (Mean)
Sugammadex28
Neostigmine33

Time From PACU Admit to Actual PACU Discharge

The time of PACU admit was defined as the actual time the participant was admitted to the PACU. The time of PACU discharge was defined as the actual time the participant was discharged from the PACU. (NCT00724932)
Timeframe: From PACU admit to actual PACU discharge (up to ~4.3 hours)

Interventionminutes (Mean)
Sugammadex260
Neostigmine203

Time From PACU Admit to PACU Discharge Ready

The time of PACU admit was defined as the actual time the participant was admitted to the PACU. The time of PACU discharge ready was defined as the time at which the participant had a Modified Aldrete Score >=9. The Modified Aldrete Score was to be assessed at PACU arrival, at 5, 15, 30, 45, 60 minutes after PACU arrival and every 15 minutes thereafter (if applicable) until the participant was ready to be discharged from the PACU. The Modified Aldrete Postoperative Recovery Score (range = 0-10) is calculated based on scores of 0 to 2 each for Activity, Respiration, Circulation, Consciousness and Oxygen Saturation, with a higher score indicating increased postoperative recovery. (NCT00724932)
Timeframe: From PACU admit to PACU discharge ready (up to ~25 minutes)

Interventionminutes (Mean)
Sugammadex20
Neostigmine25

Time From Start of Administration of IMP to Recovery of the T4/T1 Ratio to 0.7

Neuromuscular functioning was monitored by applying repetitive TOF electrical stimulations to the ulnar nerve every 15 seconds & assessing twitch response at the adductor pollicis muscle. T1 and T4 refer to the magnitudes (heights) of the first and fourth twitches, respectively, after TOF nerve stimulation. The T4/T1 Ratio (expressed as a decimal of up to 1.0). A faster time to recovery of the T4/T1 Ratio to 0.7 indicates a faster recovery from NMB. (NCT00724932)
Timeframe: From start of IMP administration to recovery of T4/T1 Ratio to 0.7 (ranging from ~2 minutes to ~5 minutes)

Interventionminutes (Geometric Mean)
Sugammadex1.6
Neostigmine4.1

Time From Start of Administration of IMP to Recovery of the T4/T1 Ratio to 0.8

Neuromuscular functioning was monitored by applying repetitive TOF electrical stimulations to the ulnar nerve every 15 seconds & assessing twitch response at the adductor pollicis muscle. T1 and T4 refer to the magnitudes (heights) of the first and fourth twitches, respectively, after TOF nerve stimulation. The T4/T1 Ratio (expressed as a decimal of up to 1.0). A faster time to recovery of the T4/T1 Ratio to 0.8 indicates a faster recovery from NMB. (NCT00724932)
Timeframe: From start of IMP administration to recovery of T4/T1 Ratio to 0.8 (ranging from ~2 minutes to ~6 minutes)

Interventionminutes (Geometric Mean)
Sugammadex1.9
Neostigmine5.6

Time From Start of Administration of Investigational Medicinal Product (IMP, Sugammadex or Neostigmine) to Recovery of the Fourth Twitch/First Twitch (T4/T1) Ratio to 0.9

Neuromuscular functioning was monitored by applying repetitive Train-Of-Four (TOF) electrical stimulations to the ulnar nerve every 15 seconds & assessing twitch response at the adductor pollicis muscle. T1 and T4 refer to the magnitudes (heights) of the first and fourth twitches, respectively, after TOF nerve stimulation. The T4/T1 Ratio (expressed as a decimal of up to 1.0) indicates the extent of recovery from neuromuscular blockade (NMB). In this study, twitch responses were recorded until the T4/T1 Ratio reached >= 0.9, the minimum acceptable ratio that indicated recovery from NMB. A faster time to recovery of the T4/T1 Ratio to 0.9 indicates a faster recovery from NMB. (NCT00724932)
Timeframe: From start of IMP administration to recovery of T4/T1 ratio to 0.9 (ranging from ~2 minutes to ~9 minutes)

Interventionminutes (Geometric Mean)
Sugammadex2.4
Neostigmine8.4

Time From Start of Administration of the Last Dose of Rocuronium to the Time of 1-2 PTC in the 4.0 mg.Kg-1 Sugammadex Group

The time of 1-2 PTC refers to when 1-2 twitches are generated after tetanic stimulation. Time to 1-2 PTC is the time point of the last single twitch >0 or baseline (in case of noise or direct stimulation) within the sequence of a PTC measurement. 1-2 PTC was the target depth of NMB at which sugammadex was to be administered. (NCT00724932)
Timeframe: From last dose of rocuronium to 1-2 PTC (up to ~9 minutes)

Interventionminutes (Geometric Mean)
Sugammadex Only8.9

Time From Start of Administration of the Last Dose of Rocuronium to the Time of Reappearance of T2 in the 50 μg.Kg-1 Neostigmine Group

The time of reappearance of T2 refers to when the second twitch reappears after TOF stimulation. Reappearance of T2 was the target depth of NMB at which neostigmine was to be administered. (NCT00724932)
Timeframe: From last dose of rocuronium to reappearance of T2 (up to ~26 minutes)

Interventionminutes (Geometric Mean)
Neostigmine Only25.6

Time From Start of IMP Administration to Actual Operating Room Discharge

The time of IMP administration was defined as the actual time at which IMP administration was started. The time of Operating Room discharge was defined as the actual time at which the participant was discharged from the Operating Room. (NCT00724932)
Timeframe: From start of IMP administration to actual Operating Room discharge (up to ~26 minutes)

Interventionminutes (Mean)
Sugammadex19
Neostigmine26

Time From Start of IMP Administration to Operating Room Discharge Ready

The time of IMP administration was defined as the actual time at which IMP administration was started. The time of Operating Room discharge ready was defined as time at which the participant had T4/T1 ratio of >=0.9 and the participant's wound dressing was in place. (NCT00724932)
Timeframe: From start of IMP administration to Operating Room discharge ready (up to ~21 minutes)

Interventionminutes (Mean)
Sugammadex15
Neostigmine21

Time From Start of IMP Administration to Tracheal Extubation

The time of IMP administration was defined as the actual time at which IMP administration was started. The time of tracheal extubation was defined as the actual time at which the participant was extubated. (NCT00724932)
Timeframe: From start of IMP administration to tracheal extubation (up to ~21 minutes)

Interventionminutes (Mean)
Sugammadex14
Neostigmine21

Time From Tracheal Extubation to Actual Operating Room Discharge

The time of tracheal extubation was defined as the actual time at which the participant was extubated. The time of Operating Room discharge was defined as the actual time at which the participant was discharged from the Operating Room. (NCT00724932)
Timeframe: From tracheal extubation to actual OR discharge (up to ~5 minutes)

Interventionminutes (Mean)
Sugammadex5
Neostigmine5

Time From Tracheal Extubation to Operating Room Discharge Ready

The time of tracheal extubation was defined as the actual time at which the participant was extubated. The time of Operating Room discharge ready was defined as time at which the participant had T4/T1 ratio of >=0.9 and the participant's wound dressing was in place. (NCT00724932)
Timeframe: From tracheal extubation to Operating Room discharge ready (up to ~1 minute)

Interventionminutes (Mean)
Sugammadex1
Neostigmine0

Mean Diastolic Blood Pressure

Diastolic Blood Pressure was measured at screening, before start of rocuronium administration, before start of IMP administration, at 2, 5, 10, 30 minutes post-IMP administration, and at the post-anesthetic visit (the day after surgery). (NCT00724932)
Timeframe: At screening, pre-rocuronium, pre-IMP, at 2, 5, 10, and 30 minutes post-IMP, and at the post-anesthetic visit (the day after surgery)

,
Interventionmm Hg (Mean)
ScreeningPre-rocuroniumPre-IMP2 minutes post-IMP (N=65, N=65)5 minutes post-IMP10 minutes post-IMP (N=66, N=66)30 minutes post-IMP (N=65, N=66)Post-anesthetic visit (N=66, N=66)
Neostigmine82.858.372.572.669.268.773.175.2
Sugammadex80.958.272.873.472.471.874.376.7

Mean Heart Rate

Heart Rate was measured at screening, before start of rocuronium administration, before start of IMP administration, at 2, 5, 10, 30 minutes post-IMP administration, and at the post-anesthetic visit (the day after surgery). (NCT00724932)
Timeframe: At screening, pre-rocuronium, pre-IMP, at 2, 5, 10, and 30 minutes post-IMP, and at the post-anesthetic visit (the day after surgery)

,
Interventionbeats per minute (Mean)
ScreeningPre-rocuroniumPre-IMP2 minutes post-IMP (N=65, N=65)5 minutes post-IMP10 minutes post-IMP (N=66, N=66)30 minutes post-IMP (N=65, N=66)Post-anesthetic visit (N=66, N=66)
Neostigmine74.663.668.065.357.156.365.171.9
Sugammadex72.963.468.366.064.967.373.172.7

Mean Systolic Blood Pressure

Systolic Blood Pressure was measured at screening, before start of rocuronium administration, before start of IMP administration, at 2, 5, 10, 30 minutes post-IMP administration, and at the post-anesthetic visit (the day after surgery). (NCT00724932)
Timeframe: At screening, pre-rocuronium, pre-IMP, at 2, 5, 10, and 30 minutes post-IMP, and at the post-anesthetic visit (the day after surgery)

,
Interventionmm Hg (Mean)
ScreeningPre-rocuroniumPre-IMP2 minutes post-IMP (N=65, N=65)5 minutes post-IMP10 minutes post-IMP (N=66, N=66)30 minutes post-IMP (N=65, N=66)Post-anesthetic visit (N=66, N=66)
Neostigmine133.9101.6121.3122.5118.0119.3131.7125.4
Sugammadex132.798.2122.1122.5122.6124.0132.9127.3

Number of Participants Who Experienced Pre-treatment Non-serious Adverse Events (AEs) and Post-treatment Non-serious AEs

An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body, whether or not considered related to the use of the product. Participants were monitored for occurrence AEs for up to 7 days after last dose IMP. Pre-treatment refers to the period from signing of the informed consent up to start of IMP administration. Post-treatment refers to the period from start of IMP administration to 7 days after IMP administration. (NCT00724932)
Timeframe: From signing of informed consent to end of trial (7 days after surgery)

,
Interventionparticipants (Number)
Pre-treatment non-serious AEPost-treatment non-serious AE
Neostigmine3465
Sugammadex3865

Number of Participants Who Experienced Pre-treatment Serious Adverse Events (SAEs) and Post-treatment SAEs

"An SAE is defined as any untoward medical occurrence that at any dose: results in death; is life-threatening; requires in-patient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; or is a congenital anomaly/birth defect.~Participants were monitored for occurrence SAEs for up to 7 days after last dose IMP. Pre-treatment refers to the period from signing of the informed consent up to start of IMP administration. Post-treatment refers to the period from start of IMP administration to 7 days after IMP administration." (NCT00724932)
Timeframe: From signing of informed consent to end of trial (7 days after surgery)

,
Interventionparticipants (Number)
Pre-treatment SAEPost-treatment SAE
Neostigmine06
Sugammadex14

Time From Start of Administration of IMP to Recovery of the T4/T1 Ratio to 0.5 and 0.6

Neuromuscular functioning was monitored by applying repetitive TOF electrical stimulations to the ulnar nerve every 15 seconds & assessing twitch response at the adductor pollicis muscle. T1 and T4 refer to the magnitudes (heights) of the first and fourth twitches, respectively, after TOF nerve stimulation. The T4/T1 Ratio (expressed as a decimal of up to 1.0). Faster times to recovery of the T4/T1 Ratios to 0.5 and 0.6 indicate faster recoveries from NMB. (NCT00724932)
Timeframe: From start of IMP administration to recovery of T4/T1 Ratio to 0.5 and 0.6 (ranging from ~1 minute to ~4 minutes)

,
Interventionminutes (Geometric Mean)
Recovery of T4/T1 Ratio to 0.5Recovery of T4/T1 Ratio to 0.6
Neostigmine2.83.4
Sugammadex1.31.5

Time From Start of Administration of the Last Dose of Rocuronium to Recovery of the T4/T1 Ratio to 0.5, 0.6, 0.7, 0.8 and 0.9

Neuromuscular functioning was monitored by applying repetitive TOF electrical stimulations to the ulnar nerve every 15 seconds & assessing twitch response at the adductor pollicis muscle. T1 and T4 refer to the magnitudes (heights) of the first and fourth twitches, respectively, after TOF nerve stimulation. The T4/T1 Ratio (expressed as a decimal of up to 1.0). A faster time to recovery of the T4/T1 Ratio indicates a faster recovery from NMB. (NCT00724932)
Timeframe: From start of last dose of rocuronium to recovery of T4/T1 Ratio to 0.5, 0.6, 0.7, 0.8 and 0.9 (ranging from ~12 minutes to ~36 minutes)

,
Interventionminutes (Geometric Mean)
Recovery of T4/T1 ratio to 0.5Recovery of T4/T1 ratio to 0.6Recovery of T4/T1 ratio to 0.7Recovery of T4/T1 ratio to 0.8Recovery of T4/T1 ratio to 0.9 (N=65, N=61)
Neostigmine30.030.731.633.235.2
Sugammadex11.711.912.112.513.3

Sugammadex ED90

"Complete reversal of neuromuscular blockade occured when the patient had a TOF T4/T1 ≥ 0.9 within eight minutes of sugammadex infusion.~The sequencial design method of up-and-down was applied to determine the minimum effective dose in 90% of patients (ED90). An effective dose is one that achieves complete reversal of neuromuscular blockade that is defined as a measure of TOF equal or higher than 0.9, or a relationship between T4 an T1 measure ≥ 0.9, within eight minutes of sugammadex infusion." (NCT02568345)
Timeframe: 8 minutes

Interventionmg/kg (Number)
Sugammadex ED902.40

Additional Rescue Doses Per Hour Ratio.

Additional Rescue Doses Per Hour Ratio is the number per hour of addition of rescue dose administrated with 10% of initial NMBAs dose. The formula is {(Addition number + 1 / Anesthetic time) x 60}. (NCT02495038)
Timeframe: Intraoperative, an average of 3 hours.

Interventionratio (Mean)
Intubating Dose, Group I1.43455
10% Reduction of Combination of Esmeron® and Nimbex®, Group S1.21014
20% Reduction of Combination of Esmeron® and Nimbex®, Group L0.82128

Anesthetic Time

Time from induction to recovery of anesthesia, asessed up to 3 hours. (NCT02495038)
Timeframe: Intraoperative, an average 4 hours.

InterventionMinute (Mean)
Intubating Dose, Group I163.0
10% Reduction of Combination of Esmeron® and Nimbex®, Group S159.9
20% Reduction of Combination of Esmeron® and Nimbex®, Group L161.4

Bispectral Index

"The BIS monitor provides a single dimensionless number, which ranges from 0 (equivalent to EEG silence) to 100. A BIS value between 40 and 60 indicates an appropriate level for general anesthesia, as recommended by the manufacturer.~Before induction of anesthesia, bispectral index was measured for baseline. And after injection of NMBAs, bispectral index was measured at 10 min." (NCT02495038)
Timeframe: Before and after induction of anesthesia, an average 10 min.

InterventionBIS score (Mean)
Intubating Dose, Group I46.0
10% Reduction of Combination of Esmeron® and Nimbex®, Group S46.1
20% Reduction of Combination of Esmeron® and Nimbex®, Group L44.3

Body Temperature

"Before induction of anesthesia, body temperature was measured for baseline by oral temperature probe.~And after injection of NMBAs, non invasive blood pressure was measured at 10 min by esophageal temperature probe." (NCT02495038)
Timeframe: Before and after induction of anesthesia, an average 10 min.

InterventionCelcius degree (Mean)
Intubating Dose, Group I36.3
10% Reduction of Combination of Esmeron® and Nimbex®, Group S36.3
20% Reduction of Combination of Esmeron® and Nimbex®, Group L36.3

Duration 25% of Neuromuscular Blocking Agents(NMBAs)

Time from administration of initial NMBAs to Train-of-four (TOF) ratio >25%, assessed up to 2 hours during general anesthesia. (NCT02495038)
Timeframe: Intraoperative, an average of 1 hours

InterventionMinute (Mean)
Intubating Dose, Group I51.3
10% Reduction of Combination of Esmeron® and Nimbex®, Group S47.9
20% Reduction of Combination of Esmeron® and Nimbex®, Group L39.4

Onset of Neuromuscular Blocking Agents(NMBAs)

Time from administration of initial NMBAs to Train-of-four (TOF) ratio=0, assessed up to 15 minutes during general anesthesia. (NCT02495038)
Timeframe: Intraoperative, an average of 5 minutes

InterventionSecond (Mean)
Intubating Dose, Group I212.8
10% Reduction of Combination of Esmeron® and Nimbex®, Group S230.1
20% Reduction of Combination of Esmeron® and Nimbex®, Group L399.3

Operation Time

Time from skin incision to wound dressing assessed up to 8 hours. (NCT02495038)
Timeframe: Intraoperative, an average of 3 hours.

InterventionMinute (Mean)
Intubating Dose, Group I151.8
10% Reduction of Combination of Esmeron® and Nimbex®, Group S147.0
20% Reduction of Combination of Esmeron® and Nimbex®, Group L145.9

Peripheral Oxygen Saturation

"Before induction of anesthesia, peripheral oxygen saturation was measured for baseline.~And after injection of NMBAs, peripheral oxygen saturation was measured at 10 min." (NCT02495038)
Timeframe: Before and after induction of anesthesia, an average 10 min.

InterventionPercentage (Mean)
Intubating Dose, Group I100
10% Reduction of Combination of Esmeron® and Nimbex®, Group S99.9
20% Reduction of Combination of Esmeron® and Nimbex®, Group L100

Recovery Index of Neuromuscular Blocking Agents(NMBAs)

Time from TOF ratio 25% to 75%, assessed up to 1 hour during general anesthesia. (NCT02495038)
Timeframe: Intraoperative, an average of 20 minutes

InterventionMinute (Mean)
Intubating Dose, Group I15.9
10% Reduction of Combination of Esmeron® and Nimbex®, Group S16.2
20% Reduction of Combination of Esmeron® and Nimbex®, Group L14.1

Non Invasive Blood Pressure,

"Before induction of anesthesia, non invasive blood pressure was measured for baseline.~And after injection of NMBAs, non invasive blood pressure was measured at 10 min." (NCT02495038)
Timeframe: Before and after induction of anesthesia, an average 10 min.

,,
InterventionmmHg (Mean)
Systolic pressureDiastolic pressure
10% Reduction of Combination of Esmeron® and Nimbex®, Group S128.376.7
20% Reduction of Combination of Esmeron® and Nimbex®, Group L128.474.8
Intubating Dose, Group I128.375.6

Reviews

50 reviews available for neostigmine and Neuromuscular Blockade

ArticleYear
Sugammadex compared with neostigmine in reducing postoperative pulmonary complications in older patients: a meta-analysis.
    British journal of anaesthesia, 2022, Volume: 128, Issue:4

    Topics: Aged; Cholinesterase Inhibitors; Humans; Neostigmine; Neuromuscular Blockade; Neuromuscular Nondepol

2022
Postoperative hypotonia in a patient with stiff person syndrome: a case report and literature review.
    Canadian journal of anaesthesia = Journal canadien d'anesthesie, 2022, Volume: 69, Issue:11

    Topics: Anesthetics, Inhalation; Chelating Agents; Cholinesterase Inhibitors; Female; Humans; Muscle Hypoton

2022
Sugammadex for reversing neuromuscular blockages after lung surgery: A systematic review and meta-analysis.
    Medicine, 2022, Sep-30, Volume: 101, Issue:39

    Topics: Humans; Length of Stay; Lung; Neostigmine; Neuromuscular Blockade; Postoperative Complications; Suga

2022
The effect of sugammadex versus neostigmine on postoperative nausea and vomiting: a meta-analysis of randomized controlled trials with trial sequential analysis.
    Minerva anestesiologica, 2023, Volume: 89, Issue:5

    Topics: Adult; Anesthesia Recovery Period; Antiemetics; Humans; Neostigmine; Neuromuscular Blockade; Postope

2023
Sugammadex
    Current drug safety, 2024, Volume: 19, Issue:1

    Topics: Adult; Child; Humans; Neostigmine; Neuromuscular Blockade; Neuromuscular Nondepolarizing Agents; Pos

2024
Superiority of sugammadex in preventing postoperative pulmonary complications.
    Chinese medical journal, 2023, Jul-05, Volume: 136, Issue:13

    Topics: Humans; Neostigmine; Neuromuscular Blockade; Pneumonia; Postoperative Complications; Respiratory Ins

2023
Reversal of neuromuscular block with sugammadex compared with neostigmine and postoperative pulmonary complications in obese patients: meta-analysis and trial sequential analysis.
    British journal of anaesthesia, 2023, Volume: 130, Issue:6

    Topics: Cholinesterase Inhibitors; Humans; Neostigmine; Neuromuscular Blockade; Postoperative Complications;

2023
Postoperative pulmonary complications after sugammadex reversal of neuromuscular blockade: a systematic review and meta-analysis with trial sequential analysis.
    BMC anesthesiology, 2023, 04-20, Volume: 23, Issue:1

    Topics: Cholinesterase Inhibitors; Humans; Neostigmine; Neuromuscular Blockade; Neuromuscular Blocking Agent

2023
Sugammadex Is Associated With Reduced Pulmonary Complications in Patients With Respiratory Dysfunction.
    The Journal of surgical research, 2023, Volume: 290

    Topics: Cholinesterase Inhibitors; Humans; Neostigmine; Neuromuscular Blockade; Pleural Effusion; Postoperat

2023
Clarifying the grey space of sugammadex induced bradycardia.
    Current opinion in anaesthesiology, 2023, Aug-01, Volume: 36, Issue:4

    Topics: Bradycardia; Humans; Neostigmine; Neuromuscular Blockade; Retrospective Studies; Sugammadex

2023
Sugammadex Reduced the Incidence of Postoperative Pulmonary Complications in Susceptible Patients Identified by ARISCAT Risk Index: Systematic Review and Meta-analysis.
    Advances in therapy, 2023, Volume: 40, Issue:9

    Topics: Humans; Incidence; Neostigmine; Neuromuscular Blockade; Postoperative Complications; Pulmonary Atele

2023
Failure of reversion of neuromuscular block with sugammadex in patient with myasthenia gravis: case report and brief review of literature.
    BMC anesthesiology, 2019, 08-17, Volume: 19, Issue:1

    Topics: Adult; Cholinesterase Inhibitors; Female; gamma-Cyclodextrins; Humans; Myasthenia Gravis; Neostigmin

2019
[Algorithm-based preventive strategies for avoidance of residual neuromuscular blocks].
    Der Anaesthesist, 2019, Volume: 68, Issue:11

    Topics: Algorithms; Cholinesterase Inhibitors; Delayed Emergence from Anesthesia; Humans; Neostigmine; Neuro

2019
The effects of acetylcholinesterase inhibitors on morbidity after general anesthesia and surgery.
    Neuropharmacology, 2020, 08-15, Volume: 173

    Topics: Anesthesia, General; Cardiovascular System; Cholinesterase Inhibitors; General Surgery; Humans; Morb

2020
Role of sugammadex in accelerating postoperative discharge: An updated meta-analysis.
    Journal of clinical anesthesia, 2020, Volume: 65

    Topics: Anesthesia Recovery Period; Cholinesterase Inhibitors; Humans; Neostigmine; Neuromuscular Blockade;

2020
Epidemiology and outcomes of residual neuromuscular blockade: A systematic review of observational studies.
    Journal of clinical anesthesia, 2020, Volume: 66

    Topics: Adult; Delayed Emergence from Anesthesia; Humans; Neostigmine; Neuromuscular Blockade; Neuromuscular

2020
Sugammadex versus neostigmine for routine reversal of rocuronium block in adult patients: A cost analysis.
    Journal of clinical anesthesia, 2020, Volume: 67

    Topics: Adult; Cholinesterase Inhibitors; Costs and Cost Analysis; gamma-Cyclodextrins; Humans; Neostigmine;

2020
Role of sugammadex in accelerating postoperative discharge: A meta-analysis.
    Journal of clinical anesthesia, 2017, Volume: 39

    Topics: Androstanols; Anesthesia, General; gamma-Cyclodextrins; Humans; Neostigmine; Neuromuscular Blockade;

2017
[Residual neuromuscular blockade].
    Der Anaesthesist, 2017, Volume: 66, Issue:6

    Topics: Anesthesia Recovery Period; Delayed Emergence from Anesthesia; gamma-Cyclodextrins; Humans; Incidenc

2017
[Residual neuromuscular blockade].
    Der Anaesthesist, 2017, Volume: 66, Issue:6

    Topics: Anesthesia Recovery Period; Delayed Emergence from Anesthesia; gamma-Cyclodextrins; Humans; Incidenc

2017
[Residual neuromuscular blockade].
    Der Anaesthesist, 2017, Volume: 66, Issue:6

    Topics: Anesthesia Recovery Period; Delayed Emergence from Anesthesia; gamma-Cyclodextrins; Humans; Incidenc

2017
[Residual neuromuscular blockade].
    Der Anaesthesist, 2017, Volume: 66, Issue:6

    Topics: Anesthesia Recovery Period; Delayed Emergence from Anesthesia; gamma-Cyclodextrins; Humans; Incidenc

2017
[Residual neuromuscular blockade].
    Der Anaesthesist, 2017, Volume: 66, Issue:6

    Topics: Anesthesia Recovery Period; Delayed Emergence from Anesthesia; gamma-Cyclodextrins; Humans; Incidenc

2017
[Residual neuromuscular blockade].
    Der Anaesthesist, 2017, Volume: 66, Issue:6

    Topics: Anesthesia Recovery Period; Delayed Emergence from Anesthesia; gamma-Cyclodextrins; Humans; Incidenc

2017
[Residual neuromuscular blockade].
    Der Anaesthesist, 2017, Volume: 66, Issue:6

    Topics: Anesthesia Recovery Period; Delayed Emergence from Anesthesia; gamma-Cyclodextrins; Humans; Incidenc

2017
[Residual neuromuscular blockade].
    Der Anaesthesist, 2017, Volume: 66, Issue:6

    Topics: Anesthesia Recovery Period; Delayed Emergence from Anesthesia; gamma-Cyclodextrins; Humans; Incidenc

2017
[Residual neuromuscular blockade].
    Der Anaesthesist, 2017, Volume: 66, Issue:6

    Topics: Anesthesia Recovery Period; Delayed Emergence from Anesthesia; gamma-Cyclodextrins; Humans; Incidenc

2017
The comparative efficacy and safety of sugammadex and neostigmine in reversing neuromuscular blockade in adults. A Cochrane systematic review with meta-analysis and trial sequential analysis.
    Anaesthesia, 2018, Volume: 73, Issue:5

    Topics: Adult; Clinical Trials as Topic; Humans; Neostigmine; Neuromuscular Blockade; Sugammadex

2018
Profile of sugammadex for reversal of neuromuscular blockade in the elderly: current perspectives.
    Clinical interventions in aging, 2018, Volume: 13

    Topics: Aged; Androstanols; Anesthesia; Cholinesterase Inhibitors; gamma-Cyclodextrins; Humans; Middle Aged;

2018
Atrio-ventricular Block Following Neostigmine-Glycopyrrolate Reversal in Non-heart Transplant Patients: Case Report.
    Anesthesia progress, 2018,Fall, Volume: 65, Issue:3

    Topics: Action Potentials; Anticonvulsants; Atrioventricular Block; Atrioventricular Node; Cholinesterase In

2018
Is lower-dose sugammadex a cost-saving strategy for reversal of deep neuromuscular block? Facts and fiction.
    BMC anesthesiology, 2018, 11-06, Volume: 18, Issue:1

    Topics: Cost Savings; Dose-Response Relationship, Drug; Humans; Neostigmine; Neuromuscular Blockade; Neuromu

2018
Reversal of mivacurium-induced neuromuscular blockade with a cholinesterase inhibitor: A systematic review.
    Acta anaesthesiologica Scandinavica, 2019, Volume: 63, Issue:5

    Topics: Cholinesterase Inhibitors; Edrophonium; Humans; Mivacurium; Neostigmine; Neuromuscular Blockade; Ran

2019
Sugammadex Administration in Pregnant Women and in Women of Reproductive Potential: A Narrative Review.
    Anesthesia and analgesia, 2020, Volume: 130, Issue:6

    Topics: Adult; Anesthesia Recovery Period; Anesthesia, General; Anesthesia, Obstetrical; Cesarean Section; C

2020
Safety of sugammadex for reversal of neuromuscular block.
    Expert opinion on drug safety, 2019, Volume: 18, Issue:10

    Topics: Cholinesterase Inhibitors; Humans; Neostigmine; Neuromuscular Blockade; Neuromuscular Nondepolarizin

2019
[Possible clinical potential in reverting muscular block with sugammadex in anaesthesia and surgery].
    Ugeskrift for laeger, 2013, Feb-11, Volume: 175, Issue:7

    Topics: Androstanols; Anesthesia; Anesthesia Recovery Period; gamma-Cyclodextrins; Humans; Intubation, Intra

2013
Residual paralysis: a real problem or did we invent a new disease?
    Canadian journal of anaesthesia = Journal canadien d'anesthesie, 2013, Volume: 60, Issue:7

    Topics: Anesthesia Recovery Period; Cholinesterase Inhibitors; gamma-Cyclodextrins; Humans; Neostigmine; Neu

2013
Residual paralysis: a real problem or did we invent a new disease?
    Canadian journal of anaesthesia = Journal canadien d'anesthesie, 2013, Volume: 60, Issue:7

    Topics: Anesthesia Recovery Period; Cholinesterase Inhibitors; gamma-Cyclodextrins; Humans; Neostigmine; Neu

2013
Residual paralysis: a real problem or did we invent a new disease?
    Canadian journal of anaesthesia = Journal canadien d'anesthesie, 2013, Volume: 60, Issue:7

    Topics: Anesthesia Recovery Period; Cholinesterase Inhibitors; gamma-Cyclodextrins; Humans; Neostigmine; Neu

2013
Residual paralysis: a real problem or did we invent a new disease?
    Canadian journal of anaesthesia = Journal canadien d'anesthesie, 2013, Volume: 60, Issue:7

    Topics: Anesthesia Recovery Period; Cholinesterase Inhibitors; gamma-Cyclodextrins; Humans; Neostigmine; Neu

2013
Residual paralysis: a real problem or did we invent a new disease?
    Canadian journal of anaesthesia = Journal canadien d'anesthesie, 2013, Volume: 60, Issue:7

    Topics: Anesthesia Recovery Period; Cholinesterase Inhibitors; gamma-Cyclodextrins; Humans; Neostigmine; Neu

2013
Residual paralysis: a real problem or did we invent a new disease?
    Canadian journal of anaesthesia = Journal canadien d'anesthesie, 2013, Volume: 60, Issue:7

    Topics: Anesthesia Recovery Period; Cholinesterase Inhibitors; gamma-Cyclodextrins; Humans; Neostigmine; Neu

2013
Residual paralysis: a real problem or did we invent a new disease?
    Canadian journal of anaesthesia = Journal canadien d'anesthesie, 2013, Volume: 60, Issue:7

    Topics: Anesthesia Recovery Period; Cholinesterase Inhibitors; gamma-Cyclodextrins; Humans; Neostigmine; Neu

2013
Residual paralysis: a real problem or did we invent a new disease?
    Canadian journal of anaesthesia = Journal canadien d'anesthesie, 2013, Volume: 60, Issue:7

    Topics: Anesthesia Recovery Period; Cholinesterase Inhibitors; gamma-Cyclodextrins; Humans; Neostigmine; Neu

2013
Residual paralysis: a real problem or did we invent a new disease?
    Canadian journal of anaesthesia = Journal canadien d'anesthesie, 2013, Volume: 60, Issue:7

    Topics: Anesthesia Recovery Period; Cholinesterase Inhibitors; gamma-Cyclodextrins; Humans; Neostigmine; Neu

2013
Is the effect of sugammadex always rapid in onset?
    Acta anaesthesiologica Belgica, 2013, Volume: 64, Issue:2

    Topics: gamma-Cyclodextrins; Humans; Neostigmine; Neuromuscular Blockade; Neuromuscular Monitoring; Sugammad

2013
A review of the interest of sugammadex for deep neuromuscular blockade management in Belgium.
    Acta anaesthesiologica Belgica, 2013, Volume: 64, Issue:2

    Topics: Algorithms; Belgium; gamma-Cyclodextrins; Humans; Muscle Relaxation; Neostigmine; Neuromuscular Bloc

2013
Neostigmine for reversal of neuromuscular block in paediatric patients.
    The Cochrane database of systematic reviews, 2014, May-05, Issue:5

    Topics: Child; Humans; Neostigmine; Neuromuscular Blockade; Neuromuscular Nondepolarizing Agents

2014
Management of neuromuscular blockade in ambulatory patients.
    Current opinion in anaesthesiology, 2014, Volume: 27, Issue:6

    Topics: Ambulatory Surgical Procedures; Cholinesterase Inhibitors; Humans; Neostigmine; Neuromuscular Blocka

2014
Reversal of neuromuscular block in companion animals.
    Veterinary anaesthesia and analgesia, 2015, Volume: 42, Issue:5

    Topics: Anesthesia, Intravenous; Anesthetics, Intravenous; Animals; Antidotes; Cholinesterase Inhibitors; De

2015
A systematic review of sugammadex vs neostigmine for reversal of neuromuscular blockade.
    Anaesthesia, 2015, Volume: 70, Issue:12

    Topics: gamma-Cyclodextrins; Humans; Neostigmine; Neuromuscular Blockade; Postoperative Nausea and Vomiting;

2015
A systematic review of sugammadex vs neostigmine for reversal of neuromuscular blockade.
    Anaesthesia, 2015, Volume: 70, Issue:12

    Topics: gamma-Cyclodextrins; Humans; Neostigmine; Neuromuscular Blockade; Postoperative Nausea and Vomiting;

2015
A systematic review of sugammadex vs neostigmine for reversal of neuromuscular blockade.
    Anaesthesia, 2015, Volume: 70, Issue:12

    Topics: gamma-Cyclodextrins; Humans; Neostigmine; Neuromuscular Blockade; Postoperative Nausea and Vomiting;

2015
A systematic review of sugammadex vs neostigmine for reversal of neuromuscular blockade.
    Anaesthesia, 2015, Volume: 70, Issue:12

    Topics: gamma-Cyclodextrins; Humans; Neostigmine; Neuromuscular Blockade; Postoperative Nausea and Vomiting;

2015
Reversing neuromuscular blockade: inhibitors of the acetylcholinesterase versus the encapsulating agents sugammadex and calabadion.
    Expert opinion on pharmacotherapy, 2016, Volume: 17, Issue:6

    Topics: Anesthesia Recovery Period; Anesthesia, General; Cholinesterase Inhibitors; Delayed Emergence from A

2016
Do we really need sugammadex as an antagonist of muscle relaxants in anesthesia?
    Current opinion in anaesthesiology, 2016, Volume: 29, Issue:4

    Topics: Androstanols; Cholinesterase Inhibitors; Delayed Emergence from Anesthesia; gamma-Cyclodextrins; Hum

2016
Residual neuromuscular blockade: management and impact on postoperative pulmonary outcome.
    Current opinion in anaesthesiology, 2016, Volume: 29, Issue:6

    Topics: Airway Obstruction; Anesthesia Recovery Period; Cholinesterase Inhibitors; Delayed Emergence from An

2016
Efficacy and safety of sugammadex compared to neostigmine for reversal of neuromuscular blockade: a meta-analysis of randomized controlled trials.
    Journal of clinical anesthesia, 2016, Volume: 35

    Topics: Androstanols; Anesthesia Recovery Period; Cholinesterase Inhibitors; gamma-Cyclodextrins; Humans; Ne

2016
Efficacy and safety of sugammadex compared to neostigmine for reversal of neuromuscular blockade: a meta-analysis of randomized controlled trials.
    Journal of clinical anesthesia, 2016, Volume: 35

    Topics: Androstanols; Anesthesia Recovery Period; Cholinesterase Inhibitors; gamma-Cyclodextrins; Humans; Ne

2016
Efficacy and safety of sugammadex compared to neostigmine for reversal of neuromuscular blockade: a meta-analysis of randomized controlled trials.
    Journal of clinical anesthesia, 2016, Volume: 35

    Topics: Androstanols; Anesthesia Recovery Period; Cholinesterase Inhibitors; gamma-Cyclodextrins; Humans; Ne

2016
Efficacy and safety of sugammadex compared to neostigmine for reversal of neuromuscular blockade: a meta-analysis of randomized controlled trials.
    Journal of clinical anesthesia, 2016, Volume: 35

    Topics: Androstanols; Anesthesia Recovery Period; Cholinesterase Inhibitors; gamma-Cyclodextrins; Humans; Ne

2016
Efficacy and safety of sugammadex compared to neostigmine for reversal of neuromuscular blockade: a meta-analysis of randomized controlled trials.
    Journal of clinical anesthesia, 2016, Volume: 35

    Topics: Androstanols; Anesthesia Recovery Period; Cholinesterase Inhibitors; gamma-Cyclodextrins; Humans; Ne

2016
Efficacy and safety of sugammadex compared to neostigmine for reversal of neuromuscular blockade: a meta-analysis of randomized controlled trials.
    Journal of clinical anesthesia, 2016, Volume: 35

    Topics: Androstanols; Anesthesia Recovery Period; Cholinesterase Inhibitors; gamma-Cyclodextrins; Humans; Ne

2016
Efficacy and safety of sugammadex compared to neostigmine for reversal of neuromuscular blockade: a meta-analysis of randomized controlled trials.
    Journal of clinical anesthesia, 2016, Volume: 35

    Topics: Androstanols; Anesthesia Recovery Period; Cholinesterase Inhibitors; gamma-Cyclodextrins; Humans; Ne

2016
Efficacy and safety of sugammadex compared to neostigmine for reversal of neuromuscular blockade: a meta-analysis of randomized controlled trials.
    Journal of clinical anesthesia, 2016, Volume: 35

    Topics: Androstanols; Anesthesia Recovery Period; Cholinesterase Inhibitors; gamma-Cyclodextrins; Humans; Ne

2016
Efficacy and safety of sugammadex compared to neostigmine for reversal of neuromuscular blockade: a meta-analysis of randomized controlled trials.
    Journal of clinical anesthesia, 2016, Volume: 35

    Topics: Androstanols; Anesthesia Recovery Period; Cholinesterase Inhibitors; gamma-Cyclodextrins; Humans; Ne

2016
Glycopyrrolate: It's time to review.
    Journal of clinical anesthesia, 2017, Volume: 36

    Topics: Biomedical Research; Dose-Response Relationship, Drug; Drug Administration Schedule; Glycopyrrolate;

2017
Clinical implications of new neuromuscular concepts and agents: so long, neostigmine! So long, sux!
    Journal of critical care, 2009, Volume: 24, Issue:1

    Topics: Androstanols; Anesthesia Recovery Period; Chemistry, Pharmaceutical; Cholinesterase Inhibitors; Dose

2009
A novel approach to reversal of neuromuscular blockade.
    Minerva anestesiologica, 2009, Volume: 75, Issue:5

    Topics: Adolescent; Adult; Androstanols; Child; Cholinesterase Inhibitors; Clinical Trials as Topic; Delayed

2009
Sugammadex, a selective reversal medication for preventing postoperative residual neuromuscular blockade.
    The Cochrane database of systematic reviews, 2009, Oct-07, Issue:4

    Topics: Adult; Androstanols; Cholinesterase Inhibitors; gamma-Cyclodextrins; Humans; Neostigmine; Neuromuscu

2009
Sugammadex, a selective reversal medication for preventing postoperative residual neuromuscular blockade.
    The Cochrane database of systematic reviews, 2009, Oct-07, Issue:4

    Topics: Adult; Androstanols; Cholinesterase Inhibitors; gamma-Cyclodextrins; Humans; Neostigmine; Neuromuscu

2009
Sugammadex, a selective reversal medication for preventing postoperative residual neuromuscular blockade.
    The Cochrane database of systematic reviews, 2009, Oct-07, Issue:4

    Topics: Adult; Androstanols; Cholinesterase Inhibitors; gamma-Cyclodextrins; Humans; Neostigmine; Neuromuscu

2009
Sugammadex, a selective reversal medication for preventing postoperative residual neuromuscular blockade.
    The Cochrane database of systematic reviews, 2009, Oct-07, Issue:4

    Topics: Adult; Androstanols; Cholinesterase Inhibitors; gamma-Cyclodextrins; Humans; Neostigmine; Neuromuscu

2009
Sugammadex, a selective reversal medication for preventing postoperative residual neuromuscular blockade.
    The Cochrane database of systematic reviews, 2009, Oct-07, Issue:4

    Topics: Adult; Androstanols; Cholinesterase Inhibitors; gamma-Cyclodextrins; Humans; Neostigmine; Neuromuscu

2009
Sugammadex, a selective reversal medication for preventing postoperative residual neuromuscular blockade.
    The Cochrane database of systematic reviews, 2009, Oct-07, Issue:4

    Topics: Adult; Androstanols; Cholinesterase Inhibitors; gamma-Cyclodextrins; Humans; Neostigmine; Neuromuscu

2009
Sugammadex, a selective reversal medication for preventing postoperative residual neuromuscular blockade.
    The Cochrane database of systematic reviews, 2009, Oct-07, Issue:4

    Topics: Adult; Androstanols; Cholinesterase Inhibitors; gamma-Cyclodextrins; Humans; Neostigmine; Neuromuscu

2009
Sugammadex, a selective reversal medication for preventing postoperative residual neuromuscular blockade.
    The Cochrane database of systematic reviews, 2009, Oct-07, Issue:4

    Topics: Adult; Androstanols; Cholinesterase Inhibitors; gamma-Cyclodextrins; Humans; Neostigmine; Neuromuscu

2009
Sugammadex, a selective reversal medication for preventing postoperative residual neuromuscular blockade.
    The Cochrane database of systematic reviews, 2009, Oct-07, Issue:4

    Topics: Adult; Androstanols; Cholinesterase Inhibitors; gamma-Cyclodextrins; Humans; Neostigmine; Neuromuscu

2009
Sugammadex, a selective reversal medication for preventing postoperative residual neuromuscular blockade.
    The Cochrane database of systematic reviews, 2009, Oct-07, Issue:4

    Topics: Adult; Androstanols; Cholinesterase Inhibitors; gamma-Cyclodextrins; Humans; Neostigmine; Neuromuscu

2009
Sugammadex, a selective reversal medication for preventing postoperative residual neuromuscular blockade.
    The Cochrane database of systematic reviews, 2009, Oct-07, Issue:4

    Topics: Adult; Androstanols; Cholinesterase Inhibitors; gamma-Cyclodextrins; Humans; Neostigmine; Neuromuscu

2009
Sugammadex, a selective reversal medication for preventing postoperative residual neuromuscular blockade.
    The Cochrane database of systematic reviews, 2009, Oct-07, Issue:4

    Topics: Adult; Androstanols; Cholinesterase Inhibitors; gamma-Cyclodextrins; Humans; Neostigmine; Neuromuscu

2009
Sugammadex, a selective reversal medication for preventing postoperative residual neuromuscular blockade.
    The Cochrane database of systematic reviews, 2009, Oct-07, Issue:4

    Topics: Adult; Androstanols; Cholinesterase Inhibitors; gamma-Cyclodextrins; Humans; Neostigmine; Neuromuscu

2009
Sugammadex, a selective reversal medication for preventing postoperative residual neuromuscular blockade.
    The Cochrane database of systematic reviews, 2009, Oct-07, Issue:4

    Topics: Adult; Androstanols; Cholinesterase Inhibitors; gamma-Cyclodextrins; Humans; Neostigmine; Neuromuscu

2009
Sugammadex, a selective reversal medication for preventing postoperative residual neuromuscular blockade.
    The Cochrane database of systematic reviews, 2009, Oct-07, Issue:4

    Topics: Adult; Androstanols; Cholinesterase Inhibitors; gamma-Cyclodextrins; Humans; Neostigmine; Neuromuscu

2009
Sugammadex, a selective reversal medication for preventing postoperative residual neuromuscular blockade.
    The Cochrane database of systematic reviews, 2009, Oct-07, Issue:4

    Topics: Adult; Androstanols; Cholinesterase Inhibitors; gamma-Cyclodextrins; Humans; Neostigmine; Neuromuscu

2009
[Indications and clinical use of sugammadex].
    Annales francaises d'anesthesie et de reanimation, 2009, Volume: 28 Suppl 2

    Topics: Algorithms; Androstanols; Anesthesia Recovery Period; Clinical Trials, Phase III as Topic; Contraind

2009
[Sugammadex: something new to improve patient safety or simply a gadget?].
    Annales francaises d'anesthesie et de reanimation, 2009, Volume: 28 Suppl 2

    Topics: Androstanols; Anesthesia Recovery Period; Atracurium; Cost-Benefit Analysis; Drug Approval; Electrod

2009
[Use of neuromuscular blocking agents and reversal of blockade: guidelines from Sociedad Española de Anestesiología, Reanimación y Terapéutica del Dolor].
    Revista espanola de anestesiologia y reanimacion, 2009, Volume: 56, Issue:10

    Topics: Algorithms; Atropine; Contraindications; Critical Care; Delayed Emergence from Anesthesia; Evidence-

2009
Cochrane corner: sugammadex, a selective reversal medication for preventing postoperative residual neuromuscular blockade.
    Anesthesia and analgesia, 2010, Apr-01, Volume: 110, Issue:4

    Topics: Adult; Androstanols; Anesthesia Recovery Period; Dose-Response Relationship, Drug; Drug Interactions

2010
Neuromuscular block and current treatment strategies for its reversal in children.
    Paediatric anaesthesia, 2010, Volume: 20, Issue:7

    Topics: Anesthesia Recovery Period; Child; Child, Preschool; Cholinesterase Inhibitors; gamma-Cyclodextrins;

2010
Sugammadex compared with neostigmine/glycopyrrolate for routine reversal of neuromuscular block: a systematic review and economic evaluation.
    British journal of anaesthesia, 2010, Volume: 105, Issue:5

    Topics: Adult; Anesthesia Recovery Period; Cholinesterase Inhibitors; Cost-Benefit Analysis; Drug Costs; gam

2010
Sugammadex compared with neostigmine/glycopyrrolate for routine reversal of neuromuscular block: a systematic review and economic evaluation.
    British journal of anaesthesia, 2010, Volume: 105, Issue:5

    Topics: Adult; Anesthesia Recovery Period; Cholinesterase Inhibitors; Cost-Benefit Analysis; Drug Costs; gam

2010
Sugammadex compared with neostigmine/glycopyrrolate for routine reversal of neuromuscular block: a systematic review and economic evaluation.
    British journal of anaesthesia, 2010, Volume: 105, Issue:5

    Topics: Adult; Anesthesia Recovery Period; Cholinesterase Inhibitors; Cost-Benefit Analysis; Drug Costs; gam

2010
Sugammadex compared with neostigmine/glycopyrrolate for routine reversal of neuromuscular block: a systematic review and economic evaluation.
    British journal of anaesthesia, 2010, Volume: 105, Issue:5

    Topics: Adult; Anesthesia Recovery Period; Cholinesterase Inhibitors; Cost-Benefit Analysis; Drug Costs; gam

2010
Sugammadex compared with neostigmine/glycopyrrolate for routine reversal of neuromuscular block: a systematic review and economic evaluation.
    British journal of anaesthesia, 2010, Volume: 105, Issue:5

    Topics: Adult; Anesthesia Recovery Period; Cholinesterase Inhibitors; Cost-Benefit Analysis; Drug Costs; gam

2010
Sugammadex compared with neostigmine/glycopyrrolate for routine reversal of neuromuscular block: a systematic review and economic evaluation.
    British journal of anaesthesia, 2010, Volume: 105, Issue:5

    Topics: Adult; Anesthesia Recovery Period; Cholinesterase Inhibitors; Cost-Benefit Analysis; Drug Costs; gam

2010
Sugammadex compared with neostigmine/glycopyrrolate for routine reversal of neuromuscular block: a systematic review and economic evaluation.
    British journal of anaesthesia, 2010, Volume: 105, Issue:5

    Topics: Adult; Anesthesia Recovery Period; Cholinesterase Inhibitors; Cost-Benefit Analysis; Drug Costs; gam

2010
Sugammadex compared with neostigmine/glycopyrrolate for routine reversal of neuromuscular block: a systematic review and economic evaluation.
    British journal of anaesthesia, 2010, Volume: 105, Issue:5

    Topics: Adult; Anesthesia Recovery Period; Cholinesterase Inhibitors; Cost-Benefit Analysis; Drug Costs; gam

2010
Sugammadex compared with neostigmine/glycopyrrolate for routine reversal of neuromuscular block: a systematic review and economic evaluation.
    British journal of anaesthesia, 2010, Volume: 105, Issue:5

    Topics: Adult; Anesthesia Recovery Period; Cholinesterase Inhibitors; Cost-Benefit Analysis; Drug Costs; gam

2010
Sugammadex: a novel agent for the reversal of neuromuscular blockade.
    Pharmacotherapy, 2007, Volume: 27, Issue:8

    Topics: Androstanols; Cholinesterase Inhibitors; Clinical Trials as Topic; Female; gamma-Cyclodextrins; Huma

2007
Sugammadex: a novel agent for the reversal of neuromuscular blockade.
    Pharmacotherapy, 2007, Volume: 27, Issue:8

    Topics: Androstanols; Cholinesterase Inhibitors; Clinical Trials as Topic; Female; gamma-Cyclodextrins; Huma

2007
Sugammadex: a novel agent for the reversal of neuromuscular blockade.
    Pharmacotherapy, 2007, Volume: 27, Issue:8

    Topics: Androstanols; Cholinesterase Inhibitors; Clinical Trials as Topic; Female; gamma-Cyclodextrins; Huma

2007
Sugammadex: a novel agent for the reversal of neuromuscular blockade.
    Pharmacotherapy, 2007, Volume: 27, Issue:8

    Topics: Androstanols; Cholinesterase Inhibitors; Clinical Trials as Topic; Female; gamma-Cyclodextrins; Huma

2007
Use of reversal agents in day care procedures (with special reference to postoperative nausea and vomiting).
    European journal of anaesthesiology. Supplement, 2001, Volume: 23

    Topics: Ambulatory Surgical Procedures; Atropine; Cholinergic Antagonists; Cholinesterase Inhibitors; Glycop

2001

Trials

107 trials available for neostigmine and Neuromuscular Blockade

ArticleYear
A randomized trial evaluating the safety profile of sugammadex in high surgical risk ASA physical class 3 or 4 participants.
    BMC anesthesiology, 2021, 10-28, Volume: 21, Issue:1

    Topics: Aged; Bradycardia; Cholinergic Agents; Double-Blind Method; Female; Glycopyrrolate; Humans; Male; Ne

2021
Sugammadex for reversal of neuromuscular blockade in pediatric patients: Results from a phase IV randomized study.
    Paediatric anaesthesia, 2022, Volume: 32, Issue:3

    Topics: Anaphylaxis; Anesthetics; Bradycardia; Child; Humans; Neostigmine; Neuromuscular Blockade; Neuromusc

2022
Comparison of recovery after sugammadex or neostigmine reversal of rocuronium in geriatric patients undergoing spine surgery: a randomized controlled trial.
    Croatian medical journal, 2021, Dec-31, Volume: 62, Issue:6

    Topics: Aged; Humans; Neostigmine; Neuromuscular Blockade; Neuromuscular Nondepolarizing Agents; Rocuronium;

2021
Half-Dose Sugammadex After Neostigmine Versus Neostigmine as a Routine Reversal Agent: A Pilot Randomized Trial.
    Journal of perianesthesia nursing : official journal of the American Society of PeriAnesthesia Nurses, 2022, Volume: 37, Issue:3

    Topics: Cholinesterase Inhibitors; Delayed Emergence from Anesthesia; gamma-Cyclodextrins; Humans; Neostigmi

2022
Comparison of the effects of neostigmine and sugammadex on postoperative residual curarization and postoperative pulmonary complications by means of diaphragm and lung ultrasonography: a study protocol for prospective double-blind randomized controlled tr
    Trials, 2022, May-07, Volume: 23, Issue:1

    Topics: Aged; Delayed Emergence from Anesthesia; Diaphragm; Double-Blind Method; Humans; Lung; Neostigmine;

2022
Sugammadex Versus Neostigmine for Neuromuscular Block Reversal and Postoperative Pulmonary Complications in Patients Undergoing Resection of Lung Cancer.
    Journal of cardiothoracic and vascular anesthesia, 2022, Volume: 36, Issue:9

    Topics: Adult; Atropine Derivatives; Cholinesterase Inhibitors; Humans; Lung; Lung Neoplasms; Neostigmine; N

2022
Reduction of Nonoperative Time Using the Induction Room, Parallel Processing, and Sugammadex: A Randomized Clinical Trial.
    Anesthesia and analgesia, 2022, 08-01, Volume: 135, Issue:2

    Topics: Glycopyrrolate; Humans; Neostigmine; Neuromuscular Blockade; Neuromuscular Nondepolarizing Agents; P

2022
A comparison of neuromuscular blockade and reversal using cisatricurium and neostigmine with rocuronium and sugamadex on the quality of recovery from general anaesthesia for percutaneous closure of left atria appendage.
    Journal of cardiothoracic surgery, 2022, Aug-26, Volume: 17, Issue:1

    Topics: Anesthesia, General; Atrial Appendage; gamma-Cyclodextrins; Humans; Hypoxia; Neostigmine; Neuromuscu

2022
Can late- or two-step administration of neostigmine reduce the reversal time of cisatracurium-induced moderate neuromuscular blockade?: A prospective, randomised controlled clinical trial.
    European journal of anaesthesiology, 2023, 02-01, Volume: 40, Issue:2

    Topics: Atracurium; Cholinesterase Inhibitors; Humans; Neostigmine; Neuromuscular Blockade; Prospective Stud

2023
'Half-Dose Sugammadex After Neostigmine Versus Neostigmine as a Routine Reversal Agent: A Pilot Randomized Trial'.
    Journal of perianesthesia nursing : official journal of the American Society of PeriAnesthesia Nurses, 2022, Volume: 37, Issue:5

    Topics: gamma-Cyclodextrins; Neostigmine; Neuromuscular Blockade; Pilot Projects; Sugammadex

2022
Sugammadex Versus Neostigmine for Recovery of Respiratory Muscle Strength Measured by Ultrasonography in the Postextubation Period: A Randomized Controlled Trial.
    Anesthesia and analgesia, 2023, 03-01, Volume: 136, Issue:3

    Topics: Adult; Anesthesia Recovery Period; Cholinesterase Inhibitors; Humans; Neostigmine; Neuromuscular Blo

2023
Routine administration of neostigmine after recovery of spontaneous breathing versus neuromuscular monitor-guided administration of neostigmine in pediatric patients: a parallel, randomized, controlled study.
    Trials, 2023, Jan-07, Volume: 24, Issue:1

    Topics: Anesthesia Recovery Period; Child; Cholinesterase Inhibitors; Delayed Emergence from Anesthesia; Hum

2023
Analysis of the association of sugammadex with the length of hospital stay in patients undergoing abdominal surgery: a retrospective study.
    BMC anesthesiology, 2023, 01-25, Volume: 23, Issue:1

    Topics: Humans; Length of Stay; Neostigmine; Neuromuscular Blockade; Neuromuscular Nondepolarizing Agents; R

2023
Effect of patient decision aids on choice between sugammadex and neostigmine in surgeries under general anesthesia: a multicenter randomized controlled trial.
    Korean journal of anesthesiology, 2023, Volume: 76, Issue:4

    Topics: Anesthesia, General; Decision Support Techniques; Humans; Neostigmine; Neuromuscular Blockade; Neuro

2023
An educational intervention to reduce the incidence of postoperative residual curarisation: a cluster randomised crossover trial in patients undergoing general anaesthesia.
    British journal of anaesthesia, 2023, Volume: 131, Issue:3

    Topics: Anesthesia, General; Cross-Over Studies; Delayed Emergence from Anesthesia; Humans; Neostigmine; Neu

2023
Optimal dose of neostigmine antagonizing cisatracurium-induced shallow neuromuscular block in elderly patients: a randomized control study.
    BMC anesthesiology, 2023, 08-10, Volume: 23, Issue:1

    Topics: Aged; Atracurium; Cholinesterase Inhibitors; Delayed Emergence from Anesthesia; Humans; Neostigmine;

2023
Effects of magnesium sulphate on neostigmine-induced recovery from moderate neuromuscular blockade with rocuronium: a randomized controlled trial.
    Magnesium research, 2023, Jun-01, Volume: 36, Issue:2

    Topics: Androstanols; Anesthetics; Humans; Magnesium; Magnesium Sulfate; Neostigmine; Neuromuscular Blockade

2023
Respiratory muscle activity after spontaneous, neostigmine- or sugammadex-enhanced recovery of neuromuscular blockade: a double blind prospective randomized controlled trial.
    BMC anesthesiology, 2019, 10-19, Volume: 19, Issue:1

    Topics: Adult; Aged; Double-Blind Method; Electromyography; Female; Humans; Male; Middle Aged; Neostigmine;

2019
Neostigmine Versus Sugammadex for Reversal of Neuromuscular Blockade and Effects on Reintubation for Respiratory Failure or Newly Initiated Noninvasive Ventilation: An Interrupted Time Series Design.
    Anesthesia and analgesia, 2020, Volume: 131, Issue:1

    Topics: Adult; Aged; Cholinesterase Inhibitors; Delayed Emergence from Anesthesia; Female; Humans; Interrupt

2020
Effect of reversal of deep neuromuscular block with sugammadex or moderate block by neostigmine on shoulder pain in elderly patients undergoing robotic prostatectomy.
    British journal of anaesthesia, 2020, Volume: 124, Issue:2

    Topics: Aged; Cholinesterase Inhibitors; Humans; Male; Neostigmine; Neuromuscular Blockade; Prostatectomy; R

2020
Effect of reversal of deep neuromuscular block with sugammadex or moderate block by neostigmine on shoulder pain in elderly patients undergoing robotic prostatectomy.
    British journal of anaesthesia, 2020, Volume: 124, Issue:2

    Topics: Aged; Cholinesterase Inhibitors; Humans; Male; Neostigmine; Neuromuscular Blockade; Prostatectomy; R

2020
Effect of reversal of deep neuromuscular block with sugammadex or moderate block by neostigmine on shoulder pain in elderly patients undergoing robotic prostatectomy.
    British journal of anaesthesia, 2020, Volume: 124, Issue:2

    Topics: Aged; Cholinesterase Inhibitors; Humans; Male; Neostigmine; Neuromuscular Blockade; Prostatectomy; R

2020
Effect of reversal of deep neuromuscular block with sugammadex or moderate block by neostigmine on shoulder pain in elderly patients undergoing robotic prostatectomy.
    British journal of anaesthesia, 2020, Volume: 124, Issue:2

    Topics: Aged; Cholinesterase Inhibitors; Humans; Male; Neostigmine; Neuromuscular Blockade; Prostatectomy; R

2020
Postoperative residual neuromuscular blockade after reversal based on a qualitative peripheral nerve stimulator response: A randomised controlled trial.
    European journal of anaesthesiology, 2020, Volume: 37, Issue:3

    Topics: Adolescent; Adult; Aged; Cholinesterase Inhibitors; Delayed Emergence from Anesthesia; Humans; Middl

2020
Randomised controlled trial of sugammadex or neostigmine for reversal of neuromuscular block on the incidence of pulmonary complications in older adults undergoing prolonged surgery.
    British journal of anaesthesia, 2020, Volume: 124, Issue:5

    Topics: Aged; Aged, 80 and over; Cholinesterase Inhibitors; Delayed Emergence from Anesthesia; Double-Blind

2020
The effect of vitamin D status on different neuromuscular blocker agents reverse time
    Turkish journal of medical sciences, 2020, 06-23, Volume: 50, Issue:4

    Topics: Adolescent; Adult; Aged; Anesthesia Recovery Period; Cholinesterase Inhibitors; Double-Blind Method;

2020
A randomised controlled trial comparing deep neuromuscular blockade reversed with sugammadex with moderate neuromuscular block reversed with neostigmine.
    Anaesthesia, 2020, Volume: 75, Issue:9

    Topics: Anesthesia Recovery Period; Cholinesterase Inhibitors; Female; Humans; Male; Middle Aged; Neostigmin

2020
A randomized-controlled trial of sugammadex versus neostigmine: impact on early postoperative strength.
    Canadian journal of anaesthesia = Journal canadien d'anesthesie, 2020, Volume: 67, Issue:8

    Topics: Hand Strength; Humans; Neostigmine; Neuromuscular Blockade; Neuromuscular Nondepolarizing Agents; Po

2020
Sugammadex for Fast-Track Surgery in Children Undergoing Cardiac Surgery: A Randomized Controlled Study.
    Journal of cardiothoracic and vascular anesthesia, 2021, Volume: 35, Issue:5

    Topics: Cardiac Surgical Procedures; Child; gamma-Cyclodextrins; Humans; Neostigmine; Neuromuscular Blockade

2021
The effects of neostigmine on postoperative cognitive function and inflammatory factors in elderly patients - a randomized trial.
    BMC geriatrics, 2020, 10-06, Volume: 20, Issue:1

    Topics: Aged; Cholinesterase Inhibitors; Cognition; Humans; Neostigmine; Neuromuscular Blockade; Neuromuscul

2020
Neuromuscular and Clinical Recovery in Thoracic Surgical Patients Reversed With Neostigmine or Sugammadex.
    Anesthesia and analgesia, 2021, 08-01, Volume: 133, Issue:2

    Topics: Aged; Aged, 80 and over; Anesthesia Recovery Period; Delayed Emergence from Anesthesia; Female; Huma

2021
Recovery of early postoperative muscle strength after deep neuromuscular block by means of ultrasonography with comparison of neostigmine versus sugammadex as reversal drugs: study protocol for a randomised controlled trial.
    BMJ open, 2021, 02-26, Volume: 11, Issue:2

    Topics: Adolescent; Adult; Aged; Anesthesia Recovery Period; Cholinesterase Inhibitors; Hand Strength; Human

2021
Effects of Sugammadex versus Neostigmine on Intraoperative Coagulation Profiles in Patients with Thyroidectomy.
    Drug design, development and therapy, 2021, Volume: 15

    Topics: Adolescent; Adult; Aged; Blood Coagulation Tests; Female; Humans; Male; Middle Aged; Neostigmine; Ne

2021
Comparison of neuromuscular blockade recovery co-administered with neostigmine and different doses of calcium gluconate: a randomized control trial.
    BMC anesthesiology, 2021, 03-29, Volume: 21, Issue:1

    Topics: Anesthesia Recovery Period; Calcium; Calcium Gluconate; Dose-Response Relationship, Drug; Double-Bli

2021
Survey of attitudes towards a randomised trial about sugammadex, neostigmine and pulmonary complications.
    Anaesthesia and intensive care, 2021, Volume: 49, Issue:3

    Topics: Attitude; Cholinesterase Inhibitors; Humans; Neostigmine; Neuromuscular Blockade; Neuromuscular Nond

2021
Sugammadex Versus Neostigmine for Reversal of Rocuronium Neuromuscular Block in Patients Having Catheter-Based Neurointerventional Procedures: A Randomized Trial.
    Anesthesia and analgesia, 2021, 06-01, Volume: 132, Issue:6

    Topics: Adult; Aged; Catheters; Cholinesterase Inhibitors; Female; Humans; Male; Middle Aged; Neostigmine; N

2021
Reversal of residual neuromuscular block with neostigmine or sugammadex and postoperative pulmonary complications: a prospective, randomised, double-blind trial in high-risk older patients.
    British journal of anaesthesia, 2021, Volume: 127, Issue:2

    Topics: Aged; Aged, 80 and over; Australia; Cholinesterase Inhibitors; Double-Blind Method; Female; Geriatri

2021
Recovery of lower oesophageal barrier function: a pilot study comparing a mixture of atropine and neostigmine and sugammadex: A randomised controlled pilot study.
    European journal of anaesthesiology, 2021, 08-01, Volume: 38, Issue:8

    Topics: Adult; Atropine; Cholinesterase Inhibitors; Female; Humans; Neostigmine; Neuromuscular Blockade; Neu

2021
Half dose sugammadex combined with neostigmine is non-inferior to full dose sugammadex for reversal of rocuronium-induced deep neuromuscular blockade: a cost-saving strategy.
    BMC anesthesiology, 2017, 04-11, Volume: 17, Issue:1

    Topics: Adult; Androstanols; Cholinesterase Inhibitors; Cost-Benefit Analysis; Dose-Response Relationship, D

2017
Half dose sugammadex combined with neostigmine is non-inferior to full dose sugammadex for reversal of rocuronium-induced deep neuromuscular blockade: a cost-saving strategy.
    BMC anesthesiology, 2017, 04-11, Volume: 17, Issue:1

    Topics: Adult; Androstanols; Cholinesterase Inhibitors; Cost-Benefit Analysis; Dose-Response Relationship, D

2017
Half dose sugammadex combined with neostigmine is non-inferior to full dose sugammadex for reversal of rocuronium-induced deep neuromuscular blockade: a cost-saving strategy.
    BMC anesthesiology, 2017, 04-11, Volume: 17, Issue:1

    Topics: Adult; Androstanols; Cholinesterase Inhibitors; Cost-Benefit Analysis; Dose-Response Relationship, D

2017
Half dose sugammadex combined with neostigmine is non-inferior to full dose sugammadex for reversal of rocuronium-induced deep neuromuscular blockade: a cost-saving strategy.
    BMC anesthesiology, 2017, 04-11, Volume: 17, Issue:1

    Topics: Adult; Androstanols; Cholinesterase Inhibitors; Cost-Benefit Analysis; Dose-Response Relationship, D

2017
Comparison of reversal with neostigmine of low-dose rocuronium vs. reversal with sugammadex of high-dose rocuronium for a short procedure.
    Anaesthesia, 2017, Volume: 72, Issue:10

    Topics: Adult; Aged; Anesthesia Recovery Period; Anesthesia, General; Attitude of Health Personnel; Dose-Res

2017
Failed Vocalis Muscle Monitoring During Thyroid Surgery Resulting From Residual Muscle Relaxation.
    A & A case reports, 2017, Sep-01, Volume: 9, Issue:5

    Topics: Adjuvants, Anesthesia; Administration, Intravenous; Atracurium; Cholinesterase Inhibitors; Glycopyrr

2017
Effects of calcium chloride coadministered with neostigmine on neuromuscular blockade recovery: A double-blind randomised study.
    European journal of anaesthesiology, 2017, Volume: 34, Issue:9

    Topics: Adult; Aged; Anesthesia, General; Calcium Chloride; Cholinesterase Inhibitors; Delayed Emergence fro

2017
Effect of sugammadex versus neostigmine/atropine combination on postoperative cognitive dysfunction after elective surgery.
    Anaesthesia and intensive care, 2017, Volume: 45, Issue:5

    Topics: Adult; Atropine; Cognitive Dysfunction; Double-Blind Method; Elective Surgical Procedures; Female; g

2017
Effects of neostigmine or edrophonium on force of contraction when administered at a train-of-four ratio of 0.9 in anesthetized dogs.
    Veterinary anaesthesia and analgesia, 2017, Volume: 44, Issue:6

    Topics: Anesthesia, General; Animals; Cross-Over Studies; Dogs; Edrophonium; Muscle Contraction; Neostigmine

2017
Recovery characteristics of patients receiving either sugammadex or neostigmine and glycopyrrolate for reversal of neuromuscular block: a randomised controlled trial.
    Anaesthesia, 2018, Volume: 73, Issue:3

    Topics: Adult; Anesthesia Recovery Period; Female; Glycopyrrolate; Humans; Neostigmine; Neuromuscular Blocka

2018
Sugammadex antagonism of rocuronium-induced neuromuscular blockade in patients with liver cirrhosis undergoing liver resection: a randomized controlled study.
    Minerva anestesiologica, 2018, Volume: 84, Issue:8

    Topics: Adolescent; Adult; Cholinesterase Inhibitors; Female; Hepatectomy; Humans; Liver Cirrhosis; Male; Mi

2018
Recovery of muscle function after deep neuromuscular block by means of diaphragm ultrasonography and adductor of pollicis acceleromyography with comparison of neostigmine vs. sugammadex as reversal drugs: study protocol for a randomized controlled trial.
    Trials, 2018, Feb-21, Volume: 19, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cholinesterase Inhibitors; Delayed Emergence from Anesth

2018
Neostigmine accelerates recovery from moderate mivacurium neuromuscular block independently of train-of-four count at injection: a randomised controlled trial.
    British journal of anaesthesia, 2018, Volume: 121, Issue:2

    Topics: Adult; Anesthesia Recovery Period; Female; Humans; Male; Middle Aged; Mivacurium; Neostigmine; Neuro

2018
Therapeutic doses of neostigmine, depolarising neuromuscular blockade and muscle weakness in awake volunteers: a double-blind, placebo-controlled, randomised volunteer study.
    Anaesthesia, 2018, Volume: 73, Issue:9

    Topics: Adult; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Drug Admini

2018
Influence of reversal of neuromuscular blockade with sugammadex or neostigmine on postoperative quality of recovery following a single bolus dose of rocuronium: A prospective, randomized, double-blinded, controlled study.
    Journal of clinical anesthesia, 2019, Volume: 57

    Topics: Aged; Anesthesia Recovery Period; Anesthesia, General; Double-Blind Method; Female; Humans; Male; Mi

2019
Reversal of Partial Neuromuscular Block and the Ventilatory Response to Hypoxia: A Randomized Controlled Trial in Healthy Volunteers.
    Anesthesiology, 2019, Volume: 131, Issue:3

    Topics: Adolescent; Adult; Anesthesia Recovery Period; Cholinesterase Inhibitors; Double-Blind Method; Elect

2019
Effects of neuromuscular block reversal with sugammadex versus neostigmine on postoperative respiratory outcomes after major abdominal surgery: a randomized-controlled trial.
    Canadian journal of anaesthesia = Journal canadien d'anesthesie, 2019, Volume: 66, Issue:11

    Topics: Abdomen; Aged; Female; Humans; Male; Middle Aged; Neostigmine; Neuromuscular Blockade; Postoperative

2019
Effects of neuromuscular blockade reversal on bispectral index and frontal electromyogram during steady-state desflurane anesthesia: a randomized trial.
    Scientific reports, 2019, 07-19, Volume: 9, Issue:1

    Topics: Adult; Anesthesia, Inhalation; Anesthetics, Inhalation; Consciousness Monitors; Desflurane; Electrom

2019
Comparison of neostigmine vs. sugammadex for recovery of muscle function after neuromuscular block by means of diaphragm ultrasonography in microlaryngeal surgery: A randomised controlled trial.
    European journal of anaesthesiology, 2020, Volume: 37, Issue:1

    Topics: Adult; Aged; Delayed Emergence from Anesthesia; Diaphragm; Double-Blind Method; Female; Humans; Lary

2020
Effect of variations in depth of neuromuscular blockade on rating of surgical conditions by surgeon and anesthesiologist in patients undergoing laparoscopic renal or prostatic surgery (BLISS trial): study protocol for a randomized controlled trial.
    Trials, 2013, Mar-01, Volume: 14

    Topics: Academic Medical Centers; Androstanols; Anesthesia Department, Hospital; Atracurium; Atropine; Attit

2013
Effect of variations in depth of neuromuscular blockade on rating of surgical conditions by surgeon and anesthesiologist in patients undergoing laparoscopic renal or prostatic surgery (BLISS trial): study protocol for a randomized controlled trial.
    Trials, 2013, Mar-01, Volume: 14

    Topics: Academic Medical Centers; Androstanols; Anesthesia Department, Hospital; Atracurium; Atropine; Attit

2013
Effect of variations in depth of neuromuscular blockade on rating of surgical conditions by surgeon and anesthesiologist in patients undergoing laparoscopic renal or prostatic surgery (BLISS trial): study protocol for a randomized controlled trial.
    Trials, 2013, Mar-01, Volume: 14

    Topics: Academic Medical Centers; Androstanols; Anesthesia Department, Hospital; Atracurium; Atropine; Attit

2013
Effect of variations in depth of neuromuscular blockade on rating of surgical conditions by surgeon and anesthesiologist in patients undergoing laparoscopic renal or prostatic surgery (BLISS trial): study protocol for a randomized controlled trial.
    Trials, 2013, Mar-01, Volume: 14

    Topics: Academic Medical Centers; Androstanols; Anesthesia Department, Hospital; Atracurium; Atropine; Attit

2013
Sugammadex allows fast-track bariatric surgery.
    Obesity surgery, 2013, Volume: 23, Issue:10

    Topics: Adult; Anesthesia Recovery Period; Bariatric Surgery; Female; gamma-Cyclodextrins; Humans; Male; Mid

2013
Low-dose neostigmine to antagonise shallow atracurium neuromuscular block during inhalational anaesthesia: A randomised controlled trial.
    European journal of anaesthesiology, 2013, Volume: 30, Issue:10

    Topics: Adult; Anesthesia Recovery Period; Anesthesia, Inhalation; Anesthetics, Inhalation; Atracurium; Chol

2013
Evaluation of neostigmine antagonism at different levels of vecuronium-induced neuromuscular blockade in isoflurane anesthetized dogs.
    The Canadian veterinary journal = La revue veterinaire canadienne, 2014, Volume: 55, Issue:2

    Topics: Anesthetics, Inhalation; Animals; Dogs; Female; Isoflurane; Male; Neostigmine; Neuromuscular Blockad

2014
Electromyographic activity of the diaphragm during neostigmine or sugammadex-enhanced recovery after neuromuscular blockade with rocuronium: a randomised controlled study in healthy volunteers.
    European journal of anaesthesiology, 2015, Volume: 32, Issue:1

    Topics: Adult; Androstanols; Cholinesterase Inhibitors; Diaphragm; Double-Blind Method; Electromyography; ga

2015
Electromyographic activity of the diaphragm during neostigmine or sugammadex-enhanced recovery after neuromuscular blockade with rocuronium: a randomised controlled study in healthy volunteers.
    European journal of anaesthesiology, 2015, Volume: 32, Issue:1

    Topics: Adult; Androstanols; Cholinesterase Inhibitors; Diaphragm; Double-Blind Method; Electromyography; ga

2015
Electromyographic activity of the diaphragm during neostigmine or sugammadex-enhanced recovery after neuromuscular blockade with rocuronium: a randomised controlled study in healthy volunteers.
    European journal of anaesthesiology, 2015, Volume: 32, Issue:1

    Topics: Adult; Androstanols; Cholinesterase Inhibitors; Diaphragm; Double-Blind Method; Electromyography; ga

2015
Electromyographic activity of the diaphragm during neostigmine or sugammadex-enhanced recovery after neuromuscular blockade with rocuronium: a randomised controlled study in healthy volunteers.
    European journal of anaesthesiology, 2015, Volume: 32, Issue:1

    Topics: Adult; Androstanols; Cholinesterase Inhibitors; Diaphragm; Double-Blind Method; Electromyography; ga

2015
Rocuronium blockade reversal with sugammadex vs. neostigmine: randomized study in Chinese and Caucasian subjects.
    BMC anesthesiology, 2014, Volume: 14

    Topics: Adult; Aged; Androstanols; Asian People; Female; gamma-Cyclodextrins; Humans; Male; Middle Aged; Neo

2014
Effects of sugammadex on incidence of postoperative residual neuromuscular blockade: a randomized, controlled study.
    British journal of anaesthesia, 2015, Volume: 115, Issue:5

    Topics: Abdomen; Adult; Aged; Androstanols; Anesthesia Recovery Period; Anesthesia, General; Delayed Emergen

2015
Effects of sugammadex on incidence of postoperative residual neuromuscular blockade: a randomized, controlled study.
    British journal of anaesthesia, 2015, Volume: 115, Issue:5

    Topics: Abdomen; Adult; Aged; Androstanols; Anesthesia Recovery Period; Anesthesia, General; Delayed Emergen

2015
Effects of sugammadex on incidence of postoperative residual neuromuscular blockade: a randomized, controlled study.
    British journal of anaesthesia, 2015, Volume: 115, Issue:5

    Topics: Abdomen; Adult; Aged; Androstanols; Anesthesia Recovery Period; Anesthesia, General; Delayed Emergen

2015
Effects of sugammadex on incidence of postoperative residual neuromuscular blockade: a randomized, controlled study.
    British journal of anaesthesia, 2015, Volume: 115, Issue:5

    Topics: Abdomen; Adult; Aged; Androstanols; Anesthesia Recovery Period; Anesthesia, General; Delayed Emergen

2015
Effects of sugammadex on incidence of postoperative residual neuromuscular blockade: a randomized, controlled study.
    British journal of anaesthesia, 2015, Volume: 115, Issue:5

    Topics: Abdomen; Adult; Aged; Androstanols; Anesthesia Recovery Period; Anesthesia, General; Delayed Emergen

2015
Effects of sugammadex on incidence of postoperative residual neuromuscular blockade: a randomized, controlled study.
    British journal of anaesthesia, 2015, Volume: 115, Issue:5

    Topics: Abdomen; Adult; Aged; Androstanols; Anesthesia Recovery Period; Anesthesia, General; Delayed Emergen

2015
Effects of sugammadex on incidence of postoperative residual neuromuscular blockade: a randomized, controlled study.
    British journal of anaesthesia, 2015, Volume: 115, Issue:5

    Topics: Abdomen; Adult; Aged; Androstanols; Anesthesia Recovery Period; Anesthesia, General; Delayed Emergen

2015
Effects of sugammadex on incidence of postoperative residual neuromuscular blockade: a randomized, controlled study.
    British journal of anaesthesia, 2015, Volume: 115, Issue:5

    Topics: Abdomen; Adult; Aged; Androstanols; Anesthesia Recovery Period; Anesthesia, General; Delayed Emergen

2015
Effects of sugammadex on incidence of postoperative residual neuromuscular blockade: a randomized, controlled study.
    British journal of anaesthesia, 2015, Volume: 115, Issue:5

    Topics: Abdomen; Adult; Aged; Androstanols; Anesthesia Recovery Period; Anesthesia, General; Delayed Emergen

2015
Effects of sugammadex on incidence of postoperative residual neuromuscular blockade: a randomized, controlled study.
    British journal of anaesthesia, 2015, Volume: 115, Issue:5

    Topics: Abdomen; Adult; Aged; Androstanols; Anesthesia Recovery Period; Anesthesia, General; Delayed Emergen

2015
Effects of sugammadex on incidence of postoperative residual neuromuscular blockade: a randomized, controlled study.
    British journal of anaesthesia, 2015, Volume: 115, Issue:5

    Topics: Abdomen; Adult; Aged; Androstanols; Anesthesia Recovery Period; Anesthesia, General; Delayed Emergen

2015
Effects of sugammadex on incidence of postoperative residual neuromuscular blockade: a randomized, controlled study.
    British journal of anaesthesia, 2015, Volume: 115, Issue:5

    Topics: Abdomen; Adult; Aged; Androstanols; Anesthesia Recovery Period; Anesthesia, General; Delayed Emergen

2015
Effects of sugammadex on incidence of postoperative residual neuromuscular blockade: a randomized, controlled study.
    British journal of anaesthesia, 2015, Volume: 115, Issue:5

    Topics: Abdomen; Adult; Aged; Androstanols; Anesthesia Recovery Period; Anesthesia, General; Delayed Emergen

2015
Effects of sugammadex on incidence of postoperative residual neuromuscular blockade: a randomized, controlled study.
    British journal of anaesthesia, 2015, Volume: 115, Issue:5

    Topics: Abdomen; Adult; Aged; Androstanols; Anesthesia Recovery Period; Anesthesia, General; Delayed Emergen

2015
Effects of sugammadex on incidence of postoperative residual neuromuscular blockade: a randomized, controlled study.
    British journal of anaesthesia, 2015, Volume: 115, Issue:5

    Topics: Abdomen; Adult; Aged; Androstanols; Anesthesia Recovery Period; Anesthesia, General; Delayed Emergen

2015
Effects of sugammadex on incidence of postoperative residual neuromuscular blockade: a randomized, controlled study.
    British journal of anaesthesia, 2015, Volume: 115, Issue:5

    Topics: Abdomen; Adult; Aged; Androstanols; Anesthesia Recovery Period; Anesthesia, General; Delayed Emergen

2015
Effects of sugammadex on incidence of postoperative residual neuromuscular blockade: a randomized, controlled study.
    British journal of anaesthesia, 2015, Volume: 115, Issue:5

    Topics: Abdomen; Adult; Aged; Androstanols; Anesthesia Recovery Period; Anesthesia, General; Delayed Emergen

2015
Effects of sugammadex on incidence of postoperative residual neuromuscular blockade: a randomized, controlled study.
    British journal of anaesthesia, 2015, Volume: 115, Issue:5

    Topics: Abdomen; Adult; Aged; Androstanols; Anesthesia Recovery Period; Anesthesia, General; Delayed Emergen

2015
Effects of sugammadex on incidence of postoperative residual neuromuscular blockade: a randomized, controlled study.
    British journal of anaesthesia, 2015, Volume: 115, Issue:5

    Topics: Abdomen; Adult; Aged; Androstanols; Anesthesia Recovery Period; Anesthesia, General; Delayed Emergen

2015
Effects of sugammadex on incidence of postoperative residual neuromuscular blockade: a randomized, controlled study.
    British journal of anaesthesia, 2015, Volume: 115, Issue:5

    Topics: Abdomen; Adult; Aged; Androstanols; Anesthesia Recovery Period; Anesthesia, General; Delayed Emergen

2015
Effects of sugammadex on incidence of postoperative residual neuromuscular blockade: a randomized, controlled study.
    British journal of anaesthesia, 2015, Volume: 115, Issue:5

    Topics: Abdomen; Adult; Aged; Androstanols; Anesthesia Recovery Period; Anesthesia, General; Delayed Emergen

2015
Effects of sugammadex on incidence of postoperative residual neuromuscular blockade: a randomized, controlled study.
    British journal of anaesthesia, 2015, Volume: 115, Issue:5

    Topics: Abdomen; Adult; Aged; Androstanols; Anesthesia Recovery Period; Anesthesia, General; Delayed Emergen

2015
Effects of sugammadex on incidence of postoperative residual neuromuscular blockade: a randomized, controlled study.
    British journal of anaesthesia, 2015, Volume: 115, Issue:5

    Topics: Abdomen; Adult; Aged; Androstanols; Anesthesia Recovery Period; Anesthesia, General; Delayed Emergen

2015
Effects of sugammadex on incidence of postoperative residual neuromuscular blockade: a randomized, controlled study.
    British journal of anaesthesia, 2015, Volume: 115, Issue:5

    Topics: Abdomen; Adult; Aged; Androstanols; Anesthesia Recovery Period; Anesthesia, General; Delayed Emergen

2015
Effects of sugammadex on incidence of postoperative residual neuromuscular blockade: a randomized, controlled study.
    British journal of anaesthesia, 2015, Volume: 115, Issue:5

    Topics: Abdomen; Adult; Aged; Androstanols; Anesthesia Recovery Period; Anesthesia, General; Delayed Emergen

2015
The effect of routine reversal of neuromuscular blockade on adequacy of recurrent laryngeal nerve stimulation during thyroid surgery.
    Anaesthesia and intensive care, 2015, Volume: 43, Issue:4

    Topics: Atracurium; Cholinesterase Inhibitors; Double-Blind Method; Electric Stimulation; Female; Glycopyrro

2015
Effect of glycopyrrolate versus atropine coadministered with neostigmine for reversal of rocuronium on postoperative catheter-related bladder discomfort in patients undergoing transurethral resection of bladder tumor: a prospective randomized study.
    Journal of anesthesia, 2015, Volume: 29, Issue:6

    Topics: Aged; Androstanols; Atropine; Double-Blind Method; Female; Glycopyrrolate; Humans; Male; Middle Aged

2015
Intraocular pressure changes associated with tracheal extubation: Comparison of sugammadex with conventional reversal of neuromuscular blockade.
    JPMA. The Journal of the Pakistan Medical Association, 2015, Volume: 65, Issue:11

    Topics: Adult; Airway Extubation; Atropine; Blood Pressure; Female; gamma-Cyclodextrins; Heart Rate; Humans;

2015
Timing of reversal with respect to three nerve stimulator end-points from cisatracurium-induced neuromuscular block.
    Anaesthesia, 2015, Volume: 70, Issue:7

    Topics: Anesthesia Recovery Period; Atracurium; Cholinesterase Inhibitors; Drug Administration Schedule; Ear

2015
Sugammadex and neostigmine dose-finding study for reversal of residual neuromuscular block at a train-of-four ratio of 0.2 (SUNDRO20)†,.
    British journal of anaesthesia, 2016, Volume: 116, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Androstanols; Anesthesia Recovery Period; Cholinesterase Inhibitors;

2016
Sugammadex and neostigmine dose-finding study for reversal of residual neuromuscular block at a train-of-four ratio of 0.2 (SUNDRO20)†,.
    British journal of anaesthesia, 2016, Volume: 116, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Androstanols; Anesthesia Recovery Period; Cholinesterase Inhibitors;

2016
Sugammadex and neostigmine dose-finding study for reversal of residual neuromuscular block at a train-of-four ratio of 0.2 (SUNDRO20)†,.
    British journal of anaesthesia, 2016, Volume: 116, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Androstanols; Anesthesia Recovery Period; Cholinesterase Inhibitors;

2016
Sugammadex and neostigmine dose-finding study for reversal of residual neuromuscular block at a train-of-four ratio of 0.2 (SUNDRO20)†,.
    British journal of anaesthesia, 2016, Volume: 116, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Androstanols; Anesthesia Recovery Period; Cholinesterase Inhibitors;

2016
Optimum dose of neostigmine to reverse shallow neuromuscular blockade with rocuronium and cisatracurium.
    Anaesthesia, 2016, Volume: 71, Issue:4

    Topics: Analysis of Variance; Androstanols; Anesthesia Recovery Period; Atracurium; Cholinesterase Inhibitor

2016
Low-Dose or High-Dose Rocuronium Reversed with Neostigmine or Sugammadex for Cesarean Delivery Anesthesia: A Randomized Controlled Noninferiority Trial of Time to Tracheal Intubation and Extubation.
    Anesthesia and analgesia, 2016, Volume: 122, Issue:5

    Topics: Adolescent; Adult; Androstanols; Anesthesia, General; Anesthesia, Obstetrical; Antidotes; Cesarean S

2016
[Comparison of neostigmine induced reversal of rocuronium in different age children].
    Zhonghua yi xue za zhi, 2016, Mar-15, Volume: 96, Issue:10

    Topics: Androstanols; Anesthesia, General; Atropine; Child; Elective Surgical Procedures; Humans; Monitoring

2016
Under sevoflurane anaesthesia, a reduced dose of neostigmine can antagonize a shallow neuromuscular block: A double-blind, randomised study.
    Anaesthesia, critical care & pain medicine, 2016, Volume: 35, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Anesthesia, Inhalation; Anesthetics, Inhalation; Anesthetics, Intrav

2016
Speed of reversal of vecuronium neuromuscular block with different doses of neostigmine in anesthetized dogs.
    Veterinary anaesthesia and analgesia, 2017, Volume: 44, Issue:1

    Topics: Anesthetics, Inhalation; Animals; Cross-Over Studies; Dogs; Female; Isoflurane; Male; Neostigmine; N

2017
Reversal of neuromuscular blockade with sugammadex or neostigmine/atropine: Effect on postoperative gastrointestinal motility.
    Journal of clinical anesthesia, 2016, Volume: 32

    Topics: Anesthesia Recovery Period; Atropine; Cholinesterase Inhibitors; Double-Blind Method; Female; gamma-

2016
The effect of sugammadex on steroid hormones: A randomized clinical study.
    Journal of clinical anesthesia, 2016, Volume: 34

    Topics: Adult; Aldosterone; Androstanols; Anesthesia Recovery Period; Atropine; Cholinesterase Inhibitors; E

2016
Operating room discharge after deep neuromuscular block reversed with sugammadex compared with shallow block reversed with neostigmine: a randomized controlled trial.
    Journal of clinical anesthesia, 2016, Volume: 35

    Topics: Adult; Androstanols; Anesthesia Recovery Period; Anesthesia, General; Anesthetics, Inhalation; Desfl

2016
Cisatracurium- and rocuronium-associated residual neuromuscular dysfunction under intraoperative neuromuscular monitoring and postoperative neostigmine reversal: a single-blind randomized trial.
    Journal of clinical anesthesia, 2016, Volume: 35

    Topics: Adult; Aged; Airway Extubation; Androstanols; Anesthesia Recovery Period; Atracurium; Cholinesterase

2016
Diaphragmatic and intercostal electromyographic activity during neostigmine, sugammadex and neostigmine-sugammadex-enhanced recovery after neuromuscular blockade: A randomised controlled volunteer study.
    European journal of anaesthesiology, 2017, Volume: 34, Issue:1

    Topics: Adult; Airway Extubation; Androstanols; Anesthesia Recovery Period; Cholinesterase Inhibitors; Diaph

2017
A comparison of sugammadex and neostigmine for reversal of rocuronium-induced neuromuscular blockade in children.
    Acta anaesthesiologica Scandinavica, 2017, Volume: 61, Issue:4

    Topics: Abdomen; Androstanols; Anesthesia Recovery Period; Anesthesia, General; Atropine; Child; Child, Pres

2017
Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine.
    Anesthesiology, 2008, Volume: 109, Issue:5

    Topics: Adult; Aged; Androstanols; Female; gamma-Cyclodextrins; Humans; Male; Middle Aged; Neostigmine; Neur

2008
Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine.
    Anesthesiology, 2008, Volume: 109, Issue:5

    Topics: Adult; Aged; Androstanols; Female; gamma-Cyclodextrins; Humans; Male; Middle Aged; Neostigmine; Neur

2008
Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine.
    Anesthesiology, 2008, Volume: 109, Issue:5

    Topics: Adult; Aged; Androstanols; Female; gamma-Cyclodextrins; Humans; Male; Middle Aged; Neostigmine; Neur

2008
Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine.
    Anesthesiology, 2008, Volume: 109, Issue:5

    Topics: Adult; Aged; Androstanols; Female; gamma-Cyclodextrins; Humans; Male; Middle Aged; Neostigmine; Neur

2008
Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine.
    Anesthesiology, 2008, Volume: 109, Issue:5

    Topics: Adult; Aged; Androstanols; Female; gamma-Cyclodextrins; Humans; Male; Middle Aged; Neostigmine; Neur

2008
Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine.
    Anesthesiology, 2008, Volume: 109, Issue:5

    Topics: Adult; Aged; Androstanols; Female; gamma-Cyclodextrins; Humans; Male; Middle Aged; Neostigmine; Neur

2008
Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine.
    Anesthesiology, 2008, Volume: 109, Issue:5

    Topics: Adult; Aged; Androstanols; Female; gamma-Cyclodextrins; Humans; Male; Middle Aged; Neostigmine; Neur

2008
Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine.
    Anesthesiology, 2008, Volume: 109, Issue:5

    Topics: Adult; Aged; Androstanols; Female; gamma-Cyclodextrins; Humans; Male; Middle Aged; Neostigmine; Neur

2008
Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine.
    Anesthesiology, 2008, Volume: 109, Issue:5

    Topics: Adult; Aged; Androstanols; Female; gamma-Cyclodextrins; Humans; Male; Middle Aged; Neostigmine; Neur

2008
Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine.
    Anesthesiology, 2008, Volume: 109, Issue:5

    Topics: Adult; Aged; Androstanols; Female; gamma-Cyclodextrins; Humans; Male; Middle Aged; Neostigmine; Neur

2008
Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine.
    Anesthesiology, 2008, Volume: 109, Issue:5

    Topics: Adult; Aged; Androstanols; Female; gamma-Cyclodextrins; Humans; Male; Middle Aged; Neostigmine; Neur

2008
Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine.
    Anesthesiology, 2008, Volume: 109, Issue:5

    Topics: Adult; Aged; Androstanols; Female; gamma-Cyclodextrins; Humans; Male; Middle Aged; Neostigmine; Neur

2008
Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine.
    Anesthesiology, 2008, Volume: 109, Issue:5

    Topics: Adult; Aged; Androstanols; Female; gamma-Cyclodextrins; Humans; Male; Middle Aged; Neostigmine; Neur

2008
Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine.
    Anesthesiology, 2008, Volume: 109, Issue:5

    Topics: Adult; Aged; Androstanols; Female; gamma-Cyclodextrins; Humans; Male; Middle Aged; Neostigmine; Neur

2008
Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine.
    Anesthesiology, 2008, Volume: 109, Issue:5

    Topics: Adult; Aged; Androstanols; Female; gamma-Cyclodextrins; Humans; Male; Middle Aged; Neostigmine; Neur

2008
Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine.
    Anesthesiology, 2008, Volume: 109, Issue:5

    Topics: Adult; Aged; Androstanols; Female; gamma-Cyclodextrins; Humans; Male; Middle Aged; Neostigmine; Neur

2008
Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine.
    Anesthesiology, 2008, Volume: 109, Issue:5

    Topics: Adult; Aged; Androstanols; Female; gamma-Cyclodextrins; Humans; Male; Middle Aged; Neostigmine; Neur

2008
Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine.
    Anesthesiology, 2008, Volume: 109, Issue:5

    Topics: Adult; Aged; Androstanols; Female; gamma-Cyclodextrins; Humans; Male; Middle Aged; Neostigmine; Neur

2008
Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine.
    Anesthesiology, 2008, Volume: 109, Issue:5

    Topics: Adult; Aged; Androstanols; Female; gamma-Cyclodextrins; Humans; Male; Middle Aged; Neostigmine; Neur

2008
Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine.
    Anesthesiology, 2008, Volume: 109, Issue:5

    Topics: Adult; Aged; Androstanols; Female; gamma-Cyclodextrins; Humans; Male; Middle Aged; Neostigmine; Neur

2008
Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine.
    Anesthesiology, 2008, Volume: 109, Issue:5

    Topics: Adult; Aged; Androstanols; Female; gamma-Cyclodextrins; Humans; Male; Middle Aged; Neostigmine; Neur

2008
Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine.
    Anesthesiology, 2008, Volume: 109, Issue:5

    Topics: Adult; Aged; Androstanols; Female; gamma-Cyclodextrins; Humans; Male; Middle Aged; Neostigmine; Neur

2008
Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine.
    Anesthesiology, 2008, Volume: 109, Issue:5

    Topics: Adult; Aged; Androstanols; Female; gamma-Cyclodextrins; Humans; Male; Middle Aged; Neostigmine; Neur

2008
Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine.
    Anesthesiology, 2008, Volume: 109, Issue:5

    Topics: Adult; Aged; Androstanols; Female; gamma-Cyclodextrins; Humans; Male; Middle Aged; Neostigmine; Neur

2008
Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine.
    Anesthesiology, 2008, Volume: 109, Issue:5

    Topics: Adult; Aged; Androstanols; Female; gamma-Cyclodextrins; Humans; Male; Middle Aged; Neostigmine; Neur

2008
Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine.
    Anesthesiology, 2008, Volume: 109, Issue:5

    Topics: Adult; Aged; Androstanols; Female; gamma-Cyclodextrins; Humans; Male; Middle Aged; Neostigmine; Neur

2008
Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine.
    Anesthesiology, 2008, Volume: 109, Issue:5

    Topics: Adult; Aged; Androstanols; Female; gamma-Cyclodextrins; Humans; Male; Middle Aged; Neostigmine; Neur

2008
Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine.
    Anesthesiology, 2008, Volume: 109, Issue:5

    Topics: Adult; Aged; Androstanols; Female; gamma-Cyclodextrins; Humans; Male; Middle Aged; Neostigmine; Neur

2008
Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine.
    Anesthesiology, 2008, Volume: 109, Issue:5

    Topics: Adult; Aged; Androstanols; Female; gamma-Cyclodextrins; Humans; Male; Middle Aged; Neostigmine; Neur

2008
Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine.
    Anesthesiology, 2008, Volume: 109, Issue:5

    Topics: Adult; Aged; Androstanols; Female; gamma-Cyclodextrins; Humans; Male; Middle Aged; Neostigmine; Neur

2008
Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine.
    Anesthesiology, 2008, Volume: 109, Issue:5

    Topics: Adult; Aged; Androstanols; Female; gamma-Cyclodextrins; Humans; Male; Middle Aged; Neostigmine; Neur

2008
Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine.
    Anesthesiology, 2008, Volume: 109, Issue:5

    Topics: Adult; Aged; Androstanols; Female; gamma-Cyclodextrins; Humans; Male; Middle Aged; Neostigmine; Neur

2008
Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine.
    Anesthesiology, 2008, Volume: 109, Issue:5

    Topics: Adult; Aged; Androstanols; Female; gamma-Cyclodextrins; Humans; Male; Middle Aged; Neostigmine; Neur

2008
Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine.
    Anesthesiology, 2008, Volume: 109, Issue:5

    Topics: Adult; Aged; Androstanols; Female; gamma-Cyclodextrins; Humans; Male; Middle Aged; Neostigmine; Neur

2008
Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine.
    Anesthesiology, 2008, Volume: 109, Issue:5

    Topics: Adult; Aged; Androstanols; Female; gamma-Cyclodextrins; Humans; Male; Middle Aged; Neostigmine; Neur

2008
Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine.
    Anesthesiology, 2008, Volume: 109, Issue:5

    Topics: Adult; Aged; Androstanols; Female; gamma-Cyclodextrins; Humans; Male; Middle Aged; Neostigmine; Neur

2008
Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine.
    Anesthesiology, 2008, Volume: 109, Issue:5

    Topics: Adult; Aged; Androstanols; Female; gamma-Cyclodextrins; Humans; Male; Middle Aged; Neostigmine; Neur

2008
Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine.
    Anesthesiology, 2008, Volume: 109, Issue:5

    Topics: Adult; Aged; Androstanols; Female; gamma-Cyclodextrins; Humans; Male; Middle Aged; Neostigmine; Neur

2008
Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine.
    Anesthesiology, 2008, Volume: 109, Issue:5

    Topics: Adult; Aged; Androstanols; Female; gamma-Cyclodextrins; Humans; Male; Middle Aged; Neostigmine; Neur

2008
Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine.
    Anesthesiology, 2008, Volume: 109, Issue:5

    Topics: Adult; Aged; Androstanols; Female; gamma-Cyclodextrins; Humans; Male; Middle Aged; Neostigmine; Neur

2008
Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine.
    Anesthesiology, 2008, Volume: 109, Issue:5

    Topics: Adult; Aged; Androstanols; Female; gamma-Cyclodextrins; Humans; Male; Middle Aged; Neostigmine; Neur

2008
Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine.
    Anesthesiology, 2008, Volume: 109, Issue:5

    Topics: Adult; Aged; Androstanols; Female; gamma-Cyclodextrins; Humans; Male; Middle Aged; Neostigmine; Neur

2008
Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine.
    Anesthesiology, 2008, Volume: 109, Issue:5

    Topics: Adult; Aged; Androstanols; Female; gamma-Cyclodextrins; Humans; Male; Middle Aged; Neostigmine; Neur

2008
Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine.
    Anesthesiology, 2008, Volume: 109, Issue:5

    Topics: Adult; Aged; Androstanols; Female; gamma-Cyclodextrins; Humans; Male; Middle Aged; Neostigmine; Neur

2008
Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine.
    Anesthesiology, 2008, Volume: 109, Issue:5

    Topics: Adult; Aged; Androstanols; Female; gamma-Cyclodextrins; Humans; Male; Middle Aged; Neostigmine; Neur

2008
Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine.
    Anesthesiology, 2008, Volume: 109, Issue:5

    Topics: Adult; Aged; Androstanols; Female; gamma-Cyclodextrins; Humans; Male; Middle Aged; Neostigmine; Neur

2008
Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine.
    Anesthesiology, 2008, Volume: 109, Issue:5

    Topics: Adult; Aged; Androstanols; Female; gamma-Cyclodextrins; Humans; Male; Middle Aged; Neostigmine; Neur

2008
Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine.
    Anesthesiology, 2008, Volume: 109, Issue:5

    Topics: Adult; Aged; Androstanols; Female; gamma-Cyclodextrins; Humans; Male; Middle Aged; Neostigmine; Neur

2008
Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine.
    Anesthesiology, 2008, Volume: 109, Issue:5

    Topics: Adult; Aged; Androstanols; Female; gamma-Cyclodextrins; Humans; Male; Middle Aged; Neostigmine; Neur

2008
Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine.
    Anesthesiology, 2008, Volume: 109, Issue:5

    Topics: Adult; Aged; Androstanols; Female; gamma-Cyclodextrins; Humans; Male; Middle Aged; Neostigmine; Neur

2008
Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine.
    Anesthesiology, 2008, Volume: 109, Issue:5

    Topics: Adult; Aged; Androstanols; Female; gamma-Cyclodextrins; Humans; Male; Middle Aged; Neostigmine; Neur

2008
Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine.
    Anesthesiology, 2008, Volume: 109, Issue:5

    Topics: Adult; Aged; Androstanols; Female; gamma-Cyclodextrins; Humans; Male; Middle Aged; Neostigmine; Neur

2008
Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine.
    Anesthesiology, 2008, Volume: 109, Issue:5

    Topics: Adult; Aged; Androstanols; Female; gamma-Cyclodextrins; Humans; Male; Middle Aged; Neostigmine; Neur

2008
Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine.
    Anesthesiology, 2008, Volume: 109, Issue:5

    Topics: Adult; Aged; Androstanols; Female; gamma-Cyclodextrins; Humans; Male; Middle Aged; Neostigmine; Neur

2008
Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine.
    Anesthesiology, 2008, Volume: 109, Issue:5

    Topics: Adult; Aged; Androstanols; Female; gamma-Cyclodextrins; Humans; Male; Middle Aged; Neostigmine; Neur

2008
Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine.
    Anesthesiology, 2008, Volume: 109, Issue:5

    Topics: Adult; Aged; Androstanols; Female; gamma-Cyclodextrins; Humans; Male; Middle Aged; Neostigmine; Neur

2008
Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine.
    Anesthesiology, 2008, Volume: 109, Issue:5

    Topics: Adult; Aged; Androstanols; Female; gamma-Cyclodextrins; Humans; Male; Middle Aged; Neostigmine; Neur

2008
Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine.
    Anesthesiology, 2008, Volume: 109, Issue:5

    Topics: Adult; Aged; Androstanols; Female; gamma-Cyclodextrins; Humans; Male; Middle Aged; Neostigmine; Neur

2008
Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine.
    Anesthesiology, 2008, Volume: 109, Issue:5

    Topics: Adult; Aged; Androstanols; Female; gamma-Cyclodextrins; Humans; Male; Middle Aged; Neostigmine; Neur

2008
Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine.
    Anesthesiology, 2008, Volume: 109, Issue:5

    Topics: Adult; Aged; Androstanols; Female; gamma-Cyclodextrins; Humans; Male; Middle Aged; Neostigmine; Neur

2008
Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine.
    Anesthesiology, 2008, Volume: 109, Issue:5

    Topics: Adult; Aged; Androstanols; Female; gamma-Cyclodextrins; Humans; Male; Middle Aged; Neostigmine; Neur

2008
Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine.
    Anesthesiology, 2008, Volume: 109, Issue:5

    Topics: Adult; Aged; Androstanols; Female; gamma-Cyclodextrins; Humans; Male; Middle Aged; Neostigmine; Neur

2008
Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine.
    Anesthesiology, 2008, Volume: 109, Issue:5

    Topics: Adult; Aged; Androstanols; Female; gamma-Cyclodextrins; Humans; Male; Middle Aged; Neostigmine; Neur

2008
Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine.
    Anesthesiology, 2008, Volume: 109, Issue:5

    Topics: Adult; Aged; Androstanols; Female; gamma-Cyclodextrins; Humans; Male; Middle Aged; Neostigmine; Neur

2008
Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine.
    Anesthesiology, 2008, Volume: 109, Issue:5

    Topics: Adult; Aged; Androstanols; Female; gamma-Cyclodextrins; Humans; Male; Middle Aged; Neostigmine; Neur

2008
Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine.
    Anesthesiology, 2008, Volume: 109, Issue:5

    Topics: Adult; Aged; Androstanols; Female; gamma-Cyclodextrins; Humans; Male; Middle Aged; Neostigmine; Neur

2008
Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine.
    Anesthesiology, 2008, Volume: 109, Issue:5

    Topics: Adult; Aged; Androstanols; Female; gamma-Cyclodextrins; Humans; Male; Middle Aged; Neostigmine; Neur

2008
Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine.
    Anesthesiology, 2008, Volume: 109, Issue:5

    Topics: Adult; Aged; Androstanols; Female; gamma-Cyclodextrins; Humans; Male; Middle Aged; Neostigmine; Neur

2008
Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine.
    Anesthesiology, 2008, Volume: 109, Issue:5

    Topics: Adult; Aged; Androstanols; Female; gamma-Cyclodextrins; Humans; Male; Middle Aged; Neostigmine; Neur

2008
Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine.
    Anesthesiology, 2008, Volume: 109, Issue:5

    Topics: Adult; Aged; Androstanols; Female; gamma-Cyclodextrins; Humans; Male; Middle Aged; Neostigmine; Neur

2008
Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine.
    Anesthesiology, 2008, Volume: 109, Issue:5

    Topics: Adult; Aged; Androstanols; Female; gamma-Cyclodextrins; Humans; Male; Middle Aged; Neostigmine; Neur

2008
Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine.
    Anesthesiology, 2008, Volume: 109, Issue:5

    Topics: Adult; Aged; Androstanols; Female; gamma-Cyclodextrins; Humans; Male; Middle Aged; Neostigmine; Neur

2008
Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine.
    Anesthesiology, 2008, Volume: 109, Issue:5

    Topics: Adult; Aged; Androstanols; Female; gamma-Cyclodextrins; Humans; Male; Middle Aged; Neostigmine; Neur

2008
Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine.
    Anesthesiology, 2008, Volume: 109, Issue:5

    Topics: Adult; Aged; Androstanols; Female; gamma-Cyclodextrins; Humans; Male; Middle Aged; Neostigmine; Neur

2008
Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine.
    Anesthesiology, 2008, Volume: 109, Issue:5

    Topics: Adult; Aged; Androstanols; Female; gamma-Cyclodextrins; Humans; Male; Middle Aged; Neostigmine; Neur

2008
Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine.
    Anesthesiology, 2008, Volume: 109, Issue:5

    Topics: Adult; Aged; Androstanols; Female; gamma-Cyclodextrins; Humans; Male; Middle Aged; Neostigmine; Neur

2008
Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine.
    Anesthesiology, 2008, Volume: 109, Issue:5

    Topics: Adult; Aged; Androstanols; Female; gamma-Cyclodextrins; Humans; Male; Middle Aged; Neostigmine; Neur

2008
Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine.
    Anesthesiology, 2008, Volume: 109, Issue:5

    Topics: Adult; Aged; Androstanols; Female; gamma-Cyclodextrins; Humans; Male; Middle Aged; Neostigmine; Neur

2008
Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine.
    Anesthesiology, 2008, Volume: 109, Issue:5

    Topics: Adult; Aged; Androstanols; Female; gamma-Cyclodextrins; Humans; Male; Middle Aged; Neostigmine; Neur

2008
Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine.
    Anesthesiology, 2008, Volume: 109, Issue:5

    Topics: Adult; Aged; Androstanols; Female; gamma-Cyclodextrins; Humans; Male; Middle Aged; Neostigmine; Neur

2008
Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine.
    Anesthesiology, 2008, Volume: 109, Issue:5

    Topics: Adult; Aged; Androstanols; Female; gamma-Cyclodextrins; Humans; Male; Middle Aged; Neostigmine; Neur

2008
Infusion requirements and reversibility of rocuronium at the corrugator supercilii and adductor pollicis muscles.
    Acta anaesthesiologica Scandinavica, 2009, Volume: 53, Issue:10

    Topics: Adult; Androstanols; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Facial Muscles; Fa

2009
Sugammadex provides faster reversal of vecuronium-induced neuromuscular blockade compared with neostigmine: a multicenter, randomized, controlled trial.
    Anesthesia and analgesia, 2010, Jan-01, Volume: 110, Issue:1

    Topics: Adult; Aged; Anesthesia Recovery Period; Cholinesterase Inhibitors; Dose-Response Relationship, Drug

2010
Sugammadex provides faster reversal of vecuronium-induced neuromuscular blockade compared with neostigmine: a multicenter, randomized, controlled trial.
    Anesthesia and analgesia, 2010, Jan-01, Volume: 110, Issue:1

    Topics: Adult; Aged; Anesthesia Recovery Period; Cholinesterase Inhibitors; Dose-Response Relationship, Drug

2010
Sugammadex provides faster reversal of vecuronium-induced neuromuscular blockade compared with neostigmine: a multicenter, randomized, controlled trial.
    Anesthesia and analgesia, 2010, Jan-01, Volume: 110, Issue:1

    Topics: Adult; Aged; Anesthesia Recovery Period; Cholinesterase Inhibitors; Dose-Response Relationship, Drug

2010
Sugammadex provides faster reversal of vecuronium-induced neuromuscular blockade compared with neostigmine: a multicenter, randomized, controlled trial.
    Anesthesia and analgesia, 2010, Jan-01, Volume: 110, Issue:1

    Topics: Adult; Aged; Anesthesia Recovery Period; Cholinesterase Inhibitors; Dose-Response Relationship, Drug

2010
Sugammadex provides faster reversal of vecuronium-induced neuromuscular blockade compared with neostigmine: a multicenter, randomized, controlled trial.
    Anesthesia and analgesia, 2010, Jan-01, Volume: 110, Issue:1

    Topics: Adult; Aged; Anesthesia Recovery Period; Cholinesterase Inhibitors; Dose-Response Relationship, Drug

2010
Sugammadex provides faster reversal of vecuronium-induced neuromuscular blockade compared with neostigmine: a multicenter, randomized, controlled trial.
    Anesthesia and analgesia, 2010, Jan-01, Volume: 110, Issue:1

    Topics: Adult; Aged; Anesthesia Recovery Period; Cholinesterase Inhibitors; Dose-Response Relationship, Drug

2010
Sugammadex provides faster reversal of vecuronium-induced neuromuscular blockade compared with neostigmine: a multicenter, randomized, controlled trial.
    Anesthesia and analgesia, 2010, Jan-01, Volume: 110, Issue:1

    Topics: Adult; Aged; Anesthesia Recovery Period; Cholinesterase Inhibitors; Dose-Response Relationship, Drug

2010
Sugammadex provides faster reversal of vecuronium-induced neuromuscular blockade compared with neostigmine: a multicenter, randomized, controlled trial.
    Anesthesia and analgesia, 2010, Jan-01, Volume: 110, Issue:1

    Topics: Adult; Aged; Anesthesia Recovery Period; Cholinesterase Inhibitors; Dose-Response Relationship, Drug

2010
Sugammadex provides faster reversal of vecuronium-induced neuromuscular blockade compared with neostigmine: a multicenter, randomized, controlled trial.
    Anesthesia and analgesia, 2010, Jan-01, Volume: 110, Issue:1

    Topics: Adult; Aged; Anesthesia Recovery Period; Cholinesterase Inhibitors; Dose-Response Relationship, Drug

2010
Reversal of rocuronium-induced neuromuscular blockade with sugammadex compared with neostigmine during sevoflurane anaesthesia: results of a randomised, controlled trial.
    European journal of anaesthesiology, 2010, Volume: 27, Issue:10

    Topics: Adult; Aged; Androstanols; Anesthetics, Inhalation; Cholinesterase Inhibitors; Female; gamma-Cyclode

2010
Reversal of rocuronium-induced neuromuscular blockade with sugammadex compared with neostigmine during sevoflurane anaesthesia: results of a randomised, controlled trial.
    European journal of anaesthesiology, 2010, Volume: 27, Issue:10

    Topics: Adult; Aged; Androstanols; Anesthetics, Inhalation; Cholinesterase Inhibitors; Female; gamma-Cyclode

2010
Reversal of rocuronium-induced neuromuscular blockade with sugammadex compared with neostigmine during sevoflurane anaesthesia: results of a randomised, controlled trial.
    European journal of anaesthesiology, 2010, Volume: 27, Issue:10

    Topics: Adult; Aged; Androstanols; Anesthetics, Inhalation; Cholinesterase Inhibitors; Female; gamma-Cyclode

2010
Reversal of rocuronium-induced neuromuscular blockade with sugammadex compared with neostigmine during sevoflurane anaesthesia: results of a randomised, controlled trial.
    European journal of anaesthesiology, 2010, Volume: 27, Issue:10

    Topics: Adult; Aged; Androstanols; Anesthetics, Inhalation; Cholinesterase Inhibitors; Female; gamma-Cyclode

2010
Reversal of rocuronium-induced neuromuscular blockade with sugammadex compared with neostigmine during sevoflurane anaesthesia: results of a randomised, controlled trial.
    European journal of anaesthesiology, 2010, Volume: 27, Issue:10

    Topics: Adult; Aged; Androstanols; Anesthetics, Inhalation; Cholinesterase Inhibitors; Female; gamma-Cyclode

2010
Reversal of rocuronium-induced neuromuscular blockade with sugammadex compared with neostigmine during sevoflurane anaesthesia: results of a randomised, controlled trial.
    European journal of anaesthesiology, 2010, Volume: 27, Issue:10

    Topics: Adult; Aged; Androstanols; Anesthetics, Inhalation; Cholinesterase Inhibitors; Female; gamma-Cyclode

2010
Reversal of rocuronium-induced neuromuscular blockade with sugammadex compared with neostigmine during sevoflurane anaesthesia: results of a randomised, controlled trial.
    European journal of anaesthesiology, 2010, Volume: 27, Issue:10

    Topics: Adult; Aged; Androstanols; Anesthetics, Inhalation; Cholinesterase Inhibitors; Female; gamma-Cyclode

2010
Reversal of rocuronium-induced neuromuscular blockade with sugammadex compared with neostigmine during sevoflurane anaesthesia: results of a randomised, controlled trial.
    European journal of anaesthesiology, 2010, Volume: 27, Issue:10

    Topics: Adult; Aged; Androstanols; Anesthetics, Inhalation; Cholinesterase Inhibitors; Female; gamma-Cyclode

2010
Reversal of rocuronium-induced neuromuscular blockade with sugammadex compared with neostigmine during sevoflurane anaesthesia: results of a randomised, controlled trial.
    European journal of anaesthesiology, 2010, Volume: 27, Issue:10

    Topics: Adult; Aged; Androstanols; Anesthetics, Inhalation; Cholinesterase Inhibitors; Female; gamma-Cyclode

2010
Reversal of rocuronium-induced neuromuscular blockade with sugammadex compared with neostigmine during sevoflurane anaesthesia: results of a randomised, controlled trial.
    European journal of anaesthesiology, 2010, Volume: 27, Issue:10

    Topics: Adult; Aged; Androstanols; Anesthetics, Inhalation; Cholinesterase Inhibitors; Female; gamma-Cyclode

2010
Reversal of rocuronium-induced neuromuscular blockade with sugammadex compared with neostigmine during sevoflurane anaesthesia: results of a randomised, controlled trial.
    European journal of anaesthesiology, 2010, Volume: 27, Issue:10

    Topics: Adult; Aged; Androstanols; Anesthetics, Inhalation; Cholinesterase Inhibitors; Female; gamma-Cyclode

2010
Reversal of rocuronium-induced neuromuscular blockade with sugammadex compared with neostigmine during sevoflurane anaesthesia: results of a randomised, controlled trial.
    European journal of anaesthesiology, 2010, Volume: 27, Issue:10

    Topics: Adult; Aged; Androstanols; Anesthetics, Inhalation; Cholinesterase Inhibitors; Female; gamma-Cyclode

2010
Reversal of rocuronium-induced neuromuscular blockade with sugammadex compared with neostigmine during sevoflurane anaesthesia: results of a randomised, controlled trial.
    European journal of anaesthesiology, 2010, Volume: 27, Issue:10

    Topics: Adult; Aged; Androstanols; Anesthetics, Inhalation; Cholinesterase Inhibitors; Female; gamma-Cyclode

2010
Reversal of rocuronium-induced neuromuscular blockade with sugammadex compared with neostigmine during sevoflurane anaesthesia: results of a randomised, controlled trial.
    European journal of anaesthesiology, 2010, Volume: 27, Issue:10

    Topics: Adult; Aged; Androstanols; Anesthetics, Inhalation; Cholinesterase Inhibitors; Female; gamma-Cyclode

2010
Reversal of rocuronium-induced neuromuscular blockade with sugammadex compared with neostigmine during sevoflurane anaesthesia: results of a randomised, controlled trial.
    European journal of anaesthesiology, 2010, Volume: 27, Issue:10

    Topics: Adult; Aged; Androstanols; Anesthetics, Inhalation; Cholinesterase Inhibitors; Female; gamma-Cyclode

2010
Reversal of rocuronium-induced neuromuscular blockade with sugammadex compared with neostigmine during sevoflurane anaesthesia: results of a randomised, controlled trial.
    European journal of anaesthesiology, 2010, Volume: 27, Issue:10

    Topics: Adult; Aged; Androstanols; Anesthetics, Inhalation; Cholinesterase Inhibitors; Female; gamma-Cyclode

2010
Neostigmine injected 5 minutes after low-dose rocuronium accelerates the recovery of neuromuscular function.
    Journal of clinical anesthesia, 2010, Volume: 22, Issue:6

    Topics: Adult; Aged; Androstanols; Anesthesia, General; Cholinesterase Inhibitors; Dose-Response Relationshi

2010
Sugammadex and neostigmine dose-finding study for reversal of shallow residual neuromuscular block.
    Anesthesiology, 2010, Volume: 113, Issue:5

    Topics: Adult; Anesthesia Recovery Period; Dose-Response Relationship, Drug; Double-Blind Method; Female; ga

2010
Sugammadex and neostigmine dose-finding study for reversal of shallow residual neuromuscular block.
    Anesthesiology, 2010, Volume: 113, Issue:5

    Topics: Adult; Anesthesia Recovery Period; Dose-Response Relationship, Drug; Double-Blind Method; Female; ga

2010
Sugammadex and neostigmine dose-finding study for reversal of shallow residual neuromuscular block.
    Anesthesiology, 2010, Volume: 113, Issue:5

    Topics: Adult; Anesthesia Recovery Period; Dose-Response Relationship, Drug; Double-Blind Method; Female; ga

2010
Sugammadex and neostigmine dose-finding study for reversal of shallow residual neuromuscular block.
    Anesthesiology, 2010, Volume: 113, Issue:5

    Topics: Adult; Anesthesia Recovery Period; Dose-Response Relationship, Drug; Double-Blind Method; Female; ga

2010
The duration of residual neuromuscular block after administration of neostigmine or sugammadex at two visible twitches during train-of-four monitoring.
    Anesthesia and analgesia, 2011, Volume: 112, Issue:1

    Topics: Adolescent; Adult; Aged; Anesthesia Recovery Period; Double-Blind Method; Female; gamma-Cyclodextrin

2011
Intraoperative reversal of neuromuscular block with sugammadex or neostigmine during extreme lateral interbody fusion, a novel technique for spine surgery.
    Journal of anesthesia, 2011, Volume: 25, Issue:5

    Topics: Androstanols; Anesthesia Recovery Period; Anesthesia, General; Cholinesterase Inhibitors; Female; ga

2011
Randomized comparison of sugammadex and neostigmine for reversal of rocuronium-induced muscle relaxation in morbidly obese undergoing general anaesthesia.
    British journal of anaesthesia, 2012, Volume: 108, Issue:2

    Topics: Adult; Androstanols; Anesthesia Recovery Period; Anthropometry; Bariatric Surgery; gamma-Cyclodextri

2012
Elevated BIS and Entropy values after sugammadex or neostigmine: an electroencephalographic or electromyographic phenomenon?
    Acta anaesthesiologica Scandinavica, 2012, Volume: 56, Issue:4

    Topics: Adult; Blood-Brain Barrier; Double-Blind Method; Electroencephalography; Electromyography; Entropy;

2012
Effect of sugammadex or neostigmine neuromuscular block reversal on bispectral index monitoring of propofol/remifentanil anaesthesia.
    British journal of anaesthesia, 2012, Volume: 108, Issue:4

    Topics: Adolescent; Adult; Androstanols; Anesthesia; Anesthesia Recovery Period; Anesthetics, Intravenous; C

2012
A randomised controlled trial comparing sugammadex and neostigmine at different depths of neuromuscular blockade in patients undergoing laparoscopic surgery.
    Anaesthesia, 2012, Volume: 67, Issue:9

    Topics: Adult; Aged; Androstanols; Anesthesia; Anesthesia Recovery Period; Anesthetics, Intravenous; Choline

2012
A randomised controlled trial comparing sugammadex and neostigmine at different depths of neuromuscular blockade in patients undergoing laparoscopic surgery.
    Anaesthesia, 2012, Volume: 67, Issue:9

    Topics: Adult; Aged; Androstanols; Anesthesia; Anesthesia Recovery Period; Anesthetics, Intravenous; Choline

2012
A randomised controlled trial comparing sugammadex and neostigmine at different depths of neuromuscular blockade in patients undergoing laparoscopic surgery.
    Anaesthesia, 2012, Volume: 67, Issue:9

    Topics: Adult; Aged; Androstanols; Anesthesia; Anesthesia Recovery Period; Anesthetics, Intravenous; Choline

2012
A randomised controlled trial comparing sugammadex and neostigmine at different depths of neuromuscular blockade in patients undergoing laparoscopic surgery.
    Anaesthesia, 2012, Volume: 67, Issue:9

    Topics: Adult; Aged; Androstanols; Anesthesia; Anesthesia Recovery Period; Anesthetics, Intravenous; Choline

2012
A randomised controlled trial comparing sugammadex and neostigmine at different depths of neuromuscular blockade in patients undergoing laparoscopic surgery.
    Anaesthesia, 2012, Volume: 67, Issue:9

    Topics: Adult; Aged; Androstanols; Anesthesia; Anesthesia Recovery Period; Anesthetics, Intravenous; Choline

2012
A randomised controlled trial comparing sugammadex and neostigmine at different depths of neuromuscular blockade in patients undergoing laparoscopic surgery.
    Anaesthesia, 2012, Volume: 67, Issue:9

    Topics: Adult; Aged; Androstanols; Anesthesia; Anesthesia Recovery Period; Anesthetics, Intravenous; Choline

2012
A randomised controlled trial comparing sugammadex and neostigmine at different depths of neuromuscular blockade in patients undergoing laparoscopic surgery.
    Anaesthesia, 2012, Volume: 67, Issue:9

    Topics: Adult; Aged; Androstanols; Anesthesia; Anesthesia Recovery Period; Anesthetics, Intravenous; Choline

2012
A randomised controlled trial comparing sugammadex and neostigmine at different depths of neuromuscular blockade in patients undergoing laparoscopic surgery.
    Anaesthesia, 2012, Volume: 67, Issue:9

    Topics: Adult; Aged; Androstanols; Anesthesia; Anesthesia Recovery Period; Anesthetics, Intravenous; Choline

2012
A randomised controlled trial comparing sugammadex and neostigmine at different depths of neuromuscular blockade in patients undergoing laparoscopic surgery.
    Anaesthesia, 2012, Volume: 67, Issue:9

    Topics: Adult; Aged; Androstanols; Anesthesia; Anesthesia Recovery Period; Anesthetics, Intravenous; Choline

2012
Effect-site concentration of propofol for recovery of consciousness is virtually independent of fentanyl effect-site concentration.
    Anesthesia and analgesia, 2003, Volume: 96, Issue:6

    Topics: Adult; Anesthesia Recovery Period; Anesthetics, Intravenous; Atropine; Bradycardia; Female; Fentanyl

2003
Antagonism of neuromuscular blockade but not muscle relaxation affects depth of anaesthesia.
    British journal of anaesthesia, 2005, Volume: 94, Issue:6

    Topics: Adult; Aged; Anesthetics, Combined; Anesthetics, Intravenous; Atracurium; Blood Pressure; Cholineste

2005
[Effect of neostigmine on atracurium-induced neuromuscular blockage in patients pretreated with magnesium sulphate].
    Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae, 2005, Volume: 27, Issue:1

    Topics: Adolescent; Adult; Anesthesia, General; Atracurium; Cholinesterase Inhibitors; Female; Humans; Lapar

2005
Sugammadex reversal of rocuronium-induced neuromuscular blockade: a comparison with neostigmine-glycopyrrolate and edrophonium-atropine.
    Anesthesia and analgesia, 2007, Volume: 104, Issue:3

    Topics: Adjuvants, Anesthesia; Aged; Androstanols; Atropine; Cholinesterase Inhibitors; Edrophonium; Female;

2007
Reversal of rocuronium-induced neuromuscular block with sugammadex is faster than reversal of cisatracurium-induced block with neostigmine.
    British journal of anaesthesia, 2008, Volume: 100, Issue:5

    Topics: Adult; Aged; Androstanols; Anesthesia Recovery Period; Anesthesia, General; Atracurium; Double-Blind

2008
Reversal of rocuronium-induced neuromuscular block with sugammadex is faster than reversal of cisatracurium-induced block with neostigmine.
    British journal of anaesthesia, 2008, Volume: 100, Issue:5

    Topics: Adult; Aged; Androstanols; Anesthesia Recovery Period; Anesthesia, General; Atracurium; Double-Blind

2008
Reversal of rocuronium-induced neuromuscular block with sugammadex is faster than reversal of cisatracurium-induced block with neostigmine.
    British journal of anaesthesia, 2008, Volume: 100, Issue:5

    Topics: Adult; Aged; Androstanols; Anesthesia Recovery Period; Anesthesia, General; Atracurium; Double-Blind

2008
Reversal of rocuronium-induced neuromuscular block with sugammadex is faster than reversal of cisatracurium-induced block with neostigmine.
    British journal of anaesthesia, 2008, Volume: 100, Issue:5

    Topics: Adult; Aged; Androstanols; Anesthesia Recovery Period; Anesthesia, General; Atracurium; Double-Blind

2008
Reversal of rocuronium-induced neuromuscular block with sugammadex is faster than reversal of cisatracurium-induced block with neostigmine.
    British journal of anaesthesia, 2008, Volume: 100, Issue:5

    Topics: Adult; Aged; Androstanols; Anesthesia Recovery Period; Anesthesia, General; Atracurium; Double-Blind

2008
Reversal of rocuronium-induced neuromuscular block with sugammadex is faster than reversal of cisatracurium-induced block with neostigmine.
    British journal of anaesthesia, 2008, Volume: 100, Issue:5

    Topics: Adult; Aged; Androstanols; Anesthesia Recovery Period; Anesthesia, General; Atracurium; Double-Blind

2008
Reversal of rocuronium-induced neuromuscular block with sugammadex is faster than reversal of cisatracurium-induced block with neostigmine.
    British journal of anaesthesia, 2008, Volume: 100, Issue:5

    Topics: Adult; Aged; Androstanols; Anesthesia Recovery Period; Anesthesia, General; Atracurium; Double-Blind

2008
Reversal of rocuronium-induced neuromuscular block with sugammadex is faster than reversal of cisatracurium-induced block with neostigmine.
    British journal of anaesthesia, 2008, Volume: 100, Issue:5

    Topics: Adult; Aged; Androstanols; Anesthesia Recovery Period; Anesthesia, General; Atracurium; Double-Blind

2008
Reversal of rocuronium-induced neuromuscular block with sugammadex is faster than reversal of cisatracurium-induced block with neostigmine.
    British journal of anaesthesia, 2008, Volume: 100, Issue:5

    Topics: Adult; Aged; Androstanols; Anesthesia Recovery Period; Anesthesia, General; Atracurium; Double-Blind

2008
Reversal of rocuronium-induced neuromuscular block with sugammadex is faster than reversal of cisatracurium-induced block with neostigmine.
    British journal of anaesthesia, 2008, Volume: 100, Issue:5

    Topics: Adult; Aged; Androstanols; Anesthesia Recovery Period; Anesthesia, General; Atracurium; Double-Blind

2008
Reversal of rocuronium-induced neuromuscular block with sugammadex is faster than reversal of cisatracurium-induced block with neostigmine.
    British journal of anaesthesia, 2008, Volume: 100, Issue:5

    Topics: Adult; Aged; Androstanols; Anesthesia Recovery Period; Anesthesia, General; Atracurium; Double-Blind

2008
Reversal of rocuronium-induced neuromuscular block with sugammadex is faster than reversal of cisatracurium-induced block with neostigmine.
    British journal of anaesthesia, 2008, Volume: 100, Issue:5

    Topics: Adult; Aged; Androstanols; Anesthesia Recovery Period; Anesthesia, General; Atracurium; Double-Blind

2008
Reversal of rocuronium-induced neuromuscular block with sugammadex is faster than reversal of cisatracurium-induced block with neostigmine.
    British journal of anaesthesia, 2008, Volume: 100, Issue:5

    Topics: Adult; Aged; Androstanols; Anesthesia Recovery Period; Anesthesia, General; Atracurium; Double-Blind

2008
Reversal of rocuronium-induced neuromuscular block with sugammadex is faster than reversal of cisatracurium-induced block with neostigmine.
    British journal of anaesthesia, 2008, Volume: 100, Issue:5

    Topics: Adult; Aged; Androstanols; Anesthesia Recovery Period; Anesthesia, General; Atracurium; Double-Blind

2008
Reversal of rocuronium-induced neuromuscular block with sugammadex is faster than reversal of cisatracurium-induced block with neostigmine.
    British journal of anaesthesia, 2008, Volume: 100, Issue:5

    Topics: Adult; Aged; Androstanols; Anesthesia Recovery Period; Anesthesia, General; Atracurium; Double-Blind

2008
Reversal of rocuronium-induced neuromuscular block with sugammadex is faster than reversal of cisatracurium-induced block with neostigmine.
    British journal of anaesthesia, 2008, Volume: 100, Issue:5

    Topics: Adult; Aged; Androstanols; Anesthesia Recovery Period; Anesthesia, General; Atracurium; Double-Blind

2008
Reversal of rocuronium-induced neuromuscular block with sugammadex is faster than reversal of cisatracurium-induced block with neostigmine.
    British journal of anaesthesia, 2008, Volume: 100, Issue:5

    Topics: Adult; Aged; Androstanols; Anesthesia Recovery Period; Anesthesia, General; Atracurium; Double-Blind

2008
Reversal of rocuronium-induced neuromuscular block with sugammadex is faster than reversal of cisatracurium-induced block with neostigmine.
    British journal of anaesthesia, 2008, Volume: 100, Issue:5

    Topics: Adult; Aged; Androstanols; Anesthesia Recovery Period; Anesthesia, General; Atracurium; Double-Blind

2008
Reversal of rocuronium-induced neuromuscular block with sugammadex is faster than reversal of cisatracurium-induced block with neostigmine.
    British journal of anaesthesia, 2008, Volume: 100, Issue:5

    Topics: Adult; Aged; Androstanols; Anesthesia Recovery Period; Anesthesia, General; Atracurium; Double-Blind

2008
Reversal of rocuronium-induced neuromuscular block with sugammadex is faster than reversal of cisatracurium-induced block with neostigmine.
    British journal of anaesthesia, 2008, Volume: 100, Issue:5

    Topics: Adult; Aged; Androstanols; Anesthesia Recovery Period; Anesthesia, General; Atracurium; Double-Blind

2008
Reversal of rocuronium-induced neuromuscular block with sugammadex is faster than reversal of cisatracurium-induced block with neostigmine.
    British journal of anaesthesia, 2008, Volume: 100, Issue:5

    Topics: Adult; Aged; Androstanols; Anesthesia Recovery Period; Anesthesia, General; Atracurium; Double-Blind

2008
Reversal of rocuronium-induced neuromuscular block with sugammadex is faster than reversal of cisatracurium-induced block with neostigmine.
    British journal of anaesthesia, 2008, Volume: 100, Issue:5

    Topics: Adult; Aged; Androstanols; Anesthesia Recovery Period; Anesthesia, General; Atracurium; Double-Blind

2008
Reversal of rocuronium-induced neuromuscular block with sugammadex is faster than reversal of cisatracurium-induced block with neostigmine.
    British journal of anaesthesia, 2008, Volume: 100, Issue:5

    Topics: Adult; Aged; Androstanols; Anesthesia Recovery Period; Anesthesia, General; Atracurium; Double-Blind

2008
Reversal of rocuronium-induced neuromuscular block with sugammadex is faster than reversal of cisatracurium-induced block with neostigmine.
    British journal of anaesthesia, 2008, Volume: 100, Issue:5

    Topics: Adult; Aged; Androstanols; Anesthesia Recovery Period; Anesthesia, General; Atracurium; Double-Blind

2008
Reversal of rocuronium-induced neuromuscular block with sugammadex is faster than reversal of cisatracurium-induced block with neostigmine.
    British journal of anaesthesia, 2008, Volume: 100, Issue:5

    Topics: Adult; Aged; Androstanols; Anesthesia Recovery Period; Anesthesia, General; Atracurium; Double-Blind

2008
Reversal of rocuronium-induced neuromuscular block with sugammadex is faster than reversal of cisatracurium-induced block with neostigmine.
    British journal of anaesthesia, 2008, Volume: 100, Issue:5

    Topics: Adult; Aged; Androstanols; Anesthesia Recovery Period; Anesthesia, General; Atracurium; Double-Blind

2008
Reversal of rocuronium-induced neuromuscular block with sugammadex is faster than reversal of cisatracurium-induced block with neostigmine.
    British journal of anaesthesia, 2008, Volume: 100, Issue:5

    Topics: Adult; Aged; Androstanols; Anesthesia Recovery Period; Anesthesia, General; Atracurium; Double-Blind

2008
Reversal of rocuronium-induced neuromuscular block with sugammadex is faster than reversal of cisatracurium-induced block with neostigmine.
    British journal of anaesthesia, 2008, Volume: 100, Issue:5

    Topics: Adult; Aged; Androstanols; Anesthesia Recovery Period; Anesthesia, General; Atracurium; Double-Blind

2008
Reversal of rocuronium-induced neuromuscular block with sugammadex is faster than reversal of cisatracurium-induced block with neostigmine.
    British journal of anaesthesia, 2008, Volume: 100, Issue:5

    Topics: Adult; Aged; Androstanols; Anesthesia Recovery Period; Anesthesia, General; Atracurium; Double-Blind

2008
Reversal of rocuronium-induced neuromuscular block with sugammadex is faster than reversal of cisatracurium-induced block with neostigmine.
    British journal of anaesthesia, 2008, Volume: 100, Issue:5

    Topics: Adult; Aged; Androstanols; Anesthesia Recovery Period; Anesthesia, General; Atracurium; Double-Blind

2008
Reversal of rocuronium-induced neuromuscular block with sugammadex is faster than reversal of cisatracurium-induced block with neostigmine.
    British journal of anaesthesia, 2008, Volume: 100, Issue:5

    Topics: Adult; Aged; Androstanols; Anesthesia Recovery Period; Anesthesia, General; Atracurium; Double-Blind

2008
Reversal of rocuronium-induced neuromuscular block with sugammadex is faster than reversal of cisatracurium-induced block with neostigmine.
    British journal of anaesthesia, 2008, Volume: 100, Issue:5

    Topics: Adult; Aged; Androstanols; Anesthesia Recovery Period; Anesthesia, General; Atracurium; Double-Blind

2008
Reversal of rocuronium-induced neuromuscular block with sugammadex is faster than reversal of cisatracurium-induced block with neostigmine.
    British journal of anaesthesia, 2008, Volume: 100, Issue:5

    Topics: Adult; Aged; Androstanols; Anesthesia Recovery Period; Anesthesia, General; Atracurium; Double-Blind

2008
Reversal of rocuronium-induced neuromuscular block with sugammadex is faster than reversal of cisatracurium-induced block with neostigmine.
    British journal of anaesthesia, 2008, Volume: 100, Issue:5

    Topics: Adult; Aged; Androstanols; Anesthesia Recovery Period; Anesthesia, General; Atracurium; Double-Blind

2008
Reversal of rocuronium-induced neuromuscular block with sugammadex is faster than reversal of cisatracurium-induced block with neostigmine.
    British journal of anaesthesia, 2008, Volume: 100, Issue:5

    Topics: Adult; Aged; Androstanols; Anesthesia Recovery Period; Anesthesia, General; Atracurium; Double-Blind

2008
Reversal of rocuronium-induced neuromuscular block with sugammadex is faster than reversal of cisatracurium-induced block with neostigmine.
    British journal of anaesthesia, 2008, Volume: 100, Issue:5

    Topics: Adult; Aged; Androstanols; Anesthesia Recovery Period; Anesthesia, General; Atracurium; Double-Blind

2008
Reversal of rocuronium-induced neuromuscular block with sugammadex is faster than reversal of cisatracurium-induced block with neostigmine.
    British journal of anaesthesia, 2008, Volume: 100, Issue:5

    Topics: Adult; Aged; Androstanols; Anesthesia Recovery Period; Anesthesia, General; Atracurium; Double-Blind

2008
Reversal of rocuronium-induced neuromuscular block with sugammadex is faster than reversal of cisatracurium-induced block with neostigmine.
    British journal of anaesthesia, 2008, Volume: 100, Issue:5

    Topics: Adult; Aged; Androstanols; Anesthesia Recovery Period; Anesthesia, General; Atracurium; Double-Blind

2008
Reversal of rocuronium-induced neuromuscular block with sugammadex is faster than reversal of cisatracurium-induced block with neostigmine.
    British journal of anaesthesia, 2008, Volume: 100, Issue:5

    Topics: Adult; Aged; Androstanols; Anesthesia Recovery Period; Anesthesia, General; Atracurium; Double-Blind

2008
Reversal of rocuronium-induced neuromuscular block with sugammadex is faster than reversal of cisatracurium-induced block with neostigmine.
    British journal of anaesthesia, 2008, Volume: 100, Issue:5

    Topics: Adult; Aged; Androstanols; Anesthesia Recovery Period; Anesthesia, General; Atracurium; Double-Blind

2008
Reversal of rocuronium-induced neuromuscular block with sugammadex is faster than reversal of cisatracurium-induced block with neostigmine.
    British journal of anaesthesia, 2008, Volume: 100, Issue:5

    Topics: Adult; Aged; Androstanols; Anesthesia Recovery Period; Anesthesia, General; Atracurium; Double-Blind

2008
Reversal of rocuronium-induced neuromuscular block with sugammadex is faster than reversal of cisatracurium-induced block with neostigmine.
    British journal of anaesthesia, 2008, Volume: 100, Issue:5

    Topics: Adult; Aged; Androstanols; Anesthesia Recovery Period; Anesthesia, General; Atracurium; Double-Blind

2008
Reversal of rocuronium-induced neuromuscular block with sugammadex is faster than reversal of cisatracurium-induced block with neostigmine.
    British journal of anaesthesia, 2008, Volume: 100, Issue:5

    Topics: Adult; Aged; Androstanols; Anesthesia Recovery Period; Anesthesia, General; Atracurium; Double-Blind

2008
Reversal of rocuronium-induced neuromuscular block with sugammadex is faster than reversal of cisatracurium-induced block with neostigmine.
    British journal of anaesthesia, 2008, Volume: 100, Issue:5

    Topics: Adult; Aged; Androstanols; Anesthesia Recovery Period; Anesthesia, General; Atracurium; Double-Blind

2008
Reversal of rocuronium-induced neuromuscular block with sugammadex is faster than reversal of cisatracurium-induced block with neostigmine.
    British journal of anaesthesia, 2008, Volume: 100, Issue:5

    Topics: Adult; Aged; Androstanols; Anesthesia Recovery Period; Anesthesia, General; Atracurium; Double-Blind

2008
Reversal of rocuronium-induced neuromuscular block with sugammadex is faster than reversal of cisatracurium-induced block with neostigmine.
    British journal of anaesthesia, 2008, Volume: 100, Issue:5

    Topics: Adult; Aged; Androstanols; Anesthesia Recovery Period; Anesthesia, General; Atracurium; Double-Blind

2008
Reversal of rocuronium-induced neuromuscular block with sugammadex is faster than reversal of cisatracurium-induced block with neostigmine.
    British journal of anaesthesia, 2008, Volume: 100, Issue:5

    Topics: Adult; Aged; Androstanols; Anesthesia Recovery Period; Anesthesia, General; Atracurium; Double-Blind

2008
Reversal of rocuronium-induced neuromuscular block with sugammadex is faster than reversal of cisatracurium-induced block with neostigmine.
    British journal of anaesthesia, 2008, Volume: 100, Issue:5

    Topics: Adult; Aged; Androstanols; Anesthesia Recovery Period; Anesthesia, General; Atracurium; Double-Blind

2008
Reversal of rocuronium-induced neuromuscular block with sugammadex is faster than reversal of cisatracurium-induced block with neostigmine.
    British journal of anaesthesia, 2008, Volume: 100, Issue:5

    Topics: Adult; Aged; Androstanols; Anesthesia Recovery Period; Anesthesia, General; Atracurium; Double-Blind

2008
Conditions to optimise the reversal action of neostigmine upon a vecuronium-induced neuromuscular block.
    Acta anaesthesiologica Scandinavica, 1996, Volume: 40, Issue:5

    Topics: Adolescent; Adult; Cholinesterase Inhibitors; Humans; Middle Aged; Neostigmine; Neuromuscular Blocka

1996
Cisatracurium during halothane and balanced anaesthesia in children.
    Paediatric anaesthesia, 1996, Volume: 6, Issue:5

    Topics: Anesthesia; Anesthesia, Inhalation; Anesthetics, Combined; Anesthetics, Inhalation; Atracurium; Bloo

1996
A comparison of cisatracurium and atracurium: onset of neuromuscular block after bolus injection and recovery after subsequent infusion.
    Anesthesia and analgesia, 1996, Volume: 83, Issue:5

    Topics: Adolescent; Adult; Aged; Anesthesia Recovery Period; Atracurium; Atropine; Cholinesterase Inhibitors

1996
Recovery from mivacurium block with or without anticholinesterase following continuous infusion in obstetric patients.
    Anaesthesia and intensive care, 1996, Volume: 24, Issue:5

    Topics: Adjuvants, Anesthesia; Adult; Anesthesia Recovery Period; Anesthesia, Inhalation; Anesthesia, Intrav

1996
The effects of reversal of neuromuscular blockade on autonomic control in the perioperative period.
    Anesthesia and analgesia, 1997, Volume: 84, Issue:1

    Topics: Adolescent; Adult; Atropine; Autonomic Nervous System; Baroreflex; Double-Blind Method; Female; Glyc

1997
Dose-response relationships for neostigmine antagonism of rocuronium-induced neuromuscular block in children and adults.
    British journal of anaesthesia, 1996, Volume: 77, Issue:6

    Topics: Adolescent; Adult; Age Factors; Androstanols; Anesthesia, Inhalation; Child; Child, Preschool; Choli

1996
Reversal of neuromuscular blockade with neostigmine has no effect on the incidence or severity of postoperative nausea and vomiting.
    Anesthesia and analgesia, 1997, Volume: 85, Issue:6

    Topics: Adult; Aged; Anesthesia, General; Double-Blind Method; Female; Humans; Hysterectomy; Isoquinolines;

1997
Susceptibility to upper airway obstruction during partial neuromuscular block.
    Anesthesiology, 1998, Volume: 88, Issue:2

    Topics: Adult; Airway Obstruction; Airway Resistance; Cholinesterase Inhibitors; Disease Susceptibility; Hum

1998
A comparison of the neuromuscular blocking effects and reversibility of cisatracurium and atracurium.
    Anaesthesia, 1998, Volume: 53, Issue:8

    Topics: Adolescent; Adult; Aged; Anesthesia, General; Atracurium; Cholinesterase Inhibitors; Female; Humans;

1998
Tactile evaluation of the response to double burst stimulation decreases, but does not eliminate, the problem of postoperative residual paralysis.
    Acta anaesthesiologica Scandinavica, 1998, Volume: 42, Issue:10

    Topics: Abdomen; Adult; Aged; Aged, 80 and over; Cholinesterase Inhibitors; Electric Stimulation; Female; Hu

1998
Antagonism of vecuronium-induced neuromuscular block in patients pretreated with magnesium sulphate: dose-effect relationship of neostigmine.
    British journal of anaesthesia, 1999, Volume: 82, Issue:1

    Topics: Adult; Anti-Arrhythmia Agents; Anticonvulsants; Bradycardia; Cholinesterase Inhibitors; Dose-Respons

1999
Early and late reversal of rocuronium and vecuronium with neostigmine in adults and children.
    Anesthesia and analgesia, 1999, Volume: 89, Issue:2

    Topics: Adult; Androstanols; Child; Child, Preschool; Cholinesterase Inhibitors; Female; Humans; Male; Neost

1999
The effects of antagonizing residual neuromuscular blockade by neostigmine and glycopyrrolate on nausea and vomiting after ambulatory surgery.
    Anesthesia and analgesia, 1999, Volume: 89, Issue:3

    Topics: Adult; Ambulatory Surgical Procedures; Androstanols; Anesthesia, General; Antiemetics; Female; Glyco

1999
Spontaneous or neostigmine-induced recovery after maintenance of neuromuscular block with Org 9487 (rapacuronium) or rocuronium following an initial dose of Org 9487.
    British journal of anaesthesia, 1999, Volume: 82, Issue:5

    Topics: Androstanols; Anesthesia, General; Cholinesterase Inhibitors; Drug Administration Schedule; Humans;

1999
Comparison of recovery following rapacuronium, with and without neostigmine, and succinylcholine.
    Anaesthesia, 2000, Volume: 55, Issue:9

    Topics: Adolescent; Adult; Anesthesia Recovery Period; Anesthesia, General; Cholinesterase Inhibitors; Femal

2000
A comparison of neuromuscular effects, tracheal intubating conditions, and reversibility of rapacuronium versus mivacurium in female patients.
    Anesthesia and analgesia, 2002, Volume: 94, Issue:4

    Topics: Cholinesterase Inhibitors; Double-Blind Method; Female; Gynecologic Surgical Procedures; Humans; Int

2002

Other Studies

203 other studies available for neostigmine and Neuromuscular Blockade

ArticleYear
Investigation of potential neuropharmacological activity of neostigmine-glycopyrrolate for intraoperative neural monitoring in thyroid surgery.
    The Kaohsiung journal of medical sciences, 2022, Volume: 38, Issue:1

    Topics: Female; Glycopyrrolate; Humans; Intubation, Intratracheal; Laryngeal Nerve Injuries; Male; Middle Ag

2022
Rocuronium Reversal in the Emergency Department: Retrospective Evaluation of Hemodynamic Instability Following Administration of Sugammadex Versus Neostigmine With Glycopyrrolate.
    Journal of pharmacy practice, 2023, Volume: 36, Issue:2

    Topics: Adult; Emergency Service, Hospital; Glycopyrrolate; Hemodynamics; Humans; Neostigmine; Neuromuscular

2023
Neuromuscular Blockade and Reversal Practice Variability in the Outpatient Setting: Insights From US Utilization Patterns.
    Anesthesia and analgesia, 2021, 12-01, Volume: 133, Issue:6

    Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Ambulatory Surgical Procedures; Anesthesia

2021
Effects of Reversal Technique for Neuromuscular Paralysis on Time to Recovery of Bowel Function after Craniotomy.
    The American surgeon, 2023, Volume: 89, Issue:5

    Topics: Adult; Craniotomy; Defecation; Glycopyrrolate; Humans; Neostigmine; Neuromuscular Blockade; Neuromus

2023
Use of provider education, intra-operative decision support, and an email-feedback system in improving compliance with sugammadex dosage guideline and reducing drug expenditures.
    Journal of clinical anesthesia, 2022, Volume: 77

    Topics: Electronic Mail; Feedback; Health Expenditures; Humans; Neostigmine; Neuromuscular Blockade; Pharmac

2022
Sugammadex Versus Neostigmine for Reversal of Residual Neuromuscular Blocks After Surgery: A Retrospective Cohort Analysis of Postoperative Side Effects.
    Anesthesia and analgesia, 2022, 05-01, Volume: 134, Issue:5

    Topics: Anaphylaxis; Bradycardia; Bronchial Spasm; Child; Cohort Studies; Delayed Emergence from Anesthesia;

2022
Association of Sugammadex or Neostigmine With Major Postoperative Pulmonary Complications in Children.
    Anesthesia and analgesia, 2022, 11-01, Volume: 135, Issue:5

    Topics: Adult; Child; Cholinesterase Inhibitors; Humans; Neostigmine; Neuromuscular Blockade; Postoperative

2022
Con: Sugammadex Should Not Be Used Routinely for Reversal of Neuromuscular Blockade in Patients Undergoing Thoracic Surgery.
    Journal of cardiothoracic and vascular anesthesia, 2022, Volume: 36, Issue:6

    Topics: Cholinesterase Inhibitors; Humans; Neostigmine; Neuromuscular Blockade; Neuromuscular Nondepolarizin

2022
Quantitative Neuromuscular Monitoring in Clinical Practice: A Professional Practice Change Initiative.
    Anesthesiology, 2022, 06-01, Volume: 136, Issue:6

    Topics: Humans; Neostigmine; Neuromuscular Blockade; Neuromuscular Monitoring; Neuromuscular Nondepolarizing

2022
Identifying high dose neostigmine as a risk factor for post-operative respiratory complications: a case-control study.
    Anaesthesiology intensive therapy, 2021, Volume: 53, Issue:4

    Topics: Acetylcholinesterase; Case-Control Studies; Cholinesterase Inhibitors; Humans; Neostigmine; Neuromus

2021
Pro: Sugammadex Should Be Used Routinely for Reversal of Neuromuscular Blockade in Patients Undergoing Thoracic Surgery.
    Journal of cardiothoracic and vascular anesthesia, 2022, Volume: 36, Issue:6

    Topics: Anesthetics; Cholinesterase Inhibitors; Humans; Neostigmine; Neuromuscular Blockade; Neuromuscular N

2022
Risk factors for administration of additional reversal following neuromuscular blockade with rocuronium in children: A retrospective case-control study.
    Paediatric anaesthesia, 2022, Volume: 32, Issue:8

    Topics: Androstanols; Anesthetics; Case-Control Studies; Child; gamma-Cyclodextrins; Humans; Neostigmine; Ne

2022
Reversal of neuromuscular block with neostigmine versus sugammadex: comment on Br J Anaesth 2021; 127: 316-23.
    British journal of anaesthesia, 2022, Volume: 129, Issue:1

    Topics: Cholinesterase Inhibitors; Humans; Neostigmine; Neuromuscular Blockade; Sugammadex

2022
Sugammadex reversal of muscle relaxant blockade provided less Post-Anesthesia Care Unit adverse effects than neostigmine/glycopyrrolate.
    Journal of the Formosan Medical Association = Taiwan yi zhi, 2022, Volume: 121, Issue:12

    Topics: Anesthesia; Glycopyrrolate; Humans; Iatrogenic Disease; Muscles; Neostigmine; Neuromuscular Blockade

2022
Association between choice of reversal agent for neuromuscular block and postoperative pulmonary complications in patients at increased risk undergoing non-emergency surgery: STIL-STRONGER, a multicentre matched cohort study.
    British journal of anaesthesia, 2023, Volume: 130, Issue:1

    Topics: Cholinesterase Inhibitors; Cohort Studies; Humans; Neostigmine; Neuromuscular Blockade; Neuromuscula

2023
Influence of Sugammadex in Decreasing Postoperative Pulmonary Complications in Thoracic Surgery, is There Evidence?
    Journal of cardiothoracic and vascular anesthesia, 2022, Volume: 36, Issue:9

    Topics: Cholinesterase Inhibitors; Humans; Neostigmine; Neuromuscular Blockade; Neuromuscular Nondepolarizin

2022
Optimizing Reversal of Neuromuscular Block in Older Adults: Sugammadex or Neostigmine.
    Drugs & aging, 2022, Volume: 39, Issue:10

    Topics: Acetylcholine; Acetylcholinesterase; Aged; Cholinesterase Inhibitors; gamma-Cyclodextrins; Humans; N

2022
A comparison between cisatracurium and rocuronium-induced neuromuscular block on laryngeal electromyography recovery after neostigmine reversal in a porcine model.
    Frontiers in endocrinology, 2022, Volume: 13

    Topics: Androstanols; Animals; Atracurium; Electromyography; Neostigmine; Neuromuscular Blockade; Neuromuscu

2022
Use of rocuronium and sugammadex for video-assisted thoracoscopic surgery is associated with reduced duration of chest tube drainage: a propensity score-matched analysis.
    British journal of anaesthesia, 2023, Volume: 130, Issue:1

    Topics: Anesthesia, General; Chest Tubes; Cholinesterase Inhibitors; Drainage; Humans; Neostigmine; Neuromus

2023
Effect of neuromuscular reversal with neostigmine/glycopyrrolate versus sugammadex on postoperative ileus following colorectal surgery.
    Techniques in coloproctology, 2023, Volume: 27, Issue:3

    Topics: Acetylcholinesterase; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Female; Glycopyrrolate; Hu

2023
The Nonirritating Concentrations of Neuromuscular Blocking Agents and Related Compounds.
    The journal of allergy and clinical immunology. In practice, 2023, Volume: 11, Issue:2

    Topics: Adult; Androstanols; gamma-Cyclodextrins; Humans; Neostigmine; Neuromuscular Blockade; Neuromuscular

2023
How robust are the STRONGER and STIL-STRONGER studies?
    British journal of anaesthesia, 2023, Volume: 130, Issue:1

    Topics: Cholinesterase Inhibitors; Humans; Neostigmine; Neuromuscular Blockade; Neuromuscular Blocking Agent

2023
Peri-operative management of neuromuscular blockade: A guideline from the European Society of Anaesthesiology and Intensive Care.
    European journal of anaesthesiology, 2023, 02-01, Volume: 40, Issue:2

    Topics: Adult; Androstanols; Anesthesiology; Anesthetics; Critical Care; Humans; Neostigmine; Neuromuscular

2023
Residual neuromuscular block in the postanesthesia care unit: incidence, risk factors, and effect of neuromuscular monitoring and reversal agents.
    Turkish journal of medical sciences, 2022, Volume: 52, Issue:5

    Topics: Delayed Emergence from Anesthesia; Humans; Incidence; Neostigmine; Neuromuscular Blockade; Neuromusc

2022
Residual neuromuscular block in the postanesthesia care unit: incidence, risk factors, and effect of neuromuscular monitoring and reversal agents.
    Turkish journal of medical sciences, 2022, Volume: 52, Issue:5

    Topics: Delayed Emergence from Anesthesia; Humans; Incidence; Neostigmine; Neuromuscular Blockade; Neuromusc

2022
Residual neuromuscular block in the postanesthesia care unit: incidence, risk factors, and effect of neuromuscular monitoring and reversal agents.
    Turkish journal of medical sciences, 2022, Volume: 52, Issue:5

    Topics: Delayed Emergence from Anesthesia; Humans; Incidence; Neostigmine; Neuromuscular Blockade; Neuromusc

2022
Residual neuromuscular block in the postanesthesia care unit: incidence, risk factors, and effect of neuromuscular monitoring and reversal agents.
    Turkish journal of medical sciences, 2022, Volume: 52, Issue:5

    Topics: Delayed Emergence from Anesthesia; Humans; Incidence; Neostigmine; Neuromuscular Blockade; Neuromusc

2022
Residual neuromuscular block in the postanesthesia care unit: incidence, risk factors, and effect of neuromuscular monitoring and reversal agents.
    Turkish journal of medical sciences, 2022, Volume: 52, Issue:5

    Topics: Delayed Emergence from Anesthesia; Humans; Incidence; Neostigmine; Neuromuscular Blockade; Neuromusc

2022
Residual neuromuscular block in the postanesthesia care unit: incidence, risk factors, and effect of neuromuscular monitoring and reversal agents.
    Turkish journal of medical sciences, 2022, Volume: 52, Issue:5

    Topics: Delayed Emergence from Anesthesia; Humans; Incidence; Neostigmine; Neuromuscular Blockade; Neuromusc

2022
Residual neuromuscular block in the postanesthesia care unit: incidence, risk factors, and effect of neuromuscular monitoring and reversal agents.
    Turkish journal of medical sciences, 2022, Volume: 52, Issue:5

    Topics: Delayed Emergence from Anesthesia; Humans; Incidence; Neostigmine; Neuromuscular Blockade; Neuromusc

2022
Residual neuromuscular block in the postanesthesia care unit: incidence, risk factors, and effect of neuromuscular monitoring and reversal agents.
    Turkish journal of medical sciences, 2022, Volume: 52, Issue:5

    Topics: Delayed Emergence from Anesthesia; Humans; Incidence; Neostigmine; Neuromuscular Blockade; Neuromusc

2022
Residual neuromuscular block in the postanesthesia care unit: incidence, risk factors, and effect of neuromuscular monitoring and reversal agents.
    Turkish journal of medical sciences, 2022, Volume: 52, Issue:5

    Topics: Delayed Emergence from Anesthesia; Humans; Incidence; Neostigmine; Neuromuscular Blockade; Neuromusc

2022
A simple technique for dosing neostigmine and glycopyrrolate in children.
    Canadian journal of anaesthesia = Journal canadien d'anesthesie, 2023, Volume: 70, Issue:2

    Topics: Child; Glycopyrrolate; Humans; Neostigmine; Neuromuscular Blockade

2023
A simple technique for dosing neostigmine and glycopyrrolate in children.
    Canadian journal of anaesthesia = Journal canadien d'anesthesie, 2023, Volume: 70, Issue:2

    Topics: Child; Glycopyrrolate; Humans; Neostigmine; Neuromuscular Blockade

2023
A simple technique for dosing neostigmine and glycopyrrolate in children.
    Canadian journal of anaesthesia = Journal canadien d'anesthesie, 2023, Volume: 70, Issue:2

    Topics: Child; Glycopyrrolate; Humans; Neostigmine; Neuromuscular Blockade

2023
A simple technique for dosing neostigmine and glycopyrrolate in children.
    Canadian journal of anaesthesia = Journal canadien d'anesthesie, 2023, Volume: 70, Issue:2

    Topics: Child; Glycopyrrolate; Humans; Neostigmine; Neuromuscular Blockade

2023
Association of sugammadex reversal of neuromuscular block and postoperative length of stay in the ambulatory care facility: a multicentre hospital registry study.
    British journal of anaesthesia, 2023, Volume: 130, Issue:3

    Topics: Aged; Ambulatory Care; Anesthesia Recovery Period; Cholinesterase Inhibitors; Hospitals; Humans; Len

2023
The effects of sugammadex vs. neostigmine on postoperative respiratory complications and advanced healthcare utilisation: a multicentre retrospective cohort study.
    Anaesthesia, 2023, Volume: 78, Issue:3

    Topics: Adult; Cholinesterase Inhibitors; Humans; Neostigmine; Neuromuscular Blockade; Patient Acceptance of

2023
Comparison of the effects of sugammadex versus neostigmine for reversal of neuromuscular block on hospital costs of care.
    British journal of anaesthesia, 2023, Volume: 130, Issue:2

    Topics: Adult; Hospital Costs; Humans; Neostigmine; Neuromuscular Blockade; Neuromuscular Nondepolarizing Ag

2023
Sugammadex and neostigmine: when better may not be best.
    Anaesthesia, 2023, Volume: 78, Issue:5

    Topics: Cholinesterase Inhibitors; Humans; Neostigmine; Neuromuscular Blockade; Postoperative Complications;

2023
Postoperative Risk of Transfusion After Reversal of Residual Neuromuscular Block With Sugammadex Versus Neostigmine: A Retrospective Cohort Study.
    Anesthesia and analgesia, 2023, 04-01, Volume: 136, Issue:4

    Topics: Adult; Cholinesterase Inhibitors; Cohort Studies; Delayed Emergence from Anesthesia; Humans; Neostig

2023
Duration of neuromuscular block is more variable and recovery time is shorter with rocuronium than cisatracurium in anesthetized dogs.
    Veterinary ophthalmology, 2023, Volume: 26, Issue:5

    Topics: Androstanols; Animals; Atracurium; Dogs; Neostigmine; Neuromuscular Blockade; Neuromuscular Nondepol

2023
Use of rocuronium and sugammadex for video-assisted thoracoscopic surgery is associated with reduced duration of chest tube drainage. Comment on Br J Anaesth 2023; 130: e119-27.
    British journal of anaesthesia, 2023, Volume: 130, Issue:6

    Topics: Chest Tubes; Drainage; Humans; Neostigmine; Neuromuscular Blockade; Rocuronium; Sugammadex; Thoracic

2023
Effects of sugammadex versus neostigmine on postoperative nausea and vomiting after general anesthesia in adult patients:a single-center retrospective study.
    Scientific reports, 2023, 04-03, Volume: 13, Issue:1

    Topics: Adult; Anesthesia, General; Cholinesterase Inhibitors; Humans; Neostigmine; Neuromuscular Blockade;

2023
Evaluation of a Protocol for the Management of Maintenance and Reversal of Rocuronium Block Using Neostigmine or Sugammadex.
    Anesthesia and analgesia, 2023, 06-01, Volume: 136, Issue:6

    Topics: Anesthesia Recovery Period; Cohort Studies; Delayed Emergence from Anesthesia; Female; gamma-Cyclode

2023
Sugammadex Use for Reversal in Nonobstetric Surgery During Pregnancy: A Reexamination of the Evidence.
    Anesthesia and analgesia, 2023, 06-01, Volume: 136, Issue:6

    Topics: Female; Humans; Neostigmine; Neuromuscular Blockade; Neuromuscular Nondepolarizing Agents; Pregnancy

2023
Reversal of neuromuscular block: what are the costs?
    British journal of anaesthesia, 2023, Volume: 131, Issue:2

    Topics: Anesthesia; Cholinesterase Inhibitors; Costs and Cost Analysis; Humans; Neostigmine; Neuromuscular B

2023
Sugammadex Is Not a Silver Bullet: Caveats Regarding Unmonitored Reversal.
    Anesthesiology, 2023, 07-01, Volume: 139, Issue:1

    Topics: Neostigmine; Neuromuscular Blockade; Rocuronium; Sugammadex

2023
An appraisal of neostigmine versus sugammadex for neuromuscular blockade reversal in patients with a prior heart transplant.
    Anaesthesiology intensive therapy, 2023, Volume: 55, Issue:1

    Topics: Anesthetics; Bradycardia; Heart Transplantation; Humans; Hypotension; Neostigmine; Neuromuscular Blo

2023
A retrospective observational cross-sectional study of intraoperative neuromuscular blocking agent choice and dosing in a US paediatric referral hospital before and after introduction of sugammadex
    British journal of anaesthesia, 2023, Volume: 131, Issue:4

    Topics: Child; Cholinesterase Inhibitors; Cross-Sectional Studies; Hospitals; Humans; Neostigmine; Neuromusc

2023
Commentary on "An appraisal of neostigmine versus sugammadex for neuromuscular blockade reversal in patients with a prior heart transplant".
    Anaesthesiology intensive therapy, 2023, Volume: 55, Issue:3

    Topics: Anesthetics; Humans; Neostigmine; Neuromuscular Blockade; Neuromuscular Diseases; Sugammadex

2023
Reply to the Commentary on "An appraisal of neostigmine versus sugammadex for neuromuscular blockade reversal in patients with a prior heart transplant".
    Anaesthesiology intensive therapy, 2023, Volume: 55, Issue:3

    Topics: Anesthetics; Humans; Neostigmine; Neuromuscular Blockade; Neuromuscular Diseases; Sugammadex

2023
Usefulness of intra-operative neuromuscular blockade monitoring and reversal agents for postoperative residual neuromuscular blockade: a retrospective observational study.
    BMC anesthesiology, 2019, 08-07, Volume: 19, Issue:1

    Topics: Cholinesterase Inhibitors; Delayed Emergence from Anesthesia; Female; Humans; Male; Middle Aged; Neo

2019
Retrospective Investigation of Grafted Kidney Function After Reversal of Neuromuscular Blockade Using Neostigmine or Sugammadex.
    Transplantation proceedings, 2019, Volume: 51, Issue:7

    Topics: Adult; Female; Humans; Kidney; Kidney Transplantation; Male; Middle Aged; Neostigmine; Neuromuscular

2019
Retrospective Analysis of the Safety and Efficacy of Sugammadex Versus Neostigmine for the Reversal of Neuromuscular Blockade in Children.
    Anesthesia and analgesia, 2019, Volume: 129, Issue:4

    Topics: Adolescent; Age Factors; Anesthesia Recovery Period; Bradycardia; Child; Child, Preschool; Cholinest

2019
Evaluating a Quality Improvement Initiative to Increase Anesthesia Providers' Use of and Understanding of Quantitative Neuromuscular Monitors.
    AANA journal, 2019, Volume: 87, Issue:5

    Topics: Female; Humans; Male; Middle Aged; Monitoring, Intraoperative; Neostigmine; Neuromuscular Blockade;

2019
[Neuromuscular residual block : Unavoidable risk or reliably treatable?]
    Der Anaesthesist, 2019, Volume: 68, Issue:11

    Topics: Humans; Neostigmine; Neuromuscular Blockade

2019
Neuromuscular monitoring, reversal and postoperative residual neuromuscular block: An intradepartmental survey over the years.
    Anaesthesia and intensive care, 2020, Volume: 48, Issue:1

    Topics: Anesthesia Recovery Period; Delayed Emergence from Anesthesia; Humans; Neostigmine; Neuromuscular Bl

2020
Heart rate changes following the administration of sugammadex in children: a prospective, observational study.
    Journal of anesthesia, 2020, Volume: 34, Issue:2

    Topics: Adolescent; Androstanols; Child; gamma-Cyclodextrins; Heart Rate; Humans; Male; Neostigmine; Neuromu

2020
Association of neuromuscular reversal by sugammadex and neostigmine with 90-day mortality after non-cardiac surgery.
    BMC anesthesiology, 2020, 02-20, Volume: 20, Issue:1

    Topics: Cholinesterase Inhibitors; Cohort Studies; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neo

2020
Neostigmine versus sugammadex: the tide may be turning, but we still need to navigate the winds.
    British journal of anaesthesia, 2020, Volume: 124, Issue:5

    Topics: Incidence; Neostigmine; Neuromuscular Blockade; Sugammadex; Wind

2020
Sugammadex: A Costly Simple Solution That Is Not Really Solving the Problem.
    Anesthesia and analgesia, 2020, Volume: 131, Issue:2

    Topics: Humans; Interrupted Time Series Analysis; Neostigmine; Neuromuscular Blockade; Noninvasive Ventilati

2020
In Response.
    Anesthesia and analgesia, 2020, Volume: 131, Issue:2

    Topics: Humans; Interrupted Time Series Analysis; Neostigmine; Neuromuscular Blockade; Noninvasive Ventilati

2020
Effect of Cognitive Aid on Sugammadex Use: Comment.
    Anesthesiology, 2020, Volume: 132, Issue:6

    Topics: Cognition; Neostigmine; Neuromuscular Blockade; Research Design; Sugammadex

2020
Effects of Cognitive Aid on Sugammadex Use: Reply.
    Anesthesiology, 2020, Volume: 132, Issue:6

    Topics: Cognition; Neostigmine; Neuromuscular Blockade; Research Design; Sugammadex

2020
Sugammadex versus Neostigmine for Reversal of Neuromuscular Blockade and Postoperative Pulmonary Complications (STRONGER): A Multicenter Matched Cohort Analysis.
    Anesthesiology, 2020, Volume: 132, Issue:6

    Topics: Cholinesterase Inhibitors; Cohort Studies; Female; Humans; Male; Middle Aged; Neostigmine; Neuromusc

2020
Sugammadex or neostigmine: should potential anaphylaxis be the overriding factor in the choice of a reversal drug? Comment on Br J Anaesth 2020; 124: 154-63.
    British journal of anaesthesia, 2020, Volume: 125, Issue:2

    Topics: Anaphylaxis; Humans; Incidence; Neostigmine; Neuromuscular Blockade; Retrospective Studies; Sugammad

2020
Sugammadex and Postoperative Pulmonary Complications: Is Stronger Evidence Required?
    Anesthesiology, 2020, Volume: 132, Issue:6

    Topics: Cohort Studies; gamma-Cyclodextrins; Humans; Neostigmine; Neuromuscular Blockade; Postoperative Comp

2020
Effects on Postoperative Gastrointestinal Motility After Neuromuscular Blockade Reversal With Sugammadex Versus Neostigmine/Glycopyrrolate in Colorectal Surgery Patients.
    The Annals of pharmacotherapy, 2020, Volume: 54, Issue:12

    Topics: Cholinesterase Inhibitors; Cohort Studies; Colorectal Surgery; Drug Therapy, Combination; Female; Ga

2020
Letter Regarding: Comparison of the Effects of Neostigmine and Sugammadex on Colonic Anastomotic Strength in Rats.
    The Journal of surgical research, 2020, Volume: 254

    Topics: Animals; Cholinesterase Inhibitors; Neostigmine; Neuromuscular Blockade; Rats; Sugammadex

2020
Does Sugammadex Reduce Postoperative Airway Failure?
    Anesthesia and analgesia, 2020, Volume: 131, Issue:1

    Topics: Humans; Interrupted Time Series Analysis; Neostigmine; Neuromuscular Blockade; Noninvasive Ventilati

2020
Comparison of the effects of sugammadex and neostigmine on hospital stay in robot-assisted laparoscopic prostatectomy: a retrospective study.
    BMC anesthesiology, 2020, 07-21, Volume: 20, Issue:1

    Topics: Aged; Cohort Studies; Humans; Laparoscopy; Length of Stay; Male; Middle Aged; Neostigmine; Neuromusc

2020
History of the development of antagonists for neuromuscular blocking agents.
    Journal of anesthesia, 2020, Volume: 34, Issue:5

    Topics: Androstanols; gamma-Cyclodextrins; Neostigmine; Neuromuscular Blockade; Neuromuscular Blocking Agent

2020
Sugammadex Neuromuscular Blockade Reversal Associated With Lower Postoperative Arterial Carbon Dioxide Levels After Congenital Cardiac Surgery.
    Journal of cardiothoracic and vascular anesthesia, 2021, Volume: 35, Issue:1

    Topics: Carbon Dioxide; Cardiac Surgical Procedures; Cholinesterase Inhibitors; Cross-Sectional Studies; Hum

2021
Sugammadex use in patients with end-stage renal disease: a historical cohort study.
    Canadian journal of anaesthesia = Journal canadien d'anesthesie, 2020, Volume: 67, Issue:12

    Topics: Cohort Studies; Humans; Kidney Failure, Chronic; Neostigmine; Neuromuscular Blockade; Sugammadex

2020
Despite Its Association With Less Postoperative Respiratory Failure, the Superiority of Sugammadex Over Neostigmine Remains Questionable.
    Anesthesia and analgesia, 2020, Volume: 131, Issue:2

    Topics: Cholinesterase Inhibitors; Humans; Interrupted Time Series Analysis; Neostigmine; Neuromuscular Bloc

2020
In Response.
    Anesthesia and analgesia, 2020, Volume: 131, Issue:2

    Topics: Humans; Interrupted Time Series Analysis; Neostigmine; Neuromuscular Blockade; Noninvasive Ventilati

2020
Pulmonary Outcomes and Sugammadex versus Neostigmine: Reply.
    Anesthesiology, 2020, 12-01, Volume: 133, Issue:6

    Topics: Cholinesterase Inhibitors; gamma-Cyclodextrins; Humans; Neostigmine; Neuromuscular Blockade; Sugamma

2020
Pulmonary Outcomes and Sugammadex versus Neostigmine: Comment.
    Anesthesiology, 2020, 12-01, Volume: 133, Issue:6

    Topics: Cholinesterase Inhibitors; Cohort Studies; Humans; Neostigmine; Neuromuscular Blockade; Sugammadex

2020
Neuromuscular blockade management and postoperative outcomes in enhanced recovery colorectal surgery: secondary analysis of POWER trial.
    Minerva anestesiologica, 2021, Volume: 87, Issue:1

    Topics: Colorectal Surgery; Humans; Neostigmine; Neuromuscular Blockade; Postoperative Period; Sugammadex

2021
Sugammadex versus neostigmine on postoperative pulmonary complications after robot-assisted laparoscopic prostatectomy: a propensity score-matched analysis.
    Journal of anesthesia, 2021, Volume: 35, Issue:2

    Topics: Humans; Laparoscopy; Male; Neostigmine; Neuromuscular Blockade; Propensity Score; Prostatectomy; Ret

2021
A Clinical and Budgetary Impact Analysis of Introducing Sugammadex for Routine Reversal of Neuromuscular Blockade in a Hypothetical Cohort in the US.
    Advances in therapy, 2021, Volume: 38, Issue:5

    Topics: Adult; gamma-Cyclodextrins; Humans; Neostigmine; Neuromuscular Blockade; Neuromuscular Nondepolarizi

2021
Is sugammadex superior to neostigmine in reversing rocuronium-induced neuromuscular blockade?
    Journal of clinical anesthesia, 2022, Volume: 79

    Topics: Androstanols; Cholinesterase Inhibitors; Humans; Neostigmine; Neuromuscular Blockade; Neuromuscular

2022
No single pressure support level can prevent residual neuromuscular blockade prior to postoperative extubation: A prospective study.
    Journal of clinical anesthesia, 2021, Volume: 73

    Topics: Airway Extubation; Delayed Emergence from Anesthesia; Humans; Neostigmine; Neuromuscular Blockade; P

2021
Vigilance: the behavioral impact of quantitative monitoring on administration and antagonism of neuromuscular blocking agents.
    Journal of clinical monitoring and computing, 2022, Volume: 36, Issue:4

    Topics: Anesthetics; Humans; Neostigmine; Neuromuscular Blockade; Neuromuscular Blocking Agents; Neuromuscul

2022
Urinary Retention Following Inguinal Herniorrhaphy: Role of Neuromuscular Blockade Reversal.
    Surgical laparoscopy, endoscopy & percutaneous techniques, 2021, May-24, Volume: 31, Issue:5

    Topics: Adult; Herniorrhaphy; Humans; Neostigmine; Neuromuscular Blockade; Neuromuscular Nondepolarizing Age

2021
[Muscle relaxant and reversal practices and impact of reversal modalities on operating room and postoperative room duration - results of a Delphi study].
    Annales pharmaceutiques francaises, 2022, Volume: 80, Issue:2

    Topics: Delphi Technique; gamma-Cyclodextrins; Humans; Muscles; Neostigmine; Neuromuscular Blockade; Neuromu

2022
Neuromuscular Blockade and Reversal Agent Practice Variability in the US Inpatient Surgical Settings.
    Advances in therapy, 2021, Volume: 38, Issue:9

    Topics: Adult; Humans; Inpatients; Neostigmine; Neuromuscular Blockade; Neuromuscular Nondepolarizing Agents

2021
A survey of current management of neuromuscular block and reversal in Australia and New Zealand.
    Anaesthesia and intensive care, 2021, Volume: 49, Issue:4

    Topics: Australia; Cholinesterase Inhibitors; Humans; Neostigmine; Neuromuscular Blockade; New Zealand; Suga

2021
Neuromuscular Blockade and Risk of Postoperative Pneumonia.
    Anesthesiology, 2017, Volume: 127, Issue:1

    Topics: Humans; Neostigmine; Neuromuscular Blockade; Neuromuscular Nondepolarizing Agents; Pneumonia; Risk

2017
Risk of Postoperative Pneumonia with Neuromuscular Blockade: Keep It Simple!
    Anesthesiology, 2017, Volume: 127, Issue:1

    Topics: Humans; Neostigmine; Neuromuscular Blockade; Neuromuscular Nondepolarizing Agents; Pneumonia; Risk

2017
Monitoring intraoperative neuromuscular blockade and blood pressure with one device (TOF-Cuff): A comparative study with mechanomyography and invasive blood pressure.
    Revista espanola de anestesiologia y reanimacion, 2017, Volume: 64, Issue:10

    Topics: Adult; Anesthesia, General; Blood Pressure; Blood Pressure Determination; Blood Pressure Monitors; B

2017
Monitoring intraoperative neuromuscular blockade and blood pressure with one device (TOF-Cuff): A comparative study with mechanomyography and invasive blood pressure.
    Revista espanola de anestesiologia y reanimacion, 2017, Volume: 64, Issue:10

    Topics: Adult; Anesthesia, General; Blood Pressure; Blood Pressure Determination; Blood Pressure Monitors; B

2017
Monitoring intraoperative neuromuscular blockade and blood pressure with one device (TOF-Cuff): A comparative study with mechanomyography and invasive blood pressure.
    Revista espanola de anestesiologia y reanimacion, 2017, Volume: 64, Issue:10

    Topics: Adult; Anesthesia, General; Blood Pressure; Blood Pressure Determination; Blood Pressure Monitors; B

2017
Monitoring intraoperative neuromuscular blockade and blood pressure with one device (TOF-Cuff): A comparative study with mechanomyography and invasive blood pressure.
    Revista espanola de anestesiologia y reanimacion, 2017, Volume: 64, Issue:10

    Topics: Adult; Anesthesia, General; Blood Pressure; Blood Pressure Determination; Blood Pressure Monitors; B

2017
Sugammadex efficacy for reversal of rocuronium- and vecuronium-induced neuromuscular blockade: A pooled analysis of 26 studies.
    Journal of clinical anesthesia, 2017, Volume: 41

    Topics: Adult; Aged; Androstanols; Anesthesia Recovery Period; Anesthesia, General; Dose-Response Relationsh

2017
Incidence of complications in the post-anesthesia care unit and associated healthcare utilization in patients undergoing non-cardiac surgery requiring neuromuscular blockade 2005-2013: A single center study.
    Journal of clinical anesthesia, 2017, Volume: 43

    Topics: Adult; Airway Extubation; Anesthesia Recovery Period; Cholinesterase Inhibitors; Elective Surgical P

2017
How to Catch Unicorns (and Other Fairytales).
    Anesthesiology, 2018, Volume: 128, Issue:1

    Topics: Anesthesia; Cholinesterase Inhibitors; Humans; Neostigmine; Neuromuscular Blockade

2018
Postoperative conditions after antagonism of neuromuscular blocking agent and extubation without use of a neuromuscular monitor.
    British journal of anaesthesia, 2017, 11-01, Volume: 119, Issue:5

    Topics: Airway Extubation; Humans; Neostigmine; Neuromuscular Blockade; Neuromuscular Blocking Agents; Sugam

2017
Neuromuscular monitoring and the cost of antagonism: when will we learn?
    Anaesthesia, 2017, Volume: 72, Issue:12

    Topics: Neostigmine; Neuromuscular Blockade; Neuromuscular Monitoring; Sugammadex

2017
Neuromuscular monitoring and the cost of antagonism: when will we learn? A reply.
    Anaesthesia, 2017, Volume: 72, Issue:12

    Topics: Neostigmine; Neuromuscular Blockade; Neuromuscular Monitoring

2017
Evidence of residual neuromuscular block with sugammadex vs neostigmine.
    British journal of anaesthesia, 2018, Volume: 120, Issue:3

    Topics: Delayed Emergence from Anesthesia; gamma-Cyclodextrins; Humans; Muscle Relaxation; Neostigmine; Neur

2018
Incidence of hypersensitivity and anaphylaxis with sugammadex.
    Journal of clinical anesthesia, 2018, Volume: 47

    Topics: Adult; Aged; Anaphylaxis; Anesthesia Recovery Period; Anesthesia, General; Cholinesterase Inhibitors

2018
Implementation of a new strategy to improve the peri-operative management of neuromuscular blockade and its effects on postoperative pulmonary complications.
    Anaesthesia, 2018, Volume: 73, Issue:9

    Topics: Adult; Aged; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Female; Hospital Costs; Hu

2018
Implementation of a new strategy to improve the peri-operative management of neuromuscular blockade and its effects on postoperative pulmonary complications.
    Anaesthesia, 2018, Volume: 73, Issue:9

    Topics: Adult; Aged; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Female; Hospital Costs; Hu

2018
Implementation of a new strategy to improve the peri-operative management of neuromuscular blockade and its effects on postoperative pulmonary complications.
    Anaesthesia, 2018, Volume: 73, Issue:9

    Topics: Adult; Aged; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Female; Hospital Costs; Hu

2018
Implementation of a new strategy to improve the peri-operative management of neuromuscular blockade and its effects on postoperative pulmonary complications.
    Anaesthesia, 2018, Volume: 73, Issue:9

    Topics: Adult; Aged; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Female; Hospital Costs; Hu

2018
Neostigmine as an antagonist of residual block: best practices do not guarantee predictable results.
    British journal of anaesthesia, 2018, Volume: 121, Issue:2

    Topics: Delayed Emergence from Anesthesia; Humans; Neostigmine; Neuromuscular Blockade; Neuromuscular Nondep

2018
Management of rocuronium neuromuscular block using a protocol for qualitative monitoring and reversal with neostigmine.
    British journal of anaesthesia, 2018, Volume: 121, Issue:2

    Topics: Adult; Aged; Airway Extubation; Clinical Protocols; Cohort Studies; Female; Humans; Incidence; Male;

2018
Investigation of intraoperative dosing patterns of neuromuscular blocking agents.
    Journal of clinical monitoring and computing, 2019, Volume: 33, Issue:3

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Androstanols; Anesthesia, General; Atracurium; Body Mass

2019
Is appropriately conducted neostigmine reversal inferior to sugammadex? A reply.
    Anaesthesia, 2018, Volume: 73, Issue:9

    Topics: gamma-Cyclodextrins; Neostigmine; Neuromuscular Blockade; Sugammadex

2018
Is appropriately conducted neostigmine reversal inferior to sugammadex?
    Anaesthesia, 2018, Volume: 73, Issue:9

    Topics: gamma-Cyclodextrins; Glycopyrrolate; Humans; Neostigmine; Neuromuscular Blockade; Neuromuscular Nond

2018
Neostigmine-induced weakness: what are the facts?
    Anaesthesia, 2018, Volume: 73, Issue:9

    Topics: Double-Blind Method; Humans; Muscle Weakness; Neostigmine; Neuromuscular Blockade; Neuromuscular Non

2018
Effectiveness of sugammadex versus neostigmine on restoration of neuromuscular function in surgical patients with myasthenia gravis undergoing rocuronium-induced neuromuscular blockade: a systematic review protocol.
    JBI database of systematic reviews and implementation reports, 2018, Volume: 16, Issue:10

    Topics: Anesthesia, General; Cholinesterase Inhibitors; Delayed Emergence from Anesthesia; Humans; Incidence

2018
Incidence, risk factors, and consequences of residual neuromuscular block in the United States: The prospective, observational, multicenter RECITE-US study.
    Journal of clinical anesthesia, 2019, Volume: 55

    Topics: Adult; Aged; Aged, 80 and over; Anesthesia, General; Body Mass Index; Cholinesterase Inhibitors; Del

2019
Neostigmine-induced weakness after sugammadex.
    Anaesthesia, 2019, Volume: 74, Issue:2

    Topics: Neostigmine; Neuromuscular Blockade; Neuromuscular Nondepolarizing Agents; Sugammadex

2019
Neostigmine-induced weakness after sugammadex - a reply.
    Anaesthesia, 2019, Volume: 74, Issue:2

    Topics: Neostigmine; Neuromuscular Blockade; Neuromuscular Nondepolarizing Agents; Sugammadex

2019
Does reversal of neuromuscular block with sugammadex reduce readmission rate after surgery?
    British journal of anaesthesia, 2019, Volume: 122, Issue:3

    Topics: gamma-Cyclodextrins; Humans; Neostigmine; Neuromuscular Blockade; Neuromuscular Nondepolarizing Agen

2019
Case series of 331 cases of sugammadex compared to neostigmine in patients under 2 years of age.
    Paediatric anaesthesia, 2019, Volume: 29, Issue:6

    Topics: Anesthesia Recovery Period; Humans; Infant; Infant, Newborn; Neostigmine; Neuromuscular Blockade; Ne

2019
Reversal of rocuronium-induced neuromuscular block: is it time for sugammadex to replace neostigmine?
    British journal of anaesthesia, 2019, Volume: 123, Issue:2

    Topics: Humans; Neostigmine; Neuromuscular Blockade; Patient Readmission; Retrospective Studies; Rocuronium;

2019
The effect of neuromuscular reversal agent on postoperative pain after laparoscopic gastric cancer surgery: Comparison between the neostigmine and sugammadex.
    Medicine, 2019, Volume: 98, Issue:26

    Topics: Adult; Aged; Analgesics; Female; Humans; Laparoscopy; Length of Stay; Male; Middle Aged; Neostigmine

2019
Evaluation of Neuromuscular Blockade Reversal on Postoperative Mechanical Ventilation Time in a Cardiovascular Surgery Population.
    Journal of cardiothoracic and vascular anesthesia, 2019, Volume: 33, Issue:12

    Topics: Aged; Cardiovascular Diseases; Cardiovascular Surgical Procedures; Female; Follow-Up Studies; Humans

2019
Reversal with sugammadex in the absence of monitoring did not preclude residual neuromuscular block.
    Anesthesia and analgesia, 2013, Volume: 117, Issue:2

    Topics: Adult; Aged; Airway Extubation; Androstanols; Anesthesia Recovery Period; Chi-Square Distribution; C

2013
Reversal with sugammadex in the absence of monitoring did not preclude residual neuromuscular block.
    Anesthesia and analgesia, 2013, Volume: 117, Issue:2

    Topics: Adult; Aged; Airway Extubation; Androstanols; Anesthesia Recovery Period; Chi-Square Distribution; C

2013
Reversal with sugammadex in the absence of monitoring did not preclude residual neuromuscular block.
    Anesthesia and analgesia, 2013, Volume: 117, Issue:2

    Topics: Adult; Aged; Airway Extubation; Androstanols; Anesthesia Recovery Period; Chi-Square Distribution; C

2013
Reversal with sugammadex in the absence of monitoring did not preclude residual neuromuscular block.
    Anesthesia and analgesia, 2013, Volume: 117, Issue:2

    Topics: Adult; Aged; Airway Extubation; Androstanols; Anesthesia Recovery Period; Chi-Square Distribution; C

2013
Reversal with sugammadex in the absence of monitoring did not preclude residual neuromuscular block.
    Anesthesia and analgesia, 2013, Volume: 117, Issue:2

    Topics: Adult; Aged; Airway Extubation; Androstanols; Anesthesia Recovery Period; Chi-Square Distribution; C

2013
Reversal with sugammadex in the absence of monitoring did not preclude residual neuromuscular block.
    Anesthesia and analgesia, 2013, Volume: 117, Issue:2

    Topics: Adult; Aged; Airway Extubation; Androstanols; Anesthesia Recovery Period; Chi-Square Distribution; C

2013
Reversal with sugammadex in the absence of monitoring did not preclude residual neuromuscular block.
    Anesthesia and analgesia, 2013, Volume: 117, Issue:2

    Topics: Adult; Aged; Airway Extubation; Androstanols; Anesthesia Recovery Period; Chi-Square Distribution; C

2013
Reversal with sugammadex in the absence of monitoring did not preclude residual neuromuscular block.
    Anesthesia and analgesia, 2013, Volume: 117, Issue:2

    Topics: Adult; Aged; Airway Extubation; Androstanols; Anesthesia Recovery Period; Chi-Square Distribution; C

2013
Reversal with sugammadex in the absence of monitoring did not preclude residual neuromuscular block.
    Anesthesia and analgesia, 2013, Volume: 117, Issue:2

    Topics: Adult; Aged; Airway Extubation; Androstanols; Anesthesia Recovery Period; Chi-Square Distribution; C

2013
Neostigmine product for NMBA reversal approved by FDA.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2013, Jul-15, Volume: 70, Issue:14

    Topics: Drug Approval; Humans; Neostigmine; Neuromuscular Blockade; Neuromuscular Nondepolarizing Agents; Pa

2013
Reversal of rocuronium induced neuromuscular block with sugammadex or neostigmine: a large observational study.
    Acta anaesthesiologica Scandinavica, 2013, Volume: 57, Issue:9

    Topics: Abdomen; Adult; Aged; Airway Extubation; Analgesics, Opioid; Androstanols; Anesthesia Recovery Perio

2013
Reversal of rocuronium induced neuromuscular block with sugammadex or neostigmine: a large observational study.
    Acta anaesthesiologica Scandinavica, 2013, Volume: 57, Issue:9

    Topics: Abdomen; Adult; Aged; Airway Extubation; Analgesics, Opioid; Androstanols; Anesthesia Recovery Perio

2013
Reversal of rocuronium induced neuromuscular block with sugammadex or neostigmine: a large observational study.
    Acta anaesthesiologica Scandinavica, 2013, Volume: 57, Issue:9

    Topics: Abdomen; Adult; Aged; Airway Extubation; Analgesics, Opioid; Androstanols; Anesthesia Recovery Perio

2013
Reversal of rocuronium induced neuromuscular block with sugammadex or neostigmine: a large observational study.
    Acta anaesthesiologica Scandinavica, 2013, Volume: 57, Issue:9

    Topics: Abdomen; Adult; Aged; Airway Extubation; Analgesics, Opioid; Androstanols; Anesthesia Recovery Perio

2013
Reasoning of an anomaly: residual block after sugammadex.
    Anesthesia and analgesia, 2013, Volume: 117, Issue:2

    Topics: Androstanols; Cholinesterase Inhibitors; Female; gamma-Cyclodextrins; Humans; Male; Muscle Weakness;

2013
Manufacturers' obligations to colour-code prefilled syringes correctly.
    Anaesthesia, 2013, Volume: 68, Issue:7

    Topics: Cholinesterase Inhibitors; Female; gamma-Cyclodextrins; Humans; Laparoscopy; Male; Neostigmine; Neur

2013
"Neostigmine-resistant curarization".
    Middle East journal of anaesthesiology, 2013, Volume: 22, Issue:2

    Topics: Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Humans; Neostigmine; Neuromuscular Bloc

2013
Retrospective investigation of postoperative outcome after reversal of residual neuromuscular blockade: sugammadex, neostigmine or no reversal.
    European journal of anaesthesiology, 2014, Volume: 31, Issue:8

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aging; Female; gamma-Cyclodextrins; Humans; Lung Disease

2014
Postoperative respiratory outcomes in laparoscopic bariatric surgery: comparison of a prospective group of patients whose neuromuscular blockade was reverted with sugammadex and a historical one reverted with neostigmine.
    Revista espanola de anestesiologia y reanimacion, 2014, Volume: 61, Issue:10

    Topics: Adult; Aged; Bariatric Surgery; Cholinesterase Inhibitors; Female; gamma-Cyclodextrins; Humans; Lapa

2014
Labelling syringe plungers to reduce medication errors.
    Anaesthesia, 2014, Volume: 69, Issue:3

    Topics: Cholinesterase Inhibitors; Female; gamma-Cyclodextrins; Humans; Laparoscopy; Male; Neostigmine; Neur

2014
Why are we using pulse oximetry but not neuromuscular monitoring routinely: the real world scenario?
    Anesthesia and analgesia, 2014, Volume: 118, Issue:3

    Topics: Androstanols; Cholinesterase Inhibitors; Female; gamma-Cyclodextrins; Humans; Male; Muscle Weakness;

2014
In response.
    Anesthesia and analgesia, 2014, Volume: 118, Issue:3

    Topics: Androstanols; Cholinesterase Inhibitors; Female; gamma-Cyclodextrins; Humans; Male; Muscle Weakness;

2014
Reversal of neuromuscular blocking agents: current practice.
    AANA journal, 2013, Volume: Suppl

    Topics: Anesthesia Recovery Period; Cholinesterase Inhibitors; Humans; Neostigmine; Neuromuscular Blockade;

2013
Use of neuromuscular monitoring to detect prolonged effect of succinylcholine or mivacurium: three case reports.
    Acta anaesthesiologica Scandinavica, 2014, Volume: 58, Issue:8

    Topics: Accelerometry; Aged; Antidotes; Apnea; Appendicitis; Butyrylcholinesterase; Cholecystectomy, Laparos

2014
Neostigmine vs. sugammadex: observational cohort study comparing the quality of recovery using the Postoperative Quality Recovery Scale.
    Acta anaesthesiologica Scandinavica, 2014, Volume: 58, Issue:9

    Topics: Adult; Anesthesia Recovery Period; Anesthesia, General; Cholinesterase Inhibitors; Cohort Studies; F

2014
The RECITE Study: A Canadian Prospective, Multicenter Study of the Incidence and Severity of Residual Neuromuscular Blockade.
    Anesthesia and analgesia, 2015, Volume: 121, Issue:2

    Topics: Abdomen; Adult; Airway Extubation; Androstanols; Anesthesia Recovery Period; Anesthesia, General; An

2015
The RECITE Study: A Canadian Prospective, Multicenter Study of the Incidence and Severity of Residual Neuromuscular Blockade.
    Anesthesia and analgesia, 2015, Volume: 121, Issue:2

    Topics: Abdomen; Adult; Airway Extubation; Androstanols; Anesthesia Recovery Period; Anesthesia, General; An

2015
The RECITE Study: A Canadian Prospective, Multicenter Study of the Incidence and Severity of Residual Neuromuscular Blockade.
    Anesthesia and analgesia, 2015, Volume: 121, Issue:2

    Topics: Abdomen; Adult; Airway Extubation; Androstanols; Anesthesia Recovery Period; Anesthesia, General; An

2015
The RECITE Study: A Canadian Prospective, Multicenter Study of the Incidence and Severity of Residual Neuromuscular Blockade.
    Anesthesia and analgesia, 2015, Volume: 121, Issue:2

    Topics: Abdomen; Adult; Airway Extubation; Androstanols; Anesthesia Recovery Period; Anesthesia, General; An

2015
The RECITE Study: A Canadian Prospective, Multicenter Study of the Incidence and Severity of Residual Neuromuscular Blockade.
    Anesthesia and analgesia, 2015, Volume: 121, Issue:2

    Topics: Abdomen; Adult; Airway Extubation; Androstanols; Anesthesia Recovery Period; Anesthesia, General; An

2015
The RECITE Study: A Canadian Prospective, Multicenter Study of the Incidence and Severity of Residual Neuromuscular Blockade.
    Anesthesia and analgesia, 2015, Volume: 121, Issue:2

    Topics: Abdomen; Adult; Airway Extubation; Androstanols; Anesthesia Recovery Period; Anesthesia, General; An

2015
The RECITE Study: A Canadian Prospective, Multicenter Study of the Incidence and Severity of Residual Neuromuscular Blockade.
    Anesthesia and analgesia, 2015, Volume: 121, Issue:2

    Topics: Abdomen; Adult; Airway Extubation; Androstanols; Anesthesia Recovery Period; Anesthesia, General; An

2015
The RECITE Study: A Canadian Prospective, Multicenter Study of the Incidence and Severity of Residual Neuromuscular Blockade.
    Anesthesia and analgesia, 2015, Volume: 121, Issue:2

    Topics: Abdomen; Adult; Airway Extubation; Androstanols; Anesthesia Recovery Period; Anesthesia, General; An

2015
The RECITE Study: A Canadian Prospective, Multicenter Study of the Incidence and Severity of Residual Neuromuscular Blockade.
    Anesthesia and analgesia, 2015, Volume: 121, Issue:2

    Topics: Abdomen; Adult; Airway Extubation; Androstanols; Anesthesia Recovery Period; Anesthesia, General; An

2015
Prolonged cholinergic effects after the reversal of neuromuscular blockade with neostigmine.
    Journal of clinical anesthesia, 2016, Volume: 28

    Topics: Adult; Cholinesterase Inhibitors; Female; Humans; Neostigmine; Neuromuscular Blockade; Parasympathet

2016
Shake Up in the Neostig- mine Methylsulfate Cholin- esterase Inhibitor Market for Neuromuscular Block Reversal.
    AANA journal, 2015, Volume: 83, Issue:4

    Topics: Cholinesterase Inhibitors; Costs and Cost Analysis; Drug Approval; Humans; Marketing of Health Servi

2015
Residual neuromuscular blockade in a real life clinical setting: correlation with sugammadex or neostigmine administration.
    Minerva anestesiologica, 2016, Volume: 82, Issue:5

    Topics: Androstanols; Anesthesia Recovery Period; Atracurium; Delayed Emergence from Anesthesia; Female; gam

2016
RESIDUAL NEUROMUSCULAR BLOCKADE (RNMB): ROCURONIUM'S DEFASCICULATING DOSE, NEOSTIGMINE- INDUCED WEAKNESS, AND AWARENESS DURING RECOVERY.
    Middle East journal of anaesthesiology, 2015, Volume: 23, Issue:2

    Topics: Androstanols; Anesthesia Recovery Period; Awareness; Electromyography; Humans; Muscle Weakness; Neos

2015
Incidence of postoperative residual neuromuscular blockade after general anesthesia: a prospective, multicenter, anesthetist-blind, observational study.
    Current medical research and opinion, 2016, Volume: 32, Issue:1

    Topics: Abdomen; Adult; Aged; Anesthesia, General; Delayed Emergence from Anesthesia; Female; Humans; Incide

2016
Prospective study of residual neuromuscular block and postoperative respiratory complications in patients reversed with neostigmine versus sugammadex.
    Minerva anestesiologica, 2016, Volume: 82, Issue:7

    Topics: Anesthesia Recovery Period; Atracurium; Cholinesterase Inhibitors; Delayed Emergence from Anesthesia

2016
Neuromuscular blocking effects of cisatracurium and its antagonism with neostigmine in a canine model of autosomal-recessive centronuclear myopathy.
    British journal of anaesthesia, 2015, Volume: 115, Issue:6

    Topics: Anesthesia Recovery Period; Anesthesia, General; Animals; Atracurium; Cholinesterase Inhibitors; Dis

2015
The Safety of Neuromuscular Blockade Reversal in Patients With Cardiac Transplantation.
    Transplantation, 2016, Volume: 100, Issue:12

    Topics: Adult; Aged; Cholinergic Agents; Cholinergic Antagonists; Cholinesterase Inhibitors; Female; Glycopy

2016
Antagonism of neuromuscular block: all things are poison; only the dose makes a thing not a poison.
    British journal of anaesthesia, 2016, Volume: 116, Issue:2

    Topics: Electromyography; Female; gamma-Cyclodextrins; Humans; Male; Neostigmine; Neuromuscular Blockade; Ne

2016
Reversing non-depolarising muscle relaxants, nausea and residual curarisation.
    Anaesthesia, 2016, Volume: 71, Issue:4

    Topics: gamma-Cyclodextrins; Humans; Neostigmine; Neuromuscular Blockade

2016
NEOSTIGMINE VERSUS SUGAMMADEX FOR REVERSAL OF NEUROMUSCULAR BLOCK.
    Middle East journal of anaesthesiology, 2016, Volume: 23, Issue:5

    Topics: gamma-Cyclodextrins; Humans; Neostigmine; Neuromuscular Blockade; Sugammadex

2016
Nondepolarizing Neuromuscular Blocking Agents, Reversal, and Risk of Postoperative Pneumonia.
    Anesthesiology, 2016, Volume: 125, Issue:4

    Topics: Causality; Cholinesterase Inhibitors; Databases, Factual; Female; Humans; Incidence; Male; Middle Ag

2016
Nondepolarizing Neuromuscular Blocking Agents, Reversal, and Risk of Postoperative Pneumonia.
    Anesthesiology, 2016, Volume: 125, Issue:4

    Topics: Causality; Cholinesterase Inhibitors; Databases, Factual; Female; Humans; Incidence; Male; Middle Ag

2016
Nondepolarizing Neuromuscular Blocking Agents, Reversal, and Risk of Postoperative Pneumonia.
    Anesthesiology, 2016, Volume: 125, Issue:4

    Topics: Causality; Cholinesterase Inhibitors; Databases, Factual; Female; Humans; Incidence; Male; Middle Ag

2016
Nondepolarizing Neuromuscular Blocking Agents, Reversal, and Risk of Postoperative Pneumonia.
    Anesthesiology, 2016, Volume: 125, Issue:4

    Topics: Causality; Cholinesterase Inhibitors; Databases, Factual; Female; Humans; Incidence; Male; Middle Ag

2016
Improved postoperative oxygenation after antagonism of moderate neuromuscular block with sugammadex versus neostigmine after extubation in 'blinded' conditions.
    British journal of anaesthesia, 2016, Volume: 117, Issue:3

    Topics: Airway Extubation; gamma-Cyclodextrins; Humans; Neostigmine; Neuromuscular Blockade; Oxygen; Sugamma

2016
Observational study on patterns of neuromuscular blockade reversal.
    BMC anesthesiology, 2016, 10-22, Volume: 16, Issue:1

    Topics: Airway Extubation; Body Weight; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Female;

2016
A discrete event simulation model of clinical and operating room efficiency outcomes of sugammadex versus neostigmine for neuromuscular block reversal in Canada.
    BMC anesthesiology, 2016, 11-16, Volume: 16, Issue:1

    Topics: Canada; Computer Simulation; Efficiency, Organizational; gamma-Cyclodextrins; Humans; Neostigmine; N

2016
Prolonged neuromuscular block in a preeclamptic patient induced by magnesium sulfate.
    The Pan African medical journal, 2016, Volume: 25

    Topics: Adult; Anesthesia, General; Cesarean Section; Female; HELLP Syndrome; Humans; Magnesium Sulfate; Neo

2016
Antagonism of moderate neuromuscular block with sugammadex versus neostigmine.
    British journal of anaesthesia, 2017, 03-01, Volume: 118, Issue:3

    Topics: Androstanols; gamma-Cyclodextrins; Neostigmine; Neuromuscular Blockade; Neuromuscular Nondepolarizin

2017
Intermediate-Acting Nondepolarizing Neuromuscular Blocking Agents and Risk of Postoperative 30-Day Morbidity and Mortality, and Long-term Survival.
    Anesthesia and analgesia, 2017, Volume: 124, Issue:5

    Topics: Adult; Aged; Anesthesia Recovery Period; Cholinesterase Inhibitors; Female; Humans; Male; Middle Age

2017
Neostigmine but not sugammadex impairs upper airway dilator muscle activity and breathing.
    British journal of anaesthesia, 2008, Volume: 101, Issue:3

    Topics: Androstanols; Anesthesia Recovery Period; Anesthetics, Inhalation; Animals; Cholinesterase Inhibitor

2008
Neostigmine but not sugammadex impairs upper airway dilator muscle activity and breathing.
    British journal of anaesthesia, 2008, Volume: 101, Issue:3

    Topics: Androstanols; Anesthesia Recovery Period; Anesthetics, Inhalation; Animals; Cholinesterase Inhibitor

2008
Neostigmine but not sugammadex impairs upper airway dilator muscle activity and breathing.
    British journal of anaesthesia, 2008, Volume: 101, Issue:3

    Topics: Androstanols; Anesthesia Recovery Period; Anesthetics, Inhalation; Animals; Cholinesterase Inhibitor

2008
Neostigmine but not sugammadex impairs upper airway dilator muscle activity and breathing.
    British journal of anaesthesia, 2008, Volume: 101, Issue:3

    Topics: Androstanols; Anesthesia Recovery Period; Anesthetics, Inhalation; Animals; Cholinesterase Inhibitor

2008
Calcium and neostigmine antagonize gentamicin, but augment clindamycin-induced tetanic fade in rat phrenic nerve-hemidiaphragm preparations.
    Journal of anesthesia, 2008, Volume: 22, Issue:4

    Topics: Animals; Anti-Bacterial Agents; Calcium; Clindamycin; Diaphragm; Electric Stimulation; Gentamicins;

2008
Delayed reversal of a potentiated rocuronium neuromuscular block.
    European journal of anaesthesiology, 2009, Volume: 26, Issue:4

    Topics: Androstanols; Cholinesterase Inhibitors; Depression; Drug Interactions; Female; Humans; Male; Middle

2009
The effect of memantine and levodopa/carbidopa on the responses of phrenic nerve-diaphragm preparations from aged rats.
    Medical science monitor : international medical journal of experimental and clinical research, 2009, Volume: 15, Issue:11

    Topics: Aging; Animals; Carbidopa; Diaphragm; Electric Stimulation; Gallamine Triethiodide; Gene Expression

2009
Antagonism of low degrees of atracurium-induced neuromuscular blockade: dose-effect relationship for neostigmine.
    Anesthesiology, 2010, Volume: 112, Issue:1

    Topics: Anesthesia; Anesthesia Recovery Period; Atracurium; Cholinesterase Inhibitors; Dose-Response Relatio

2010
Relative contribution of pre- and post-synaptic effects to the neostigmine-induced recovery of neuromuscular transmission blocked by vecuronium.
    Fundamental & clinical pharmacology, 2011, Volume: 25, Issue:1

    Topics: Animals; Cholinesterase Inhibitors; Electric Stimulation; Electrophysiological Phenomena; Female; Ma

2011
Rapid chemical antagonism of neuromuscular blockade by L-cysteine adduction to and inactivation of the olefinic (double-bonded) isoquinolinium diester compounds gantacurium (AV430A), CW 002, and CW 011.
    Anesthesiology, 2010, Volume: 113, Issue:1

    Topics: Alkenes; Animals; Atracurium; Chemical Phenomena; Cholinesterase Inhibitors; Chromatography, High Pr

2010
Reversal of vecuronium with neostigmine: a comparison between male and female patients.
    Fukushima journal of medical science, 2009, Volume: 55, Issue:2

    Topics: Adult; Aged; Cholinesterase Inhibitors; Female; Humans; Male; Middle Aged; Neostigmine; Neuromuscula

2009
Neostigmine versus sugammadex: which, when, and how much?
    Anesthesiology, 2010, Volume: 113, Issue:5

    Topics: Androstanols; Dose-Response Relationship, Drug; gamma-Cyclodextrins; Humans; Neostigmine; Neuromuscu

2010
Sugammadex and cholinesterase inhibitors.
    Anaesthesia and intensive care, 2010, Volume: 38, Issue:5

    Topics: Androstanols; Atropine; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; gamma-Cyclodext

2010
Neostigmine/glycopyrrolate administered after recovery from neuromuscular block increases upper airway collapsibility by decreasing genioglossus muscle activity in response to negative pharyngeal pressure.
    Anesthesiology, 2010, Volume: 113, Issue:6

    Topics: Adult; Air Pressure; Androstanols; Anesthesia Recovery Period; Cholinesterase Inhibitors; Electric S

2010
Neostigmine/glycopyrrolate administered after recovery from neuromuscular block increases upper airway collapsibility by decreasing genioglossus muscle activity in response to negative pharyngeal pressure.
    Anesthesiology, 2010, Volume: 113, Issue:6

    Topics: Adult; Air Pressure; Androstanols; Anesthesia Recovery Period; Cholinesterase Inhibitors; Electric S

2010
Neostigmine/glycopyrrolate administered after recovery from neuromuscular block increases upper airway collapsibility by decreasing genioglossus muscle activity in response to negative pharyngeal pressure.
    Anesthesiology, 2010, Volume: 113, Issue:6

    Topics: Adult; Air Pressure; Androstanols; Anesthesia Recovery Period; Cholinesterase Inhibitors; Electric S

2010
Neostigmine/glycopyrrolate administered after recovery from neuromuscular block increases upper airway collapsibility by decreasing genioglossus muscle activity in response to negative pharyngeal pressure.
    Anesthesiology, 2010, Volume: 113, Issue:6

    Topics: Adult; Air Pressure; Androstanols; Anesthesia Recovery Period; Cholinesterase Inhibitors; Electric S

2010
Neostigmine/glycopyrrolate administered after recovery from neuromuscular block increases upper airway collapsibility by decreasing genioglossus muscle activity in response to negative pharyngeal pressure.
    Anesthesiology, 2010, Volume: 113, Issue:6

    Topics: Adult; Air Pressure; Androstanols; Anesthesia Recovery Period; Cholinesterase Inhibitors; Electric S

2010
Neostigmine/glycopyrrolate administered after recovery from neuromuscular block increases upper airway collapsibility by decreasing genioglossus muscle activity in response to negative pharyngeal pressure.
    Anesthesiology, 2010, Volume: 113, Issue:6

    Topics: Adult; Air Pressure; Androstanols; Anesthesia Recovery Period; Cholinesterase Inhibitors; Electric S

2010
Neostigmine/glycopyrrolate administered after recovery from neuromuscular block increases upper airway collapsibility by decreasing genioglossus muscle activity in response to negative pharyngeal pressure.
    Anesthesiology, 2010, Volume: 113, Issue:6

    Topics: Adult; Air Pressure; Androstanols; Anesthesia Recovery Period; Cholinesterase Inhibitors; Electric S

2010
Neostigmine/glycopyrrolate administered after recovery from neuromuscular block increases upper airway collapsibility by decreasing genioglossus muscle activity in response to negative pharyngeal pressure.
    Anesthesiology, 2010, Volume: 113, Issue:6

    Topics: Adult; Air Pressure; Androstanols; Anesthesia Recovery Period; Cholinesterase Inhibitors; Electric S

2010
Neostigmine/glycopyrrolate administered after recovery from neuromuscular block increases upper airway collapsibility by decreasing genioglossus muscle activity in response to negative pharyngeal pressure.
    Anesthesiology, 2010, Volume: 113, Issue:6

    Topics: Adult; Air Pressure; Androstanols; Anesthesia Recovery Period; Cholinesterase Inhibitors; Electric S

2010
[Neuromuscular blockade after a chain of two laparotomies in a few hours].
    Masui. The Japanese journal of anesthesiology, 2011, Volume: 60, Issue:2

    Topics: Colectomy; Foreign Bodies; Humans; Kidney Failure, Chronic; Laparotomy; Male; Middle Aged; Neostigmi

2011
Possible augmentation of neuromuscular blockade by propofol during recovery from rocuronium.
    Journal of anesthesia, 2011, Volume: 25, Issue:3

    Topics: Adjuvants, Anesthesia; Adult; Androstanols; Anesthesia Recovery Period; Anesthesia, General; Anesthe

2011
Muscle relaxants and electroencephalogram.
    Anesthesiology, 2011, Volume: 114, Issue:4

    Topics: Animals; Dogs; Electroencephalography; Isoflurane; Neostigmine; Neuromuscular Blockade; Neuromuscula

2011
[Neostigmine-induced neuromuscular blockade in the corrugator supercilii muscle].
    Revista espanola de anestesiologia y reanimacion, 2011, Volume: 58, Issue:3

    Topics: Adolescent; Adult; Aged; Case-Control Studies; Cholinesterase Inhibitors; Facial Muscles; Female; Hu

2011
Different doses of atropine on heart rate fluctuations during reversal of neuromuscular blockade.
    Mymensingh medical journal : MMJ, 2011, Volume: 20, Issue:4

    Topics: Adult; Atropine; Female; Heart Rate; Humans; Male; Middle Aged; Neostigmine; Neuromuscular Blockade;

2011
Prolonged neuromuscular block associated to non-alcoholic steatohepatitis in morbidly obese patient: neostigmine versus sugammadex.
    Minerva anestesiologica, 2012, Volume: 78, Issue:1

    Topics: Adult; Biopsy; Cholinesterase Inhibitors; Fatty Liver; gamma-Cyclodextrins; Humans; Male; Monitoring

2012
Managing perioperative neuromuscular block. Facial muscle monitoring may lead to faulty clinical decisions.
    Revista espanola de anestesiologia y reanimacion, 2011, Volume: 58, Issue:10

    Topics: Cholinesterase Inhibitors; Facial Muscles; Female; Humans; Male; Neostigmine; Neuromuscular Blockade

2011
[Comments on the article "Neostigmine-induced neuromuscular blockade in the corrugator supercilii muscle"].
    Revista espanola de anestesiologia y reanimacion, 2011, Volume: 58, Issue:10

    Topics: Cholinesterase Inhibitors; Facial Muscles; Female; Humans; Male; Neostigmine; Neuromuscular Blockade

2011
[Utility of neuromuscular monitoring to diagnose neostigmine ceiling effect].
    Revista espanola de anestesiologia y reanimacion, 2011, Volume: 58, Issue:10

    Topics: Aged; Electromyography; Humans; Male; Neostigmine; Neuromuscular Blockade

2011
The influence of unrestricted use of sugammadex on clinical anaesthetic practice in a tertiary teaching hospital.
    Anaesthesia and intensive care, 2012, Volume: 40, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Androstanols; Anesthesia; Cholinesterase Inhibitors; Drug Utilizatio

2012
[Comments on the editorial article "Managing perioperative neuromuscular block. Facial muscle monitoring may lead to faulty clinical decisions"].
    Revista espanola de anestesiologia y reanimacion, 2012, Volume: 59, Issue:4

    Topics: Cholinesterase Inhibitors; Facial Muscles; Female; Humans; Male; Neostigmine; Neuromuscular Blockade

2012
Accidental intra-arterial injection of neostigmine with glycopyrrolate or atropine for reversal of residual neuromuscular blockade: a report of two cases.
    Anesthesia and analgesia, 2012, Volume: 115, Issue:1

    Topics: Adolescent; Atropine; Cholinesterase Inhibitors; Female; Glycopyrrolate; Humans; Injections, Intra-A

2012
Use of sugammadex after neostigmine incomplete reversal of rocuronium-induced neuromuscular blockade.
    Revista brasileira de anestesiologia, 2012, Volume: 62, Issue:4

    Topics: Aged; Androstanols; Cholinesterase Inhibitors; Female; gamma-Cyclodextrins; Humans; Neostigmine; Neu

2012
A prospective, observational study comparing postoperative residual curarisation and early adverse respiratory events in patients reversed with neostigmine or sugammadex or after apparent spontaneous recovery.
    Anaesthesia and intensive care, 2012, Volume: 40, Issue:6

    Topics: Adult; Aged; Anesthesia Recovery Period; Body Mass Index; Female; gamma-Cyclodextrins; Humans; Male;

2012
A prospective, observational study comparing postoperative residual curarisation and early adverse respiratory events in patients reversed with neostigmine or sugammadex or after apparent spontaneous recovery.
    Anaesthesia and intensive care, 2012, Volume: 40, Issue:6

    Topics: Adult; Aged; Anesthesia Recovery Period; Body Mass Index; Female; gamma-Cyclodextrins; Humans; Male;

2012
A prospective, observational study comparing postoperative residual curarisation and early adverse respiratory events in patients reversed with neostigmine or sugammadex or after apparent spontaneous recovery.
    Anaesthesia and intensive care, 2012, Volume: 40, Issue:6

    Topics: Adult; Aged; Anesthesia Recovery Period; Body Mass Index; Female; gamma-Cyclodextrins; Humans; Male;

2012
A prospective, observational study comparing postoperative residual curarisation and early adverse respiratory events in patients reversed with neostigmine or sugammadex or after apparent spontaneous recovery.
    Anaesthesia and intensive care, 2012, Volume: 40, Issue:6

    Topics: Adult; Aged; Anesthesia Recovery Period; Body Mass Index; Female; gamma-Cyclodextrins; Humans; Male;

2012
Anesthesiology in the era of drug shortages: use of a succinylcholine infusion for a laparoscopic sigmoid colectomy due to a shortage of neostigmine.
    Journal of clinical anesthesia, 2013, Volume: 25, Issue:1

    Topics: Colectomy; Colon, Sigmoid; Female; Humans; Laparoscopy; Middle Aged; Neostigmine; Neuromuscular Bloc

2013
Comparing sugammadex and neostigmine reversal of neuromuscular blockade in laparoscopic surgery.
    Anaesthesia, 2013, Volume: 68, Issue:3

    Topics: Cholinesterase Inhibitors; Female; gamma-Cyclodextrins; Humans; Laparoscopy; Male; Neostigmine; Neur

2013
A reply.
    Anaesthesia, 2013, Volume: 68, Issue:3

    Topics: Cholinesterase Inhibitors; Female; gamma-Cyclodextrins; Humans; Laparoscopy; Male; Neostigmine; Neur

2013
Failure of prefilled thiopental to induce anaesthesia.
    Anaesthesia, 2013, Volume: 68, Issue:3

    Topics: Cholinesterase Inhibitors; Female; gamma-Cyclodextrins; Humans; Laparoscopy; Male; Neostigmine; Neur

2013
Coloured drug labels and prefilled syringes - another mistake waiting to happen.
    Anaesthesia, 2013, Volume: 68, Issue:3

    Topics: Cholinesterase Inhibitors; Female; gamma-Cyclodextrins; Humans; Laparoscopy; Male; Neostigmine; Neur

2013
Effects of isoeugenol on in vitro neuromuscular blockade of rat phrenic nerve-diaphragm preparations.
    American journal of veterinary research, 2003, Volume: 64, Issue:6

    Topics: Anesthetics, Local; Animals; Benzocaine; Diaphragm; Drug Therapy, Combination; Eugenol; In Vitro Tec

2003
Recurarization in the recovery room following the use of magnesium sulphate.
    British journal of anaesthesia, 2003, Volume: 91, Issue:3

    Topics: Aged; Anesthesia Recovery Period; Anti-Arrhythmia Agents; Atracurium; Cholecystectomy, Laparoscopic;

2003
The influence of anticholinesterases on the neuromuscular block produced by suxamethonium.
    The Journal of pharmacy and pharmacology, 1956, Volume: 8, Issue:5

    Topics: Cholinesterase Inhibitors; Humans; Neostigmine; Neuromuscular Blockade; Physostigmine; Succinylcholi

1956
Effects of edrophonium and neostigmine on neuromuscular block in the cat.
    Acta pharmacologica et toxicologica, 1958, Volume: 14, Issue:4

    Topics: Animals; Cats; Edrophonium; Felis; Muscle Relaxants, Central; Neostigmine; Neuromuscular Blockade; N

1958
The neuromuscular blocking action of benzoquinonium chloride in the cat and in the hen.
    British journal of pharmacology and chemotherapy, 1958, Volume: 13, Issue:4

    Topics: Acetylcholine; Animals; Cats; Chickens; Cholinesterase Inhibitors; Cholinesterases; Edrophonium; Fem

1958
Neuromuscular blockade by streptomycin and dihydrostreptomycin.
    British journal of pharmacology and chemotherapy, 1960, Volume: 15

    Topics: Dihydrostreptomycin Sulfate; Humans; Neostigmine; Neuromuscular Blockade; Neuromuscular Junction; St

1960
COMPARISON OF THE NEUROMUSCULAR BLOCKING ACTION OF TOXIFERINE, RO 4-3816 AND D-TUBOCURARINE IN THE CAT.
    Acta medica et biologica, 1963, Volume: 11

    Topics: Cats; Neostigmine; Neuromuscular Blockade; Neuromuscular Diseases; Neuromuscular Junction; Pharmacol

1963
THE MECHANISM OF THE NEUROMUSCULAR BLOCKADE BY ANTIBIOTICS.
    Archives internationales de pharmacodynamie et de therapie, 1963, Dec-01, Volume: 146

    Topics: Anti-Bacterial Agents; Antibiotics, Antitubercular; Calcium; Cats; Decamethonium Compounds; Dihydros

1963
NEUROMUSCULAR BLOCKING AND HYPOTENSIVE ACTIONS OF STREPTOMYCIN, AND THEIR REVERSAL.
    British journal of anaesthesia, 1964, Volume: 36

    Topics: Autonomic Nerve Block; Calcium; Chloralose; Chlorides; Dogs; Hypotension; Neostigmine; Neuromuscular

1964
[NEUROMUSCULAR BLOCK CAUSED BY ANTIBIOTICS. RELATIONSHIPS BETWEEN CURARE-LIKE DRUGS AND ANTIBIOTICS. EXPERIMENTS WITH ANTAGONISTS].
    Minerva anestesiologica, 1964, Volume: 30

    Topics: Anesthesia; Anesthesiology; Animals; Anti-Bacterial Agents; Curare; Dihydrostreptomycin Sulfate; Kan

1964
THE AGGRAVATING EFFECT OF SOME ANTIBIOTICS ON THE NEUROMUSCULAR BLOCKADE IN MYASTHENIA GRAVIS.
    Acta neurologica Scandinavica, 1964, Volume: 40, Issue:4

    Topics: Anti-Bacterial Agents; Dihydrostreptomycin Sulfate; Edrophonium; Kanamycin; Myasthenia Gravis; Neost

1964
NEUROMUSCULAR BLOCK AS A POSSIBLE MECHANISM OF DEATH IN AMPHETAMINE POISONING.
    The Journal of pharmacology and experimental therapeutics, 1964, Volume: 146

    Topics: Carbachol; Curare; Dextroamphetamine; Injections; Injections, Intraperitoneal; Neostigmine; Neuromus

1964
Reversal of vecuronium with neostigmine in patients with diabetes mellitus.
    Anaesthesia, 2004, Volume: 59, Issue:8

    Topics: Aged; Cholinesterase Inhibitors; Diabetes Mellitus, Type 2; Female; Humans; Male; Middle Aged; Neost

2004
Neostigmine-induced prolonged neuromuscular blockade in a patient with atypical pseudocholinesterase.
    Journal of clinical anesthesia, 2005, Volume: 17, Issue:3

    Topics: Butyrylcholinesterase; Cholinesterase Inhibitors; Cystoscopy; Humans; Male; Middle Aged; Neostigmine

2005
Residual paralysis at the time of tracheal extubation.
    Anesthesia and analgesia, 2005, Volume: 100, Issue:6

    Topics: Adolescent; Adult; Aged; Anesthesia Recovery Period; Anesthesia, Inhalation; Cholinesterase Inhibito

2005
Residual paralysis at the time of tracheal extubation.
    Anesthesia and analgesia, 2005, Volume: 100, Issue:6

    Topics: Adolescent; Adult; Aged; Anesthesia Recovery Period; Anesthesia, Inhalation; Cholinesterase Inhibito

2005
Residual paralysis at the time of tracheal extubation.
    Anesthesia and analgesia, 2005, Volume: 100, Issue:6

    Topics: Adolescent; Adult; Aged; Anesthesia Recovery Period; Anesthesia, Inhalation; Cholinesterase Inhibito

2005
Residual paralysis at the time of tracheal extubation.
    Anesthesia and analgesia, 2005, Volume: 100, Issue:6

    Topics: Adolescent; Adult; Aged; Anesthesia Recovery Period; Anesthesia, Inhalation; Cholinesterase Inhibito

2005
Coronary vasospasm during the reversal of neuromuscular block using neostigmine.
    Acta anaesthesiologica Scandinavica, 2005, Volume: 49, Issue:9

    Topics: Cholinesterase Inhibitors; Coronary Vasospasm; Electrocardiography; Humans; Male; Middle Aged; Neost

2005
Chemical encapsulation of rocuronium by synthetic cyclodextrin derivatives: reversal of neuromuscular block in anaesthetized Rhesus monkeys.
    British journal of anaesthesia, 2006, Volume: 96, Issue:2

    Topics: Androstanols; Animals; Atropine; Cyclodextrins; Drug Compounding; Drug Evaluation, Preclinical; Elec

2006
Sugammadex: a revolutionary approach to neuromuscular antagonism.
    Anesthesiology, 2006, Volume: 104, Issue:4

    Topics: Androstanols; Anesthesia; Animals; gamma-Cyclodextrins; Humans; Neostigmine; Neuromuscular Blockade;

2006
Neostigmine-induced reversal of vecuronium in normal weight, overweight and obese female patients.
    British journal of anaesthesia, 2006, Volume: 97, Issue:2

    Topics: Adult; Body Mass Index; Body Weight; Cholinesterase Inhibitors; Female; Humans; Middle Aged; Neostig

2006
Comparative use of muscle relaxants and their reversal in three European countries: a survey in France, Germany and Great Britain.
    European journal of anaesthesiology, 1996, Volume: 13, Issue:4

    Topics: Alcuronium; Cholinesterase Inhibitors; Drug Utilization; France; Germany; Humans; Intubation, Intrat

1996
Simple and cost effective clinical methods for measuring neuromuscular fade responses with emphasis on "train of four" fade.
    Journal of clinical monitoring, 1997, Volume: 13, Issue:1

    Topics: Anesthesia, General; Cost-Benefit Analysis; Evaluation Studies as Topic; Hand; Humans; Intraoperativ

1997
[Effects of halothane and sevoflurane on reversal of neuromuscular blockade induced by vecuronium in man].
    Masui. The Japanese journal of anesthesiology, 1997, Volume: 46, Issue:2

    Topics: Adult; Aged; Anesthesia, Inhalation; Anesthetics, Inhalation; Drug Residues; Ethers; Female; Halotha

1997
Neuromuscular block in children.
    British journal of anaesthesia, 1997, Volume: 78, Issue:5

    Topics: Adult; Child; Cholinesterase Inhibitors; Drug Administration Schedule; Humans; Neostigmine; Neuromus

1997
Antagonism of atracurium-induced block in obese patients.
    Canadian journal of anaesthesia = Journal canadien d'anesthesie, 1998, Volume: 45, Issue:1

    Topics: Adult; Anesthetics, Inhalation; Anesthetics, Intravenous; Atracurium; Body Mass Index; Body Weight;

1998
Neuromuscular blocking and cardiovascular effects of Org 9487, a new short-acting aminosteroidal blocking agent, in anaesthetized animals and in isolated muscle preparations.
    European journal of anaesthesiology, 1998, Volume: 15, Issue:4

    Topics: Adrenergic alpha-Agonists; Animals; Cats; Chickens; Cholinesterase Inhibitors; Dogs; Dose-Response R

1998
Reversal of neuromuscular blockade.
    Anesthesia and analgesia, 1998, Volume: 87, Issue:2

    Topics: Female; Humans; Hysterectomy; Nausea; Neostigmine; Neuromuscular Blockade; Postoperative Complicatio

1998
The effects of donepezil and neostigmine in a patient with unusual pseudocholinesterase activity.
    Anesthesia and analgesia, 1998, Volume: 87, Issue:5

    Topics: Aged; Aged, 80 and over; Anesthesia; Butyrylcholinesterase; Cholinesterase Inhibitors; Donepezil; Dr

1998
Ventricular fibrillation related to reversal of the neuromuscular blockade in a patient with long QT syndrome.
    Acta anaesthesiologica Scandinavica, 1999, Volume: 43, Issue:3

    Topics: Adult; Cholinesterase Inhibitors; Female; Glycopyrrolate; Humans; Long QT Syndrome; Neostigmine; Neu

1999
Undernutrition in children--effect on vecuronium induced neuromuscular blockade.
    Anaesthesia and intensive care, 1999, Volume: 27, Issue:4

    Topics: Body Mass Index; Child; Child, Preschool; Cholinesterase Inhibitors; Electric Stimulation; Evoked Po

1999
Factors predicting atracurium reversal time.
    Acta anaesthesiologica Scandinavica, 1999, Volume: 43, Issue:8

    Topics: Adult; Anesthesia Recovery Period; Anesthetics, Inhalation; Anesthetics, Intravenous; Atracurium; Ch

1999
Which is better in children: edrophonium or neostigmine?
    British journal of anaesthesia, 2000, Volume: 84, Issue:2

    Topics: Child; Cholinesterase Inhibitors; Edrophonium; Humans; Neostigmine; Neuromuscular Blockade

2000
Anaphylaxis caused by neostigmine.
    Anaesthesia, 2000, Volume: 55, Issue:10

    Topics: Anaphylaxis; Cholinesterase Inhibitors; Edrophonium; Humans; Neostigmine; Neuromuscular Blockade

2000
Decreased parasympathetic activities in Malayan krait (Bungarus candidus) envenoming.
    Toxicon : official journal of the International Society on Toxinology, 2001, Volume: 39, Issue:9

    Topics: Adult; Animals; Autonomic Nervous System Diseases; Brain Damage, Chronic; Bungarus; Child; Female; H

2001
Rapacuronium: first experience in clinical practice.
    European journal of anaesthesiology. Supplement, 2001, Volume: 23

    Topics: Ambulatory Surgical Procedures; Cholinesterase Inhibitors; Humans; Intubation, Intratracheal; Neosti

2001
[Erroneous attitudes in the use of neuromuscular blocking agents].
    Revista espanola de anestesiologia y reanimacion, 2002, Volume: 49, Issue:2

    Topics: Anesthesia Recovery Period; Anesthesiology; Attitude of Health Personnel; Cholinesterase Inhibitors;

2002